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1 Introduction 
In the world, about 1.7 billion cases of diarrheal illness are reported every year. According to 
the global health estimates (GHE) for 2000-2015, diarrheal diseases are the eighth leading 
cause of death of the global population with 1.4 million deaths in 2015. Alarmingly, diarrheal 
disease in children under five years is actually the second leading cause of death worldwide 
(World Health Organization (WHO), Fact sheet No. 330, April 2013; WHO, GHE 2000-2015). 
In Germany, the main bacterial agents of diarrheal illness are Campylobacter (70,190 cases in 
2015), Salmonella (13,823 cases in 2015) and Yersinia (2,752 cases in 2015) 
(“Infektionsepidemiologisches Jahrbuch meldepflichtiger Krankheiten für 2015”, Robert-
Koch-Institut). However, there are no global estimates or epidemiological studies that report 
about the prevalence of persistent bacterial infections or the amount of complications that 
accompany/follow bacterial infections. Although some persistent bacterial infections and their 
health risks have long been known, the mechanisms and factors that are required for bacterial 
persistence are just beginning to be understood. Even the full comprehension of the complex 
host-pathogen interactions during acute infections is not complete. These topics are of interest, 
as chronic infections increase health care expenses. Thus, there is a consequent need for 
exploration of new treatment possibilities to decrease the burden of chronic infections for the 
society and human health. In order to identify new treatment targets and strategies, the 
mechanisms, which cause chronic disease, have to be elucidated. This study investigates the 
influence and role of a Yersinia encoded toxin on pathogenesis and host-pathogen interactions 
during acute and persistent infection. 
1.1 Mammalian host defense strategies against bacterial infection 
In order to defend the organism against bacterial infection, mammals have evolved a complex 
defense machinery to prevent, recognize and clear infection. This is enabled by the 
maintenance and defense traits of barriers (1.1.1), cell autonomous immunity programs (1.1.2), 
secretion of protective factors facilitating phagocytosis (e.g. complement, opsonins) (1.1.3), 
and specific immune cells that are responsible for pathogen elimination (1.1.4). 
1.1.1 Immune defenses at the intestinal barrier 
The gastrointestinal tract constitutes the largest surface in mammals and is colonized by a 
commensal microbiota that gives a home to 10
13
 to 10
14
 microorganisms supporting the 
digestive process (Ley et al., 2006; Hill and Artis, 2010). The intestine’s main function is to 
absorb nutrients from the digestive tract to guarantee energy and essential component supply. 
Beyond that, the intestinal tract has to defend and prevent microbial encroachment by 
commensal or pathogenic bacteria. On top, the organism must retain tolerance to food antigens 
and the microbiota, yet preserving the capacity to mount effective immune defense and 
inflammation upon intestinal infection. 
Nutrient and essential component absorption is mainly facilitated through enterocytes, which 
make up the majority of all intestinal epithelial cells (IECs). However, enterocytes also create a 
dense physiological barrier. To this purpose, they affiliate to a selective, impermeable lining. 
This barrier is assembled by the formation of junctional complexes that consist of tight 
junctions and adherens junctions (Turner, 2009; Goto and Kiyono, 2012). Moreover, 
enterocytes express alkaline phosphatases that support detoxification of microbiota-derived 
INTRODUCTION 
2 
 
lipopolysaccharides (LPS) (Bates et al., 2007). Another IEC type is the goblet cell that secretes 
highly glycosylated mucins into the intestinal lumen in order to create a contact barrier 
(mucus) between the epithelium and the commensals (Bergstrom et al., 2010). The 
glycosylation of mucins also generates adhesive attachment sites that are able to capture 
bacteria (Sansonetti, 2004; Barr et al., 2013). In addition, the mucus contains immunoglobin A 
(IgA) and bactericidal molecules. The mucosal IgA captures antigens and microbes, thus 
inhibiting their encroachment to the epithelium, a mechanism termed immune exclusion 
(Brandtzaeg, 2009). The antimicrobial molecules are produced and secreted by IECs, called 
paneth cells, consequently mediating killing of the mucus-trapped bacteria. Among the 
antimicrobial effectors are α-defensins, C-type lectins, lysozymes, phospholipase A2 (PLA2), 
and angiogenin 4 (Mukherjee et al., 2008). Especially, the bacteriolytic C-type lectin RegIIIγ is 
important for prevention of microbial invasion, since it creates a 50 µm thick bacteria-free area 
above the epithelial cell layer (Vaishnava et al., 2011; Mukherjee et al., 2014).  
The intact microbiota is also considered as a protective organ that usually expels other bacteria 
from manifestation. Hence, the normal microbiota outcompetes the invader by vying for 
colonization niches and nutrients (O’Hara and Shanahan, 2006). 
Immune responses and tolerance to harmless antigens are conferred by a special part of the 
intestinal epithelium, referred to as follicle-associated epithelium (FAE), that overlays the gut-
associated lymphoid tissue (GALT), denoted as Peyer’s patches (PPs) (Miller et al., 2007). 
Embedded into the FAE are microfold (M) cells, which sample antigens from the lumen and 
transfer them to the PP (Kraehenbuhl and Neutra, 2000). Controversially, this function makes 
the organism vulnerable to infection since many pathogens evolved mechanisms to exploit 
M cells as primary entry sites, e.g. Salmonella (Jepson and Clark, 2001). Inside the PP, antigen 
presentation by dendritic cells (DCs) stimulates B cells to mature into mucosal IgA-producing 
B cells (Wershil and Furuta, 2008). In addition, DC-mediated transport of antigens into the 
draining mesenteric lymph nodes (MLNs) triggers development of systemic antigen tolerance 
(Pabst et al., 2007). 
Upon infection, intestinal epithelial cells are also able to initiate inflammation and contribute to 
pathogen killing (Eckmann and Kagnoff, 2005; Ramanan and Cadwell, 2016). These defense 
mechanisms are described in section 1.1.2. 
1.1.2 Cell-autonomous immunity  
Eukaryotic cells are a source of nutrients for pathogens. Therefore, evolution drove the 
development of intrinsic cellular immune defense mechanisms, referred as cell-autonomous 
immunity, which protect both individual immune and non-immune cells against the microbial 
invaders. Cellular compartmentalization and pattern recognition receptors (PRRs) that sense 
cellular integrity and microbial components are central elements of cellular self-defense. These 
sensors recognize damage-associated molecular patterns (DAMPs; e.g. mitochondrial DNA, 
glycans) after breakdown of cellular compartments or pathogen-associated molecular patterns 
(PAMPs; e.g. LPS, flagellin) (Figure 1.1). Furthermore, the PRRs are categorized into Toll-
Like Receptors (TLRs), Retinoic acid-Inducible Gene I (RIG I)-Like Receptors (RLR), C-
type Lectin Receptors (CLRs), Nucleotide-binding and Oligomerization Domain (NOD)- and 
Leucine-rich repeat-containing Receptors (NLRs), Absent In Melanoma II (AIM2)-Like 
Receptors (ALRs) and Sequestosome I-Like Receptors (SLRs) (Barton and Kagan, 2009; 
Ronald and Beutler, 2010; Hansen et al., 2011; Mostowy and Shenoy, 2015; Yu and Gao, 
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Figure 1.1 Mechanisms of cell autonomous immunity. 
The eukaryotic immune and non-immune cells are able to sense DAMPs and PAMPs by the expression of special 
PRRs in the extracellular space, the cytosol and inside compartments, e.g. phagosome. Moreover, these cells are 
able to respond to the exposure to cytokines. After sensing of cytokines or DAMPs/ PAMPs, downstream cascades 
are triggered that induce cellular death pathways, the production and/or maturation of cytokines and chemokines or 
the activation of various bacteriostatic and/ or bactericidal defense paths. 
2015). In particular, activation of TLR, RLR and ALR initiates signal transduction cascades, 
for instance via mitogen-activated protein kinases (MAPK), which result in the induction of 
transcription factors. Those trigger the expression of cellular defense genes such as pro-
inflammatory cytokines (Bonizzi and Karin, 2004; Arthur and Ley, 2013). However, the 
immune signaling cascades can also induce apoptosis or necroptosis (programmed necrosis). 
Apoptosis is an immunologically silent cell death program, which facilitates the clearance of 
infected cells by phagocytosis, whereas necroptosis promotes membrane permeabilization, 
cellular swelling and finally plasma membrane rupture, thereby releasing cellular contents 
(Oberst, 2016; Vanden Berghe et al., 2016). Besides removal of infected cells, the role of 
necroptosis in driving inflammation by the release of DAMPs is less clear. There are many 
hypotheses discussed that suggest necroptosis rather as an intrinsic adjuvant or terminator of 
inflammatory programs (Kiraz et al., 2016; Oberst, 2016). Moreover, NLRs and ALRs 
recognize microbial infection through the detection of e.g. microbial DNA, flagellin or 
bacterial proteins in the host cell cytosol. Subsequently, multi-protein-platforms called 
inflammasomes, containing NLR/ALR, apoptosis-associated speck-like protein containing 
CARD (ASC) and pro-caspase-1 are assembled, leading to the proteolytic activation of pro-
caspase-1. Active caspase-1 processes the pro-inflammatory cytokines interleukin (IL)-1β/-18 
and triggers pro-inflammatory lytic cell death, known as pyroptosis. Besides potent induction 
of inflammation through the release of ATP or IL-1α, pyroptosis also supports intracellular 
pathogen elimination (Aachoui et al., 2013; Broz and Monack, 2011). Since pathogens have 
evolved multiple mechanisms to subvert different types of cell death, the variety of cell death 
mechanisms highlights the importance for the host to eliminate infected cells (Figure 1.1) 
(Ashida et al., 2011). In turn, production and secretion of cytokines and chemokines alerts the 
host immune system, fostering the activation and recruitment of immune cells to the site of 
infection. In addition, secreted cytokines, such as interferons (IFN), prompt further cell-
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autonomous host defenses by induction of IFN-stimulated effector genes. Among those are the 
oxidative and nitrosative defense, phagosome maturation and autophagy (Figure 1.1) 
(MacMicking, 2012). Furthermore, eukaryotic cells create hostile intracellular environments by 
the limitation of deoxynucleotide triphosphates, amino acids, essential ions such as Zn
2+
and 
Mn
2+
, through the production and delivery of antimicrobial peptides, and via acidification of 
phagosomes (Figure 1.1) (Randow et al., 2013). 
Those mechanisms are essential for sterilizing immunity in both immune and non-immune 
cells promoting microbial clearance or at least growth and dissemination control. 
1.1.3 First defense lines of innate immunity 
As described before, the recognition of microbial infection via PRRs not only activates cell-
autonomous immunity, but also triggers secretion of pro-inflammatory cytokines. Among these 
are tumor necrosis factor α (TNFα), IL-1 and IL-6 that are potent inducers of acute phase 
response in the liver and other tissues. After the induction of the acute phase response, a set of 
acute phase proteins are produced and secreted, in order to enhance systemic resistance to 
bacterial infection (Heinrich et al., 1990; Alcorn et al., 1992; Baumann and Gauldie, 1994; 
Kopf et al., 1994; Urieli-Shoval et al., 2000). The major acute phase proteins are C-reactive 
protein (CRP) and serum amyloid A (SAA), though other proteins additionally contribute to 
the acute phase response, e.g. complement factor-3 (C3), the iron chelator haptoglobin or LPS-
binding protein (Gruys et al., 2005). During the acute phase response, the major acute phase 
reactant CRP opsonizes the microbial invader concomitantly activating the complement system 
and phagocytosis (described below) (Black et al., 2004). In mice, SAA is produced as three 
different isoforms that fulfill diverse functions (Butler and Whitehead, 1996; Chiba et al., 
2009). SAAs opsonize bacteria, bind retinol to restrict bacterial loads, attract phagocytes and 
modulate immune responses (Badolato et al., 1994; Patel et al., 1998; Furlaneto and Campa, 
2000; Shah et al., 2006; De Santo et al., 2010; Derebe et al., 2014; Sun et al., 2015). Hence, 
the acute phase response participates in pathogen growth control and mediation of proper 
immune responses upon infection. 
The complement system is one of the oldest first lines of innate immune defense (Zhu et al., 
2004). Upon bacterial infection, the complement system is activated through three alternate 
pathways: the classical, the alternative and the lectin pathway. Two of these pathways require 
the initial detection of the pathogen surface by antibodies (classical pathway) or PRRs (lectin 
pathway) (Figure 1.2). However, the activation of complement through the alternative pathway 
depends on self-amplification loops via spontaneous hydrolysis of C3 or C3-binding to LPS 
(Figure 1.2) (Joiner et al., 1986; Janeway et al., 2001). Sequential proteolytic cascades then 
lead to opsonization of the pathogen with complement, resulting in phagocytosis, formation of 
a lytic membrane attack complex and production of pro-inflammatory mediators 
(anaphylatoxins) (Figure 1.2) (Dunkelberger and Song, 2010). The interaction of opsonized 
pathogens and phagocytes induces not only clearance of immune complexes, but also advances 
secretion of pro-inflammatory cytokines (IL-1), antigen presentation to B cells and their 
activation (Papamichail et al., 1975; O’Neil et al., 1988; Bacle et al., 1990; Carter and Fearon, 
1992; Fang et al., 1998; Krych-Goldberg and Atkinson, 2001; Helmy et al., 2006). Hence, 
complement serves also as an adjuvant for development of adaptive immunity (Dempsey et al., 
1996). Furthermore, complement by-products stimulate cytokine production, degranulation, 
oxidative burst and recruitment of innate immune cells (e.g. neutrophils and macrophages) 
(Figure 1.2) (Hugli and Muller-Eberhard, 1978; Haas and van Strijp, 2007).  
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Figure 1.2 The complement system. 
The recognition of bacterial pathogens leads to the activation of the complement system cascade via the classical, 
lectin or alternative pathway. The decomposition of C3 leads to self-amplification of the cascade. Sequential 
proteolysis leads to opsonization of certain pathogens and cells, the formation of the lytic membrane attack complex 
and immune cell recruitment/ inflammation. 
Another important system of early immune defense is the coagulation cascade. As upon 
activation of the complement system, coagulation activation by the extrinsic pathway (tissue 
factor-mediated) or intrinsic pathway (contact-mediated activation at the bacterial surface) 
leads to a proteolytic cascade that leads to the formation of a fibrin clot (van der Poll and 
Herwald, 2014). This fibrin clot is able to trap pathogens prohibiting further bacterial 
dissemination (Loof et al., 2011). In addition, the whole coagulation cascade is linked to 
antimicrobial activities and the induction of inflammatory responses. The tissue factor 
regulators and the generation/release of antimicrobial peptides were associated with 
bactericidal actions during active coagulation (Nordahl et al., 2005; Frick et al., 2006; 
Papareddy et al., 2010). Moreover, the tissue factor and other coagulation factors were shown 
to trigger production of pro-inflammatory cytokines and chemokines such as IL-6, IL-8, IFNγ 
and MCP-1 (Chu, 2005; Monteiro et al., 2006; Shrivastava et al., 2007; Srinivasan and 
Bogdanov, 2012; Åberg and Siegbahn, 2013). Besides its roles during inflammation, 
coagulation also facilitates wound closure, tissue healing and regeneration (Versteeg et al., 
2013). Therefore, coagulation provides a powerful innate immune mechanism during early 
host immunity to control bacterial dissemination, kill invading pathogens and restore tissue 
homeostasis. 
1.1.4 Cellular defense effectors in immunity  
Mammalians home a complex diversity of immune cells in their organism, which is constantly 
expanded by new cellular sub-populations and maturation states with specialized functions. 
Moreover, cellular immune defense is a multifaceted orchestra that is able to react to incoming 
stimuli and interact with other immune cells. In the classical view, leukocytes are divided into 
innate and adaptive immune cells (Dranoff, 2004). However, these distinct borders are 
constantly blurring. This section will concentrate on the most important basic functions of 
innate and adaptive immune cells. 
Next to the initial recognition of bacterial infection (1.1.2), innate immune cells are rapidly 
recruited to the site of infection. Among them are polymorphonuclear phagocytes (PMNs), 
macrophages, DCs and monocytes. PMNs, also known as neutrophils, are the first recruited 
leukocytes before others arrive (Witko-Sarsat et al., 2000). After encountering the pathogenic 
agent, neutrophils execute potent microbial killing programs. To this purpose, neutrophils 
phagocytose the pathogen into the phagosome, where they are killed by the production of 
reactive oxygen species (ROS), and via fusion with intracellular stored granules, which contain 
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antimicrobial/digestive proteins (Leto and Geiszt, 2006; Borregaard et al., 2007; Nordenfelt 
and Tapper, 2011). Moreover, neutrophils de-granulate their intracellular vesicle contents and 
extrude nuclear DNA into the extracellular space, both inhibiting bacterial growth in the 
surrounding environment (Brinkmann et al., 2004; Soehnlein, 2009). However, PMNs are 
short living cells that enter apoptosis after several days, thereby commencing the resolution of 
inflammation and their removal by macrophages (El Kebir and Filep, 2010; Mantovani et al., 
2011). 
Since macrophages harbor diverse functionalities, they are central parts of innate immunity 
(Gordon and Taylor, 2005). In general, there are two main functional phenotypes of 
macrophages, i.e. classically activated (M1) and alternatively activated (M2) macrophages 
(Gordon and Martinez, 2010). M1 macrophages differentiate upon LPS and IFNγ exposure and 
proceed to pro-inflammatory (e.g. TNFα secretion) and antimicrobial actions. In contrast, 
stimulation with IL-4 and IL-13 drives M2 macrophage polarization. Those cells are 
participating in tissue repair, immune-regulatory and anti-inflammatory processes, for example 
IL-10 secretion (Locati et al., 2013; Striz et al., 2014; Juhas et al., 2015). The capability of 
phagocytosis plays not only an important role in pathogen killing, but also in the resolution of 
inflammation by removing dead cells and cell debris (Biswas et al., 2012). Macrophages 
process the collected pathogen-derived antigens and present them via major histocompatibility 
class II complexes (MHCII) to T cells (Kaye, 1995). Hence, macrophages collaborate with 
different arms of immunity, i.e. inflammation modulation, infection resolution, and adaptive 
immunity. 
DCs are primarily known for their professional antigen presentation abilities to T cells. Via the 
expression of PRRs, DCs sense pathogens and tissue damage subsequently triggering 
phagocytosis (Merad et al., 2013). After antigen processing, DCs present the antigens to  
T cells (Dudziak et al., 2007; Villadangos and Schnorrer, 2007; Segura and Villadangos, 2009; 
Joffre et al., 2012). Importantly, DCs are not only able to present antigens to CD4
+
 T cells (TH 
cells) via MHCII, but also cross-present MHCI bound antigens to CD8
+
 T cells (cytotoxic T 
cells, CTLs). Therefore, DCs are unique antigen presenting cells that are able to prime TH cell 
and CTL responses (Banchereau and Steinmann, 1998; den Haan et al., 2000; Idoyaga et al., 
2008). Yet, DCs also contribute to the development of central and peripheral tolerance through 
the induction of regulatory T cells (Tregs) (Proietto et al., 2008; McLachlan et al., 2009; Vitali 
et al., 2012). 
The mounting of specific adaptive immunity is important to clear the infection and develop 
immunological memory. In general, naïve T cells become activated when they recognize their 
equivalent antigen and receive co-stimulatory signals. Thereafter, those cells undergo a clonal 
expansion and differentiate to effector T cells, for instance CTLs, TH1, TH2, and TH17 
(Figure 1.3) (Murphy, 2012). Effector CTLs are cytotoxic and antigen-specifically lyse target 
cells by degranulation of vesicles containing perforin, and granzymes A and B (Figure 1.3) 
(Gerritsen and Pandit, 2016). On the other hand, TH cells are subdivided into different subsets 
depending on their cytokine profiles thereby performing different functions during adaptive 
immune responses (Figure 1.3) (Raphael et al., 2015; Golubovskaya and Wu, 2016).  
TH1 cells mainly produce IFNγ, thus enhancing bacterial killing by phagocytes (Berger, 2000). 
In contrast, TH2 cells are immune modulatory, promoting immunoglobin class switches in  
B cells, M2 macrophage polarization and suppress TH1 differentiation (Vitetta et al., 1985; 
Swain et al., 1990; Chen et al., 2012). Moreover, TH17 cells are highly inflammatory effector 
cells, which induce the recruitment of neutrophils, production of antimicrobial peptides and 
tissue repair (Ouyang et al., 2008). On the contrary, immune responses are dampened by  
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Figure 1.3 T cell differentiation. 
Interaction of a naïve T cell with an antigen-presenting cell triggers effector T cell differentiation. The 
differentiation of activated T cells involves signaling by different cytokines, which drive the expression of 
transcription factors. These initiate T cell subset commitment and secretion of a certain cytokines profile. The 
picture is adapted from Jetten, 20071 and Pennock et al., 20132. 
Tregs. Thus, Tregs inhibit the activation, expansion and function of various immune cell types, 
for example cytokine production and cytotoxic activities (Miyara and Sakaguchi, 2007). 
The other branch of adaptive immunity is B cells. Those produce protective antibodies specific 
for an antigen. As upon T cell activation, B cells become activated by the exposure to an 
antigen. This is followed by somatic hyper-mutation leading to the development of high-
affinity antibodies. Those antibodies opsonize pathogens, tagging them for phagocytosis 
(Zhang et al., 2016b). 
1.2 The enteropathogenic Yersinia  
The genus Yersinia belongs to the phylum of γ-Proteobacteria in the family of 
Enterobacteriaceae (Bottone, 1997). Generally, yersiniae are Gram-negative, non-spore 
forming rod-shaped coccobacilli that grow as facultative anaerobes. As they are 
psychrotolerant, they are capable of growing at temperatures between 4 °C and 43 °C with an 
optimal growth behavior at 25-29 °C (Bercovier and Mollaret, 1984; Kapatral and Minnich 
1995).  
In 1894, the bacteriologist Alexandre Yersin first isolated the causative agent of plague 
(Pasteurella pestis), which was later re-named in memory of its discoverer, Yersinia pestis 
(van Loghem 1944; Hawgood, 2008). Up to date, the Yersinia genus encompasses 15 non-
human-pathogenic and three recognized human-pathogenic species (spp.): the causative agent 
of bubonic and pneumonic plague, Y. pestis, and the two enteropathogens, Y. enterocolitica and 
Y. pseudotuberculosis (Lehmann and Neumann 1896; van Loghem 1944; Smith and Thal 
1965; Ewing et al. 1978; Bercovier et al. 1981; Brenner et al. 1981; Ursing et al. 1981; 
Bercovier et al. 1984; Aleksic et al. 1987; Wauters et al. 1988; Cover and Aber, 1989; Pfeiffer 
1889; Sprague and Neubauer 2005; Sprague et al. 2008; Hurst et al. 2011; Merhej et al. 2008; 
Murros-Kontiainen et al. 2011a,b; Savin et al. 2014). These pathogenic Yersinia spp. share the 
ability to transmit via zoonotic infections but differ between their transmission and infection 
route. Whereas the enteropathogenic Yersinia spp. are transmitted via the fecal-oral route, 
                                                     
1
 Jetten (2007) is licensed under the Creative Commons Non-Commercial Attribution license. 
2
 Permitted for use/adaptation in a doctoral thesis/dissertation by the American Physiological Society [T cell responses: naïve to 
memory and everything in between, Pennock et al., copyright ©2013]. 
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Y. pestis exhibits a complex lifestyle and is transmitted to humans by fleas, inhalation of 
infectious aerosols or more rarely, via infected animals (Perry and Fetherston, 1997; Galindo et 
al., 2011) However, they still share a common tropism for lymphatic tissues and the ability to 
subvert host innate immune responses (Cornelis et al., 1998). In silico phylogenetic analyses 
revealed that the enteropathogenic Yersinia spp. experienced a parallel and independent 
evolution. Thereby, they presumably separately acquired the major Yersinia pathogenic factor, 
the virulence plasmid pYV (Reuter et al., 2014). Moreover, genomic and ancient DNA 
analysis of Y. pestis genomes revealed that the most virulent Yersinia spp., Y. pestis, emerged 
from the less pathogenic, environmental-stress adaptable Y. pseudotuberculosis about 35,000 
to 79,000 years ago. Surprisingly, Y. pseudotuberculosis and Y. pestis still share a sequence 
identity of 97 % (Achtman et al., 1999; Rasmussen et al., 2015). However, about 13 % of the 
Y. pseudotuberculosis genes are either inactivated (e.g. yadA, O antigen cluster) or absent (e.g. 
lpxL) in Y. pestis. Furthermore, Y. pestis has acquired two additional virulence plasmids pPCP1 
and pMT1 that encode important factors for vector-borne transmission and establishment of 
bubonic and pneumonic plague. This acquisition and decay of genes drove the evolution 
towards a highly virulent human pathogen with extreme adaptation capacity to its vector and 
hosts (Zhou and Yang, 2009; Hinnebusch et al., 2016). 
Usually, infection with Y. pseudotuberculosis and Y. enterocolitica takes place by the ingestion 
of contaminated food products. Yet, both Yersinia spp. were isolated from environmental 
sources such as soil and water but were also found in animal reservoirs (e.g. bats, wild boars, 
rodents and goats) (Langford, 1972; Fukushima et al., 1995; Sulakvelidze et al., 1996; 
Mühldorfer et al., 2010; Giannitti et al., 2014; von Altrock et al., 2015). In the past years, 
several outbreaks and reports of Yersinia infections were documented in association with 
contaminated pork products, milk and vegetables (Nuorti et al., 2004; Rahman et al., 2011; 
Longenberger et al., 2014; Vasala et al., 2014; Pärn et al., 2015). 
Infections with enteropathogenic Yersinia, referred to as yersiniosis, usually cause self-limiting 
invasive disease accompanied by an acute inflammatory response comprising of afflictions 
such as gastro-enterocolitis, acute mesenteric lymphadenitis, terminal ileitis and 
pseudoappendicitis. Furthermore, acute disease symptoms resemble most enteric bacterial 
infections including fever, abdominal pain and watery to bloody diarrhea (Dube, 2009). 
Incidence of yersiniosis is age-linked. It occurs frequently in infants and young children in case 
of Y. enterocolitica, whereas Y. pseudotuberculosis cases are more commonly documented in 
adolescents and young adults (Smego et al., 1999). In rare cases, yersiniosis or transfusion of 
Yersinia-contaminated blood might manifest systemically in healthy individuals or patients 
with either pre-existing disorders or immunodeficiency, resulting in high fatality rates 
(Bottone, 1997). 
Occasionally, individuals develop autoimmune disorders and severe sequelae after an acute 
intestinal Yersinia infection. Besides Kawasaki disease, inflammatory bowel disease and 
Grave’s disease, reactive arthritis and erythema nodosom are the most common ones (Hannu et 
al., 2003; Jalava et al., 2006 Hargreaves et al., 2013; Leu et al., 2013; Horinouchi, et al., 
2015). Reactive arthritis frequently occurs after acute enteric infections in individuals that are 
positive for human leukocyte antigen (HLA) type B27 (Stavropoulos et al., 2015). Yet, the 
pathogenesis of reactive arthritis is not well understood. Upon reactive arthritis, bacterial 
components (microbial DNA or proteins) are detectable in synovial fluids of patients 
suggesting the transport of bacteria/bacterial components from the primary infection site to the 
joint (Granfors et al., 1989). This might initiate the infiltration of Yersinia-specific CD4
+
 and 
CD8
+
 T cells into the synovial fluids of reactive arthritis patients (Ugrinovic et al., 1997; Mertz 
et al., 1998). Moreover, imbalances of TH1/TH2 responses in the synovial fluids of patients 
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with reactive arthritis were documented; including decreased pro-inflammatory cytokine 
production (i.e. TNFα and IFNγ) with elevated anti-inflammatory cytokine release (i.e. IL-10) 
by CD4
+
 T cells (Simon et al. 1994; Yin et al., 1997; Smeets et al., 1998; Braun et al., 1999; 
Mertz et al., 2000). The imbalance of cytokine production was proposed to either control the 
hypersensitive immune response against the bacterium or contribute to bacterial persistence 
and prolonged arthritis. Indeed, more studies hint towards a contribution of IL-10 to sustained 
reactive arthritis and delayed bacterial clearance (Sieper, 2004). 
In rodent animal models, most characteristics of human yersiniosis are mimicked, including 
enteritis and the development of reactive arthritis (Heesemann et al., 1993a). Hence, the 
natural rodent pathogen Y. pseudotuberculosis, which is able to cause enteric disease in 
humans, represents an ideal model organism to study pathogenicity and virulence mechanisms. 
1.2.1 Virulence factors of enteropathogenic Yersinia spp. 
Virulence factors are crucial for pathogens to promote and maintain infection in a susceptible 
host. Furthermore, pathogens require them to gain the competence to develop a certain 
pathogenic mechanism, referred to as bacterial pathogenesis. Common microbial pathogenic 
mechanisms include (1) attachment and invasion, (2) evasion of/resistance to host immunity, 
(3) nutrient acquisition and growth, and (4) transmission to the environment or a new host 
(Groisman, 2001). Additionally, host specificity and host species barrier crossing depends on 
the pathogens virulence factor repertoire (Bäumler and Fang, 2013).  
The enteropathogenic yersiniae possess a large collection of chromosomally and virulence 
plasmid encoded virulence factors to colonize different hosts and develop pathogenicity 
(Gemski et al., 1980; Portnoy and Falkow 1981; Brubaker, 1991). Although the virulence 
plasmid is crucial for the invasiveness of Yersinia, additional chromosomal factors are required 
to cause full pathogenicity (Zink et al., 1980; Heesemann and Laufs, 1983; Heesemann et al., 
1984; Green et al., 2016). Since expression of virulence factors constitutes a metabolic burden 
for the pathogen, virulence factors of Yersinia are tightly regulated and respond mostly to 
temperature (Brubaker, 1983; Straley et al., 1993; Ramamurthi and Schneewind, 2002; Erhardt 
and Dersch, 2015).  
Early after the ingestion of contaminated nutrition, Yersinia has to tolerate the acidic gastric 
environment ranging from pH 1.0 to 2.5 (Evans et al., 1988). To this purpose, 
enteropathogenic yersiniae harbor a chromosomally encoded urease operon, which leads to the 
neutralization of protons, diminishing acidity (De Koning-Ward and Robins-Browne, 1995; Hu 
et al., 2009). 
To cross the intestinal barrier and to effectively deliver their main virulence factors into the 
host cells, Yersinia expresses several adhesins either on their chromosome (e.g. ail, inv and 
psa) or virulence plasmid (yadA). In the initial infection phase, invasin (InvA) is essential for 
initial tissue invasion in the intestine (Isberg et al., 1987; Clark et al., 1998; Hamburger et al., 
1999). At later stages of infection, Yersinia adhesion A (YadA) is the major adhesin 
performing diverse functions. Thus, YadA mediates close contact to a broad range of host cells 
facilitating effector protein translocation into the host cell via binding to extracellular  
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Figure 1.4 Yersinia type three secretion.  
The TTSS is a molecular nanomachine, which, upon host cell contact, spans from the bacterial cytosol into the host 
cell membrane, translocating effector proteins (Yops) into the host cytosol. (A) The TTSS consists of an export 
apparatus conferring secretion competence (yellow), a membrane spanning basal body anchoring the secretion 
system into the bacterial membranes (green), a needle structure (red), and the translocon that forms a pore in the 
host membrane (blue). (B) The Yop effectors disrupt the host immune response by inhibition of phagocytosis and 
pro-inflammatory gene expression. YpkA is primary involved in inhibition of phagocytosis by deregulating actin 
polymerization and small Rho GTPase activities. Likewise, phagocytosis is also blocked by YopE, which 
deactivates small Rho-GTPases, YopT that delocalizes small Rho-GTPases from the plasma membrane, and YopH 
that interrupts focal adhesion complexes. The deactivation of the small Rho-GTPases interrupts caspase-1 activation 
and the production of pro-inflammatory reactions by the inflammasome. Moreover, YopH and YopM block 
inflammasome activation. Controversially, YopJ activates caspase-1 and promotes inflammation, though it blocks 
NFkB and MAPK signaling preventing the expression of pro-inflammatory cytokines. In line with its anti-
inflammatory function, YopM also blocks transcription of pro-inflammatory cytokines and induces anti-
inflammatory cytokine production (e.g. IL-10). G protein-coupled receptor (GPCR). The figure is adapted from Pha 
and Navarro, 2016.3  
                                                     
3
 Pha and Navarro (2016) is licensed under the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license. 
http://creativecommons.org/licenses/by-nc/4.0/ 
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matrix components (e.g. collagen, fibronectin, laminin) or αV integrins (Tertti et al., 1992; 
Flügel et al., 1994; Visser et al., 1995; Tahir and Skurnik, 2001; Keller et al., 2015). 
Moreover, YadA was shown to induce hemagglutination, promote epithelial cell invasion, 
serum resistance, and cause bacterial auto-aggregation to phagocytosis-resistant microcolonies 
(Skurnik et al., 1984; Balligand et al., 1985; Hoiczyk et al., 2000; Eitel and Dersch, 2002; 
Biedzka-Sarek et al., 2008a; Biedzka-Sarek et al., 2008b; Kirjavainen et al., 2008). As 
Yersinia expresses several adhesins, their functions are also redundant: the chromosome 
encoded adhesin Ail (attachment invasion locus) and the PsaA fimbriae mediate the adherence 
of the bacterium to host cells, but are also contributing to agglutination of erythrocytes, serum 
resistance and binding of human immunoglobin (Bichowsky-Slomnicki and Ben-Efrain, 1963; 
Pierson and Falkow, 1993; Yang et al., 1996; Zav’yalov et al., 1996; Yamashita et al., 2011). 
This redundancy might facilitate adherence to a broad spectrum of host cells and manage 
crossing of host species barriers. Subsequent to invasion into the host tissue, bacteria are 
confronted with the host innate immune system functioning to combat the invaded pathogen. In 
order to evade the host immune response, pathogens employ a virulence mechanism known as 
Type III secretion (TTS), which allows the bacteria to directly inject effector proteins into the 
host cell cytosol (He et al., 2004a). In Yersinia, this TTS system (TTSS) is encoded on the 
virulence plasmid consisting of a collection of effector proteins, termed Yersinia outer proteins 
(Yops), and the Yop secretion (Ysc) apparatus (Cornelis, 2002). The Ysc machinery is 
composed of a cytosolic export apparatus, a membrane-spanning multi-protein complex called 
the basal body, an extracellular needle-like structure consisting of polymerized protein and the 
translocon at the needle tip that inserts into the host membrane (Figure 1.4A) (Izoré et al., 
2011). Upon host cell contact, this machinery is able to translocate six different Yop effectors, 
namely YopH, YopE, YopT, YpkA, YopJ and YopM into the host cell cytosol to manipulate 
host cell functions and signaling (Figure 1.4) (Cornelis et al., 1998). The Yop effector proteins 
display diverse functions that primarily target Rho GTPases (YpkA, YopE, YopT) and 
ultimately lead to inhibition of phagocytosis (YopH, YpkA, YopE, YopT) (Viboud and Bliska, 
2005). However, Yops also serve to inhibit/activate caspase-1 (YopM, YopE, YopJ), suppress 
pro-inflammatory cytokine/chemokine production (YopE, YopH, YopJ, YopM), inhibit 
production of ROS (YopH), activate apoptosis (YopJ, YopM), inhibit cellular immune 
signaling pathways (YopH, YopT) or induce anti-inflammatory cytokine production (YopM) 
(Figure 1.4B) (Pha and Navarro, 2016).  
As the host limits the availability of essential ions (e.g. iron, magnesium), pathogenic bacteria 
have evolved iron up-take systems to ensure bacterial fitness and physiology (Carniel, 2001; 
Abu Kwaik and Bumann, 2013). Thus, enteropathogenic yersiniae acquired the iron 
siderophore yersiniabactin (Ybt). The Ybt-biosynthesis genes and its uptake system are both 
encoded on a high-pathogenicity island, of which the presence is linked to the level of Yersinia 
virulence (Carniel et al., 1987; Heesemann, 1987; Heesemann et al., 1993b; Fetherston et al., 
1999). 
Intriguingly, two sequenced strains of Y. pseudotuberculosis express the cytotoxic necrotizing 
factor (CNF) toxin, which was identified as a novel virulence factor of Y. pseudotuberculosis 
and will be discussed in more detail in section 1.3 (Lockman et al., 2002; Schweer et al., 
2013).  
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1.2.2 Pathogenesis of enteric Yersinia infections 
Upon the ingestion of contaminated food or water, Yersinia passes through the stomach and 
reaches the gut compartment. In the intestine, primary infection takes place in the terminal 
ileum and proximal colon (Figure 1.5) (Robins-Browne et al., 1985; Skurnik and Poikonen, 
1986). There, yersiniae express invasin (1.2.1) and bind with high affinity to β1-integrins at the 
apical site of M cells (1.1.1) (Pepe, et al., 1994; Marra and Isberg, 1997; Clark et al., 1998; 
Schulte et al., 2000b). Invasin-binding further promotes β1-integrin clustering, which drives 
the formation of a phagocytic cup around Yersinia and its subsequent closure (zipper 
mechanism) (Cossart and Sansonetti, 2004). Moreover, yersiniae are able to re-invade the 
epithelial cell lining via basolaterally-expressed β1-integrins (Coconnier et al., 1994). Inside 
the M cell, the bacteria are transcytosed to the basolateral site and enter the underlying PP.  
 
Figure 1.5 Infection route of enteropathogenic Yersinia spp. 
After ingestion of contaminated nutrition, yersiniae pass through the stomach and reach the small intestine. In the 
ileum, they cross through the epithelial layer by exploiting M cells (microfold cells) that overlay the PP. After initial 
replication inside the PP, Yersinia is able to disseminate to the draining MLNs. Occasionally, highly virulent 
bacteria enter the blood stream and disseminate to systemic organs (e.g. liver and spleen). However, yersiniae are 
also able to directly disseminate from the gut to systemic organs. The picture is adapted from Azizi et al., 20104 and 
Sansonetti, 20025. 
The PPs home a large population of innate and especially adaptive immune cells, 
encompassing B- and T-lymphocytes, DCs and macrophages (Wershil and Furuta, 2008). 
Hence, yersiniae are instantly encountering innate immunity by resident and infiltrating 
phagocytes (Galindo et al., 2011). In order to defend against the phagocytic attack, Yersinia 
utilizes its TTSS to prevent phagocytosis and pro-inflammatory cytokine production (1.2.1; 
Lian et al., 1987). Thus, yersiniae are primarily extracellular pathogens that generate 
extracellular microcolonies within abscesses that seem to resist phagocytosis (Simonet et al., 
1990). Upon disease progression, Yersinia can disseminate to the draining MLNs. Some highly 
virulent Y. pseudotuberculosis and Y. enterocolitica strains even enter the blood stream and 
disseminate to systemic organs, i.e. liver and spleen (Figure 1.5) (Carter, 1975; Lian et al, 
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 Azizi et al. (2010) is licensed under the Creative Commons Attribution (CC BY 4.0) license. 
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5
 Adapted by permission from BMJ Publishing Group Ltd. [Host-pathogen interactions: the seduction of molecular cross talk, 
Sansonetti, 50, suppl 3: III2-8, copyright ©2002].  
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1987; Autenrieth and Firsching, 1996). However, a recent study revealed that yersiniae also 
directly disseminate from the small intestine to the MLNs and systemic organs by association 
to mononuclear phagocytes, i.e. CX3CR1
+
 monocyte-derived cells and CD103
+
 DCs 
(Figure 1.5) (Drechsler-Hake et al., 2016). 
1.2.3 Immune responses during Yersinia infection 
After traversal of the epithelium, yersiniae are challenged by extracellular immune elements 
that recognize the invader and initiate immune reactions. To prevent eradication, Yersinia spp. 
express a variety of virulence factors to antagonize host immunity (1.2.1). During invasion of 
Yersinia into the sub-epithelial tissue, the bacteria elicit the infiltration of PMNs, which attack 
the pathogen and are important for initial pathogen reduction (Hanski et al., 1989; Conlan, 
1997; Nuss et al., 2017). This attraction of phagocytic cells is mediated through binding of 
invasin to the β1-integrins at the basolateral site of intestinal epithelial cells, eventually leading 
to the expression of pro-inflammatory cytokines and chemokines, such as IL-8 (KC in mice), 
MCP-1, IL-1, GM-CSF and IL-18 (Schulte and Autenrieth, 1998; Kampik et al., 2000; Schulte 
et al., 2000a; Thinwa et al., 2014). However, yersiniae utilize their TTSS to counteract 
initiated cell autonomous immunity, pro-inflammatory cytokine production, as well as 
phagocytosis, and to induce apoptosis of naïve macrophages. Altogether, the activity of the 
TTSS prevents inflammation during initial colonization (1.2.1; Denecker et al., 2001; 
Grabenstein et al., 2004; Bergsbaken and Cookson, 2009; Moreau et al., 2010; Zhang et al., 
2011). This manipulation of phagocytic and antigen presenting cells also affects the 
development of acquired immunity by down-regulation of MHCII (Schoppet et al., 2000). 
However, the host immune system is still able to recognize Yersinia-derived PAMPs such as 
LPS, the TTSS and Yop effectors by diverse PRR (e.g. TLR), triggering immune cell 
activation and the production of pro-inflammatory mediators (Chung and Bliska, 2016). Upon 
progressing Yersinia infection, host cell death programs switch in activated macrophages from 
apoptosis to caspase-1-dependent pyroptosis (1.1.2), mediating amplification of inflammatory 
signaling (Bergsbaken and Cookson, 2007; Bergsbaken et al., 2009; Philip et al., 2014; Weng 
et al., 2014). Moreover, it was shown that acute Y. pseudotuberculosis infection triggers a 
strong neutrophil driven inflammatory immune response, acute-phase response induction, and 
the expression of coagultination cascade proteins as well as metal ion scavengers in the PP of 
the host (Nuss et al., 2017). Previous studies also demonstrated that pro-inflammatory 
cytokines such as IL-18, IL-12, TNFα and IFNγ or IFN consensus-sequence binding protein 
(ICSBP) confer protection against Yersinia colonization and that the development of T cell 
immunity limits Yersinia infection (Autenrieth et al., 1992; Autenrieth et al. 1994; Bohn and 
Autenrieth, 1996; Bohn et al., 1998; Hein et al., 2000). In particular TH1 and CTLs are 
controlling Yersinia infection, e.g. through production of cytokines that assist phagocyte-
mediated bacterial killing or by targeting and killing infected cells (Autenrieth et al., 1992; 
Autenrieth et al., 1993; Bohn and Autenrieth, 1996; Bergmann et al., 2009; Zhang et al., 2015; 
Shen et al., 2016). Recently, a transcriptome analysis of Y. pseudotuberculosis-infected PPs 
detected enriched expression of TH1 and TH17 cytokines, suggesting that acute Yersinia 
infection elicits a mixed TH1/TH17 immune response to control the infection (Nuss et al., 
2017).  
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1.3 Bacterial interference with the eukaryotic actin cytoskeleton  
The actin cytoskeleton is an integral part of eukaryotic cell function critical for proper cellular 
functions and life, thereby participating in a variety of eukaryotic cell processes that involve 
migration, cellular shape, adhesion, phagocytosis and polarity (Freeman and Grinstein, 2014; 
Callan-Jones and Voituriez, 2016). Consequently, bacteria have evolved mechanisms to 
manipulate actin functions in order to invade the host and evade immunity. 
1.3.1 The actin cytoskeleton and its regulation 
The actin cytoskeleton consists of filamentous (F)-actin formed by two chains of non-covalent 
polymerized globular (G)-actin that twist around each other (Dominguez and Holmes, 2011). 
Actin reorganizes constantly and cycles between G- and F-actin states. During the assembly of 
F-actin, G-actin slowly forms pivotal trimeric nuclei that are elongated through G-actin 
association to either end, resulting in the growth of the filament. The steady-state phase 
structure of F-actin is also dynamic, since G-actin associates and dissociates to equal extends at 
both ends of the filament. Moreover, F-actin possesses a kinetic polarity defined by distinct 
assembly and dissociation rates at the ends of the filament: At the (+)-end G-actin associates 
faster than at the (-)-end (Hild et al., 2010). Furthermore, diverse proteins participate in the 
regulation of F-actin nucleation, elongation, crosslinking and bundling (Lee and Dominguez, 
2010). One important class of actin cytoskeleton regulators is the small Ras-homologous (Rho) 
guanosine triphosphatases (GTPases) that are involved in numerous actin cytoskeleton 
dynamics (Heasman and Ridley, 2008). The small Rho GTPases are approximately 21-25 kDa, 
monomeric GTP-binding proteins that belong to the Ras superfamily and are classified into six 
subfamilies: Rho, Cdc42, Rac, Rnb, RhoBTB and RhoF (Wennerberg and Der, 2004; 
Wennerberg et al., 2005; Murali and Rajalingam, 2014). As other GTPases, Rho GTPases 
cycle between two conformational states: a GTP-bound active conformation and a GDP-bound 
inactive conformation (Figure 1.6A) (Bourne et al., 1991). 
 
Figure 1.6 Cycling of small Rho GTPases and their influence on actin cytoskeleton morphology. 
F-actin polymerization is controlled by small Rho GTPases. (A) The small GTPases cycle between a active (GTP-
bound) and a inactive (GDP-bound) state. The activities are tightly controlled by GAPs, GEFs and GDIs. GEFs 
exchange GDP to GTP, whereas GAPs antagonize GTPase activity by assisting GTP hydrolysis and, therefore, lead 
to their inactivation. GDIs sequester GTPases in the cytosol stabilizing their inactivity. (B) The activation of the 
small Rho GTPases RhoA, Rac1 and Cdc42 drives formation of different F-actin structures. RhoA activation 
preferentially induces stress fibers, Cdc42 mainly participates in the formation of filopodia and Rac1 drives 
lamellipodia growth. The microscopy pictures were derived from Bulgin et al., 20106.  
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In the active state, the small Rho GTPases are able to interact with proteins to target actin 
reorganization (Etienne-Manneville and Hall, 2002). As important key regulators of the actin 
cytoskeleton, three additional classes of proteins called guanine nucleotide exchange factors 
(GEFs), GTPase-activating proteins (GAPs) and guanine nucleotide dissociation inhibitors 
(GDIs) control Rho GTPase cycling between active and inactive conformation (Figure 1.6A). 
The GEFs release GDP from the small Rho GTPases and further GTP-loading in response to 
extracellular signals (Buchsbaum, 2007). Since small Rho GTPases harbor weak GTPase 
activity, GAPs mediate GTP hydrolysis to antagonize small Rho GTPase activation 
(Tcherkezian and Lamarche-Vane, 2007). Additionally, GDIs sequester small Rho GTPases in 
the cytosol maintaining their inactivity (Zegers and Friedl, 2013). The best-studied Rho 
GTPases are RhoA, Rac1 and Cdc42, which are important regulators of cellular migration and 
polarization. Upon activation, RhoA mainly participates in the formation of stress fibers; Rac1 
drives lamellipodia growth and Cdc42 the development of filopodia (Figure 1.6B) (Nobes and 
Hall, 1995). Stress fibers are formed by large bundles of F-actin that are anchored at least at 
one end by a focal adhesion complex and extend through most of the cell body (Figure 1.6B). 
They participate mostly in cell migration and cellular tension (Pellegrin and Mellor, 2007; 
Burridge and Wittchen, 2013; Burridge and Guilluy, 2016). The lamellipodia are plane 
protrusions of the plasma membrane formed by short, branched F-actin filaments 
(Figure 1.6B). They are the main drivers of directed cell migration (Akhshi et al., 2014; 
Alblazi and Siar, 2015). The third cellular structures, called filopodia, are fine protrusions of 
the cell surface formed by bundled, linear-polymerized F-actin (Figure 1.6B). Along these F-
actin bundles numerous proteins are transported to the tip of the filopodium. The filopodia 
participate in the sensing of environmental cues, cell migration, cell-to-cell adhesion, and 
dendritic spine formation (Jacquemet et al., 2015; Mattila and Lappalainen, 2008). 
1.3.2 Manipulation of small Rho-GTPases – bacterial virulence strategies 
The eukaryotic actin cytoskeleton is involved in universal cell functions, thereby also 
contributing to immunity. It participates in processes such as the maintenance of 
epithelial/endothelial barriers, immune cell migration, phagocytosis, immunological synapse 
formation and immune signaling (Bokoch, 2005; Mostowy and Shenoy, 2015). Therefore, it is 
an ideal target for pathogens to evade immunity, facilitate dissemination, and establish 
infection. The pathogenic bacteria have evolved a large repertoire of virulence factors that 
manipulate actin cytoskeleton dynamics (Popoff, 2014). These virulence factors are either 
secreted into the environment (toxins) or directly injected into host cells (effectors), e.g. via 
TTSS. Toxins are known to diffuse into the surrounding tissue causing tissue destruction, 
which fosters bacterial growth and dissemination, whereas injected effectors rather function to 
evade immune defenses (Boquet and Lemichez, 2003). Most actin manipulating bacterial 
toxins/ effectors target small Rho GTPases (Lemichez and Aktories, 2013). Some virulence 
factors such as SopE of Salmonella enterica serovar Typhimurium and the WxxxE effector 
family mimic GEFs (e.g. Map from Escherichia coli, IpgB1/2 from Shigella flexineri and 
SifA/B from S. Typhimurium) or inhibit GAP binding (e.g. DrrA from Legionella 
pneumophila), resulting in GTPase activation (Hardt et al., 1998; Ohya et al., 2005; Alto et al., 
2006; Huang et al., 2008; Ohlson et al., 2008; Schoebel et al., 2009; Klink et al., 2010). There 
are also GAP-like bacterial virulence factors, i.e. YopE (Y. pseudotuberculosis), ExoS/T 
(Pseudomonas aeruginosa) or AexT (Aeromonas salmonicida) that inactivate the small 
GTPases (Goehring et al., 1999; Krall et al., 2000; von Pawel-Rammingen et al., 2000; Fehr et 
al., 2007; Mohammadi and Isberg, 2009). Bacterial virulence factors are also able to covalently 
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modify small Rho GTPases leading either to their inactivation or activation. Accordingly, Rho 
GTPases are activated through ADP-ribosylation by Ctx (Vibrio cholera) or deamidation by 
Pmt (Pasteurella multocida), while they are inactivated via ADP-ribosylation by C3 from 
Clostridium botulinum, glycosylation by TcsL from Clostridium sordellii or adenylation by 
VopS from Vibrio paraheamolyticus (Cassel et al., 1978; Aktories et al., 1987; Rubin et al., 
1988; Just et al., 1996; Popoff et al., 1996; Orth et al., 2009; Yarbrough et al., 2009). The 
activation or inactivation of Rho GTPases influences different cellular functions. TcdA/B of 
Clostridium difficile enhances epithelial barrier permeability by disruption of tight and 
adherens junctions (Hecht et al., 1988; Nusrat et al., 2001). CyaA (Bacillus pertussis) and 
edema toxin (Bacillus anthracis) increase the endothelial cell permeability, resulting in edema 
formation and bacterial dissemination from the intestinal tract (Maddugoda et al., 2011; 
Gonzalez-Rodriguez et al., 2012). Moreover, invasive bacteria manipulate the Rho GTPases to 
enter cells, e.g. SopE from Salmonella mediates membrane ruffling in epithelial cells for 
subsequent uptake (Patel and Galán, 2005). Some pathogens evolved effectors to block 
phagocytosis by innate immune cells to prevent killing, for instance ExoT from P. aeruginosa 
is crucial to counteract Rac-mediated phagocytosis (Barbieri and Sun, 2004). 
Yersinia also encodes for several Rho-GTPase activity modifying effectors, i.e. YopT, YopE 
and YpkA (1.2.1). In addition, two Y. pseudotuberculosis serogroup O:3 strains also produce 
the CNF toxin that modifies small Rho GTPases (1.3.3). 
1.3.3 The cytotoxic necrotizing factor toxin - CNF 
The first CNF toxin was discovered in E. coli isolated from stool samples of acute enteric 
infections (CNF1, Caprioli et al., 1983). However, CNF-positive E. coli are more prevalent in 
extraintestinal infections, especially in bladder infections (Johnson, 1991; de Rycke et al., 
1999). To date, four CNF isoforms (CNF1-3 from E. coli; CNFY from Y. pseudotuberculosis) 
have been identified, of which CNF1 is the best studied (Oswald et al., 1989; Lockman et al., 
2002; Orden et al., 2007). In Y. pseudotuberculosis, two sequenced and characterized strains 
from serotype O:3, i.e. YPIII and IP2666, encode the functional protein. Other 
Y. pseudotuberculosis strains and Y. pestis were found to encode truncated forms of the CNF 
toxin (Lockman et al., 2002).  
All CNFs covalently modify small Rho GTPases at glutamine-61/63 by deamidation to 
glutamate (Schmidt et al., 1997; Flatau et al., 1997; Lerm et al., 1999). Due to the constitutive 
activation, intoxication with CNF induces several F-actin rearrangements in eukaryotic cells 
including cell flattening, inhibition of cytokinesis resulting in multinucleated cells, membrane 
ruffling, stress fiber and filopodia formation (Fiorentini et al., 1988; Fiorentini et al., 1997; 
Knust et al., 2009). Additionally, epithelial cells develop atypical phagocytic behavior and 
internalize bacteria (Falzano et al., 1993). 
All CNFs are single chain AB-toxins of identical length (1014 amino acids) and are predicted 
to have a modular structure: they consist of an N-terminal binding domain, a central 
translocation domain and a C-terminal catalytic domain (Lemichez et al., 1997; Falnes and 
Sandvig, 2000; Pei et al., 2001). Binding studies revealed that CNF1 requires interaction with 
the laminin receptor and the Lutheran (Lu) adhesion glycoprotein/basal cell adhesion molecule 
(BCAM) (Lu/BCAM) receptor for toxin action (Kim et al., 2005; Piteau et al., 2014). 
Moreover, it was demonstrated that CNF1 and CNFY toxins interact with heperansulfate 
proteoglycan (HSPG). Although HSPG was crucial for CNFY cellular access, CNF1 displayed 
delayed cell entry, proposing HSPG as part of a receptor complex for CNF1 (Figure 1.7;  
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Figure 1.7 Eukaryotic uptake mechanism of CNF. 
After receptor binding of the putative N-terminal binding domain of CNF (1), CNF is internalized by receptor-
mediated endocytosis (2). Subsequently, the endosomal compartment gets acidified and the central translocation 
domain inserts into the endosomal membrane exposing the predicted C-terminal catalytic domain of CNF into the 
cytosol (3 & 4). The putative catalytic domain is released into the cytosol through cleavage by endosomal-located 
serine proteases (5). The picture is adapted from Knust and Schmidt, 20107. 
step 1) (Blumenthal et al., 2007). After receptor binding, CNFs are taken up by receptor-
mediated endocytosis. In the acidified endosome, the central translocation domain inserts into 
the endosomal membrane transferring the C-terminal catalytic domain into the cytosol. This 
acidification step is crucial for cytosolic access of the CNF toxin (Figure 1.7; step 2-4) 
(Contamin et al., 2000; Pei et al., 2001; Blumenthal et al., 2007). For full biological activity, 
the C-terminal domain of CNF(1) is released into the cytosol by serine protease-dependent 
unspecific proteolytic cleavage in the endosome (Figure 1.7; step 5) (Knust et al., 2009). Since 
CNF lacks classical secretion signals, the secretion mechanism of CNF from bacteria into the 
environment is quite understudied. For E. coli it was found that CNF1 is secreted into the 
environment by outer membrane vesicles (OMVs) (Davis, 2006; Kouokam et al., 2006). Two 
other studies showed that ferredoxin contributes to the translocation across the bacterial inner 
membrane and YgfZ to the secretion into the OMVs (Yu and Kim, 2010; Yu and Kim, 2012). 
However, the full secretion mechanism remains unknown. Whether CNFY secretion from 
Y. pseudotuberculosis is also conducted by OMVs remains unclear, as OMV production was 
only demonstrated for Y. pestis yet (Eddy et al., 2014). 
In the past decade, the knowledge about the action of CNF in pathogenesis was expanded. 
Nevertheless, the impact of CNF1 from E. coli on immune cells, signaling and pathogenesis is 
much better understood than for Y. pseudotuberculosis CNFY. Several studies showed that the 
production of CNF1 increases inflammation in different infection models (Rippere-Lampe et 
al., 2001a; Rippere-Lampe et al., 2001b; Smith et al., 2015). A study by Schweer and 
colleagues on in vivo effects of CNFY revealed that CNFY also increased inflammation and 
tissue damage (Schweer et al., 2013). Moreover, production of CNF assisted bacterial 
colonization abilities during urinary tract and intestinal infections, respectively (Rippere-
Lampe et al., 2001b; Schweer et al., 2013). CNFY was also shown to increase the translocation 
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of Yop effectors in vitro and in vivo, which is crucial for Y. pseudotuberculosis YPIII virulence 
and pathogenesis (Schweer et al., 2013; Wolters et al., 2013). Further work on CNF1 
suggested, that it might participate in colon cancer development and contributes to E. coli-
caused meningitis by facilitating blood-brain barrier traversal (Khan et al., 2002; Wang and 
Kim, 2013; Raisch et al., 2014). In several publications, CNF1 and CNFY were also shown to 
promote destabilization of epithelial and endothelial barriers via activation of Rho-GTPases. 
However, contradicting results were obtained using different cell lines and incubation periods 
(Hopkins et al., 2003; Baumer et al., 2008; Schlegel et al., 2011). In addition, CNF1 was 
reported to affect immune cell functions of natural killer (NK) cells, DCs and neutrophils. In 
NK cells and DCs, characteristic immune functions were enhanced, whereas neutrophils were 
modulated in their actions (Hofman et al., 2000; Malorni et al., 2003; Davis et al., 2005; 
Shurin et al., 2005; Davis et al., 2006). In addition, the host is able to sense activation of small 
Rho GTPases and consequently induces pro-inflammatory responses (Müller et al., 2010; 
Keestra et al., 2013). For instance CNF1 was reported to trigger pro-inflammatory cytokine 
production and induce defense mechanisms (Falzano et al., 2003; Boyer et al., 2011; 
Reipschläger et al., 2012; Diabate et al., 2015). 
1.4 Persisting bacterial infections - reservoirs and risks for disease 
Individuals experience numerous bacterial and viral infections during their lifetime. Most of 
the time, acute infections are self-limited by the intervention of innate and adaptive immunity 
leading to pathogen clearance and restoration of tissue homeostasis. Nevertheless, resolution of 
acute infections requires initial disruption of tissue homeostasis. This might provoke long-
lasting consequences by promoting immune dysfunction and altered tissue homeostasis. There 
is evidence that acute bacterial infections might initiate inflammatory diseases such as 
rheumatic heart disease, multiple sclerosis, Alzheimer’s disease and type II diabetes 
(Wucherpfennig, 2001; Karin et al., 2006; Medzhitov, 2010; Miklossy and McGeer, 2016). 
Moreover, some pathogens are able to establish prolonged infections. The most prominent 
historical case of persistent bacterial infection was Mary Mallon, called “Typhoid Mary”, who 
was an asymptomatic carrier of S. enterica serovar Typhi. During her lifetime, she caused 
several outbreaks and deaths by transmitting S. Typhi via the fecal-oral route (Marineli et al., 
2013). Up to date, there are several known examples of human persistent bacterial infections 
including Mycobacterium tuberculosis, S. Typhi, Brucella spp., uropathogenic E. coli (UPEC), 
Chlamydia spp. or Helicobacter pylori (Monack et al., 2004b). Most persistent infections are 
asymptomatic but imply potential risks for the host leading to reactivation/recurrent infections 
(M. tuberculosis; UPEC) or severe diseases such as gastric cancer (H. pylori), mucosa-
associated lymphoid tissue lymphomas (Campylobacter jejuni) or gall bladder cancer 
(S. Typhi) (Shukla et al., 2000; Peek and Blaser, 2002; Stewart et al., 2003; Guidoboni et al., 
2006; Scott et al., 2015). Additionally, treatment of persistent bacterial infections is quite 
challenging since it requires prolonged administration of antimicrobials. Treatment of latent 
M. tuberculosis infection requires at least six month of antibiotic treatment, whereas latent 
syphilis demands a tremendous antibiotic treatment over 24 month (Brown and Frank, 2003; 
Munro et al., 2007). These extensive treatment periods are thought to be due to the protected 
bacterial habitat in the host and/or changed bacterial metabolic states that allow antibiotic 
tolerance without genotypic resistance. This protection is achieved by intracellular localization 
(e.g. UPEC, S. Typhi), formation of metabolically altered small colony variants 
(P. aeruginosa, Staphylococcus aureus), initiation of bacterial stringent responses due to 
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Figure 1.8 Genotypic determinants that distinguish commensals, and pathogens causing 
symptomatic or asymptomatic infections. 
Commensal bacteria co-exist with their human host without causing any harm. They are usually not invasive and 
hardly induce host immune responses. Pathogens causing symptomatic disease harbor several virulence factors that 
are encoded on virulence plasmids, on the genome or on pathogenic islands. Acute infections with these pathogens 
cause a strong induction of host innate and adaptive immune responses. However, loss of virulence genes, genomic 
diversity and altered gene expression drives the emergence of less virulent pathogens that are adapted to 
asymptomatically persist in their host and provoke scarce host immunity. The picture is modified from Dobrindt et 
al., 20108. 
environmental stresses (M. tuberculosis), or formation of biofilms (P. aeruginosa) (Schmidt-
Grant and Hung, 2013; Cohen et al., 2013). Besides the health risks for the host, asymptomatic 
carriers are a public concern since they are reservoirs for spreading disease in a population, as 
in the case of “Typhoid Mary” (Young et al., 2008). Thus, commensal bacteria of the normal 
microbial community should be distinguished from pathogens that elicit persistent infections. 
A commensal bacterium harbors limited abilities to invade host tissues and does not harm its 
host compared to a pathogen that causes acute or persistent infection. In comparison to 
pathogens causing acute disease, bacteria that are able to persist asymptomatically were proven 
to exhibit altered gene expression and loss of virulence genes. This process, called micro-
evolution, represents an adaptation mechanism to establish persistency and avoid induction of 
host immunity (Figure 1.8) (Oh et al., 2006; Dobrindt et al., 2010). However, some members 
of an individual’s microbial community can also acquire context-dependent pathogenicity, by 
attainment of new virulence factors, outgrowth in immune-compromised patients 
(pathobionts), populating new niches, or shifts in the relative abundances in the microbial 
community (dysbiosis). These asymptomatical “context-dependent” pathogens only cause 
disease in a certain situation and are not considered as a persistent bacterial infection (Buttó et 
al., 2015; Nathan, 2015). 
Currently, scientists hypothesize that an individual’s immunity allows bacterial persistence 
through a complex balance between protective immune responses and pathologic consequences 
(Figure 1.9). In other words, the infected host will dim the immune response when it becomes 
more destructive than persistence of the pathogen. This is a vicious cycle, as down-regulation 
of protective immunity will decrease pathology but enhance pathogen persistence. Moreover, 
low virulence and bacterial persistence factors might potentiate pathogen persistence and  
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Figure 1.9 Balance of protective immunity and pathologic consequences during bacterial 
persistence. 
Hypothetically, bacterial persistence is mediated by a complex balance between protective immune responses and 
pathological consequences. If protective immunity induces more damage than the pathogen itself, immune 
responses are limited through immune response modulation, for instance by regulatory T cells. Furthermore, 
persistent pathogens encode persistence factors that might cause limited inflammation and tissue disruption that 
restrict pathological consequences, facilitating bacterial survival and persistence. Persistent bacteria might also 
directly or indirectly affect regulatory T cells to their benefit. The figure is adapted from Monack et al., 2004b9. 
survival by means of low immunity induction and limited tissue injury (Figure 1.9). In this 
setting, regulatory T cells are of reasonable importance, since they are involved in limiting 
collateral tissue damage. They are either activated in consequence of host immune responses to 
restore tissue homeostasis and/or via (in-)direct stimulation by pathogens promoting prolonged 
infection. (Figure 1.9) (Monack et al., 2004b; Belkaid, 2007). 
1.4.1 Persistence of Salmonella, Helicobacter and UPEC 
As previously mentioned, there are a couple of recognized persistent bacterial infections in 
humans (1.4). In the following section, three examples will be discussed in more detail, i.e. 
S. enterica, H. pylori and UPEC. 
S. enterica persistence 
S. Typhi and S. Typhimurium infections in humans are leading to illnesses ranging from 
gastroenteritis to systemic infection (Monack et al., 2004b). In humans, systemic (typhoid 
fever) and persistent Salmonella infection mostly originates from infections with S. Typhi 
(Parry et al., 2002). In contrast, S. Typhimurium causes predominantly gastrointestinal disease 
in humans. However, murine S. Typhimurium infections resemble human infections with S. 
Typhi. Therefore, murine S. Typhimurium infections are employed to study Salmonella 
persistent infections (Monack et al., 2004a).  
Salmonella infects individuals via the gastrointestinal tract by ingestion of contaminated food 
products. From there, they are able to disseminate to the underlying and deeper tissues 
employing multiple mechanisms (Kohbata et al, 1986; Jones et al., 1994; Vazquez-Torres et 
al., 1999). After an acute Salmonella infection, about 1-6 % of typhoid fever patients are 
persistently infected with Salmonella inside the gall bladder or bone marrow (Levine et al., 
1982; Sinnott and Teall, 1987; Wain et al., 2001). Through the excretion of Salmonella 
containing bile from the gall bladder, bacteria are transferred into the gastrointestinal tract and 
                                                     
9
 Adapted by permission from Macmillan Publishers Ltd: Nature Reviews Microbiology, Monack et al., 2004b, copyright ©2004. 
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urine. Some people are egesting large amounts of Salmonella, which possibly lasts for one year 
or even the whole lifetime without the development of recurrent disease. These so-called 
super-shedders, such as “Typhoid Mary”, frequently transfer Salmonella to other people 
(Vogelsang and Boe, 1948; Lawley et al., 2008). Knowledge about persistence mechanisms in 
humans is limited, but IL-22/IFNγ production and effective immune response mounting are 
crucial for reservoir clearance and prevention of prolonged Salmonella infection (Mastroeni 
and Ménager, 2003; Thompson et al., 2009; Dougan et al., 2011). Moreover, S. Typhi is able 
to generate biofilms on the surface of gallstones, potentially facilitating persistence and 
transmission (Crawford et al., 2008; Crawford et al., 2010). 
In the murine persistent Salmonella infection model, S. Typhimurium persists inside 
macrophages. Therefore, survival and replication ability inside macrophages may support the 
establishment of persistence (Helaine et al., 2010). One study on S. Typhimurium persistence 
demonstrated that the TTSS effector SseI facilitates systemic long-term infection by altering 
phagocyte migration, thereby impairing the development of adaptive immunity. Yet, S. Typhi 
does not encode SseI (McLaughlin et al., 2009). Regulatory T cells have also been implicated 
in controlling the onset of persistent Salmonella infection in the mouse model. In one particular 
study, regulatory T cell activities were shown to reduce effector T cell responses during the 
first phase of persistent infection allowing the increase of bacterial loads (Johanns et al., 2010). 
H. pylori persistence 
H. pylori is the best-studied human pathogen that effectively manifests persistent infection in 
about 50 % of the world’s population (Calvet et al., 2013). It is orally transmitted during the 
early childhood and thereafter able to persist for decades in the gastric mucosa. About 80 to 
90 % of infected people with chronic gastritis never develop symptomatic disease but the 
infection comprises a major risk to acquire more severe diseases such as gastric cancer, 
mucosa-associated lymphoid tissue lymphoma or ischemic heart disease (Hunt, 1996; Amieva 
and El-Omar, 2008; Franceschi et al., 2013). 
Initial colonization of H. pylori in the stomach is facilitated by a bacterial urease that confers 
acid resistance (Mobley et al., 1995; Weeks et al., 2000). After that, H. pylori chemotaxis 
permits directional movement through the mucus to the gastric epithelium (Ottemann et al., 
2002; Croxen et al., 2006). At the epithelial lining, H. pylori persist either free-swimming in 
the mucus or directly adherent at the epithelium (Hessey et al., 1990; Ilver et al., 1998; 
Mahdavi et al., 2002). The cytotoxin-associated gene A (CagA) and vacuolating cytotoxin A 
(VacA) are important epithelial colonizing factors, supporting growth in microcolonies and 
iron acquisition (Tan et al., 2009; Tan et al., 2011). Besides the colonization strategies, 
H. pylori employs several immune evasion strategies to circumvent the activation of host 
immune responses and to establish persistence. To this purpose, H. pylori modifies its surface 
antigens, e.g. LPS or flagellin, to avoid PAMP recognition (Gewirtz et al., 2004; Moran, 
2007). The activation of the inflammasome by recognition of H. pylori drives also the 
induction of Tregs that limit effector T cell activation and consequently enhances prolonged 
infection (Tomita et al., 2001; Hitzler et al., 2012; Oertli et al., 2012). TH1 and TH17 
differentiated effector cells are essential to control H. pylori infection (Akhiani et al., 2002; 
Sayi et al., 2009; Velin et al., 2009). Hence, H. pylori evolved mechanisms to block T cell 
proliferation and to enhance Treg differentiation via programming of tolerogenic DCs (Gebert 
et al., 2003; Sundrud et al., 2004; Gerhard et al., 2005; Schmees et al., 2007; Kao et al., 2010; 
Zhang et al., 2010; Oertli et al., 2012).  
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UPEC persistence 
About every third woman will experience a urinary tract infection (UTI) during her lifetime. 
Therefore, bacterial urinary tract infections are amongst the most prevalent infectious diseases 
with high recurrence risks (Foxman, 2003; Mehnert-Kay, 2005). The most collective source of 
cystitis is UPEC infection (Ronald, 2002). In order to establish an infection, UPEC has to 
ascent the urethra against the stream and adhere with its mannose-binding type I pili (FimH) to 
the urothelium to resist eradication via urination (Bahrani-Mougeot et al., 2002; Thomas et al., 
2002). These pili also mediate invasion of the bacteria into superficial umbrella cells within the 
urothelium by the zippering mechanism (Martinez et al., 2000; Martinez and Hultgren, 2002). 
Inside the urothelial cells, UPEC persists inside secretory lysosome-like vesicles that can only 
be exocytosed via a TLR-4-dependent mechanism (Mulvey et al., 2001; Song et al., 2009). 
However, UPEC is able to disrupt the secretory lysosome-like compartments and replicates 
inside the cytosol creating bacterial biofilm-like aggregates, termed intracellular bacterial 
communities (IBCs). Due to the cellular turnover at barrier surfaces, maturating, smaller cells 
replace mature umbrella cells. These maturing cells are not supporting the formation of large 
IBCs, possibly restricting the infection extent (Anderson et al., 2003; Justice et al., 2004). Still, 
UPEC is able to exit the urothelium into the urine, facilitating bacterial spread and 
dissemination to other urothelial cells. The formation of IBC-like quiescent intracellular 
reservoirs at later infection stages supports the development of persistent UPEC infection 
(Justice et al., 2004; Scott et al., 2015).  
TLR-4 and TLR-5 signaling pathways were shown to protect against acute UPEC infection 
(Andersen-Nissen et al., 2007; Song et al., 2007). Controversially, defective TLR-4 signaling 
and immunodeficiency were found to decrease the development of chronic cystitis. In line with 
this, Hannan and colleagues demonstrated that severe inflammation supports acquisition of 
chronic cystitis in women (Hawn et al., 2009; Hannan et al., 2010; Hannan et al., 2012). As in 
other bacterial infections, T cells were found to be associated with UPEC clearance (Hopkins 
et al., 1993; Jones-Carson et al., 1999). However, this research area needs to be further 
extended. 
1.4.2 Yersinia persistence 
Y. enterocolitica and Y. pseudotuberculosis are known to elicit acute and self-limiting 
gastrointestinal diseases in immunocompetent individuals (1.2). However, Yersinia persistence 
or incomplete elimination is frequently discussed to be interrelated with the development of 
reactive arthritis (Granfors et al., 1998; Cargnelutti and Di Genaro, 2013). Case reports of 
persistent Yersinia infections that resulted in inflammatory complications and reactivation of 
disease are supporting this hypothesis (Gaston et al., 1999; Watson et al., 2013). An interesting 
study by Hoogkamp-Korstanje and co-workers showed persistent Yersinia infections in human 
tissue biopsies from the intestine (i.e. the colon) and lymph nodes. These persistent Yersinia 
infections were also linked to recurrent and chronic inflammatory diseases (i.e. chronic ileitis, 
arthritis, lymphadenopathy, hepatosplenomegaly and hepatitis) (Hoogkamp-Korstanje et al., 
1988). Furthermore, enteropathogenic yersiniae have also been isolated from pig and rodent 
reservoirs implicating their ability to persist in these animals (Mair et al., 1979; Fredriksson-
Ahomaa et al., 2006; Backhans et al., 2011). This is reinforced by a study demonstrating 
Yersinia persistence in three rat strains after intra-venous challenge (Curfs et al., 1995). More 
recently, Fahlgren and colleagues demonstrated that yersiniae are able to persist in the cecum 
of mice after oral challenge with sub-lethal infection doses of Y. pseudotuberculosis YPIII for 
 
INTRODUCTION 
23 
 
 
Figure 1.10 Model of Yersinia persistency development via transcriptional reprogramming. 
To facilitate initial infection Yersinia is flagellated and expresses virulence genes (e.g. adhesins and the TTSS). 
During acute infection (2 dpi), bacteria become non-flagellated and strongly express the TTSS to defend against 
resident and attracted phagocytes, for instance PMNs. During persistent phase (42 dpi), Y. pseudotuberculosis 
becomes re-flagellated, down-regulates virulence gene expression and induces stress responses gene expression. The 
figure is derived from Avican et al., 201510. p.i. post infection. 
up to 115 days post infection (dpi) (Fahlgren et al., 2014). In the cecum of the FVB/N mice, 
Y. pseudotuberculosis primarily colonized the lymphoid tissue and resided in bacterial 
microcolonies or as single cells inside inflamed neutrophil containing tissue lesions (Fahlgren 
et al., 2014). Moreover, the persistently colonized mice continuously shed the Yersinia into the 
environment (Fahlgren et al., 2014). In a follow-up study by the same group, it was shown that 
persistent yersiniae are able to reprogram their gene expression profile from acute to persistent 
infection. Upon acute infection, Y. pseudotuberculosis expressed important virulence genes 
and regulators, such as yopM, yopJ, ail and lcrF, whereas these were down-regulated during 
persistence (Figure 1.10). Moreover, genes involved in environmental stress adaption and 
motility, such as arcA, fliC, napA, frdA, rfaH, sodB, wrbA, hdeB, cspC and uspA, were induced 
in the persistent state compared to acute infection (Figure 1.10) (Avican et al., 2015). The 
Y. pseudotuberculosis transcriptional reprogramming from acute to persistent infection stage 
also caused the up-regulation of crp, csrA, and rovA (Figure 1.10) (Avican et al., 2015). The 
increased expression of theses regulators was also interconnected with the up-regulation of 
their respective regulons during Yersinia persistence (Avican et al., 2015).  
The reduction of virulence and adaptation to environmental stresses by adjusting the gene 
expression profile is a known mechanism of persistent bacteria (1.4). Still, nothing is known 
about host factors and mechanisms that contribute to the development of persistent Yersinia 
infections. 
                                                     
10
 Avican et al. (2015) is licensed under the Creative Commons Attribution 4.0 (CC BY 4.0) license. 
https://creativecommons.org/licenses/by/4.0/ 
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1.5 Aim of the study 
Yersinia persistence after acute gastro-intestinal infection in humans has long been suggested 
to trigger secondary disease (Hoogkamp-Korstanje et al., 1988; Granfors et al., 1998; Gaston 
et al., 1999). However, a suitable murine infection model to study the mechanisms of Yersinia 
pathogenesis during persistent infections was not available until recently (Fahlgren et al., 
2014). The establishment of such a model enabled the identification of Yop effectors necessary 
to establish persistent Yersinia infection (Fahlgren et al., 2014). Interestingly, down-regulation 
of TTSS expression seems important for persistent Yersinia infection (Avican et al., 2015), but 
in-depth knowledge about the host-pathogen interactions and the influence of further virulence 
factors during the switch from acute to persistent Yersinia infection is currently lacking. 
Previous work of Schweer and co-workers proposed that modulation of the Yop effector 
delivery by CNFY might dictate the competence to long-term colonize the gut of BALB/c mice 
(Schweer et al., 2013).  
Given these premises, this study aims at dissecting the complex CNFY-dependent host-
pathogen relationship during acute and chronic Yersinia infection. To address this, the 
influence of CNFY on the ability to persist and the course of persistent infection in BALB/c 
mice are investigated. In order to characterize CNFY-dependent pathogenic mechanisms during 
acute and persistent infection, tissue architecture, bacterial colonization patterns and cytokine 
production are examined. Moreover, the consequences of CNFY-dependent inflammation on 
the microbial community composition are analyzed. In order to obtain knowledge of the 
molecular mechanisms of the host-pathogen interactions, the main target of this study is to 
identify CNFY-dependent host and pathogenic factors that affect development of CNFY-
dependent persistence. To this purpose, the host transcriptome during acute and persistent 
infection and the expression of important Yersinia virulence and persistence genes are profiled. 
As little is known about the effect of decreased Yop translocation on Yop-targeted immune 
signaling pathways during acute in vivo infection, the impact of CNFY on the inflammasome 
network during oral infection of C57BL/6N mice is investigated. At first, CNFY-dependent 
virulence, organ colonization, tissue architecture, immune and cytokine responses in 
C57BL/6N mice are explored. Thereafter, the impact of the inflammasome and downstream 
cytokine signals on organ colonization and dissemination are elucidated. 
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2 Material and methods 
2.1 Material 
2.1.1 Equipment and material 
Equipment and materials were purchased from the following manufacturers: Amersham, BD 
Biosciences, BD Falcon, Beckmann Coulter, Biolegend, BioRad, BioChrom, Biometra, Brand, 
Braun, CytoOne, Eppendorf, GE Healthcare, Greiner bio-one, Heidolph, Heraeus, Infors, 
Kinematika, Millipore, Microflex Corporation, PeqLab, QIAGEN, Roth, Sarstedt, Sartorius, 
Schott, Scientific Industries, Sorvall, Starlab, TEMCA, Thermo Fisher Scientific, TPP, VWR 
International, WLD-TEC, WU Mainz and Zeiss if not mentioned otherwise. 
2.1.2 Buffers and solutions 
Chemicals used for the buffers and solutions were obtained from the following companies: 
Ambion, Applichem, BD Biosciences, Biolegend, Bioline, eBioscience, Fermentas, Fisher 
Scientific, Fluka, GIBCO, Hartmann Analytic, Invitrogen, Illumina, Merck, Metabion, New 
England Biolabs (NEB), Oxoid, PeqLab, Promega, QIAGEN, Roche, Roth, Sigma Aldrich, 
T.H. Geyer, VWR, and Zeiss. 
The composition of the used buffers and solutions is shown in Table 2.1. 
Table 2.1 Composition of buffers and solutions 
Buffer/solution Composition 
ACK buffer 150 mM NH4Cl, 10 mM KHCO3, 1 mM EDTA, pH 7.4 
2x Buffer A 200 mM NaCl, 200 mM Tris, 20 mM EDTA, pH 8 
2x Buffer A with SDS 500 µl 2x buffer A, 200 µl 20 % SDS (w/v) 
NP-40 buffer 150 mM NaCl, 50 mM Tris-HCl (pH 8.0), 1 % NP-40 
10x PBS 80 g/l NaCl, 2 g/l KCl, 6.1 g/l Na2HPO4, 2 g/l KH2PO4, pH 7.3 
PBS/BSA 0.2 % (w/v) BSA in 1x PBS 
PMSF 100 mM in isopropyl alcohol 
RNA loading buffer 9.5 ml formamide, 360 µl 0.5 M EDTA (pH 8.0), 10 µl 20 % SDS, 
xylen cyanol and bromphenol blue 
10x TBE 900 mM Tris-HCl, 900 mM boric acid, 25 mM EDTA, pH 8.0 
TE 10 mM Tris-HCl, 1 mM EDTA, pH 7.5 
50x TAE 2 M Tris, 100 mM EDTA, pH 8.0 
Solution D 4 M guanidinium thiocyanate, 25 mM sodium citrate, 0.5 % N-
laurosylsarcosine (w/v), 0.1 M β-mercaptoethanol 
TFBI 20 mM KAc, 10 mM CaCl2, 50 mM MnCl2, 100 mM RbCl2, 15 % 
glycerol, pH 5.8 
TFBII 10 mM PIPES, 75 mM CaCl2, 10 mM RbCl, 15 % glycerol, pH 6.5 
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2.1.3 Media and antibiotics 
All media were prepared with distilled water (dist. water). Media employed for this study and 
their compositions are listed in Table 2.2.  
Table 2.2 Media composition 
Medium Composition 
BHI (brain-heart infusion) broth 37 g/l BHI 
LB (Luria Bertani) broth 5 g/l NaCl, 5 g/l yeast extract, 10 g/l tryptone 
LB solid medium LB broth, 18 g/l agar 
SOC (super optimal broth) medium 20 g/l tryptone, 5 g/l yeast extract, 0.5 g/l NaCl, 
2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4, 0.2 % 
glucose 
Yersinia selective medium Yersinia selective agar base with Yersinia selective 
supplement (Oxoid) 
To specifically select for resistant bacteria, antibiotics were added to the media (Table 2.3). 
Table 2.3 Final concentrations of antibiotics 
Antibiotic Final concentration 
Carbenicillin 100 µg/ml 
Irgasan 0.5 µg/ml 
Kanamycin 50 µg/ml 
2.1.4 Enzymes, antibodies and commercial kits 
Enzymes used in this study were applied with their respective buffers provided by the 
manufacturer and are listed in Table 2.4. 
Table 2.4 Enzymes 
Enzyme  Reference source 
DNA-Polymerases 
MangoTaq
TM
 DNA polymerase Bioline 
Phusion® High-Fidelity DNA Polymerase NEB 
Digesting enzymes 
AvrII NEB 
NotI-HF NEB 
SacI NEB 
TURBO
TM
 DNase Ambion 
XhoI NEB 
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Enzyme  Reference source 
Others 
Antarctic Phosphatase NEB 
T4 DNA Ligase NEB 
Antibodies, their respective clones and the reference source are given in Table 2.5. The 
dilution for the antibody staining was titrated before the experiments as described in 2.6.2. 
Table 2.5 Antibodies for flow cytometry 
Antibody 
Working 
concentration* 
Reference 
source 
CD16/CD32 (Fcγ III/II Receptor) 1:100 BD Biosciences 
CD3 v450 rat anti-mouse 1:100 BD Biosciences 
CD19 FITC anti-mouse 1:200 BioLegend 
NKp46 APC anti-mouse (CD335) 1:400 BioLegend 
CD11b eFluor® 450 human, mouse (M1/70) 1:800 eBioscience 
CD11c APC-eFluor® 780 anti-mouse (N418) 1:1000 eBioscience 
Ly6G PE-Cy
TM
7 rat-mouse 1:500 BD Biosciences 
Ly6C, Lymphocyte antigen 6 complex, locus C 1:1000 BioLegend 
F4/80 PE mouse (BM8) 1:100 eBioscience 
Streptavidin-Fluorescein Isothiocyanate (SA-FITC) 1:500 BD Biosciences 
CD3e Biotin hamster anti-mouse 1:100 BD Biosciences 
CD19 Biotin anti-mouse  1:100 eBioscience 
NKp46 Biotin anti-mouse 1:100 BioLegend 
LIVE/DEAD
®
 Fixable Blue Dead Cell Stain Kit 1:500 Invitrogen 
* dependent on the batch 
The used commercial kits and the supplying company are mentioned in Table 2.6. 
Table 2.6 Kits 
Kit  Reference source 
Agilent RNA 6000 Nano kit Agilent Technologies 
Agilent RNA 6000 Pico kit Agilent Technologies 
Pierce
TM
 BCA Protein Assay Kit Thermo Fisher Scientific 
ERCC RNA spike-in control mixes Ambion 
IL-1α ELISA MAXTM Deluxe Biolegend 
IL-1β ELISA MAXTM Deluxe Biolegend 
IL-12p70 ELISA MAX
TM
 Deluxe BioLegend 
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Kit  Reference source 
LEGENDplex
TM
 Mouse TH Cytokine Panel (13-plex) BioLegend 
LEGENDplex
TM
 Mouse Cytokine Panel 2 (13-plex) BioLegend 
ProcartaPlex
®
 Mouse Cytokine & Chemokine Panel 1A (36-
plex) 
eBioscience 
QIAprep® Spin Miniprep kit QIAGEN 
QIAquick® Gel Extraction kit QIAGEN 
QIAquick® PCR purification kit QIAGEN 
ScriptSeq
TM
 complete kit (Human/Mouse/Rat) Illumina 
SensiFast
TM
 SYBR® No-ROX One-Step kit Bioline 
SV total RNA Isolation System kit Promega 
T-PER
TM
 Tissue Protein Extraction Reagent Thermo Scientific 
2.1.5 Oligonucleotides and plasmids 
Oligonucleotides (Table 2.7) were purchased from Metabion, considering the manufacturer’s 
advices for purification, synthesis scale and quality control. Primers were shipped at 100 µM in 
dist. water. Restriction enzyme recognition sites are bold and underlined. 
Table 2.7 Oligonucleotides 
Name Sequence (5’  3’) Description 
PCR 
II348 CGGCTGCAGGTTTAAGGAGGAATA
ACCATGAC 
Sense primer for yopD, creates PstI 
site 
II349 CGGGCGGCCGCCTAACCAAGGTCA
TCAATGG 
Antisense primer for yopD, creates 
NotI site 
II360 CGGCTGCAGGCGACAGGAGACTCG
ATG 
Sense primer for lcrQ, creates PstI site 
II361 CGGGCGGCCGCCAGTAGATATATA 
TTATCTCAGC 
Antisense primer for lcrQ, creates NotI 
site 
III784 GCGGCGGCATGCGCAAGGCGTTCA
GGGAGC 
Antisense primer for rovA, creates 
SphI site 
III947 GCGGTCGACGGCGTGCTAACGACA
ATGAC 
Sense primer for rovA, creates SalI site 
III981 TGAACGGCAGGTATATGTG Sequencing primer for pAKH3 
III982 CACTTAACGGCTGACATGG Sequencing primer for pAKH3 
IV281 GGCCCGGATCCTGATCTGGTGTTC
AGTGAATCA 
Sense primer for yadA, creates BamHI 
site 
IV282 CCGGGGCGGCCGCTTACCACTCGA
TATTAAATGATGCG 
Antisense primer for yadA, creates 
NotI site 
VI392 GCGCGAGCTCTCATCTCGCACAAC
CAAGTTATA 
Sense primer upstream fragment for 
integration into the Y. pseudotuber-
culosis genome; creates SacI site 
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Name Sequence (5’  3’) Description 
VI393 TTCATTTTCTAACTTCCGCTCTCGA
GGCGGCCGCATGTCATAAAAGGT
AAATGGCATAATGG 
Sense primer downstream fragment for 
integration into the Y. pseudotubercu-
losis genome; creates NotI and XhoI 
sites 
VI394 CCATTTACCTTTTATGACATGCGGC
CGCCTCGAGAGCGGAAGTTAGAA
AATGAAATTGA 
Antisense primer upstream fragment 
for integration into the Y. pseudotuber-
culosis genome; creates XhoI and NotI 
sites 
VI395 GCGCGAGCTCTCTTTATTTTAACTT
ACTTGGCATAACTGG 
Antisense primer downstream 
fragment for integration into the 
Y. pseudotuberculosis genome; creates 
SacI site 
VI504 GCCGAACCACAGTTATGGAGG Sequencing primer for chromosomal 
integration of PLtetO-1::mRuby2 
VI505 AGACACTGTAAGTCTCCTGTGATAG
G 
Sequencing primer for chromosomal 
integration of PLtetO-1::mRuby2 
VI545 GCCCCTCGAGTCCCTATCAGTGAT
AGAGATTGACA 
Sense primer for PLtetO-1; creates XhoI 
site 
VI548 GCCCGCGGCCGCTCATTTATACAG
TTCATCCATGCCG 
Antisense primer for mRuby2, creates 
NotI site 
VI556 TTTTTTTTCCTCCTTATTTTGTCGAC
GC 
Reverse primer for PLtetO-1  
VI557 AAAATAAGGAGGAAAAAAAAATG
GTGAGCAAAGGTGAAGAGT 
Sense primer for mRuby2 
Yersinia qRT-PCR 
III44 GAGACAACTCCACACCCAAAC Sense primer for lcrF (pYV0076) 
III45 GCAAAAGCAGTAATTCCTCAATAC Antisense primer for lcrF (pYV0076) 
III186 TGTAGTCGGGGACGTTATCG Sense primer for gyrA (YPK_2846) 
III187 CCCATCCACCAGCATATAGC Antisense primer for gyrA 
(YPK_2846) 
III393 CCGACGTAAAGCCGCGATAC Sense primer for sopB (pYV0031) 
III394 CCTCGTTCATAAGCACTCGTC Antisense primer for sopB (pYV0031) 
III788 GCTGAAACCGTTGGAACTGAC Sense primer for rovA (YPK_1876) 
III789 CTTCGCACGACGATCATTT Antisense primer for rovA 
(YPK_1876) 
IV549 CACCACACGAACTGGCCG Sense primer for wrbA (YPK_2363) 
IV550 CACGAGTCTGCGAGACATC Antisense primer for wrbA 
(YPK_2363) 
IV555 TTTCCACCGCGGCAACTACC Sense primer for hdeB (YPK_1140) 
IV556 CTTTCTGGGGCCTTCTTAC Antisense primer for hdeB 
(YPK_1140) 
IV961 GGTTATGAGATATTGTCACGCC Sense primer cnfY (YPK_2615) 
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Name Sequence (5’  3’) Description 
IV962 CGTTCCTCTCATTAGAATTACCG Antisense primer for cnfY (YPK_2615) 
IV966 GCCTTTCCATGACCTGCCCC Antisense primer for ail (YPK_1268) 
IV967 CTGATTGACGTTAATCTCGGCG Sense primer for uspA (YPK_0120) 
IV968 CTCCAGAAATCCTGATGATGACC Antisense primer for uspA 
(YPK_0120) 
V4 TGATTGGCGATGAGGTTACGG Sense primer for csrA (YPK_3372) 
V5 TTCTGCTTGGATGCGCTGGT Antisense primer for csrA 
(YPK_3372) 
V56 TGCGGCTGGCACTAAAGACA Sense primer for yadA (pYV0013) 
V57 TTTGGCCGCATCCAAAACAT Antisense primer for yadA (pYV0013) 
V588 CGTGAAAGGCTCCGTTGCGG Sense primer for crp (YPK_0248) 
V589 GTAAGAAATTTCAGCCACTTCAC Antisense primer for crp (YPK_0248) 
VI863 GGTGGCTCAAACGCTCAAGA Sense primer for yscF (pYV0082) 
VI864 GTAAGTCAGCAAGTAGCGCCG Antisense primer for yscF (pYV0082) 
VI865 CCGGGGGTTCGAGGAATCTG Sense primer for ail (YPK_1268) 
VI866 GCCCGCATTGGTAATCCAGG Sense primer for yopJ (pYV0098) 
VI867 CCCCCATGTTAATTATGAAGCGGG Antisense primer for yopJ (pYV0098) 
VI868 CCTGACTCAGGCTGCACGTA Sense primer for fliC (YPK_2381) 
VI869 CGCAGGCTGATTTCATCCTGA Antisense primer for fliC (YPK_2381) 
VI870 GCGGCATCGAAACCAATCCG Sense primer for frdA (YPK_3813) 
VI871 GTAAAGCGGCTTGTTCACCGG Antisense primer for frdA (YPK_3813) 
VI872 CGCTGAGTTTGACCCGGAAA Sense primer for rfaH (YPK_3937) 
VI873 CAGCAATGACGGTTGCTGGG Antisense primer for rfaH 
(YPK_3937) 
VI874 CGGCCCAAGTTTGGAACCAT Sense primer for sodB (YPK_1863) 
VI875 GGCAGCATCAGTAAATTGCGCT Antisense primer for sodB 
(YPK_1863) 
VI893 CTGCCAGGCAAAAATGGCTTG Sense primer for arcA (YPK_3606) 
VI894 CAGGTTACGGGCACGGATG Antisense primer for arcA 
(YPK_3606) 
VI895 GGTTTCCATCTGGCGGGTGA Sense primer for fnr (YPK_1944) 
VI896 GCGCAGATTGGGCATTTTACCG Antisense primer for fnr (YPK_1944 
VI897 CGACCGCGGTCGGTATGTTC Sense primer for napA (YPK_1387) 
VI898 ACCGAGGACGCCATACAATGG Antisense primer for napA 
(YPK_1387) 
VI899 GCTTCGGTTTCATCACTCCAGC Sense primer for cspC (YPK_2474) 
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Name Sequence (5’  3’) Description 
VI900 GGCCTTCAGCCAAGGTTTTGAAG Antisense primer for cspC 
(YPK_2474) 
VI901 CCGTCCTGGTACCGATGATGG Sense primer for if-3 (YPK_1821) 
VI902 CATTTCACGCCCACGGAACC Antisense primer for if-3 (YPK_1821) 
The plasmids used in this work are listed in Table 2.8. The construction of the plasmids pWH9 
and pWH14 is described in 2.3.10. 
Table 2.8 Plasmids 
Plasmid Description Reference and source 
pAKH3 pGP704bla, sacB
+
, Amp
R
 Heroven et al., 2012 
pFS43 pFS42, PLtetO-1::mCherry, Kan
R
 Franziska Schuster, PhD 
thesis 
pWH9 pAKH3, -1063bp YPK_3294 to -67bp 
YPK_3295 
This study 
pWH14 pWH9, PLtetO-1::mRuby2 This study 
2.1.6 Bacterial strains and isolates 
Bacterial strains employed in this study are mentioned in Table 2.9. The construction of 
Y. pseudotuberculosis strains YP339 and YP340 is described in 2.3.11. 
Table 2.9 Bacterial strains 
Strain Description Reference 
E. coli 
DH10 F
-
 endA1 recA1 galE15 galK16 nupG rpsL ΔlacX74 
Φ80lacZΔM15 araD139Δ(ara, leu)7697 mcrA Δ(mrr-
hsdRMS-mcrBC)λ- 
Grant et al., 1990 
S17-1pir recA1 thi pro hsdR- 
 
RP4-2Tc::Mu Km::Tn7 λpir Simon et al., 1983 
Y. pseudotuberculosis 
YPIII pIB1, wild type Bölin et al., 1982 
YP147 YPIII, pIB1, ΔcnfY, KanR Schweer et al., 2013 
YP339 YPIII, pIB1, PLtetO-1::mRuby2 (integrated between 
YPK_3294 and YPK_3295; genome position 
3606960-3607832) 
This study 
YP340 YP147, pIB1, PLtetO-1::mRuby2 (integrated between 
YPK_3294 and YPK_3295; genome position 
3606960-3607832) 
This study 
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Y. pseudotuberculosis YPIII re-isolates and their isolation source after one passage through 
BALB/c mice (2.5.10) are given in Table 2.10. 
Table 2.10 Y. pseudotuberculosis YPIII re-isolates 
No. Isolation source Mouse no. 
Acute colonization phase, 6 dpi 
1 Cecum 1 
2 Cecum 1 
3 Cecum 1 
4 Cecum 2 
5 Cecum 2 
6 Cecum 2 
7 Cecum 3 
8 Cecum 3 
9 Cecum 3 
10 Cecal content 1 
11 Cecal content 1 
12 Cecal content 1 
13 Cecal content 2 
14 Cecal content 2 
15 Cecal content 2 
16 Cecal content 3 
17 Cecal content 3 
18 Cecal content 3 
19 Spleen 1 
20 Spleen 1 
21 Spleen 1 
22 Spleen 2 
23 Spleen 2 
24 Spleen 2 
25 Spleen 3 
26 Spleen 3 
27 Spleen 3 
28 Liver 1 
29 Liver 1 
30 Liver 1 
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No. Isolation source Mouse no. 
31 Liver 2 
32 Liver 2 
33 Liver 2 
34 Liver 3 
35 Liver 3 
36 Liver 3 
37 PP (small intestine) 2 
38 PP (small intestine) 2 
39 PP (small intestine) 2 
40 PP (small intestine) 2 
Persistent colonization phase, 42 dpi 
41 Spleen 4 
42 Spleen 4 
43 Spleen 4 
44 Spleen 4 
45 Spleen 4 
46 Spleen 4 
47 Liver 4 
48 Liver 4 
49 Liver 4 
50 PP (small intestine) 4 
51 PP (small intestine) 4 
52 PP (small intestine) 4 
53 PP (small intestine) 4 
54 PP (small intestine) 5 
55 PP (small intestine) 5 
56 PP (small intestine) 5 
57 PP (small intestine) 5 
58 Cecal content 4 
59 Cecal content 4 
60 Cecal content 4 
61 Cecal content 5 
62 Cecal content 5 
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No. Isolation source Mouse no. 
63 Cecal content 5 
64 Cecal content 6 
65 Cecal content 6 
66 Cecal content 6 
67 Cecum 4 
68 Cecum 4 
69 Cecum 4 
70 Cecum 4 
71 Cecum 6 
72 Cecum 6 
73 Cecum 6 
74 Cecum 6 
 
2.1.7 Mice 
In this study, several mouse strains of different backgrounds, origins and ages at the beginning 
of the experiment were used for Y. pseudotuberculosis infection (Table 2.11). 
Table 2.11 Mice 
Background Strain Origin 
Age 
(weeks) 
Section Reference/ origin 
BALB/c Wild type Janvier 8 3.1 - 3.5 Zentralinstitut für 
Versuchstierzucht 
(Hannover)-1988(F172) 
C57BL/6N Wild type Janvier 8-9 3.6.1; 3.6.3 National Institutes of 
Health (USA)-1999 
C57BL/6N Wild type HZI 8-9 3.6.2; 3.6.4 In house breeding 
C57BL/6N Caspase-1
-/- 
HZI 9-11 3.6.4 Kayagaki et al., 2011 
C57BL/6N Caspase-11
-/-
 HZI 8-10 3.6.4 Kayagaki et al., 2011 
C57BL/6N Caspase-1/11
-/-
 HZI 8-10 3.6.4 Kuida et al., 1995; Li et 
al., 1995 
C57BL/6N Il-1α-/- HZI 8-10 3.6.4 Horai et al., 1998  
C57BL/6N Il-1β-/- HZI 8-10 3.6.4 Horai et al., 1998  
FVB/N Wild type Janvier 8 Appendix National Institutes of 
Health (USA)-1996 
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2.1.8 Software and databases 
In this study, the following applications were used: Adobe Illustrator CS4 (Adobe Systems 
Software Ireland Ltd.), Adobe Photoshop CS4 (Adobe Systems Software Ireland Ltd.), A 
plasmid Editor (ApE), FACSDiva
TM
 (BD Biosciences), FlowJo v9.9.4 (Treestar Inc.), Graph 
Pad PRISM 6.0 (Graphpad Software, Inc.), Image Lab 2.0.1 (BioRad), LEGENDplex
TM
 V7.0 
(VigeneTech), Microsoft
® 
Excel
®
 14.4.1 (Microsoft), Rotor-Gene Q Series Software 2.0.2 
(QIAGEN), SkanIt Software 2.4.3 Research edition Varioskan Flash (Thermo Scientific), 
VisRseq (Younesy et al., 2015), ZEN 2012 (Zeiss). Furthermore, the following databases were 
employed: Kyoto Encyclopedia of Genes and Genomes (KEGG), Immunological Genome 
Project (ImmGen), National Center for Biotechnology Information (NCBI), Universal Protein 
Resource (UniProt). 
2.2 Microbiological methods 
2.2.1 Sterilization 
Media and solutions were moist heat sterilized in an autoclave for 20 min at 121 °C with 1 bar 
overpressure. Not heat sterilizable solutions (e.g. antibiotics or sucrose) were filter sterilized 
using a pore diameter of 0.2 µm. Dry heat sterilization at 180 °C was employed for glassware 
such as pipettes or flasks. 
2.2.2 Growth conditions and bacterial storage 
Y. pseudotuberculosis and E. coli strains (Table 2.9) were aerobically grown in appropriate 
volumes of broth or solidified broth. Medium additives were added if necessary (Table 2.2; 
Table 2.3). If not differently stated, Y. pseudotuberculosis strains were cultivated at 25 °C and 
E. coli at 37 °C, respectively. Liquid cultures were incubated in a shaking incubator at 
200 rpm. For long-term storage, bacteria were stocked with 30 % (v/v) glycerol at -80 °C. 
2.2.3 Cell density determination 
Cell densities of liquid bacterial suspensions were determined by measurement of the optical 
density (OD) with a spectral photometer (Amersham Biosciences) at 600 nm. It was assumed 
that an OD600 corresponds to a cell density of 1x10
9
 colony-forming units (CFU) per milliliter. 
2.2.4 Growth curves  
To analyze and compare the growth behavior of different Y. pseudotuberculosis strains, an 
overnight culture of the respective strain was diluted into 5 ml LB broth to OD600 = 0.1. At 
several time points, the optical density at 600 nm was measured in a black 96 well clear bottom 
plate (Becton Dickson) using the Varioskan Flash plate reader (Thermo Scientific; bandwidth 
5 nm; measurement time 100 ms).  
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2.2.5 Fixation of bacteria and fluorescence microscopy 
For fluorescence microscopic analysis, yersiniae stably-labeled with mRuby2 were grown to 
exponential growth phase (5 h), early stationary growth phase (8 h) or late stationary growth 
phase (24 h). At the respective time points, 500 µl of the bacterial culture were harvested by 
centrifugation (5.000 rpm, 2 min) and fixed in 500 µl 4 % paraformaldehyde (PFA) (w/v) for 
20 min in the dark. After that, bacteria were washed twice and resuspended in 1x PBS 
(Table 2.1) for microscopic analysis. 
Fluorescence microscopy was performed with the Axiovert II fluorescence microscope (Zeiss) 
using the Axiocam HR digital charge-coupled device (CCD) camera (Zeiss) and the software 
ZEN 2012 (Zeiss). For analysis of fixed bacteria under the microscope, bacteria were spotted 
on a glass slide. Images were processed utilizing Adobe Photoshop CS4 (Version 11.0; Adobe 
Systems Incorporated). 
2.3 Genetic and molecular biological methods for DNA 
2.3.1 Polymerase chain reaction 
The polymerase chain reaction (PCR) was used to amplify specific DNA fragments with heat-
stable polymerases. The annealing temperature depends on the length and nucleotide contents 
of the primer pairs, whereas the elongation time and temperature are dependent on the 
polymerase and the size of the amplified DNA fragment.  
The Phusion High-Fidelity (HF) DNA polymerase is one of the most accurate polymerases, 
which possesses high processivity, and low error rates combined with proofreading capability. 
Therefore, it was used for cloning and sequencing applications. Amplification of DNA 
fragments for test-PCRs or colony-PCRs was performed using the MangoTaq
TM
 polymerase.  
PCR reactions and conditions were composed according to the manufacturer’s instructions in 
volumes ranging from 10 to 50 µl. 
2.3.2 Agarose gel electrophoresis 
Agarose gel electrophoresis separates DNA fragments depending on their size. The principle is 
based on the natural negative charge of DNA, which drives the migration of DNA in the 
agarose gel by the applied electric field. Routinely, 1x TAE gels (Table 2.1) containing agarose 
ranging from 1 to 2 % (w/v) were employed. DNA samples were mixed with 6x loading dye 
and separated at 100-120 V for 45 to 60 min. The GeneRuler DNA Ladder Mix (Thermo 
Scientific) was used as DNA fragment standard. Subsequently, the DNA was visualized by 
ethidium bromide staining and detected upon UV-light excitation. Gel images were 
documented with the BioRad Gel Doc XR+ gel documentation system. 
2.3.3 Determination of DNA concentration and purity 
The DNA concentration and purity was measured with the NanoDrop spectral photometer 
(Peqlab) by assessing the absorption of the solution at 230, 260 and 280 nm. For concentration 
calculation it was expected that A260 of 1 corresponds to a DNA concentration of 50 µg/ml.  
Furthermore, the ratios of A260/A280 and A260/A230 were calculated to estimate the purity of the 
DNA samples. 
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2.3.4 DNA sequencing 
To ensure the quality of the cloned plasmids and PCR fragments, the respective DNA was 
sequenced by the genome analytics in-house sequencing platform.  
2.3.5 Isolation of DNA 
Plasmid preparation 
Plasmid DNA was isolated using the QIAprep® Spin Miniprep kit according to the 
manufacturer's instructions. The obtained plasmid DNA was eluted in dist. water.  
Genomic DNA isolation 
For genomic DNA isolation, 750 µl of a bacterial overnight culture was gently mixed with one 
volume of phenol/chloroform/isoamyl alcohol (25:24:1) and centrifuged (13,000 rpm; 2 min; 
room temperature (RT)). Subsequently, the watery supernatant was transferred to a clean 
reaction tube and was mixed with one volume chloroform. After centrifugation at 13,000 rpm 
for 2 min at RT, the watery supernatant was transferred to a clean reaction tube. This 
purification step was repeated. The extracted DNA in the watery supernatant was precipitated 
by addition of two volumes 100 % ethanol and subsequent centrifugation at 13,000 rpm for 
20 min at RT. The obtained DNA was washed twice with 70 % ethanol and air-dried. The 
genomic DNA was resuspended in 100 to 200 µl of dist. water. 
Genomic DNA isolation for Yersinia colony PCR 
To perform colony-PCR with Y. pseudotuberculosis, colony material was resuspended in 30 to 
50 µl of dist. water and heated at 95 °C for 10 min. 1 to 4 µl of the supernatant were further 
used as template for PCR. 
2.3.6 Purification of DNA fragments 
Gel extraction 
For DNA fragment exclusion and purification of DNA fragments, DNA was separated with 
agarose gel electrophoresis and visualized (2.3.2). Subsequently, the fragment of choice was 
excised and extracted from the gel using the QIAquick® Gel Extraction kit (QIAGEN) 
according to the manufacturer’s instructions. The obtained DNA was eluted in dist. water. 
PCR purification 
To remove excess primers from PCR reactions (2.3.1), the DNA was purified with the 
QIAquick® PCR Purification Kit (QIAGEN) following the manufacturer’s instructions. The 
purified PCR reaction was recovered in dist. water. 
2.3.7 16S DNA Sequencing 
To isolate the crude DNA of the microbial community (sampled in 2.5.11), 500 µl of 0.1 mm 
zirconia/silica, 700 µl of buffer A with SDS (Table 2.1) and 500 µl phenol/chloroform/isoamyl 
alcohol (25:24:1, pH 7.9) were added to the feces and chilled on ice. Thereafter, the samples 
were homogenized twice with a bead-beater (BioSpec) for 2 min and centrifuged (3 min, 
8,000 rpm, 4 °C). The supernatant was transferred into a new reaction tube for phenol-
chloroform extraction. To do this, one volume phenol/chloroform/isoamyl alcohol was mixed 
with the supernatant by inversion and centrifuged (5 min, 13,000 rpm, RT). The aqueous phase 
was precipitated with 0.1 volumes of 3 M sodium acetate (pH 5.5) and 1 volume of 
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isopropanol. For precipitation, the samples were incubated at -20 °C for 1 h. Subsequently, the 
DNA was pelleted by centrifugation (20 min, 13,000 rpm, 4 °C). The DNA pellet was washed 
once with 70 % ethanol, dried using the Speedvac (15 min, no heat, auto run) and dissolved in 
200 µl TE buffer (Table 2.1) by incubation at 50 °C for 30 min. The DNA was further purified 
by treating the dissolved DNA with 100 µg/ml RNase A (2 min, RT) followed by purification 
with spin columns (BioBasic) according to the manufacturer’s specifications. The DNA 
extracts were eluted with 52 µl EB (BioBasic) delivered with the kit. The DNA extracts were 
adjusted to 25 ng/µl in EB (BioBasic).  
16S DNA amplification was performed at the HZI by the group Microbial Immune Regulation. 
Briefly, the 16S DNA V4 region (F515/R806) was amplified in triplicates by PCR using 
Phusion DNA Polymerase and 3’ end labeled barcode primers for the 16S DNA. Thereafter, 
the triplicates were pooled together checked on an agarose gel and quantified using 
PicoGreen®. The dsDNA was adjusted to 10 nM and samples were pooled. The pooled 16S 
libraries were quantified with KAPA Library Quantify Kit and handed in for sequencing on the 
Illumina MiSeq platform (PE250) at the HZI to the Genome Analytics group. Data set analysis 
was again performed at the HZI by the group of Microbial Immune Regulation. Briefly, 
filtering of sequences for low quality reads and barcode-based binning was carried out with 
QIIME v1.8.0 (Caporaso et al., 2010). The obtained reads were clustered into 97 % ID 
operational taxonomic units (OTUs) using UCLUST and taxonomic classification using RDP 
Classifier (80 % bootstrap confidence cut off) (Edgar, 2010; Wang et al., 2007). Sequences 
without matching reference dataset, were sorted as de novo using UCLUST. The phylogenetic 
relationships between the OTUs were set with FASTTREE to the PyNAST alignment (Price et 
al., 2010). The OTU absolute abundance table and mapping file were utilized for analysis and 
data visualization. 
2.3.8 Cloning techniques 
Restriction digestion 
For DNA fragment insertion into a specific plasmid site, plasmid and DNA fragment were 
digested with endonucleases (Table 2.4) to gain compatible 5’ and 3’ ends. The digestion 
reactions were carried out following the manufacturer’s advice. The restriction enzymes were 
heat inactivated at 65 °C for 20 min, if recommended. 
Dephosphorylation 
The 5’-phosphate groups of linearized vector DNA were removed in order to decrease the re-
ligation rate of the vector DNA. To this purpose, the Antarctic phosphatase (NEB) was 
employed according to the manufacturer’s advice. The phosphatase was heat inactivated at 
70 °C for 5 min. 
Ligation 
DNA ligases are commonly applied to join two DNA sequences by exploiting their property to 
form phosphodiester bonds between the 5’-phosphate and the 3’-hydroxylgroup of DNA 5’- 
and 3’-ends. This technique was utilized to integrate a desired DNA fragment into a vector 
DNA using the T4 Ligase (NEB) according to the manufacturer’s instructions.  
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2.3.9 DNA transfer 
To transfer DNA into bacterial cells different methods were applied. For direct transfer, 
chemical transformation, and for cell-contact mediated transfer, conjugation was employed. 
Chemocompetent E. coli and transformation 
For production of chemocompetent E. coli, bacteria were grown in LB broth supplemented 
with 20 mM MgSO4 until the culture reached an OD600 of 0.5 to 0.8. The bacterial culture was 
harvested by centrifugation (2,755 g; 10 min; 4 °C) and resuspended in 0.4 volumes of ice-cold 
TFBI (Table 2.1). The suspension was chilled on ice for 10 min and was subsequently 
centrifuged for 10 min (2,755 g; 4 °C). The pellet was resuspended in 0.04 volumes of TFBII 
(Table 2.1) and kept on ice for 60 min. After that, the chemocompetent cells were stored in 
100 µl aliquots at -40 °C. 
For heat shock transformation of a desired plasmid, 50 to 100 µl of chemocompetent E. coli 
were mixed with 1 to 10 µl of plasmid DNA and incubated for 30 min on ice. Thereafter, 
bacteria were heat-shocked at 42 °C for 45 to 60 s and immediately chilled on ice for 2 min. 
Subsequently, 400 µl SOC broth was added and bacteria were incubated at 37 °C for 1 h. The 
bacterial suspension was streaked onto LB agar plates containing the appropriate antibiotic and 
incubated overnight. 
Conjugation 
The mechanisms of conjugation, also named mating, describes the cell-contact mediated 
horizontal gene transfer via fertility pili (F pili). During the conjugation process, a donor strain 
(E. coli S17-1λpir) harboring conjugal traits (based on RP4) transfers genetic mobilizable 
material to the acceptor strain. For conjugation, an overnight culture of E. coli S17-1λpir 
carrying the appropriate mobilizable plasmid and Y. pseudotuberculosis were inoculated into 
10 ml LB broth in 1:100 or 1:50 dilutions, respectively. After 2.5 h of incubation, E. coli were 
shifted to 37 °C without shaking for 0.5 h, allowing the F pili to build up. Thereafter, 300 µl of 
E. coli were harvested by centrifugation (5,000 rpm; 1 min) and washed twice with LB broth to 
remove the remaining antibiotics. Subsequently, 900 µl of Y. pseudotuberculosis were mixed 
with the E. coli S17-1λpir and centrifuged (5,000 rpm; 2 min). The bacterial mixture was 
resuspended in 200 µl LB and incubated on a nitrocellulose membrane (0.22 µm, Millipore) 
placed on solid LB broth for 4 h at 25 °C. After that, bacteria were detached from the filter and 
plated on Yersinia selective agar plates supplemented with the appropriate antibiotics. 
2.3.10 Construction of plasmid pWH14 
For stable integration of mRuby2 under the control of the PLtetO-1 promoter into the 
Y. pseudotuberculosis genome, the mobilizable suicide plasmid pWH14 based on pAKH3 was 
created. To construct a backbone vector that enables integration of different genetic elements 
into the desired Y. pseudotuberculosis genomic site (NCBI accession path 
>gi|170022262|ref|NC_010465.1|:3606960-3607832; Y. pseudotuberculosis YPIII, complete 
genome), the genomic region was amplified as an upstream fragment with primer pairs VI392 
and VI394 and a downstream fragment with primer pairs VI393 and VI395. To fuse the up- 
and downstream fragments creating an XhoI and NotI cloning site in between, the two 
fragments were fused by PCR using primers VI392 and VI395. Subsequently, pWH9 was 
generated by digestion of the created fusion DNA and pAKH3 with SacI and ligation of the 
fragments as described in 2.3.8. The sequence was verified by sequencing with primers III981, 
III982, VI392 and VI395. 
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To integrate mRuby2 under the control of the PLtetO-1 promoter into pWH9, the PLtetO-1 promoter 
and the Shine-Dalgarno sequence from pFS43 were amplified with VI545 and VI556 and 
mRuby2 (supplied by Marc Erhardt, HZI) with VI557 and VI548. The two fragments were 
fused by PCR using the primers VI545 and VI548. The resulting fragment and pWH9 were 
digested with XhoI and NotI. Following dephosphorylation of pWH9 and ligation with the 
fusion DNA fragment, pWH14 was generated. 
2.3.11 Construction of Y. pseudotuberculosis strains YP339 and YP340 
The Y. pseudotuberculosis strains YPIII mRuby2 (YP339) and YPIII ΔcnfY mRuby2 (YP340) 
were constructed by introduction of pWH14 into Y. pseudotuberculosis YPIII and YPIII ΔcnfY 
by conjugation (2.3.9). The plasmid was integrated via homologous recombination into the 
Yersinia genome. To obtain colonies that spontaneously lost the integrated plasmid (including 
sacB and amp
R
) leaving PLtetO-1::mRuby2 inserted into the genomic locus, a counter selection on 
LB solid medium containing 10 % sucrose was employed. This technique exploits the 
expression of the sacB from the integrated plasmid, which leads to the production of toxic 
compounds out of sucrose thereby inducing selective pressure on the bacterium to lose the 
integrated plasmid. Thereafter, the selected colonies were patched on antibiotic plates to select 
for plasmid loss. The obtained colonies were further subjected to colony-PCR to screen for 
integration of mRuby2 under the control of the PLtetO-1 promoter. The correct integration was 
further validated by sequencing using primers VI504, VI505, VI545 and VI548. 
2.4 Molecular biological methods for RNA 
2.4.1 Determination of RNA concentration, purity and quality 
The RNA concentration and purity was measured with the NanoDrop spectral photometer by 
assessing the absorption of the solution at 230, 260 and 280 nm. For concentration calculation 
it was expected that A260 of 1 corresponds to a RNA concentration of 40 µg/ml. Furthermore, 
the ratios of A260/A280 and A260/A230 were calculated to estimate the purity of the DNA samples. 
 
Figure 2.1 RNA electropherogram. 
RNA electropherogram obtained from an Agilent RNA 6000 Nano kit using Expert Software B02.08 (Agilent 
Technologies). 
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To evaluate the RNA integrity and quality, appropriate concentrations of RNA were analyzed 
at the in-house genome analytics platform with the Agilent 2100 Bioanalyzer using either the 
Agilent RNA 6000 Nano kit or Pico kit or by denaturating urea polyacrylamide gel 
electrophoresis (2.4.2). Using the Aligent 2100 Bioanalyzer, the quality of the RNA (RNA 
integrity number; RIN) was calculated by the obtained electropherograms (Figure 2.1) utilizing 
the Expert Software B02.08 (Agilent Technologies). 
2.4.2 Denaturating urea polyacrylamide gel electrophoresis (Urea PAGE) 
To evaluate the integrity of isolated RNA from in vitro cultures, RNA was checked on 
denaturating urea polyacrylamide gels (7 M urea, 10% acrylamide): 
4.2 g Urea 
0.6 ml 10x TBE 
2.5 ml Acrylamide/bisacrylamide (40%) 
3.75 ml Dist. water 
6 µl Tetramethylethylenediamine (TEMED) 
60 µl 10 % ammonium persulfate (APS) 
10 ml 1 gel 
RNA loading buffer (2x, Table 2.1) was added to 1 µg RNA, boiled 10 min at 70 °C and 
chilled for 2 min on ice before loading. The RNA was subsequently separated at 140 V for 
2.5 h in 1x TBE (Table 2.1). RNA was visualized by ethidium bromide staining. 
2.4.3 RNA isolation 
Total RNA isolation from bacterial cultures 
To analyze bacterial expression patterns by qRT-PCR, RNA of bacterial in vitro cultures was 
isolated. For this purpose, Y. pseudotuberculosis grown at 25 °C or 37 °C for 16 h, were pooled 
from 3 independent biological replicates, resuspended in 0.2 volumes stop solution (5 % (v/v) 
water-saturated phenol in ethanol) and snap-frozen in liquid nitrogen. The suspension was 
thawed on ice and centrifuged (14.000 g; 4 °C; 2 min). Subsequently, the pellet was 
resuspended in lysozyme-TE buffer (50 mg/ml, Table 2.1) and incubated for 10 min at RT. The 
RNA of the sample was purified with the SV Total RNA-Isolation kit following the 
manufacturer’s advice. The RNA was eluted into a reaction tube in 100-200 µl RNase-free 
water. The quality of the RNA was determined as described in 2.4.1 and stored at -80 °C. 
Total RNA extraction from mouse tissue and sample pooling 
For total RNA extraction, 4 ml solution D (Table 2.1), freshly supplemented with β-
mercaptoethanol, were added to the snap frozen cecum (2.5.9) and subsequently transferred to 
a pre-cooled 14 ml tube (Greiner) on ice. The cecum was homogenized on ice with the 
Polytron PT 2100 homogenizer (Kinematica) at 11,000 rpm for 10 s. The homogenate was split 
to three 750 µl aliquots into pre-cooled 2 ml reaction tubes with previously added 0.1 mm and 
1 mm acid washed glass beads (Sigma). Afterwards, the bacterial cells in the samples were 
disrupted using the bead beater (TissueLyser II, QIAGEN) for 1 min with a frequency of 
30 beats per second and immediately cooled on ice for 1 min. This cell disruption procedure 
was repeated for three times. Subsequently, 500 µl of the homogenate were transferred to a 
pre-cooled 2 ml reaction tube and the following solutions were sequentially mixed with the 
homogenate:  
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0.1 volumes 2 M sodium acetate, pH 4 
1 volume Water-saturated phenol 
0.2 volumes Chloroform/isoamyl alcohol (24:1) 
Thereafter, the tubes were vigorously shaken by hand for 10 s, cooled on ice for 15 min and 
centrifuged (10,000 g; 4 °C; 20 min). The watery supernatant was transferred to a new 1.5 ml 
reaction tube. For extraction of phenol, 1 volume chloroform/isoamyl alcohol was added, 
vortexed for 30 s and centrifuged (10,000 g; 4 °C; 3 min). Subsequently, the watery 
supernatant was transferred to a fresh reaction tube. The extraction step was repeated. 
Thereafter, the RNA extract in the watery supernatant was precipitated with 0.1 volumes of 
2 M sodium acetate pH 4.0 and 2.5 volumes of ethanol. The samples were incubated overnight 
at -20 °C. The RNA was recovered by centrifugation (10,000 g; 4 °C; 30 min), washed with 
70 % (v/v) ethanol and air-dried. The RNA pellet was dissolved in 50 µl TE buffer (Table 2.1) 
or RNase and DNase free water. The quality and concentration of the RNA extracts was 
assessed as mentioned in 2.4.1 and stored at -80 °C. 
To receive a robust data set, equal amounts of the RNA extracts of 3 to 4 ceca (5 days post 
infection (dpi)) or 5 ceca (42 dpi) of one experiment were pooled. In the end, three independent 
pools of each condition were obtained. 
2.4.4 DNA digestion 
The TURBO
TM
 DNase (Ambion) is a genetically engineered DNA endonuclease derived from 
the bovine DNase I that harbors increased catalytic efficiency at higher salt and lower DNA 
concentrations. The TURBO
TM
 DNase was applied to remove contaminating trace DNA from 
RNA total extracts for qRT-PCR or RNA sequencing. A standard DNA digestion for 10 µg 
total RNA extract or 40 µg of the total RNA pools was composed of: 
2 µl TURBO
TM
 DNase 
24 µl 10x TURBO
TM
 DNase buffer 
1 µl RiboLock
TM
 RNase Inhibitor (40 U/µl) 
213 µl RNA  
240 µl Final volume 
The digestion was incubated at 37 °C for 1 h. To inactivate the TURBO
TM
 DNase 
phenol/chloroform/isoamyl alcohol extraction (2.4.5) was performed. 
2.4.5 Phenol/chloroform/isoamyl alcohol purification 
For removal and inactivation of proteins from RNA solutions, the RNA solution volume was 
increased to 300 µl with RNase-free water. Subsequently, 1 volume of 
phenol/chloroform/isoamyl alcohol (25:24:1) was added and vortexed. After that, the samples 
were centrifuged (>10.000 g; 10 min; 4 °C) and the supernatant was extracted twice with 
1 volume chloroform/isoamyl alcohol. The supernatant was precipitated with 0.1 volumes of 
3 M sodium acetate and 2.5 volumes of ethanol at -20 °C. The RNA was recovered by 
centrifugation (>10.000 g; 30 min; 4 °C), washed with 70 % (v/v) ethanol, air-dried and 
resuspended in 20-50 µl RNase-free water.  
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2.4.6 Quantitative real-time PCR 
Quantitative real-time PCR (qRT-PCR) was employed to assess bacterial expression patterns 
using the SensiFast
TM
 SYBR
®
 No-ROX One-Step kit (Bioline). During qRT-PCR, total RNA 
was reverse-transcribed by a reverse transcriptase into complementary DNA (cDNA). 
Subsequently, the desired cDNA was amplified via PCR. After each PCR-cycle, fluorescence 
intensity of the green fluorescent dye SYBR
®
, which intercalates into double-stranded DNA, 
was monitored. The measured fluorescence intensity was used for relative quantification of 
transcript abundance. 
For qRT-PCR, DNA-depleted RNA (2.4.4) was adjusted to a final concentration of 25 ng/µl. A 
typical qRT-PCR reaction was composed of: 
6.25 µl 2x SensiFast
TM
 SYBR No-ROX One-Step Mix 
0.5 µl 10 µM forward primer 
0.5 µl 10 µM reverse primer 
0.125 µl Reverse transcriptase 
0.25 µl RiboSafe RNase inhibitor 
2.375 µl RNase-free water 
2.5 µl RNA (25 ng/µl) 
12.5 µl Final volume 
Reverse transcription and subsequent qRT-PCRs were performed in the Rotor-Gene Q real-
time PCR cycler (QIAGEN) in technical duplicates. A 3-step-cycling program with subsequent 
melt-profile analysis to monitor product specificity was applied (Table 2.12). 
Table 2.12 qRT-PCR program design 
Step Cycles T °C Time Description 
1. cDNA generation 1 45 20 min Reverse transcription 
2. Polymerase 
activation 
1 95 5 min  
3. PCR <50 95 10 s Denaturation 
52-62 20 s Annealing 
72 10-30 s Extension and acquisition 
 1 72 5 min Final extension 
Melt profile analysis  58-99  Ramp heating and fluorescence 
detection 
The acquired data was further processed with the Gene-Rotor Q Series software. The 
normalization method was typically set to dynamic tube normalization and normalization was 
user-defined starting from cycle 1-10. The cycle threshold (Ct) was determined by setting the 
threshold routinely to 0.005. This threshold reflects the lower fluorescence detection limit of 
the instrument and constitutes the baseline of the amplification plot. The exceedance of the 
threshold indicates the accumulation of PCR product and determines the Ct of the sample.  
The melt profile was analyzed by setting the threshold to >2. The obtained melt profile and 
PCR product melt temperatures were used to determine product specificity and to exclude the 
abundance of primer dimers. 
To calculate the relative expression of a target gene compared to a reference gene, the relative 
quantification method described by Pfaffl was used (Pfaffl, 2001) (Formula 1 to 4). According 
to formula 4, an ideal primer efficiency of 2 (one duplication per cycle) was assumed. As it 
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was shown that normalization to a single gene while comparing different conditions could be 
instable (Vandesompele et al., 2002), the total RNA samples were normalized to sopB and if-3 
in order to get more stable normalization of relative gene expression. To this end, the mean of 
the calculated Ct reference gene (Formula 2) was calculated (Formula 3). 
∆𝐶𝑡𝑔𝑒𝑛𝑒 𝑜𝑓 𝑖𝑛𝑡𝑒𝑟𝑒𝑠𝑡 = 𝑚𝑒𝑎𝑛 𝐶𝑡 𝑔𝑒𝑛𝑒 𝑜𝑓 𝑖𝑛𝑡𝑒𝑟𝑒𝑠𝑡𝑟𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑐𝑜𝑛𝑑𝑖𝑡𝑖𝑜𝑛
− 𝐶𝑡𝑔𝑒𝑛𝑒 𝑜𝑓 𝑖𝑛𝑡𝑒𝑟𝑒𝑠𝑡𝑡𝑒𝑠𝑡 𝑐𝑜𝑛𝑑𝑖𝑡𝑖𝑜𝑛  (1) 
∆𝐶𝑡𝑟𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑔𝑒𝑛𝑒 = 𝑚𝑒𝑎𝑛 𝐶𝑡 𝑟𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑔𝑒𝑛𝑒𝑠𝑟𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑐𝑜𝑛𝑑𝑖𝑡𝑖𝑜𝑛
− 𝐶𝑡𝑟𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑔𝑒𝑛𝑒𝑡𝑒𝑠𝑡 𝑐𝑜𝑛𝑑𝑖𝑡𝑖𝑜𝑛 (2) 
∆𝐶𝑡𝑟𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑔𝑒𝑛𝑒𝑠 = 𝑚𝑒𝑎𝑛 ∆𝐶𝑡𝑟𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑔𝑒𝑛𝑒 1&2 (3) 
𝑟𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑒𝑥𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛 =  
2
∆𝐶𝑡𝑔𝑒𝑛𝑒 𝑜𝑓 𝑖𝑛𝑡𝑒𝑟𝑒𝑠𝑡
2
∆𝐶𝑡𝑟𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑔𝑒𝑛𝑒(𝑠)
 (4) 
2.4.7 RNA transcriptomics (ScriptSeqTM) 
To assess and compare the murine transcriptome during different stages of infection, the total 
RNA extract pools (2.4.3) were send to the in-house genome analytics platform for library 
preparation. The libraries were generated with the epicenter ScriptSeq
TM
 complete kit 
(human/mouse/rat). For this purpose, 1 µg of DNA-depleted total RNA (2.4.4) was depleted 
for murine rRNA with the Ribo-Zero
TM
 kit (human/mouse/rat) following the manufacturer’s 
specifications. To determine the dynamic range, the lower detection limit and to evaluate the 
accuracy of the libraries, External RNA Controls Consortium (ERCC) Spike-In control mixes 
(Ambion) were added. Subsequently, library preparations were performed following the 
manufacturer’s advice. Briefly, the RNA was fragmented and random 5’-end tagged cDNA 
primers were annealed. Thereafter, cDNA was synthesized with the StarScript reverse 
transcriptase delivered with the kit. The RNA was removed and the cDNA was labeled with a 
3’-terminal-tag. For 5’-end bar code labeling, the di-tagged cDNA library was purified and 
amplified by PCR. The finalized libraries were sequenced using an Illumina cluster station 
(HiSeq, short reads, strand specific). The obtained data was processed as described in Nuss et 
al., 2015 and Nuss et al., 2017). After demultiplexing, quality assessment and in silico adaptor 
clipping, the remaining reads were mapped with Tophat to the mm10 genome. To identify 
differential expression profiles in the cecum of the mouse, DESeq2 analysis package was 
applied (Love et al., 2014).  
2.5 Mouse experiments 
All experiments involving mice were carried out in strict accordance to the European Health 
Law of the Federation of Laboratory Animal Science Associations (FELASA) and the German 
Recommendations of the Society of Laboratory Animal Science (GV-SOLAS). Mice were 
housed under specific pathogen-free conditions in the animal facility of the Helmholtz Centre 
for Infection Research, Braunschweig. The animal protocol was approved by the 
Niedersächsisches Landesamt für Verbraucherschutz und Lebensmittelsicherheit: animal 
licensing committee permission No. 33.9-42502-04-13/1166. 
All mouse strains of this study are listed in Table 2.11. Purchased mice were allowed to 
acclimatize to the new housing conditions for one week prior to infection. Every effort was 
made to minimize suffering. 
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2.5.1 Infection of mice 
Mice were challenged with bacterial loads via the gastro-intestinal route using a ball-tipped 
feeding needle to mimic natural infection or by intravenous administration to provoke a 
systemic infection. For gastrointestinal infections, 200 µl of the appropriate 
Y. pseudotuberculosis strain and dosage suspended in PBS (Table 2.1) were fed, whereas for 
intravenous infections 100 µl were injected via the tail vein. 
For both infection routes, bacteria were prepared as follows: 20 ml LB broth of a bacterial 
overnight culture was washed twice with 1x PBS and suspended in 10 ml 1x PBS. 
Subsequently, the optical density was determined (2.2.3) and adjusted according to the desired 
bacterial loads by dilution (intra-gastric infections: 1x10
6
, 2x10
7
 or 2x10
8
 CFU per mouse; 
intravenous infections: 5x10
4
 CFU per mouse). Revision of the infection loads was achieved 
by plating appropriate dilutions of the bacterial suspensions on LB agar. 
2.5.2 Survival experiments 
To evaluate the role of certain bacterial and host factors on the survival of the host, mice 
(Table 2.11) were challenged either intra-gastrically (2x10
8
 CFU per mouse) or intravenously 
(5x10
4
 CFU per mouse) with Y. pseudotuberculosis bacterial suspensions (2.5.1). The fitness 
of the mice was monitored daily for two to three days prior to infection to determine the 
baseline and up to 14 days post infection to assess infection progression. The mice were 
sacrificed painlessly and were considered as dead for the ongoing experiment if they showed 
one or both of the following abort criteria: (a) mice that lost more than 20 % of their initial 
bodyweight, (b) mice with a health scoring with less than three (according to Table 2.13). 
Table 2.13 Mouse health scores 
Score Health status 
6 Vigorous, curious, very active, shiny clean fur 
5 Curious, active, some resting 
4 Reacts to care, frequently resting, some untended fur 
3 Dozy, rare activity, reduced food intake 
2 Little activity, resting, no food intake, hunchback 
1 No activity, hunchback, expected death, no social interactions 
2.5.3 Chemokine and cytokine profiling 
To analyze chemokine and cytokine concentrations in the serum and tissues of untreated and 
Y. pseudotuberculosis infected mice (1x10
6
 or 2x10
8
 CFU per mouse), serum and tissue 
samples were taken and subjected to a multiplex immunoassay, or enzyme-linked 
immunosorbent assay (ELISA). 
Serum isolation 
At certain time points post infection (e.g. 3, 9, 14 dpi, etc.), uninfected and 
Y. pseudotuberculosis infected mice were euthanized via CO2 asphyxiation. Immediately, 300 
to 500 µl heart blood were isolated via cardiac puncture and transferred to Microvette
® 
500 Z-
Gel tubes (Sarstedt). The blood samples were centrifuged (5 min, 10.000 g, 20 °C) and the 
separated serum was frozen at -80 °C.  
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Tissue lysates from C57BL/6N mice 
Tissue lysates of small intestines, MLNs, spleens, and livers at 3 dpi were generated to assess 
the cytokine concentration of IL-1α, IL-1β and IL-12p70 with ELISA. To this end, uninfected 
and Y. pseudotuberculosis-infected C57BL/6N mice were sacrificed via CO2 asphyxiation. The 
tissues were excised, weighed and snap frozen in liquid nitrogen. Subsequently, the tissues 
were placed on ice and tissue protein extraction reagent (T-PER; Thermo Scientific) 
supplemented with phosphatase and protease inhibitors was added. The tissues were 
homogenized and centrifuged for 15 min, 14,000 g at 4 °C to remove remaining debris. 
Thereafter, homogenates were aliquoted and stored at -80 °C until further analysis. 
Tissue lysates from BALB/c mice 
Tissue lysates from the cecum were generated at 3, 9, 14, 21, 30 and 42 dpi to assess the global 
cytokine profiles with LEGENplex
TM
 bead-based immunoassays (BioLegend). For this 
purpose, uninfected and Y. pseudotuberculosis-infected BALB/c mice were sacrificed via CO2 
asphyxiation. The cecum was isolated, flushed, weighted and snap-frozen in liquid nitrogen. 
The cecal contents were plated in serial dilutions to determine the Y. pseudotuberculosis load 
(2.5.4). The ceca were stored at -80°C until further processing. For protein isolation, frozen 
ceca were transferred to 2 ml ice-cold NP-40 buffer (Table 2.1) containing 1 mM PMSF 
(Table 2.1). Thereafter, ceca were homogenized (15,000 rpm, Polytron PT 2100) on ice and 
centrifuged (4 °C, 1,000 g, 5 min) to reduce foam and to pellet large debris. The homogenate 
was aliquoted and frozen at -80 °C until assays were carried out. The protein concentrations 
were determined with the Pierce
TM
 BCA protein assay kit (Thermo Fisher Scientific) according 
to the manufacturer’s recommendations. 
Enzyme-linked immunosorbent assay - ELISA 
In order to determine the IL-1α, IL-1β and IL-12p70 protein levels in tissue homogenates, 
ELISAs for the respective cytokines were performed. For this purpose, tissue homogenates 
were thawn on ice and analyzed on ELISA plates (Table 2.6) according to the manufacturer's 
instructions. Subsequently, the absorbance at 450 nm was determined utilizing the Varioskan 
Flash plate reader (Thermo Scientific). The cytokine concentrations were calculated using a 
standard curve (Prism 6.0). 
Multiplex immunoassay (ProcartaPlex
®
) 
To determine the chemokine and cytokine concentrations in the serum samples, the 
ProcartaPlex
®
 Mouse Cytokine & Chemokine Panel 1A (36-plex) magnetic bead based kit 
(eBioscience) was used. The kit included the analytes: ENA-78/CXCL5, eotaxin, G-CSF, GM-
CSF, GROα, IFNα, IFNγ, IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-9, IL-10, IL12p70, IL-
13, IL-15/IL-15R, IL-17A, IL-18, IL-22, IL-23, IL-27, IL-28, IL-31, IP-10, LIF, MCP-1; 
MCP-3, M-CSF, MIP-1α, MIP-1β, MIP-2, RANTES, and TNFα. 
The assay was performed according to the manufacturer’s instructions. Briefly, the color-coded 
bead mix coated with its respective analyte-specific antibody was incubated with the serum 
samples or the standard. Subsequently, biotinylated detection antibody mix specific for the 
analyte (antibody-antigen sandwich) and phycoerythrin (PE)-conjugated streptavidin (SA), 
which specifically binds to biotin (Figure 2.2), was added. 
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Figure 2.2 Multiplex assay principle. 
The analyte binds to the capture antibody coated cytokine/chemokine-specific Luminex bead. Thereafter, 
biotinylated-detection antibody and streptavidin are added to detect the analyte concentration.  
The beads were detected with the Luminex® 100
TM 
system, which is able to detect and 
quantify multiple analytes in parallel. To this purpose, the single beads were (1) classified (e.g. 
TNFα-Luminex bead) and (2) the intensity of PE-derived signal of this bead was detected. This 
signal is proportional to the amount of bound analyte. The cytokine concentrations were 
calculated with best-fit curves of the supplied standards. 
Multiplex Immunoassay (LEGENDplex
TM
) 
To determine the cytokine and chemokine concentrations in serum samples and tissue 
homogenates at different time points post infection, the LEGENDplex
TM
 Mouse TH Cytokine 
Panel and the Mouse Cytokine Panel 2 bead-based immunoassay (BioLegend) were used. The 
kits included the analytes: IL-2, IL-4, IL-5, IL-6, IL-9, IL-10, IL-13, IL-17A, IL-17F, IL-21, 
IL-22, IFNγ, TNFα, GM-CSF, IFNβ, IL-1α, IL-1β, IL-3, IL-7, IL-11, IL-12 (p40), IL-12 (p70), 
IL-23, IL-27, IL-33 and TSLP. 
The assay was performed according to the manufacturer’s instructions with the following 
optimizations. Standard or sample was incubated for 1.5 h at RT with shaking as listed below: 
20 µl Assay buffer 
20 µl Standard/sample 
20 µl Mixed beads (1:4) 
12.5 µl Detection antibodies 
Thereafter 12.5 µl of SA-PE (LEGENDplex
TM
) were added and incubated for 30 min. The 
beads were washed twice with washing buffer and finally suspended in 100 µl of washing 
buffer. 
The beads were detected with the flow cytometer (LSRFortessa
TM
, BD Biosciences) following 
the assay requirements for flow cytometer setups and acquisition. Data analysis was performed 
with the LEGENDplex
TM
 Data Analysis Software V7.0 (BioLegend).  
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2.5.4 Bacterial burden assay 
To assess the Y. pseudotuberculosis loads in particular tissues bacterial burden assays were 
performed. For this purpose, infected mice (2.5.1; 5x10
4
, 1x10
6
 or 2x10
8
 CFU per mouse) were 
sacrificed at different days and stages post infection by CO2 asphyxiation. Depending on the 
experimental setup the cecum, small intestine, PP (of small intestine), MLNs, spleen and liver 
were removed, flushed if applicable, weighted and homogenized in sterile PBS (Table 2.1) 
with the Polytron PT 2100 (Kinematica) homogenizer at 22.000 rpm for 10 s. Contents of gut 
compartments like cecum and small intestine were flushed out with a defined volume of sterile 
1x PBS and also homogenized. Heart blood was isolated via cardiac puncture with a 
0.60x25 mm needle and mixed with 500 mM EDTA (1:2) to prevent clotting. To determine the 
bacterial loads in the different organs or compartments, the homogenates were plated in 
appropriate 10-fold serial dilutions onto LB medium plates containing irgasan. 
2.5.5 Detection of colonizing Yersinia 
To follow bacterial long-term colonization of infected mice (1x10
6
 CFU per mouse) by 
quantification of Yersinia loads and assessment of colonization qualities in the feces (positive 
or negative for colonization), fecal samples from individual mice were analyzed. To this end, 
approximately 10 to 50 mg feces were sampled directly from the mice, weighted and 
homogenized in 1 ml BHI broth supplemented with 1 µg/ml irgasan. For determination of 
bacterial quantities in the feces 10-fold serial dilutions were plated on LB medium plates 
containing irgasan. The remaining homogenate was cold-enriched overnight at 25°C with 
shaking and plated on LB medium containing irgasan to evaluate the colonization quality. 
2.5.6 Severity of diarrhea 
In order to document severity of diarrhea during the course of long-term infection experiments 
with Y. pseudotuberculosis, diarrheal severity was evaluated. At different time points after 
Y. pseudotuberculosis infection (1x10
6
 CFU) feces of individual mice were sampled and 
analyzed with the following scoring system (Table 2.14) (Pearson et al., 2013). 
Table 2.14 Diarrheal scoring 
Score Description 
0 No diarrhea 
Solid stool with no signs of soiling around the anus; stool is very firm when 
subjected to pressure with tweezers 
1 Very mild diarrhea 
Formed stools appear moist on the outside and no signs of soiling around the anus; 
stool is less firm when considerable pressure is applied with tweezers 
2 Mild diarrhea 
Formed stools appear moist on the outside and some signs of soiling around the 
anus; stool will easily submit to pressure applied with tweezers 
3 Diarrhea 
No formed stools with mucus-like appearance; considerable soiling around the anus 
and the fur around the tail; mouse takes long to pass stool 
4 Severe, watery diarrhea 
Mostly clear or mucus-like liquid stool containing very minimal solids and 
considerable soiling around the anus; mouse may not be able to pass stool at all and 
may have hunched appearance; occasionally blood may be observed in the stool 
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2.5.7 Histology 
Scoring of tissue alterations during and after Y. pseudotuberculosis infection, were performed 
in cooperation with the in-house mouse pathology platform. For this purpose mice infected 
with Y. pseudotuberculosis were sacrificed via CO2 asphyxiation at either 3 or 5 dpi (infected 
with 2x10
8
 CFU per mouse) or at 42 dpi (infected with 1x10
6
 CFU per mouse). Subsequently, 
organs of interest were removed, fixed in 4 % formalin for 24 to 48 h and paraffin embedded. 
Sections of the organs were stained with hematoxylin & eosin (H&E stain). Organs of 3 to 
5 mice were blindly analyzed by light microscopy and scored by a histopathologist (Ulrike 
Heise (BALB/c) or Marina Pils (C57BL/6N)). 
2.5.8 Cryo-sections of infected murine ceca 
To localize bacteria and analyze bacterial colonization patterns inside the infected tissue, mice 
infected with fluorescently labeled Y pseudotuberculosis (2.3.11) were euthanatized at either 
3 dpi (infected with 2x10
8
 CFU per mouse) or 42 dpi (infected with 1x10
6
 CFU per mouse). 
Immediately, the cecum was excised, vigorously flushed with 1x PBS (Table 2.1) and filled 
with a mixture of 1x PBS and Tissue-Tek OCT freezing medium (Sakurma Finetek; 1:2 
dilution). Subsequently, the organ was frozen in Tissue-Tek OCT Medium on dry ice. Sections 
of 7 µm thickness were trimmed with the Microm HM 560 cryostat (Thermo Scientific), 
recovered on SuperFrost Plus slides (Thermo Scientific) and fixed in ice-cold 4 % PFA (w/v) 
for 20 min. The fixed sections were washed twice in 1x PBS and air-dried. To stain the nuclear 
DNA and for section mounting, Roti-Mount FluorCare (Roth) was employed. The cryo-
sections were examined with the Axiovert II fluorescence microscope (Zeiss) using the 
Axiocam HR digital CCD camera (Zeiss) and the software ZEN 2012 (Zeiss). Multiple fields 
of multiple sections were scored for bacterial colonization grades and patterns. The scoring 
criteria are listed in Table 2.15. The obtained images were further processed using Adobe 
Photoshop CS4 (version 11.0; Adobe Systems Incorporated). 
Table 2.15 Bacterial colonization scores 
Score Description 
Microcolony 
0 No microcolony 
1 Small microcolony >20 µm, <50 µm diameter 
2 Medium microcolony <100 µm diameter 
3 Large microcolony >100 µm diameter 
Lesion 
0 No lesion 
1 Small lesion 
2 Large lesion 
Small bacterial foci <20 µm 
0 No colonization 
1 <25 % of the PP colonized 
2 <50 % of the PP colonized 
3 >50 % of the PP colonized 
Bacterial localization in the intracellular space around whole cells 
0 No associations 
1 <25 % of small bacterial foci associated 
2 <50 % of small bacterial foci associated 
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Score Description 
3 >50 % of small bacterial foci associated 
Lamina propria colonization 
0 No colonization 
1 Partially colonized, single colonized areas of the lamina propria within the entire 
section 
2 Moderate colonized, single to dense colonized areas of the lamina propria within the 
entire section 
3 Highly colonized, dense colonization of the lamina propria within the entire section 
2.5.9 Isolation of cecal tissue for total RNA extraction 
For total RNA extraction (2.4.3) of murine ceca, uninfected equally aged mice and mice 
infected with either Y. pseudotuberculosis YPIII or YPIII ΔcnfY were sacrificed at 5 or 42 dpi 
(infection doses: day 5: 2x10
7
 CFU per mouse of Y. pseudotuberculosis YPIII, 2x10
8 
CFU per 
mouse of Y. pseudotuberculosis YPIII ΔcnfY; day 42: 1x106 CFU per mouse of 
Y. pseudotuberculosis YPIII or YPIII ΔcnfY, respectively). Immediately, the cecum of 
uninfected or colonized mice (as determined in 2.5.5) was removed, extensively flushed with a 
defined volume of 1x PBS (Table 2.1) and snap frozen in liquid nitrogen. The organs were 
stored at -80 °C until further processing. Additionally, the contents of the flushed ceca were 
analyzed for Y. pseudotuberculosis loads as described in 2.5.4 to determine the severity of 
colonization. 
2.5.10 Re-isolation 
To determine presence of the virulence plasmid in bacteria during different stages post 
Y. pseudotuberculosis infection, Y. pseudotuberculosis YPIII was re-isolated from cecum, 
cecal content, PP (of the small intestine), spleen and liver of infected mice at 6 dpi (2x10
7
 CFU 
per mouse) or 42 dpi (1x10
6
 CFU per mouse). For this purpose, mice were euthanized via CO2 
asphyxiation and the desired organs were removed. Organ homogenates were prepared as 
described in 2.5.4. Thereafter, randomly chosen colonies of each organ (3 to 6) and mouse 
were stocked. The re-isolates are listed in Table 2.10 und were used for further experiments. 
2.5.11 Composition of the microbiota 
To assess the microbial composition of mice during persistency and its development, 16S DNA 
Sequencing was used. To this purpose 10 to 70 mg feces were directly sampled from individual 
mice. The feces were weighed, homogenized in 1 ml BHI and plated as mentioned in 2.5.5 to 
assay the Y. pseudotuberculosis loads. The rest of the homogenate was pelleted in 2 ml micro 
tubes (Sarstedt). The supernatant was discarded and the pellet was frozen at -20°C until further 
processing (2.3.7).  
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2.6 Flow cytometry 
2.6.1 Single cell suspensions and cell counting 
In order to assess the immune cell dynamics upon Y. pseudotuberculosis infection in 
C57BL/6N mice, the animals were challenged with 2x10
8
 CFU. At 3 dpi, mice were sacrificed 
by CO2 asphyxiation and the PP, MLN and spleen were dissected. Single cell suspensions were 
obtained by passage through a cell strainer (100 µm, BD Biosciences) using 10 ml PBS/BSA 
(Table 2.1). For erythrocyte lysis, splenocytes were resuspended in 2 ml ammonium-chloride-
potassium (ACK) buffer (Table 2.1) and incubated for 5 min at RT. The reaction was stopped 
with 20 ml PBS/BSA. The splenocytes were pelleted (5 min, 400 g, 4 °C) and resuspended in 
2 ml PBS/BSA. To assess cellular concentrations, the cell suspensions were counted at the 
Beckman Coulter Counter. 
2.6.2 Antibody titration 
To titrate the optimal antibody concentration for flow cytometry stainings, splenic single cell 
suspensions of uninfected mice were generated (2.6.1). For each titration 1x10
6
 cells were 
used. To block the Fc receptor, the cells were incubated with 10 µg/ml CD16/CD32 (5 min, 
4 °C). Subsequently, cells were stained for 15 min at 4 °C with different dilutions of the 
antibody ranging between 1:100 and 1:2000. Thereafter, cells were washed using PBS/BSA 
(Table 2.1), resuspended and detected at the flow cytometer (LSRFortessa
TM
, BD Biosciences). 
The optimal antibody working concentrations are depicted in Table 2.5. 
2.6.3 Flow cytometry staining 
Flow cytometry analysis was performed employing two different antibody panels, which were 
denoted “innate” and “adaptive” panel. Single antibody and fluorescence minus one (all 
antibodies except one) control stainings for both multi-color panels were performed with 
splenocytes. In the “innate” panel 2.5x106 cells and in the “adaptive” panel 1x106 cells were 
stained. After two washes with PBS, the Fc receptor was blocked using 10 µg/ml CD16/CD32 
(15 min, 4 °C). Thereafter, the “innate” and “adaptive” panel stainings followed different 
protocols. 
“Innate” panel 
To discriminate T cells, B cells and NK cells from the innate immune cells, the biotinylated 
antibody mix (CD3, CD19, NKp46; Table 2.5) was added to the blocking antibodies and 
incubated for 20 min. Subsequently, the cells were washed two times with PBS, resuspended 
with the antibody mix (CD11b, Streptavidin, F4/80, Ly6G, Ly6C, CD11c, LIVE/DEAD, 
Table 2.5) and incubated for 30 min at 4 °C. After washing with PBS, the cells were fixed with 
4 % PFA (w/v) (20 min, 4 °C). For the acquisition at the flow cytometer (LSRFortessa
TM
, BD 
Biosciences), cells were washed and resuspended in PBS/BSA (Table 2.1). 
“Adaptive” panel 
To stain for T cells, B cells and NK cells, the antibody mix containing CD3, CD19, NKp46 
and LIVE/DEAD was added to the cells (30 min, 4°C). After two washes with PBS, cells were 
fixed with 4 % PFA (20 min, 4 °C). Subsequently, cells were washed and resuspended in 
PBS/BSA (Table 2.1) for the acquisition at the flow cytometer (LSRFortessa
TM
, BD 
Biosciences) 
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2.6.4 Flow cytometry data analysis 
The acquired flow cytometry data was analyzed using FlowJo (v9.9.4). Single stainings were 
employed to compensate fluorescence leaking into other detection channels. The FMO control 
staining was used to discriminate the cell populations from each other. Cell populations of both 
panels were evaluated by two distinct gating strategies (Figure S1 & Figure S2). In either 
gating strategy, dead cells (Figure S1A & Figure S2A), doublets (Figure S1B/C & 
Figure S2B/C) and cell debris (Figure S1D, Figure S2D) were excluded. 
The “innate” panel was gated as follows: For exclusion of lymphocytes and NK cells, 
streptavidin negative cells were gated (Figure S1E). Subsequently, F4/80
hi
 cells were 
considered to be macrophages (Figure S1F). The remaining cells were cleared for auto-
fluorescent cells (Figure S1G). Thereafter, CD11c
+
 Ly6G
-
 cells were identified as DCs 
(Figure S1H) and Ly6G
+
 cells as PMNs (Figure S1I). Finally, CD11b
+
 Ly6C
-
 cells were 
denoted as monocytes (Figure S1J). 
After cell debris removal from the “adaptive” panel, auto-fluorescent cells were excluded 
(Figure S2E). Thereafter, CD19
+
 cells were identified as B cells and CD3
+
 cells as  
T cells (Figure S2F). The remaining cells were gated for NKp46
+
 NK cells (Figure S2G). To 
calculate the absolute cell numbers, the population percentage was multiplied by the cell 
numbers (2.6.1). 
2.7 Statistical analyses 
Statistical analyses were performed with Graph Pad PRISM 6.0 (2.1.8). For comparison of two 
groups the Mann-Whitney U test was implemented. Column based data containing more than 2 
groups was compared employing One-way ANOVA or the non-parametric Kruskal-Wallis test. 
To compare two groups at different time points, the data was analyzed with multiple t-tests. All 
multiple comparisons were p-value-adjusted utilizing Holm-Šídák’s method or Dunn’s 
correction (Kruskal-Wallis test). Correlation analysis was executed using the Spearman 
correlation method. Survival data was statistically evaluated with the Mantel-Cox log-rank test. 
Sequencing data was statistically analyzed by Dr. Michael Beckstette and is provided in the 
appendix (Table S1-S10). 
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3 Results 
The Y. pseudotuberculosis strains YPIII and IP2666 encode the cytotoxic necrotizing factor 
CNFY, which is a homologue of CNF1 of UPEC (Lockman et al., 2002; Caprioli et al., 1983). 
Deletion of cnf1 in UPEC leads to attenuation in colonization abilities in the urine, bladder and 
kidney in a murine UTI model (Rippere-Lampe et al., 2001b). Additionally, presence of CNF1 
results in higher inflammatory states and tissue damage in mice and rats (Rippere-Lampe et al., 
2001a; Rippere-Lampe et al., 2001b). 
Previous work by Schweer and colleagues elucidated that the lack of CNFY also reduces 
pathogenicity of Y. pseudotuberculosis YPIII and completely abolishes its ability to cause 
lethal infections (Schweer et al., 2013). When using lethal infection doses, deletion of cnfY in 
Y. pseudotuberculosis YPIII led to asymptomatic colonization of the gut compartments (small 
intestine, cecum) and associated lymphoid tissues (i.e. PPs) (Schweer et al., 2013).  
In 2014, it was discovered that Y. pseudotuberculosis YPIII (cnfY
+
) is able to persist in mice 
after oral infection with sub-lethal infection doses for up to 115 days (Fahlgren et al., 2014). 
However, there is little known about the influence of Yersinia encoded virulence factors, 
especially CNFY, on the establishment and manifestation of persistent Y. pseudotuberculosis 
infection. 
Preliminary infection experiments with high infection doses (2x10
8
 CFU) of 
Y. pseudotuberculosis strain YPIII ΔcnfY demonstrated that the cnfY mutant is able to cause 
long-lasting infections in the gut and its associated lymphoid tissues (small intestine, PPs, 
cecum, colon) (Janina Schweer, unpublished data). Moreover, Avican and colleagues showed 
that the cnfY-expression is down-regulated during persistent infection (Avican et al., 2015). 
Thus, it was hypothesized that the avirulent Y. pseudotuberculosis strain YPIII ΔcnfY might 
more effectively cause prolonged infections than the wild type.  
This study addresses the influence of CNFY on Y. pseudotuberculosis pathogenesis during 
acute and persistent infection. 
3.1 Uncoupling of CNFY increases the establishment of asymptomatic, 
persistent infections 
To test the assumption that CNFY influences the development of persistent Yersinia infections, 
the persistence abilities of Y. pseudotuberculosis YPIII and YPIII ΔcnfY in BALB/c mice after 
sub-lethal challenge were compared. Therefore, BALB/c mice were intra-gastrically infected 
with 1x10
6 
CFU of YPIII or YPIII ΔcnfY and disease progression was monitored over a period 
of 40 days (Figure 3.1). 
About 40 % of YPIII infected mice succumbed to the infection between 5 and 21 dpi (data not 
shown). Weight loss analysis of the surviving mice demonstrated that YPIII infected mice 
displayed a weight loss of almost 3 % of their initial weight in the first 12 dpi (Figure 3.1A). 
However, the mice recovered weight beginning at day 9 to 16 post infection (data not shown). 
In contrast, YPIII ΔcnfY infected mice presented no weight loss during the course of the 
experiment: despite the infection, these mice constantly gained weight (Figure 3.1A, data not 
shown).  
To get more information about the Yersinia colonization status and diarrheal severity during 
the progress of the experiment, fecal egesta of individual mice were analyzed for their Yersinia  
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Figure 3.1 Uncoupling of cnfY leads to mild disease with enhanced persistence rates in the gut of 
BALB/c mice. 
BALB/c mice were intra-gastrically infected with 1x106 CFU of Y. pseudotuberculosis YPIII or YPIII ΔcnfY. At 
indicated time points, body weight, diarrhea score and Yersinia colonization in the feces were monitored.  
(A) Relative body weights of surviving mice after infection. The data represent the mean ±SEM of one independent 
experiment, the experiment was conducted in triplicate; YPIII n=15; YPIII ΔcnfY n=30. The data were analyzed 
with multiple t-test’s utilizing Holm-Šídák’s correction: * p<0.05; ns, not significant. (B) Individual Yersinia loads 
in the feces. The Yersinia burden was determined in the egesta of infected mice at indicated time points. The bar 
represents the geometric mean. The dotted line indicates the detection limit. The graph shows combined data from 
two independent experiments; YPIII n=50, YPIII ΔcnfY n=35. The data were statistically analyzed with the Mann-
Whitney U test: ** p<0.01, *** p<0.001. (C) Number of BALB/c mice positively tested for Yersinia after culture 
enrichment of yersiniae from egesta samples. Rates were calculated using data of YPIII n=50 and YPIII ΔcnfY n=35 
from two independent experiments. (D) Diarrheal severity scores: 0: no diarrhea; 1: very mild diarrhea; 2: mild 
diarrhea; 3: diarrhea; 4: severe, watery diarrhea. The bar represents the mean ±SEM of one representative 
experiment. The experiment was repeated two times. The data were analyzed with One-way ANOVA employing 
Holm-Šídák’s correction: * p<0.05, *** p<0.001; YPIII n=50, YPIII ΔcnfY n=30. 
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burden and diarrheal status. While the global YPIII loads decreased starting from 12 dpi, the 
burden of YPIII ΔcnfY remained at the same level (Figure 3.1B). The observed global decrease 
of wild type Yersinia burdens was mostly due to the bacterial load decreasing below the 
detection limit (Figure 3.1B). Culture enrichment of the fecal sample material further revealed 
that the overall reduction of YPIII below the detection limit was accompanied by bacterial 
clearance from the feces (Figure 3.1C). Of 75.5 % initially YPIII positively tested mice (5 dpi) 
only 11.7 % of the surviving mice were still colonized at 40 dpi (Δ63.8 %). In turn, clearance 
events were rarely observed upon YPIII ΔcnfY infection; of 88.6 % initially colonized mice, 
64.4 % were still colonized at 40 dpi (Δ24.2 %). This accounts for an almost 3-fold increase of 
persistence events upon deletion of cnfY (Figure 3.1C). Moreover, diarrheal severity greatly 
differed between the two Y. pseudotuberculosis strains at the beginning of the infection 
(Figure 3.1D). Mice infected with YPIII ΔcnfY on average displayed no- to very mild-diarrhea, 
whereas mice infected with the wild type demonstrated very mild- to mild-diarrhea at 5 dpi 
(Figure 3.1D; data not shown). The severity of diarrhea further increased, reaching the highest 
overall scores between 10 and 13 dpi for both strains. Up to 20 dpi the diarrheal severity scores  
 
 
Figure 3.2 Deletion of cnfY drastically enhances persistency and colonization rates in the cecum of 
BALB/c mice. 
Mice were intra-gastrically infected with 1x106 CFU of Y. pseudotuberculosis YPIII or YPIII ΔcnfY. At 42 dpi, 
Yersinia colonization levels in the cecum and the luminal content of the cecum were determined. (A) Yersinia 
colonization in the cecum of surviving mice. The rates were calculated using bacterial burden data of the cecum: 
YPIII n= 31, YPIII ΔcnfY n=25. (B) Yersinia loads in the cecum. The presented data were obtained from three 
combined experiments: YPIII n= 31, YPIII ΔcnfY n= 25. The detection limit was ca. 125 CFU/g. (C) Yersinia 
burdens in the luminal content of the cecum. The data were combined from two independent experiments: YPIII 
n=23, YPIII ΔcnfY n=15. The detection limit was at 50 CFU. (B-C) The plots show bacterial burdens of individual 
mice. The bar represents the median. The data were statistically analyzed with the Mann-Whitney U test: *** 
p<0.001.  
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were slightly more pronounced upon YPIII infection compared to YPIII ΔcnfY infection 
(Figure 3.1D). Thereafter, all mice displayed very mild diarrhea, which did not differ between 
the two groups. Interestingly, the majority of mice still displayed very mild diarrhea until the 
end of the experiment (Figure 3.1D). Taken together, these results support the assumption that 
YPIII ΔcnfY initiates a more frequent long-term infection and is less frequently cleared from 
the gut luminal compartment than the wild type after intra-gastric challenge with sub-lethal 
infection doses. 
To corroborate that YPIII ΔcnfY indeed persists more efficiently, bacterial burden assays in the 
persistency niche, the cecum, were performed at 42 dpi. About 68 % of the analyzed ceca were 
still colonized with YPIII ΔcnfY, whereas only 16 % of the ceca were inhabited by YPIII 
(Figure 3.2A). Moreover, around 52 % of YPIII ΔcnfY infected mice presented Yersinia 
burdens higher than 10
4
 CFU/g, while the same was true for only 9.7 % of YPIII infected mice 
(Figure 3.2B). This tendency was verified for the luminal contents of the cecum (53.3 % 
YPIII ΔcnfY; 8.7 % YPIII) (Figure 3.2C). In addition, correlation analysis revealed that cecal 
tissue loads highly correlated with luminal loads (Figure S3A). Therefore, it was 
undistinguishable if the persistence reservoir is mainly located in the cecal tissue or the luminal 
contents. This suggests that both compartments might constitute a persistence reservoir, which 
enables bacterial shedding into the environment. In addition, cecal tissue burdens strongly 
correlated with the fecal loads (Figure S3B). Taken together, fecal and cecal content screenings 
provided a reliable means to screen for highly colonized ceca. 
The analysis of the small intestinal colonization, i.e. small intestinal tissue, luminal contents 
and PPs, revealed that YPIII ΔcnfY, like YPIII, primarily persists in the cecum after sub-lethal 
infection (Figure S4; Fahlgren et al., 2014). Remarkably, enhanced persistence ability of 
YPIII ΔcnfY compared to YPIII was also confirmed using a different mouse strain, i.e. FVB/N 
(Figure S5).  
In summary, these experiments indicated that the absence of cnfY expression strongly promotes 
persistence of Y. pseudotuberculosis in the cecum. Moreover, long-term cecal colonization was 
accompanied by continuous shedding of Yersinia, which reflected the colonization levels. 
3.2 Cecal pathology is linked to the stage of infection 
In general, the delivery of toxins and/or effector proteins contributes to tissue destruction and 
inflammation during acute bacterial infections (Pothoulakis, 2000; Geiser et al., 2001). Also 
CNF toxins were shown to increase tissue inflammation and destruction during infection 
(Rippere-Lampe et al., 2001a; Schweer et al., 2013). Until now, nothing is yet known about 
the impact of CNFY on tissue architecture and inflammation during persistent Yersinia 
infections, which might account for the rate of prolonged infection manifestation. Thus, the 
pathologic appearance of cecal tissue architecture and colonization upon acute and persistent 
infection was examined.   
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3.2.1 Histopathology of the cecum during acute and persistent infection 
stage 
To examine the inflammatory reactions and tissue architecture of the cecum during acute 
(3 dpi) and persistent (42 dpi) infection, the histopathologic presentation of cecal tissue 
sections was studied. To this end, mice were intra-gastrically infected with either 2x10
8
 CFU 
per mouse (3 dpi) or 1x10
6
 CFU per mouse (42 dpi) of YPIII and YPIII ΔcnfY, respectively. 
The histopathologic analysis was performed by Ulrike Heise of the Mouse Pathology, Animal 
Experimental Unit at the Helmholtz Centre for Infection Research. 
During acute infection, YPIII caused more severe tissue alterations of the cecal lamina propria 
than YPIII ΔcnfY. The villi of YPIII infected ceca were heavily elongated and high-grade 
edema formation occurred at the basal site of the lamina propria. Infiltrated lymphocytes 
dominated in the basal parts of the lamina propria, while only few infiltrated PMNs were 
detected. Additionally, the lumen was filled with scaled-off epithelial cells and infiltrated 
PMNs. This luminal pathology quality was also observed upon YPIII ΔcnfY infection to 
comparable extents (Figure 3.3 upper panel). On the other hand, YPIII ΔcnfY infected animals 
 
 
Figure 3.3 Acute Y. pseudotuberculosis infection in the cecum causes severe tissue inflammation 
with CNFY-dependent qualities. 
BALB/c mice were intra-gastrically infected with 2x108 CFU of Y. pseudotuberculosis YPIII or YPIII ΔcnfY. Three 
days post infection, the cecum was removed and sections were stained with H&E. The lamina propria (upper panel) 
and cecal lymphoid tissue (lower panel) of uninfected and infected mice were analyzed for inflammatory alterations. 
The microscopic pictures are representatives of multiple microscopic areas (>10) of groups of four mice. B: 
bacterial microcolony, E: epithelial cells, Ed: edema, U: ulcus, black/white asterisks: mixed inflammatory infiltrate, 
dashed halo: lymphocytes, parenthesis: length of villi of uninfected mice. The bar represents 100 µm. 
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displayed medium to high inflammation of the cecal lamina propria with mild villi elongation. 
Also in contrast to YPIII infection, diffusely distributed PMNs dominated in the lamina propria 
and quite rare edema formation in the basal part of the lamina propria was observed 
(Figure 3.3 upper panel). The lymphoid tissue of the cecum in YPIII infected mice also showed 
more severe tissue remodeling than YPIII ΔcnfY infected mice. This included massive necrosis 
with strong lymphocyte reduction, vast granulocyte infiltration and partial ulcus formation 
(Figure 3.3 lower panel). Compared to that, the cecal lymphoid tissue of YPIII ΔcnfY infected 
mice showed medium to high grades of inflammation. The tissue remodeling comprised partial 
necrosis with slight lymphocyte reduction, a high degree of granulocyte infiltration and rare 
edema formation in the crypts above the cecal lymphoid tissue. In both experimental groups, 
comparable numbers of bacterial microcolonies surrounded by mixed inflammatory infiltrates 
were detected inside the cecal lymphoid tissue (Figure 3.3 lower panel). 
Only very mild to no alterations of the lamina propria were identified in YPIII and YPIII ΔcnfY 
infected mice at 42 dpi (Figure S6A; data not shown). In contrast to acute infection, only 
isolated diffuse infiltration of PMNs was observed in the basal parts of the lamina propria in 
both groups (Figure 3.4 upper panel). Strikingly, no histological alterations of the cecal 
lymphoid tissue were observed when compared to equally-aged uninfected mice (Figure 3.4 
lower panel; Figure S6B). Although high Yersinia colonization levels were expected, no 
bacterial colonization was detectable by H&E staining at 42 dpi. 
This suggests that enhanced persistence of YPIII ΔcnfY compared to YPIII was not associated 
with divergent inflammatory reactions during persistent infection phase (42 dpi), but 
demonstrated that Yersinia persists in the cecal tissue without eliciting strong immune 
responses. However, CNFY-dependent tissue inflammation during acute infection might affect 
persistence development.  
 
Figure 3.4 Persistent Y. pseudotuberculosis infection in the cecum displays no to very mild inflam-
mation independent of CNFY. 
BALB/c mice were intra-gastrically infected with 1x106 CFU of Y. pseudotuberculosis YPIII or YPIII ΔcnfY. At 
42 dpi, the ceca of highly colonized mice were isolated and sections were stained with H&E. Persistently colonized 
mice (YPIII middle panel; YPIII ΔcnfY: right panel) and uninfected mice of the same age (left panel) were analyzed 
for inflammatory alterations in the lamina propria (upper panel) and cecal lymphoid tissue (lower panel) at 42 dpi. 
The shown microscopic pictures are representatives of multiple microscopic areas (>10) of groups of 4 to 5 mice. 
White asterisks: mixed inflammatory infiltrate. The bar represents 50 µm (upper panel) or 100 µm (lower panel). 
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3.2.2 Stable expression of mRuby2 is suitable for in vivo localization studies 
The previous results indicated a divergent bacterial localization and/or distribution during 
persistent Yersinia infection compared to acute infection phase. To uncover and compare the 
distinct colonization patterns of Y. pseudotuberculosis especially during persistent infection in 
mice, a straightforward tool was designed and evaluated to study Y. pseudotuberculosis 
localization inside the cecal tissue. Here, the red fluorescent protein mRuby2 under the control 
of the tetracyclin promoter (PLtetO-1) was integrated into a transcriptionally silent locus of the 
Y. pseudotuberculosis chromosome between YPK_3294 (LysR family transcriptional 
regulator) and YPK_3295 (pepD, aminoacyl-histidine dipeptidase) (Figure 3.5) (Nuss et al., 
2015; Nuss et al., 2017). 
 
Figure 3.5 PLtetO-1::mRuby2 integration site into the Y. pseudotuberculosis YPIII chromosome. 
PLtetO-1::mRuby2 was introduced into the Y. pseudotuberculosis YPIII genome between YPK_3294 (LysR family 
transcriptional regulator) and YPK_3295 (pepD, aminoacyl-histidine dipeptidase). The distances to the neighboring 
genes are depicted in the picture. 
As the integration of a new and energy demanding genetic element into the Yersinia 
chromosome could impact energy consumption and affect polar genes, the transgenic 
Y. pseudotuberculosis strains YPIII (mRuby2) and YPIII ΔcnfY (mRuby2) were characterized 
for their growth behavior and mRuby2 expression patterns in vitro. The analysis revealed no 
growth defects at neither 25 °C nor 37 °C (Figure 3.6). Moreover, fluorescence microscopy of 
the mRuby2 expressing Yersinia strains at 25 °C and 37 °C during different growth phases  
 
 
Figure 3.6 Chromosomal integration of PLtetO-1::mRuby2 does not impact Y. pseudotuberculosis 
growth. 
Bacterial cultures were grown in LB medium at (A) 25 °C or (B) 37 °C for 24 h. At several time points, optical 
density at 600 nm (OD600) was determined. The data show the mean ±SEM of three combined independent 
experiments performed in duplicates. 
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(exponential, early stationary, late stationary) demonstrated mRuby2 expression during all 
assessed conditions (Figure S7-S8). As expected, no red fluorescence was detectable in YPIII 
and YPIII ΔcnfY without the fusion constructs (Figure S9). Thus, the genomic modification at 
the desired genomic region did yield stable mRuby2 expressing Y. pseudotuberculosis without 
a growth defect. 
The Y. pseudotuberculosis mRuby2-labeled strains were further evaluated for their in vivo 
phenotypes during lethal and sub-lethal infections. To assess the virulence and colonization  
 
 
Figure 3.7 Chromosomal Integration of PLtetO-1::mRuby2 does not alter virulence and colonization 
of the cecum. 
BALB/c mice were intra-gastrically infected with 2x108 CFU of Y. pseudotuberculosis YPIII, YPIII ΔcnfY or the 
isogenic mRuby2 labeled strains. (A-B) Health status and survival were monitored over 14 days. The presented data 
were combined from two independent experiments: YPIII n=9, YPIII ΔcnfY n=8, YPIII (mRuby2) n=8, 
YPIII ΔcnfY (mRuby2) n=9. (A) Survival of BALB/c mice. Survival data were statistically analyzed with the log-
rank (Mantel-Cox) test: ns, not significant: *** p<0.001. (B) Weight loss curves. Mice that lost more than 20 % of 
their initial body weight or reached a health score of lower than three were sacrificed and recorded as dead (2.5.2; 
Table 2.13). The graphs represent the mean  ± SD. The data were statistically analyzed with multiple t-tests using 
Holm-Šídák’s correction: * p<0.05. (C) Yersinia burden in the cecum at 3 and 5 dpi. The presented data were 
combined from two independent experiments with 8 to 10 mice per group. Statistical analysis was performed using 
the Kruskal-Wallis test and Dunn’s correction: ns, not significant.  
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abilities upon lethal infections, mice were intra-gastrically challenged with 2x10
8
 CFU of 
YPIII, YPIII ΔcnfY or their isogenic mRuby2 mutants, respectively. Thereafter, survival, 
weight loss and the cecal bacterial colonization levels were recorded (Figure 3.7). Similar to 
the parental strain YPIII ΔcnfY, YPIII ΔcnfY (mRuby2) did not cause mortality in BALB/c 
mice (Figure 3.7A). Comparison of the weight loss between YPIII ΔcnfY and 
YPIII ΔcnfY (mRuby2) further revealed that both groups lost about 1-10 % of their body 
weight until 6 dpi, but recovered quickly until 11 dpi and did not differ significantly from each 
other (Figure 3.7B, data not shown). On the other hand, YPIII and YPIII (mRuby2) infected 
mice succumbed to the infection around 6 dpi, displaying no significant differences in 
virulence (Figure 3.7A). Accordingly, there were also no significant differences in body weight 
between YPIII and YPIII (mRuby2). Both groups of mice rapidly lost similar amounts  
of body weight starting from 2 dpi (Figure 3.7B). YPIII and YPIII ΔcnfY differed significantly 
in virulence and body weight loss, irrespective of the chromosomal integration of  
PLtetO-1::mRuby2 (Figure 3.7A, B). Therefore, the chromosomal integration of PLtetO-1::mRuby2 
did not alter neither virulence (Figure 3.7A) nor disease progression (Figure 3.6B) upon lethal 
infection.  
Comparison of the colonization abilities in the cecum revealed, that the mRuby2-producing 
strains YPIII (mRuby2) and YPIII ΔcnfY (mRuby2) colonized the cecal tissue to the same 
extend as their parental strains with approximately 3-4x10
7
 CFU/g at 3 dpi and 2-4x10
6
 CFU/g 
at 5 dpi (Figure 3.7C). In the other organs no significant differences were observed due to 
integration of PLtetO-1::mRuby2 into the chromosome of YPIII or YPIII ΔcnfY at 3 and 5 dpi 
(Figure S10). Hence, lethal infections with YPIII and YPIII ∆cnfY were not affected by the 
integration and expression of mRuby2. 
To exclude that chromosomal integration of PLtetO-1::mRuby2 impacts persistence development, 
long-term colonization of YPIII (mRuby2) and YPIII ΔcnfY (mRuby2) were also tested in the 
persistent BALB/c infection model. To this end, mice were intra-gastrically infected with 
1x10
6
 CFU of YPIII (mRuby2), YPIII ΔcnfY (mRuby2) or their parental strains. Subsequently, 
disease progression was monitored for up to 42 dpi. As for acute infections, no alterations of 
disease progression upon sub-lethal infections with the transgenic Y. pseudotuberculosis 
mRuby2 strains were detected compared to the parental strains YPIII and YPIII ΔcnfY 
(Figure 3.8A). Like YPIII infected mice, YPIII (mRuby2) infected mice lost about 10 % of 
their initial body weight in the first 9 to 12 dpi, but regained it over the following two weeks. 
Similarly, YPIII ΔcnfY (mRuby2) infected mice did not lose any body weight but constantly 
gained body weight like YPIII ΔcnfY infected mice. In addition, the bacterial loads in the feces 
of YPIII (mRuby2) and YPIII ΔcnfY (mRuby2) infected mice did not differ significantly from 
the bacterial burden of the respective parental strain at all indicated time points 
(Figure 3.8B, C). In line with the previous results, broth enrichment revealed the same 
rates/number of persistent YPIII (mRuby2) and YPIII ΔcnfY (mRuby2) in the feces of mice as 
their parental strains (Figure S11). Therefore, chromosomal integration of PLtetO-1::mRuby2 did 
not impact prolonged infection abilities and phenotypes in the persistent infection model. 
To confirm that YPIII (mRuby2) and YPIII ΔcnfY (mRuby2) persist in the cecum like their 
parental strains, the colonization rates and bacterial burden were assayed at 42 dpi 
(Figure 3.8D, Figure S12). YPIII (mRuby2) still colonized about 18.2 % of the ceca and 
YPIII ΔcnfY (mRuby2) about 60 % of the ceca, thereby reproducing the persistence frequencies 
of YPIII (16 %) and YPIII ΔcnfY (68 %) in the cecum (Figure 3.8D, 3.1). Moreover, the 
YPIII (mRuby2) and YPIII ΔcnfY (mRuby2) loads in the cecal tissue and the cecal luminal 
contents also resembled those obtained with the unlabeled strains (Figure S12, 3.1), indicating 
RESULTS 
62 
 
that integration of PLtetO-1::mRuby2 into the YPIII and YPIII ΔcnfY chromosome did not impact 
persistence and long term colonization abilities in the cecum. Notably, the recovered bacteria 
from the egesta exhibited mRuby2-derived red fluorescence at all analyzed time points (data 
not shown).  
 
Figure 3.8 Chromosomal integration of PLtetO-1::mRuby2 does not affect Yersinia persistency 
phenotypes. 
BALB/c mice were intra-gastrically infected with 1x106 CFU of Y. pseudotuberculosis YPIII, YPIII ΔcnfY or the 
isogenic mRuby2 encoding strains. Health status and bacterial colonization in the egesta were monitored during 40 
days. (A) Relative body weights compared to the initial weight. The data show the mean: YPIII n=20; YPIII ΔcnfY 
n=10, YPIII (mRuby2) n=40, YPIII ΔcnfY (mRuby2) n=20. The data were statistically analyzed with multiple t-test’s 
employing Holm-Šídák’s correction. Results were not significant. (B, C) Individual Yersinia loads in the feces of 
mice at indicated time points post infection. The bar represents the geometric mean. The data were combined from 
two experiments and statistically analyzed with Mann-Whitney U test. The results were not significant. YPIII n=40; 
YPIII ΔcnfY n=10, YPIII (mRuby2) n=40, YPIII ΔcnfY (mRuby2) n=20. (D) Yersinia colonization frequencies in the 
cecum of surviving mice. The frequencies were calculated using bacterial burden data of the cecum: 
YPIII (mRuby2) n=11; YPIII ΔcnfY (mRuby2) n=10.  
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These data confirm that chromosomal integration of PLtetO-1::mRuby2 yielded stable mRuby2-
expressing Y. pseudotuberculosis that phenotypically behave like the parental strains during 
lethal and sub-lethal infections in vivo. 
3.2.3 Yersinia colonization patterns during acute and persistent infection 
phase 
Yersiniae are classical extracellular located pathogens that grow in large bacterial foci, referred 
to as microcolonies, inside infected tissues during early infection (Simonet et al., 1990; 
Autenrieth and Firsching, 1996; Balada-Llasat and Mecsas, 2006). In contrast to the acute 
infection, no bacterial microcolonies were detected during persistent infection with 
Y. pseudotuberculosis by H&E staining (3.2.1) in BALB/c mice, suggesting divergent 
localization and/or distribution during persistent infection compared to acute infection. 
Y. pseudotuberculosis YPIII (mRuby2) and YPIII ΔcnfY (mRuby2) were employed to elucidate 
the localization and colonization patterns during acute (3 dpi; 2x10
8
 CFU/mouse) and 
persistent (42 dpi; 1x10
6
 CFU/mouse) infection. To this end, the ceca of the infected mice were 
sectioned and subsequently analyzed using fluorescence microscopy. 
 
Figure 3.9 Yersinia colonization in the lamina propria is dependent on infection stage and cnfY. 
Groups of three BALB/c mice were intra-gastrically infected with either 2x108 CFU (acute) or 1x106 CFU 
(persistent) of Y. pseudotuberculosis YPIII (mRuby2) or YPIII ΔcnfY (mRuby2). At 3 dpi (acute) or 42 dpi 
(persistent), sections of highly colonized ceca (data not shown) were prepared, fixed, stained and analyzed under the 
fluorescence microscope. (A) The microscopy pictures are representatives of multiple microscopic areas (>15) of 
the lamina propria. Red: Y. pseudotuberculosis (mRuby2), Blue: DAPI stained host cell nuclei. (B) Lamina propria 
colonization score (Table 2.15). The sections were scored for bacterial colonization by analyses of n sections of 
multiple fields; 3 dpi: YPIII n=51, YPIII ΔcnfY n=45; 42 dpi: YPIII n=56, YPIII ΔcnfY n=58; * p<0.01. The data 
show the mean scores ±SEM combined from 3 mice per group. Statistical analyses were performed using multiple  
t-tests with Holm-Šídák’s correction. 
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Upon acute infection, YPIII (mRuby2) and YPIII ΔcnfY (mRuby2) colonized the basal site of 
the cecal lamina propria in small single or multi-cell aggregates (Figure 3.9A; upper panel), 
whereby the lamina propria was significantly stronger colonized by YPIII (mRuby2) than 
YPIII ΔcnfY (mRuby2), as determined by scoring of the colonization grades (Figure 3.9B). 
As during acute infection, YPIII (mRuby2) and YPIII ΔcnfY (mRuby2) also colonized the basal 
site of the cecal lamina propria at 42 dpi (Figure 3.9A; lower panel). The colonization scores in 
the lamina propria of both Yersinia strains were lower during persistent infection compared to 
acute infection. However, they did not differ between YPIII (mRuby2) and 
YPIII ΔcnfY (mRuby2) during prolonged infection (Figure 3.9B).  
In the cecal lymphoid tissue two distinct Yersinia colonization patterns were observed during 
acute infection. YPIII (mRuby2) and YPIII ΔcnfY (mRuby2) were either found in large 
bacterial aggregates (microcolonies) with a diameter greater than 20 µm (Figure 3.10A; upper 
panel) or in dispersely-distributed small single to multi-cell aggregates that had a maximal 
diameter of 20 µm (Figure 3.10B; upper panel). 
The microcolony sizes did not differ significantly between YPIII (mRuby2) and 
YPIII ΔcnfY (mRuby2) (Figure 3.10C) and the vast majority of YPIII (mRuby2) and 
YPIII ΔcnfY (mRuby2) microcolonies caused small to large tissue lesions, which did not differ 
between the groups (Figure S13, data not shown). However, the area covered with small single 
and multi-cell aggregates of YPIII (mRuby2) was slightly greater in the cecal lymphoid tissue 
than in YPIII ΔcnfY (mRuby2)-infected mice (Figure 3.10D). 
Interestingly, both Yersinia strains colonized the cecal lymphoid tissue in a completely 
different pattern during persistent infection (Figure 3.10). Densely packed microcolonies were 
found only very rarely (Figure 3.10A; lower panel). In the vast majority of the analyzed cecal 
lymphoid tissues no bacterial microcolonies were visible (Figure 3.10C). The yersiniae were 
generally located in dispersely distributed small multi-cell aggregates (Figure 3.9B; lower 
panel). Nevertheless, the grade of cecal lymphoid tissue colonization was comparable to acute 
infection and did not differ between YPIII (mRuby2) and YPIII Δ cnfY (mRuby2) 
(Figure 3.10D). Furthermore, most bacteria were found in the intercellular space, forming 
halo-like structures around single lymphocytes (Figure 3.10B; lower panel). This cell-
association was significantly stronger during persistent infection compared to acute infection, 
but did not differ between YPIII (mRuby2) and YPIII ΔcnfY (mRuby2) (Figure 3.10E). 
Strikingly, during the persistent stage no differences in the colonization patterns of 
YPIII (mRuby2) and YPIII ΔcnfY (mRuby2) were observed. 
Altogether, Y. pseudotuberculosis localizes to the basal parts of the lamina propria and inside 
the cecal lymphoid tissue, displaying different colonization patterns during the acute and 
persistent phase inside the cecal lymphoid tissue: During acute infection, bacteria localize in 
large microcolonies and dispersely distributed as single to small multi-cell aggregates. 
However, upon persistent bacterial infection, discovery of densely-packed small bacterial 
microcolonies was an exception. Yersiniae localized predominantly as dispersely distributed 
small multi-cell aggregates in the intercellular space, forming a halo-like structure around 
single lymphocytes. In contrast to persistent infection, YPIII (mRuby2) seemed to colonize 
larger tissue areas of the lamina propria and the cecal lymphoid tissue during the acute 
infection than YPIII ΔcnfY (mRuby2) during the acute phase.  
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Figure 3.10 The Yersinia colonization patterns in the cecal lymphoid tissue differ independently of 
CNFY between the infection stages. 
BALB/c mice were intra-gastrically infected with either 2x108 CFU (3 dpi) or 1x106 CFU (42 dpi) of 
Y. pseudotuberculosis YPIII (mRuby2) or YPIII ΔcnfY (mRuby2). At 3 dpi (acute) or 42 dpi (persistent), sections of 
highly colonized ceca were prepared, fixed, and stained. (A) Microcolonies in the cecal lymphoid tissue. (B) 
Dispersely distributed small multi-cell aggregates in the cecal lymphoid tissue. The microscopy pictures are 
representatives of multiple microscopic areas (>15). Red: Y. pseudotuberculosis (mRuby2), Blue: DAPI stained host 
cell nuclei. (C-E) The sections were scored for bacterial colonization by the analyses of multiple sections (>15) of n 
fields. The data show the mean scores ±SEM combined from 3 mice per group. Statistical analyses were performed 
using multiple t-tests with Holm-Šídák’s correction. (C) Microcolony size score (Table 2.15). 3 dpi: YPIII n=141, 
YPIII ΔcnfY n=237; 42 dpi: YPIII n=166, YPIII ΔcnfY n=167; * p<0.001. (D) Disperse small multi-cell aggregate 
scores in the cecal lymphoid tissue (Table 2.15). 3 dpi: YPIII n=150, YPIII ΔcnfY n=167; 42 dpi: YPIII n=141, 
YPIII ΔcnfY n=237; * p<0.01. (E) Association of bacteria in the intercellular space around cells in the cecal 
lymphoid tissue (Table 2.15). 3 dpi: YPIII n=78, YPIII ΔcnfY n=127; 42 dpi: YPIII n=149, YPIII ΔcnfY n=165; 
* p<0.05.  
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3.3 Microbial community composition upon Y. pseudotuberculosis 
infection 
Up to date, many research groups described alterations in the commensal community 
composition upon inflammation and infection that might influence outcome and chronicity 
(McKenney and Pamer, 2015; Iizasa et al., 2015; Hawrelak and Myers, 2004). Recent studies 
also showed that Yersinia infection can lead to global alterations of the commensal microbial 
community, which might alter infection outcomes (Avican et al. 2015; Fonseca et al., 2015; 
Kamdar et al., 2016). 
Since stronger inflammatory reactions were observed due to Y. pseudotuberculosis YPIII 
infection than upon infection with Y. pseudotuberculosis YPIII ΔcnfY (3.2.1), it was 
hypothesized that this could lead to more pronounced alterations in the commensal microbial 
community. In order to analyze this, the commensal microbial composition was assessed via 
16S rDNA sequencing of acute and persistently colonized mice after intra-gastric challenge 
with 1x10
6 
CFU of Y. pseudotuberculosis YPIII or YPIII ΔcnfY at various time points post 
infection. These experiments were performed in collaboration with Sophie Thiemann of the 
Microbial Immune Regulation group at the Helmholtz Center for Infection Research. Further 
analysis of the relative abundances of phyla demonstrated that both groups initially displayed 
comparable relative abundances of phyla, which did not change drastically over the first 3 days 
of infection (Figure 3.11A). However, YPIII infected animals showed pronounced alterations 
of the commensal microbial composition at 9 dpi (Figure 3.11). This was also visible in the 
principal coordinates analysis, which revealed clustering of the feces samples of YPIII at 9 dpi 
which was distinct from the others (Figure S14). At 9 dpi, there was a relative increase in the 
abundance of Proteobacteria (particularly Desulfovibrionales), Firmicutes (in particular 
Clostridiales and Lactobacillales), and Cyanobacteria (YS2), as well as a strong decrease of 
Bacteroidetes (Bacteroidales) (Figure 3.11A, B). Nevertheless, the relative abundances of the 
commensal microbiota recovered after acute infection and were completely restored to the 
initial state at 42 dpi. Interestingly, the relative abundance of Lactobacillales slightly increased, 
whereas the relative abundance of Bacteroidales decreased during persistent YPIII infection 
(42 dpi; Figure 3.11B). 
Strikingly, no such drastic changes were observed during YPIII ΔcnfY infection 
(Figure 3.11A). There was only a slight increase in Verrucomicrobiota (Verrucomicrobiales) 
and a minor decrease in Bacteroidetes (Bacteroidales) at 9 and 21 dpi (Figure 3.11). Within the 
Firmicutes the Clostridiales decreased in their relative abundance whereas there was an 
increase in Erysipelotrichales at 21 dpi (Figure 3.11B). Nonetheless, at 42 dpi the relative 
abundances of all phyla recovered to the initial composition (Figure 3.11A). 
In mice and humans, the phyla Firmicutes and Bacteroidetes make up the majority of 
commensal bacteria (Lei et al., 2005). Since the relative abundances of both phyla were altered 
during Y. pseudotuberculosis infection, the relative abundance of the single families in the 
phyla was subjected to detailed analysis (Figure 3.12).  
Upon YPIII ΔcnfY infection, the proportions of the families within the Firmicutes remained 
fairly stable over the whole course of infection (Figure 3.12). Only within the Bacteroidetes the 
relative abundances of Prevotellaceae and Rikenellaceae (both Bacteroidales) reduced at 9 dpi.  
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Figure 3.11 Y. pseudotuberculosis infection leads to an altered commensal composition. 
BALB/c mice were infected with 1x106 CFU of Y. pseudotuberculosis YPIII or YPIII ΔcnfY, respectively. At 
indicated time points post infection fresh feces was sampled from individual mice and screened for Yersinia 
colonization. Mice with persistent Yersinia infection were analyzed for their commensal microbial composition by 
16S rDNA analysis. Each time point includes the average relative abundance from data of 5 to 6 mice. (A) Relative 
abundance of detected microbial phyla in the feces of persistently colonized mice over time. (B) Relative abundance 
of detected microbial orders in the feces of persistently colonized mice over time. 
While the relative abundance of Prevotellaceae recovered quickly after the late acute infection 
phase, the relative abundance of Rikenellaceae remained as low. Instead, the relative 
abundance of S24-7 (Bacteroidales) continuously increased starting from 9 dpi. 
In contrast, a massive remodeling of commensal relative abundances was observed within the 
Firmicutes and particularly within the Bacteroidetes upon a YPIII infection (Figure 3.12). 
Within the Firmicutes the relative abundance of Lachnospiraceae (Clostridiales), 
Ruminococcaceae (Clostridiales), Eubacteriaceae (Clostridiales), other Clostridiales, 
Enterococcaceae (Lactobacillales) and Streptococcaceae (Lactobacillales) increased at 9 dpi. 
On the other hand, the relative abundance of Lactobacillaceae (Lactobacillales) drastically 
decreased (Figure 3.12). Later during the infection course, all of these families normalized to 
initial levels, whereas the relative abundance of the Lachnospiraceae kept rather stable. In the 
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phylum Bacteroidetes, more drastic alterations of microbial relative abundances were observed 
(Figure 3.12). Similar to YPIII ΔcnfY infection, the relative abundance of Prevotellaceae 
decreased to comparable amounts at 9 dpi. In particular, the relative abundance of S24-7 
decreased in the late acute YPIII infection (Figure 3.12). Interestingly, the Odoribacteraceae 
(Bacteroidales) were the exclusive family, which increased in their relative abundance within 
the Bacteroidetes at 9 dpi. At later time points post infection, the relative abundances of the 
mentioned families restored to their initial levels of relative abundances, except the 
Prevotellaceae (Figure 3.12). 
Altogether, these results suggest that infection-triggered inflammation might cause alteration 
of commensal composition. Especially, the exacerbated inflammatory reaction upon YPIII 
infection might strongly impact the composition of the intestinal microbiota. 
 
Figure 3.12 Y. pseudotuberculosis infection triggers remodeling of the commensal relative abun-
dance in the phyla Firmicutes and Bacteroidetes. 
BALB/c mice were infected with 1x106 CFU of Y. pseudotuberculosis YPIII or YPIII ΔcnfY, respectively. At 
indicated time points post infection fresh feces was sampled from individual mice and screened for Yersinia 
colonization. Mice with persistent Yersinia infection were analyzed for their commensal microbial composition by 
16S rDNA analysis. Every time point includes the average relative abundance of families within the Bacteroidetes 
and Firmicutes. The averages were calculated from data of 5 to 6 mice at each time point.  
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3.4 Study of infection stage dependent host-pathogen interactions 
In contrast to acute bacterial infections, the comprehension of host immune responses and 
host-pathogen interactions during chronic infections has just started to be obtained. In order to 
explore the global immune mechanisms underlying the development of Yersinia persistence 
and its characteristics during acute (5 dpi) and persistent (42 dpi) infection, the global host 
transcriptome of the cecum upon Y. pseudotuberculosis YPIII or YPIII cnfY infection was 
evaluated by employing strand-specific RNA sequencing (Figure 3.13A). 
To this purpose, high quality RNA pools (Figure S15A) obtained from ceca of equally-aged 
and equally-colonized mice (Figure S15B) were depleted for mouse ribosomal RNA (rRNA) in 
order to raise the informative mouse transcript coverage, as described by Nuss et al., 2017 
(Figure 3.13A). Commercial ERCC (external RNA controls consortia) spike-in controls 
comprising a 10
6
-fold concentration range, were added to determine sequencing precision and 
platform performance (Figure 3.13A). For strand specific deep sequencing, cDNA libraries 
were generated with the Illumina ScriptSeq
TM
 kit (Figure 3.13A). The cDNA library deep 
sequencing produced around 26 million reads of which approximately 16 million mapped to 
the murine mm10 genome, achieving sufficient coverage. Moreover, of the 16 million genomic 
mappings, an average of 11 million reads mapped to genes (Table S1). The dynamic range of 
the sequencing run was calculated to be about 18 log2-units of concentration (Figure S16A) 
and the assessment of the fold change estimates revealed high platform accuracy, which was 
adequate to reliably determine and compare transcript abundance across a broad dynamic range 
(Figure S16B). Additionally, all replicates strongly correlated to the replicates of the same 
group with a Pearson correlation coefficient of r >0.97 (Figure S17). As high quality data were 
obtained, reliable transcript quantification, global host expression profile analysis and 
comparison was conducted. 
The global gene expression profiles (GGEPs) of the nine different conditions were distinct and 
each condition clustered well together (Figure 3.13B, C). The GGEPs of acute infected ceca 
were both most distant to the GGEPs of uninfected ceca (Figure 3.13B, C). This most probably 
reflects the induction of inflammatory immune responses by epithelial cells and infiltrating 
immune cells that, in all likelihood, are the main drivers of altered gene expression profiles 
during acute infection. However, the GGEPs of acute YPIII- and YPIII cnfY-infected ceca 
were distinct and clustered hierarchically distant from each other emphasizing that the host 
tissue reactions are distinct in response to YPIII and YPIII ΔcnfY acute infections 
(Figure 3.13C). Interestingly, the GGEPs of persistently YPIII-colonized ceca also clustered 
separately from those of uninfected and chronically YPIII cnfY-infected ceca (Figure 3.13C). 
These results show that the host gene expression profile is somewhat more altered in response 
to YPIII than YPIII cnfY during the persistent infection stage. 
To gain further knowledge about the Yersinia-triggered gene expression changes during acute 
and persistent infection, which might impact the development and maintenance of persistent 
Y. pseudotuberculosis infection, the differential expression analysis package DESeq2 was 
applied (Love et al., 2014). The results of these analyses are described in the following 
sections. 
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Figure 3.13 The host expression profile during acute and persistent Y. pseudotuberculosis 
infections in the cecum. 
BALB/c mice were intra-gastrically infected with either 2x107 CFU (5 dpi)/1x106 CFU (42 dpi) of 
Y. pseudotuberculosis YPIII or 2x108 CFU (5 dpi)/1x106 CFU (42 dpi) of Y. pseudotuberculosis YPIII ΔcnfY. 
(A) Work flow for murine expression profile assessment. At the indicated time points, ceca of highly colonized 
mice or equally aged uninfected mice were snap frozen. The complete RNA was extracted using a water-saturated 
phenol-based extraction protocol. Subsequently, the isolated RNA was pooled together using material from three to 
five mice. After the removal of contaminating DNA and the depletion of ribosomal RNA (rRNA), ERCC spike in 
control mixes were added to control the platform performance. Thereafter, complementary DNA (cDNA) libraries 
were prepared and subjected to strand specific deep sequencing. The assessed reads were demultiplexed, the quality 
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of the sequences libraries was assessed and adaptors were clipped of the fragments in silico. The remaining reads 
were mapped to the ERCC spike in controls and platform-performance control parameters were calculated. Finally, 
the remaining reads were mapped with Tophat to the murine genome and submitted to differential expression 
analysis for sequencing data (DESeq2). (B) Three dimensional principle component analysis of the replicates. The 
third replicate of YPIII ΔcnfY at 42 dpi clusters closely with the first replicate. See also (C). (C) Euclidian sample-
to-sample distances calculated for the single replicates. 
3.4.1 Host gene expression profiling during acute infection in the cecum 
At first, the host gene-expression profiles during acute infection were analyzed. Upon acute 
infection, 16,974/15,609 (YPIII/YPIII cnfY) murine genes were profiled by comparison of the 
infected to the uninfected group, respectively (data not shown). Of those genes, 75/120 
(YPIII/YPIII cnfY) were more abundant (induced) with a corresponding log2-
fold change (FC) > 2. Furthermore, 26/16 genes were less abundant (repressed) owing a 
log2 FC < -2 (Table S2; Table S3). Gene ontology (GO) enrichment analysis revealed that 
Yersinia infection significantly altered the host transcriptome. Many of the most highly 
regulated genes were connected to inflammatory responses, immune cell chemotaxis, and acute 
phase response (data not shown). Comparison of both expression profiles (YPIII/YPIII ΔcnfY 
vs. uninfected) revealed three groups of genes: those that where commonly highly (up-) 
regulated (Figure 3.14C), or only highly (up-) regulated upon the respective infection (YPIII 
 
 
Figure 3.14 Differentially expressed genes upon acute infection with Y. pseudotuberculosis in the 
cecum 
Venn diagram of the differentially expressed genes during acute infection (5 dpi) comparing Y. pseudotuberculosis 
infected ceca to uninfected. (B) Venn diagram of induced genes comparing Y. pseudotuberculosis infected ceca to 
uninfected. (C) Heat map of Yersinia-increased transcripts (log2 FC > 2; p < 0.05) at 5 dpi comparing 
Y. pseudotuberculosis infected ceca to uninfected samples (YPIII left column; YPIII cnfY right column).  
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or YPIII ΔcnfY) compared to gene expression levels of uninfected mice (Figure 3.14A, B). 
Interestingly, YPIII ΔcnfY infection caused the up-regulation of about 2-fold more genes than 
YPIII infection in comparison to the uninfected samples (Figure 3.14B). 
Among the commonly highly up-regulated genes were several metal ion scavenging proteins 
that limit metal ion availability (i.e. lcn2, hp, s100a9, s100a8), cytokines and chemokines (i.e. 
il-6, cxcl3, ccl2, cxcl2, il-1β, cxcl5, cxcl1, cxcl10, il-1α), acute-phase response proteins (chil1, 
saa3), an inflammasome component (i.e. nlrp3), genes involved in reactive compound 
protection/detoxification (i.e. cyp1b1, arg1) (Popovic et al., 2007; Jaeger et al., 2015), and a 
versatile g-protein coupled receptor fpr2 that triggers multiple cellular events after activation, 
such as activation/inhibition of NFκB, chemotaxis, superoxide generation, healing and cell 
proliferation (Cattaneo et al., 2013) (Figure 3.14C). Furthermore, matrix metalloproteinases 
and inhibitors (mmp3, mmp8, mmp10, timp1, hp), controlling multiple immune functions, e.g. 
cytokine in-/activation, tissue permeability, cytokine gradients, and antimicrobial peptide or 
defensin activation (Elkington et al., 2005), were induced upon Y. pseudotuberculosis infection 
(Figure 3.14C). The analysis also revealed increased expression of irg1, which produces 
bactericidal and immune modulatory itaconate (Luan and Medzhitov, 2016) and the endocytic 
receptors, clec4d and clec4e, involved in bacterial recognition and uptake (Wilson et al., 2015; 
Sharma et al., 2014) (Figure 3.14C). Although these genes were commonly induced upon both 
Yersinia infections, a stronger induction of il-6, cxcl2, mmp8, haptoglobin (hp) and cytochrome 
P450 (cyp1b1) expression was detected upon YPIII infection (Figure 3.14C). 
As the comparison of the GGEPs suggested differential gene expression between the two 
Y. pseudotuberculosis stains (3.4), the gene expression profiles of acute infected mice were 
compared to each other. This analysis yielded detection of 14,244 genes, of which two genes 
were induced with a log2 FC > 2, and 113 genes with a log2 FC > 1. Moreover, two genes were 
repressed with a log2 FC < -2 and 36 genes demonstrated a log2 FC < -1 upon acute 
YPIII cnfY infection in comparison to acute YPIII infection (Table S4). GO enrichment 
analysis and GAGE KEGG gene perturbation analysis showed that cnfY-deficiency 
significantly altered the host transcriptome, with many of the up-regulated pathways involved 
in the regulation of immune responses (data not shown). Moreover, the majority of 
differentially regulated genes (log2FC > 1, log2FC < -1) between YPIII and YPIII ΔcnfY 
infection at 5 dpi were also differentially regulated by comparison to uninfected mice, 
respectively (Figure 3.15A). 
The direct comparison of the two gene expression profiles revealed that genes acting on iron 
depletion from tissue, i.e. scara5 and hp, and reactive compound protection (cyp1b1) are more 
strongly induced during acute YPIII infection compared to acute YPIII ΔcnfY infection 
(Figure 3.15B). Moreover, the expression of the LPS detoxifying tissue non-specific alkaline 
phosphatase alpl and the PMN chemoattractant during barrier immune responses chil3 was 
highly induced (Bender et al., 2015; Muallem and Hunter, 2014). The data analysis also 
revealed stronger induction of genes associated with tissue turn-over/architecture 
modifications, such as wisp2, has2, adam12, adamts5, adamts4, thbs1, csgalnact1, and cdh3 
(Maytin, 2014; Nyren-Erickson et al., 2013; Lin and Liu, 2010; Kintakas and McCulloch, 
2011; Sabbah et al., 2011; Kelwick et al., 2015; Masli et al., 2014; Sato et al., 2011; 
Hubmacher and Apte, 2015). In addition, there was an up-regulation of a couple of genes  
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Figure 3.15 The host induces bacterial defense mechanisms upon Y. pseudotuberculosis 
YPIII ΔcnfY acute infection. 
(A) Venn diagram of the differentially expressed genes during acute infection (5 dpi). (B) Heat map of a selection of 
more/less abundant transcripts (-1 < log2 FC > 1; p < 0.05) at 5 dpi comparing YPIII ΔcnfY to YPIII infection (left 
column). The respective log2 FC of each gene compared to uninfected mice are displayed: YPIII infected mice 5 dpi 
compared to uninfected (middle column) and YPIII ΔcnfY infected mice 5 dpi compared to uninfected (right 
column). Grey fields indicate no significant changes (p ≥ 0.05) compared to uninfected mice. 
involved in angiogenesis, i.e. col8a1, eln, fgf2, cyp1b1, angptl4, and vip (Iruela-Arispe et al., 
1991; Delgado et al., 2001; Jiang et al., 2016; Li et al., 1998; Liu et al., 2013a; Bäckhed et al., 
2007; Palenski et al., 2013) (Figure 3.15B).  
Altogether, these findings lead to the assumption that massive tissue remodeling occurs during 
acute YPIII infection due to high induction of inflammation, which is not observed during 
acute YPIII ∆cnfY infection.  
In contrast to YPIII infection, many immune response-associated GTPases and interferon-
inducible genes (e.g. gbp1, gbp2, gbp2b, gbp4, gbp6, gbp8, gbp10, igtp, iigp, Ifgga2 
(Gm4951), Ifgga3 (Gm4841), Ifgga4 (F830016B08Rik)) involved in cell-autonomous immune 
responses (Meunier and Broz, 2016) were up-regulated during YPIII ΔcnfY infection compared 
to YPIII infected samples (Figure 3.15B). Furthermore, the expression of genes encoding 
bactericidal gene products like the reactive oxygen producing enzyme Nos2 and the Duox2 
maturation factor Duoxa2 (Gogoi et al., 2016; Leto and Geiszt, 2006; Hoste et al., 2012), the 
defensins RegIIIβ, RegIIIγ, and Pla2g5 (Dann and Eckmann, 2007; van Ampting et al., 2012; 
Grönroos et al., 2001), the bactericidal chemokine Cxcl9 (Cole et al., 2001), and the acute 
phase proteins Saa1/2 were more strongly induced compared to acute YPIII infection. The 
expression of genes associated with phagosome maturation and antigen processing (i.e. rab39, 
tap1, psmb8, h2-dma, h2-q1) was also more highly induced upon acute YPIII ΔcnfY infection 
(Kasmapour et al., 2012; Abele and Tampé, 2011; Joeris et al., 2012; Russell et al., 1999; 
Zeng et al., 2012). In accordance with that, the expression of loci encoding for immunoglobin 
variable chains (e.g. ighv2-4, igkv12-98) was strongly up-regulated in comparison to YPIII 
infection at 5 dpi. Interestingly, upon acute YPIII ΔcnfY infection the expression of T cell 
associated genes such as ido1, involved in suppression of T cell proliferation and development 
of Tregs (Murakami et al., 2013), ly6a, which is up-regulated in activated T cells (Holmes and 
Stanford, 2007), cd274 an immune-inhibitory receptor on activated T cells important for 
peripheral tolerance (Freeman et al., 2000) and the T cell chemoattractants cxcl9/11 were 
highly induced (Figure 3.14C). Moreover, the expression of icos, which is involved in multiple 
T and B cell activities, for instance enhancement of T cell responses to a foreign antigen and 
assistance of antibody secretion by B cells (Wikenheiser and Stumhofer, 2016), was increased 
during acute infection with YPIII ΔcnfY. On the other hand, there was a profound up-
regulation of genes encoding proteins that modulate and limit inflammation and the immune 
response: ubd, which regulates activation of NFκB (Gong et al., 2010), socs1 that inhibits the 
JAK pathway and plays a key role in Treg stability (Ahmed et al., 2015), tnip3 that inhibits 
NFκB activation (Verstrepen et al., 2009), pla2g5 that is involved in the regulation of 
inflammation (Ohta et al., 2013; Giannattasio et al, 2010; Lapointe et al., 2010; Munoz et al., 
2009; Balestrieri et al., 2009), and pla2g2d that drives production of anti-inflammatory factors 
(Miki et al., 2013; Seroussi et al., 2013).  
These data suggest that YPIII ΔcnfY infection elicits a regulated immune response 
encompassing cell autonomous immunity, antigen processing/presentation, antibody 
maturation and immune modulation, implicating that YPIII ΔcnfY has to deal with harsher host 
environmental stresses during acute infection than YPIII. 
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All in all, these data indicate that Y. pseudotuberculosis infection induces a common acute 
inflammatory host immune response, which also differs between the two strains: YPIII acute 
infection drives massive tissue remodeling, whereas YPIII ΔcnfY acute infection induces cell 
autonomous and adaptive immune responses. 
3.4.2 Host expression pattern reprogram from acute to persistent Yersinia 
infection 
Next, the murine gene expression pattern changes from acute to persistent infection were 
analyzed. To this purpose, DESeq2 analysis was applied to compare acute to persistently 
infected mice or uninfected mice at the respective age (Table S5-Table S7).  
By comparing persistently YPIII-infected mice to acute YPIII-infected mice, 354 genes 
displayed a log2FC greater than 1.5 or less than -1.5. Of these genes, 134 genes overlapped 
with genes that were also differentially regulated upon YPIII infection at either infection stage 
(log2 fold change > 1.5; log2 fold change < -1.5; p-value < 0.05) (Figure 3.16A). The following 
analysis was concentrated on these 134 genes (Figure 3.16A). The 134 genes could be divided 
into four different groups. The first group comprises genes, which were down-regulated in the 
acute phase and then again up-regulated to the level of uninfected mice during the persistent 
infection stage (Figure 3.16B). These genes included transporter, channels and pores (i.e. 
slc20a1, slc30a10, slc37a2, slc9a3, abcb1a, aqp8, slc22a4, kcnf1, trpm6) and genes involved 
in diverse biosynthetic pathways (e.g. acetyl-CoA desaturase 1 (scd1), carboxylesterases 
(ces1c/d/f), cytochrome P450 2c55 (cyp2c55), alanine aminotransferase 1 (gpt), 
phosphoenolpyrovate carboxykinase (pck1), or galactose-3-O- sulfotransferase 2 (gal3st2)). 
This expression increase effect during persistent YPIII infection is most likely due to decreased 
relative abundance of immune cell-derived transcripts and the regeneration of the tissue in the 
persistent infection phase. 
The second group encompasses genes that were more abundant upon persistent YPIII infection 
compared to acute phase, and were more abundant during persistent infection compared to 
uninfected mice (Figure 3.16B). The majority of these genes is associated with the induction of 
immune responses. Those are described in section 3.4.3 in more detail.  
The third group includes genes that were less abundant during persistent YPIII infection 
compared to acute infection but were still slightly induced during persistent YPIII infection 
(Figure 3.16B): iron sequestration (lcn2, hp), chemokines and cytokines (e.g. cxcl5, il-1α, 
cxcl1, cxcl2, and il1f9), endocytic receptors (clec4d, clec4e), metalloproteinases and their 
inhibitors (mmp8, timp1) and inflammation modulators (chil1, chil3, irg1). 
In the fourth group, few genes were detected. This group encompasses genes that were down-
regulated upon persistent YPIII infection compared to acute YPIII infection and were not 
significantly altered during persistent YPIII infection in comparison to uninfected mice 
(Figure 3.16B). These genes were il-6, ly6g and saa3. 
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Figure 3.16 The host remodels its gene expression upon persistent Y. pseudotuberculosis YPIII 
infection 
(A) Venn diagram of the differentially expressed genes during persistent infection (42 dpi) compared to acute 
infection during YPIII challenge. (B) Heat map of a selection of differentially abundant transcripts  
(-1.5 < log2 FC > 1.5; p < 0.05) upon YPIII infection at 42 dpi compared to 5 dpi (left column). The respective 
log2 FC of each gene compared to uninfected mice at the respective time point are displayed: YPIII-infected mice at 
5 dpi (middle column) and at 42 dpi (right column) compared to uninfected mice. Grey fields indicate no significant 
changes (p ≥ 0.05) compared to uninfected mice. 
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By comparing persistently YPIII ΔcnfY-infected mice to acute YPIII ΔcnfY-infected mice 177 
genes displayed a log2FC greater than 1.5 or less than -1.5. 155 of these genes overlapped with 
genes that were also differentially regulated at either infection stage (log2 fold change > 1.5; 
log2 fold change < -1.5; p-value < 0.05) (Figure 3.17A). As for YPIII, a similar set of four 
differentially expressed transcript groups was observed. The first group includes genes that 
were more abundant during persistent stage but did not display a significant different 
expression upon persistent YPIII ΔcnfY infection compared to uninfected mice. These genes 
also encompassed transporters and channels (i.e. trpm6, slc30a10) and genes involved in 
diverse biosynthetic pathways, for instance cytochrome P450 2c55 (cyp2c55), 
carboxyltransferase (ces1d), creatine kinase M-type (ckm), and hydroxymethylglutaryl-CoA 
synthase (hmgcs2) (Figure 3.17B). Once more, this increased expression during persistent 
YPIII ∆cnfY infection is also most likely due to the reduction of immune cell-derived 
transcripts and the regeneration of the tissue in the persistent infection stage. 
In contrast to YPIII infection, the second group of this analysis comprises only one gene, 
which was more abundant during persistent YPIII ΔcnfY infection phase compared to acute 
infection and was also more abundant during persistent infection compared to uninfected mice, 
i.e. mast cell protease 1 (mcpt1). 
The third group encompasses genes that were down-regulated during persistent YPIII ΔcnfY 
infection compared to acute YPIII ΔcnfY infection, but were still slightly induced during 
persistent YPIII ΔcnfY infection (Figure 3.17B): iron scavenger (hp), chemokines and 
cytokines (i.e. cxcl2, cxcl5, cxcl9, il-1α, il-1β), bactericidal effectors (e.g. cxcl9, duox2, nos2), 
proteins that contribute to inflammation or its modulation (i.e. trem1, socs3, chil1, pla2g5), 
matrix metalloproteinase mmp3, T cell activation marker ly6a and the endocytic receptors 
(clec4d/e). 
In the fourth group, plenty of genes were detected that were down-regulated upon persistent 
YPIII ΔcnfY infection compared to acute YPIII ΔcnfY infection and demonstrated no 
significant changes in their expression compared to uninfected mice during persistent 
YPIII ∆cnfY infection (Figure 3.17B). These included the cell autonomous immunity 
associated GTPases (i.e. gbp2/2b/4/6/7/8, Ifgga2/3, igtp, iigp1), metal ion scavengers (i.e. 
s100a8/9, lcn2), acute phase response genes (saa1/2/3), matrix metalloproteinases (mmp8/10, 
pappa2), immune response modulators (e.g. ido1, irg1, tnip3, tifa, tnfaip2), chemokines and 
cytokines (i.e. ccl3, cxcl1, cxcl10, cxcl11, il-6, tnf), bactericidal or bacteriostatic proteins 
(regIIIα, regIIIβ, regIIIγ, ido1, irg1), and the granulocyte marker ly6g. 
In conclusion, the analysis of the switch of the host transcriptome profiles from acute to 
persistent Y. pseudotuberculosis infection demonstrated that the initial disruption of the tissue 
homeostasis during the acute infection phase is restored to almost homeostatic conditions at 
42 dpi. However, it appears that persistent YPIII infection still triggers stronger immune 
responses than persistent YPIII ΔcnfY infection, as (1) more immune response-associated 
genes are up-regulated during persistent YPIII infection than in YPIII ΔcnfY-infected cecal 
tissue, and (2) more immune response-linked genes in persistently YPIII ΔcnfY infected mice 
are expressed at levels as in the uninfected cecal tissue. 
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Figure 3.17 The murine gene expression patterns upon Y. pseudotuberculosis YPIII ΔcnfY 
infection reprogram from acute to persistent infection and resemble gene expression profiles of 
uninfected mice. 
(A) Venn diagram of the differentially expressed genes during persistent infection (42 dpi) compared to acute 
infection during YPIII ΔcnfY challenge. (B) Heat map of a selection of increased transcripts (-1.5 < log2 FC > 1.5; 
p < 0.05) upon YPIII ΔcnfY infection at 42 dpi compared to 5 dpi (left column). The respective log2 FC of each gene 
compared to uninfected mice at the respective time point are displayed: YPIII ΔcnfY infected mice at 5 dpi (middle 
column) and at 42 dpi (right column) compared to uninfected. Grey fields indicate no significant changes (p ≥ 0.05) 
compared to uninfected mice. 
3.4.3 Y. pseudotuberculosis dependent host gene expression profiles during 
persistent infection 
Lastly, the host gene-expression patterns during persistent Y. pseudotuberculosis infection 
were compared using DESeq2 analysis. Upon persistent infection (42 dpi), 14,244/22,434 
(YPIII/YPIII cnfY) murine genes were profiled by comparison of the infected to the 
uninfected group, respectively (data not shown). During persistent YPIII infection, 178 of 
these genes were induced with a log2 FC > 1 (5 genes with log2 FC > 2) and 112 genes were 
repressed with a log2 FC < -1 (4 genes with log2 FC < -2) compared to uninfected, equally-
aged mice (Table S8). On the other hand, the analysis of persistent YPIII cnfY infection 
compared to uninfected, equally-aged mice demonstrated that 19 genes were induced with a 
log2 FC > 1 (no genes with log2 FC > 2), and 19 genes were repressed with a log2 FC < -1 (no 
genes with log2 FC < -2) (Table S9). Noteworthy, these data demonstrate that there were 
almost 8-times more genes differentially (up-)regulated upon persistent YPIII infection 
compared to persistent YPIII ΔcnfY infection (Figure 3.18A, B). 
The following analysis was concentrated on the genes that were induced during persistent 
Y. pseudotuberculosis infection. Comparison of both expression profiles (YPIII/YPIII ΔcnfY 
vs. uninfected) revealed three groups of genes: those that where commonly up-regulated, or 
only up-regulated upon the respective infection (YPIII or YPIII ΔcnfY) compared to cecal 
tissue of uninfected mice (Figure 3.18A, B). Among the commonly up-regulated genes were 
the iron scavenger haptoglobin (hp), the immunoglobin C-regions (i.e. ighg1 and ighg2c), the 
mast cell proteases 1 and 2 (mcpt1/2), the cytokine il-1β, the chemokine cxcl2, the endocytic 
receptor clec4d, the matrix metalloproteinase mmp3, the immune-modulatory arginase-1 (arg1) 
(Popovic et al., 2007), the pro-inflammatory receptor Trem-1, which induces inflammatory 
responses such as cytokine production and phagocytosis (Arts et al., 2013), and the immune 
regulatory and anti-microbial protein secretory leukocyte protease inhibitor (slpi) (Weldon and 
Taggart, 2007) (Figure 3.18C).  
As the comparison of the GGEPs suggested differential gene expression between the two 
Y. pseudotuberculosis stains (3.4), the gene expression profiles of persistently infected mice 
were compared to each other. The direct comparison revealed that there were two large classes 
of genes: (1) immune response related (Figure 3.19) and (2) tissue organization/repair related 
genes (Figure S18). 
Further analysis showed that the metal ion scavenger systems, haptoglobin (hp), 
lactotransferrin (ltf), the ferritin receptor Scara5, and metallotheonein-1 and -2 (mt1/2) were 
significantly more strongly induced upon persistent YPIII infection compared to persistent 
YPIII ΔcnfY infection (Figure 3.19B). Interestingly, haptoglobin was the only gene among all 
genes that was also differentially expressed during persistent YPIII ΔcnfY infection compared  
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Figure 3.18 Host differentially expressed genes during persistent infection with 
Y. pseudotuberculosis  
(A) Venn diagram of the differentially expressed genes during persistent infection (42 dpi) comparing 
Y. pseudotuberculosis infected ceca to uninfected. (B) Venn diagram of induced genes comparing persistently 
Y. pseudotuberculosis infected ceca to uninfected. (C) Heat map of induced transcripts (log2 FC > 1; p < 0.05) at 
42 dpi comparing Y. pseudotuberculosis infected ceca to uninfected samples (YPIII left column; YPIII cnfY right 
column). 
to uninfected mice (Figure 3.19B). Moreover, the complement system, i.e. c7, c3, c1rb and 
c4b, and PAMP receptors (i.e. spon2, lbp and tlr9) (He et al., 2004b; Lengacher et al., 1995) 
were more highly up-regulated during persistent YPIII infection compared to YPIII ΔcnfY-
infected cecal tissue (Figure 3.19B). The persistent YPIII infection also induced the expression 
of matrix metalloproteinases (i.e. mmp8, mmp10, mmp11, mmp19), the defensin and immune 
regulatory gene pla2g5 (Table S8), and genes involved in antigen presentation or antibody 
production (e.g. h2-k2, lilra4, lilra6, igkv3-10, igkv3-1, ighv1-39, ighv1-74) (Figure 3.19B; 
Table S8). Additionally, there was an induction of genes that are involved in reactive 
metabolite/oxygen production (i.e. duoxa2 and cyp2e1), reactive metabolite/oxygen protection 
(i.e. sod3, gpx3 and cygp), and immune modulation, such as card10, aebp1, nr4a1, c1qtnf3, 
s100a9, cd300lf, socs3, alox5, il12b, chil1 and chil3 (Grabiner et al., 2007; Majdalawieh et al., 
2007; Wu et al., 2016; Schmid et al., 2014), compared to uninfected and/or YPIII ΔcnfY-
infected cecal samples (Figure 3.19B; Table S8). Interestingly, the comparison of the cecal 
tissue expression profile of YPIII-infected mice with YPIII ΔcnfY-infected mice also revealed 
that persistent YPIII infection more strongly triggered the expression of genes connected with 
adaptive immunity: Ccl21a that is important to recruit T cells to the periphery (Lo et al., 2003), 
the nuclear factor of activated T-cells Nfatc4 that is involved in expression of T cell cytokines 
(Rao et al., 1997), Chst1 that is important for lymphocyte homing in lymph nodes (Hemmerich 
and Rosen, 2000), and the TH1-specific transcription factor Hlx that interacts with the TH1-
specific transcription factor T-bet to optimally induce IFNγ expression (Mullen et al., 2002) 
(Figure 3.19B). 
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Figure 3.19 The host still responds to Y. pseudotuberculosis YPIII persistent infection 
(A) Venn-diagram of the differentially expressed genes during persistent infection (42 dpi). (B) Heat map of more 
abundant transcripts (log2FC>1; p-value<0.05) at 42 dpi comparing YPIII to YPIII ΔcnfY infection (left column). 
The respective log2FC of each gene compared to uninfected mice are displayed: YPIII infected mice 42 dpi 
compared to uninfected (middle column) and YPIII ΔcnfY infected mice 42 dpi compared to uninfected (right 
column). Grey fields indicate no significant changes (p>0.05) compared to uninfected mice. 
In contrast, persistent YPIII ΔcnfY infection induced the expression of only six genes with a 
log2FC>1 that were not increased during YPIII infection by comparison to uninfected cecal 
tissue transcription profiles: immunoglobin heavy variables 1-78 and 5-2, immunoglobin kappa 
variable 2-116, the important neutrophil chemoattractant cxcl1 (Kobayashi, 2008), and two 
mast cell proteases, i.e. mcpt9 and cma2 (Table S9). 
In summary, persistent YPIII infection drives pronounced immune reactions and tissue 
organization/repair, while changes of the host expression profile in response to persistent 
YPIII ΔcnfY infection are restricted.  
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3.4.4 In vivo-characterization of Y. pseudotuberculosis gene expression 
Recently, an in vivo deep sequencing approach demonstrated that Y. pseudotuberculosis 
reprograms its transcription profile from acute to persistent infection inside the cecal lymphoid 
tissue. The transcriptional remodeling encompassed the repression of virulence genes and 
induction of flagellar, anaerobiosis, oxidative and acid stress gene expression during persistent 
Y. pseudotuberculosis YPIII infection compared to acute infection. Furthermore, important 
virulence and metabolic regulators, i.e. crp, csrA, rovA, were induced during persistent 
infection (42 dpi) unlike during acute infection (2 dpi) (Avican et al., 2015). 
In order to compare the gene expression patterns of Y. pseudotuberculosis during the infection 
of the cecum, relative expression of Y. pseudotuberculosis genes in the total RNA extracts of 
acute (5 dpi) and chronically (42 dpi) infected ceca was evaluated employing qRT-PCR. The 
obtained expression levels were normalized to the gene expression levels of acute YPIII 
infected ceca (Figure 3.20; Figure 3.21).  
Upon persistent infection, YPIII and YPIII ΔcnfY induced the expression of the anaerobiosis 
genes (i.e. arcA, frdA, napA). ArcA (aerobic respiration control protein A) represses aerobic 
genes under anaerobic conditions, whereas FrdA (fumarate reductase flavoprotein subunit A) 
and NapA (periplasmic nitrate reductase) participate in anaerobic respiration (Figure 3.20A). 
Interestingly, the expression of the anaerobic respiration regulator Fnr (fumarate and nitrate 
reduction regulatory protein) and CspC (cold shock-like protein), which is involved in acid and 
salt stress responses were not infection phase regulated in either Yersinia strains (Figure 3.20A, 
B). Moreover, expression of flagellin (fliC), the acid stress chaperone hdeB required for acid 
stress protection, the transcription antitermination protein rfaH involved in increased 
lipopolysaccharide expression, the NAD(P)H dehydrogenase wrbA involved in oxidative stress 
response and the superoxide dismutase sodB, which removes superoxide radicals, were up-
regulated during persistent YPIII and YPIII ΔcnfY infection (Figure 3.20B). The universal 
stress protein A (uspA), which is needed to protect against DNA damage was more strongly 
induced upon persistent YPIII ΔcnfY infection than during persistent YPIII infection 
(Figure 3.20B). In addition, YPIII ΔcnfY induced the expression of flagellin more pronounced 
than YPIII at 42 dpi.  
The expression of virulence genes like yscF (TTSS needle), yadA (adhesin), cnfY and the 
TTSS regulator lcrF were down-regulated during persistent Yersinia infection (Figure 3.21A, 
B). Intriguingly, the expression of the TTSS effector yopJ was up-regulated during persistent 
YPIII and YPIII ΔcnfY infection (Figure 3.21A). Additionally, the ail (adhesin) expression 
levels were independent of the infection stage, but were more strongly induced upon 
YPIII ΔcnfY infection than YPIII infection at both, 5 dpi and 42 dpi (Figure 3.21A). On the 
other hand, the expression of the metabolism and virulence regulators, i.e. cAMP-activated 
global transcriptional regulator gene (crp), the carbon storage regulator (csrA) and the 
regulator of virulence A (rovA), was induced during persistent Yersinia infection compared to 
acute infection (Figure 3.21B) as previously described. 
Remarkably, relative gene-expression analysis at 5 dpi revealed that anaerobiosis genes (arcA, 
frdA, napA), stress genes (hdeB, rfaH, sodB, wrbA), yopJ, and the regulators crp and rovA 
were more strongly induced upon acute YPIII ΔcnfY infection compared to YPIII. The relative 
transcript levels of those genes during acute YPIII ΔcnfY infection ranged between the lowest  
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Figure 3.20 Y. pseudotuberculosis reprograms anaerobiosis and stress gene expression dependent 
on cnfY and infection stage. 
BALB/c mice were intra-gastrically infected with either 2x107 CFU (acute infection, 5 dpi)/1x106 CFU (persistent, 
42 dpi) of Y. pseudotuberculosis YPIII or 2x108 CFU (acute infection, 5 dpi)/1x106 CFU (persistent infection, 42 
dpi) of Y. pseudotuberculosis YPIII ΔcnfY. Total RNA of highly infected ceca were isolated, DNA depleted and 
analyzed for Yersinia transcript expression levels using qRT-PCR. The relative expression levels were normalized 
to sopB and if-3 expression levels and calculated relative to YPIII 5 dpi. (A) Anaerobiosis genes. (B) Stress genes 
reacting to environmental cues. The data show the mean ±SEM and was statistically analyzed with multiple t-tests 
employing Holm-Šídák’s correction: *, comparison between YPIII and YPIII ΔcnfY: ** p<0.01; +, comparison 
between 5 dpi and 42 dpi upon YPIII infection: + p<0.05, ++ p<0.01, +++ p<0.001; #, comparison between 5 dpi 
and 42 dpi upon YPIII ΔcnfY infection: ## p<0.01, ### p<0.001. 
induction during acute YPIII infection and the highest upon persistent Y. pseudotuberculosis 
infection (both YPIII and YPIII ΔcnfY). These expression differences between the two 
Y. pseudotuberculosis strains are specific for in vivo since in vitro expression analysis showed 
no gene expression differences at 25 °C and 37 °C (Figure S19, Figure S20). Strikingly, 
comparison of in vivo cnfY transcript levels during acute and persistent infection to in vitro 
cnfY transcript levels revealed that the cnfY mRNA is less increased during murine infection at 
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the assessed time points than in vitro (Figure S21). All in all, these data suggest that both 
Y. pseudotuberculosis strains exhibit comparable RNA expression profiles during persistent 
infection in the cecum. Nevertheless, slightly different host-derived environmental challenges 
that depend on the presence of cnfY might drive slightly altered Yersinia gene expression (e.g.  
 
 
Figure 3.21 Y. pseudotuberculosis adapts virulence and regulator gene expression dependent on 
cnfY and infection stage. 
BALB/c mice were intra-gastrically infected with either 2x107 CFU (acute infection, 5 dpi)/1x106 CFU (persistent, 
42 dpi) of Y. pseudotuberculosis YPIII or 2x108 CFU (acute infection, 5 dpi)/1x106 CFU (persistent infection, 42 
dpi) of Y. pseudotuberculosis YPIII ΔcnfY. Total RNA from highly infected ceca were isolated, DNA depleted and 
analyzed for Yersinia transcript expression levels using qRT-PCR. The relative expression levels were normalized 
to sopB and if-3 expression levels and calculated relative to YPIII 5 dpi. (A) Virulence genes. (B) Metabolic and 
virulence regulators. The data show the mean ±SEM and was statistically analyzed with multiple t-tests employing 
Holm-Šídák’s correction: *, comparison between YPIII and YPIII ΔcnfY: ** p<0.01; +, comparison between 5 dpi 
and 42 dpi upon YPIII infection: +++ p<0.001; #, comparison between 5 dpi and 42 dpi upon YPIII ΔcnfY infection: 
## p<0.01, ### p<0.001. nd: not detected. 
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fliC, uspA, ail) during persistent infection (Figure 3.20; Figure 3.21). Moreover, the analysis of 
relative gene expression at 5 dpi strongly implies that YPIII ΔcnfY is confronted with other 
host-mediated stresses and cues than YPIII, which triggers different transcriptional adaptations 
during the acute infection stage. 
3.4.5 Virulence plasmid stability in Y. pseudotuberculosis during long-term 
infection 
The virulence plasmid pYV of Yersinia is crucial for virulence (Ben-Gurion and Shafferman, 
1981). However, it was reported that Y. pseudotuberculosis lacking the virulence plasmid was 
isolated from diseased patients (Fukushima et al., 1991; Eppinger et al., 2007). Moreover, it is 
assumed that pYV is the least stable virulence factor of Yersinia in comparison to the iron-
scavenging high-pathogenicity island (HPI) and the Y. pseudotuberculosis-derived mitogens 
(YPM) (Ch’ng et al., 2011). Accordingly, a Y. pseudotuberculosis heterogeneity study 
analyzing isolates from multiple sources (human, animals and environment) in 2001 found that 
the Yersinia virulence plasmid was lacking in around 25 % of virulent serotypes (Fukushima et 
al., 2001). All in all, this implicates that the presence of the virulence plasmid is not sufficient 
to determine pathogenicity and colonization abilities of Y. pseudotuberculosis, which is further 
supported by a study showing that the virulence plasmid is not required for colonization of the 
mesenteric lymph nodes in mice (Balada-Llasat and Mecsas, 2006). 
 
Figure 3.22 The virulence plasmid is stable during persistency. 
BALB/c mice were infected with 2x107 CFU (acute infection, 6 dpi) or 1x106 CFU (persistent infection, 41 dpi) of 
Y. pseudotuberculosis YPIII. At the indicated time points, Y. pseudotuberculosis was re-isolated from the cecum, 
the luminal content of the cecum, PPs of the small intestine, spleen and liver. The re-isolated bacteria were further 
tested for plasmid loss by PCR. Genes located on pIB: lcrQ, yadA, yopD genomic control: rovA (A) Re-isolates at 6 
dpi. (B) Re-isolates at 42 dpi. 
Hence, it was hypothesized that Y. pseudotuberculosis might undergo a heterogenic selection 
during long-term infection, which triggers virulence plasmid loss in a fraction of the 
population. This, in turn, could lead to decreased virulence gene expression as observed in 
3.3.4 and by Avican and colleagues in 2015 (Avican et al., 2015). To analyze this further, re-
isolated Y. pseudotuberculosis YPIII from different tissue localizations were screened for 
virulence plasmid loss during acute (Figure 3.22A) and persistent infection (Figure 3.22B). To 
this purpose, single colonies were tested for the virulence plasmid encoded genes lcrQ, yadA 
and yopD. The chromosomally encoded virulence regulator rovA was used as control. 
Single colony analysis revealed that neither re-isolates of Y. pseudotuberculosis YPIII from 
acute infection phase nor from persistent infection phase demonstrated virulence plasmid loss 
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(Figure 3.22). Therefore, Y. pseudotuberculosis YPIII shows strong virulence plasmid stability 
during persisting infection.  
3.5 Cytokine profiling over the course of persistent Yersinia infection 
In this study, distinctive immune and inflammatory responses were detected by 
histopathological analysis (3.2.1) and host transcriptome profiling (3.4.1 to 3.4.3) during 
Y. pseudotuberculosis YPIII and YPIII ΔcnfY infection. To identify the cytokine levels in the 
serum and in the cecum of Yersinia-colonized mice, BALB/c mice were intra-gastrically 
challenged with 1x10
6
 CFU of Y. pseudotuberculosis YPIII or YPIII ΔcnfY. Thereafter, the 
cytokine levels of 26 cytokines in Yersinia-colonized mice (Figure S22) were assessed.  
 
Figure 3.23 Systemic cytokine response to Yersinia infection. 
BALB/c mice were intra-gastrically challenged with 1x106 CFU of Y. pseudotuberculosis YPIII or YPIII ΔcnfY, 
respectively. At indicated time points post infection the mice were sacrificed and the cytokines in serum of Yersinia 
colonized mice were measured: uninfected n=10; YPIII n=8 (3-30 dpi); n=3 (42 dpi); YPIII ΔcnfY n≥7. The bars 
represent the geometric mean and the dotted lines the detection limits. The data were statistically analyzed with the 
Kruskal-Wallis test employing Dunn’s correction; + indicates comparison to uninfected samples and * indicates 
comparison of YPIII to YPIII ΔcnfY: + p<0.05; **, ++ p<0.01; +++ p<0.001. 
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In the serum of Yersinia colonized mice, the abundance of only few pro-inflammatory 
cytokines was detected compared to uninfected mice and further analysis revealed CNFY-
dependent cytokine abundances (Figure 3.23). Among the Yersinia-induced cytokines in the 
serum were IFNγ, GM-CSF, IL-12p40, IL-17A and IL-22. 
IFNγ and IL-17A were significantly more abundant in the serum of YPIII ΔcnfY-infected mice 
compared to uninfected mice at 9 dpi, and the geometric mean of IFNγ was about 2-fold higher 
than upon YPIII infection (Figure 2.23). GM-CSF was also significantly induced in the serum 
of YPIII ΔcnfY-infected mice at 9 dpi compared to uninfected mice, while the GM-CSF level 
was higher in YPIII-infected mice at 14 dpi (Figure 3.23). Moreover, the IL-6 level was 
strongly increased in the serum of YPIII-infected mice during acute infection phase and also 
higher by comparison to YPIII ΔcnfY infection (Figure 3.23). IL-12p40 is a subunit of IL-
12p70 and IL-23, but it is also able to form homodimers (IL-12p80) (Gee et al., 2009). This 
cytokine was more abundant in the serum of both Y. pseudotuberculosis infections in 
comparison to uninfected mice (Figure 3.23). While the levels of IL-12p40 in YPIII ΔcnfY 
infected mice were reduced at 42 dpi, they remained at increased levels upon YPIII infection 
compared to YPIII ΔcnfY infected mice (Figure 3.23). In YPIII-colonized mice, IL-22 was 
more abundant from 3 to 21 dpi compared to uninfected mice (Figure 3.23), whereas the IL-22 
level in the serum of YPIII ΔcnfY-infected mice was only increased at 3 and 9 dpi. Strikingly, 
the IL-22 levels in YPIII ΔcnfY-infected mice were somewhat higher than in YPIII-colonized 
mice at 9 dpi (Figure 3.23).  
Taken together, divergent systemic cytokine dynamics and inflammatory responses were 
observed in the serum of Yersinia-colonized mice during the course of infection. In particular 
at the early stages of infection, pro-inflammatory cytokine circulation in the serum of infected 
mice was observed, while there were no cytokines detected at later stages of the infection 
(≥30 dpi). 
In the cecum of Yersinia colonized mice a couple of cytokines were differentially produced 
(Figure 3.24). As it was already observed in the serum, IL-6 and also IL-33 were significantly 
more abundant in Yersinia-infected ceca compared to uninfected ceca. The IL-6 and IL-33 
levels were also higher in YPIII-infected than in YPIII ΔcnfY-infected ceca during the acute 
infection (Figure 3.24). The IL-1α levels were increased at all assessed time points post 
infection in Yersinia-infected ceca compared to uninfected ceca (Figure 3.24), however the IL-
1α levels were higher in YPIII ΔcnfY-infected than in YPIII-infected ceca during early 
infection stages (Figure 3.24). Moreover, the cytokines IL-17A, IL-22, IL-7, IL-12p70, IL-23 
and the anti-inflammatory cytokine IL-11 were increased during the early to late acute 
infection phase in Yersinia-infected ceca compared to uninfected ceca (Figure 3.24). 
Furthermore, two other anti-inflammatory cytokines IL-10 and IL-13 were also more strongly 
induced at 3 dpi in YPIII-infected ceca compared to uninfected and YPIII ΔcnfY-colonized 
ceca (data not shown). Remarkably, the IL-22, IL-7, IL-12p70 and IL-23 levels in 
Y. pseudotuberculosis-infected ceca were lower during the late infection phase by comparison 
to uninfected ceca, while the IL-12p40 levels were continuously increased during Yersinia 
infection (Figure 3.24).  
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Figure 3.24 Local cytokine response in the cecum during Yersinia infection. 
BALB/c mice were intra-gastrically infected with 1x106 CFU of Y. pseudotuberculosis YPIII or YPIII ΔcnfY, 
respectively. At the indicated time points post infection the mice were sacrificed and the cytokines in the tissue of 
colonized ceca (Figure S22) were determined: uninfected n=10, YPIII n=8 (3-30 dpi); n=3 (42 dpi); YPIII ΔcnfY 
n≥7. The bars represent the geometric mean and the dotted lines the detection limits. The data were statistically 
analyzed with the Kruskal-Wallis test employing Dunn’s correction; + indicates comparison to uninfected samples: 
+ p<0.05; ++ p<0.01; +++ p<0.001. 
As in the serum, diverging cytokine dynamics and profiles were detected in the cecum of 
YPIII- and YPIII ΔcnfY-infected mice. YPIII infection was found to predominantly trigger the 
production of IL-6 and IL-33, while YPIII ΔcnfY infection induced the production of IL-1α. 
During the onset of the infection until 14 dpi, pro-inflammatory cytokine production was 
observed upon either Yersinia infection. However, the production of IL-22, IL-7, IL-12p70 and 
IL-23 was reduced in the cecum upon persistent Yersinia infection compared to uninfected 
mice indicating suppression of inflammation. 
RESULTS 
89 
 
3.6 The influence of CNFY on inflammation in the C57BL/6N mouse 
model 
As the inflammasome-interleukin-1 axis is associated with resistance to bacterial infections 
and bacterial clearance, bacterial pathogens have evolved mechanisms to control 
inflammasome activities. These mechanisms include LPS modification, down-regulation of 
flagella gene expression, altered flagellin, metabolite regulation and expression of bacterial 
effectors proteins that interfere with inflammasome activation and function (Shin and Brodsky, 
2015; Stewart and Cookson, 2016). Yersinia spp. also manipulate the inflammasome by 
multiple means. The effectors YopE and YopT are known to inhibit caspase-1 activation via 
interference with small Rho-GTPase activity (Schotte et al., 2004), whereas YopM directly 
binds to caspase-1, preventing its activation (LaRock and Cookson, 2012). In turn, YopK 
regulates the amount of translocated Yop effector proteins, thereby limiting inflammasome 
activation (Holmström et al., 1997; Brodsky et al., 2010). Interestingly, translocation of YopJ 
into naïve macrophages induces cell death and activates caspase-1, while it synergizes with 
YopM in activated macrophages in order to restrain caspase-1 activation (Philip et al., 2014; 
Weng et al., 2014; Ratner et al., .2016; Schoberle et al., 2016). However, whether the Yop 
translocation-enhancing toxin CNFY influences the activity of the inflammasome remains to be 
determined. 
In this study, previous analysis showed high up-regulation of il-1α, il-1β and nlrp3 gene 
expression during acute Yersinia infection (3.4.1). il-1β was also still significantly up-regulated 
during persistent Y. pseudotuberculosis infection (3.4.2, 3.4.3). Cytokine profiling in the 
cecum of YPIII ΔcnfY-infected mice showed high IL-1α levels in the cecal tissue during the 
early infection stage and slightly increased IL-1α levels during persistent infection phases. 
Hence, the influence of the inflammasome on Y. pseudotuberculosis infections was examined. 
3.6.1 C57BL/6N mice develop patho-physiologies resembling those of 
BALB/c mice 
As caspase-1, caspase-11 and IL-1 knockout mice are of the C57BL/6N genetic background, 
the Y. pseudotuberculosis YPIII ΔcnfY infections were performed in C57BL/6N mice. In order 
to review the phenotypes observed in BALB/c mice, the survival, histopathology, immune and 
cytokine response in Y. pseudotuberculosis YPIII- or YPIII ΔcnfY-infected C57BL/6N mice 
(2x10
8
 CFU/mouse) were assessed. 
The analysis of the survival of C57BL/6N mice revealed that 80 % of the YPIII-infected mice 
succumbed to the infection until 12 dpi, whereas all YPIII ΔcnfY-infected mice survived the 
infection (Figure 3.25A). Body weight analysis further demonstrated that YPIII-infected mice 
started to lose weight from 2 dpi and on average lost 14 % of their body weight until 6 dpi 
(Figure 3.25B). Interestingly, YPIII ΔcnfY infection of C57BL/6N mice did not cause any body 
weight loss during the assessed time period (Figure 3.25B). Despite the fact that C57BL/6N  
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Figure 3.25 C57BL6/N mice are more resistant to Y. pseudotuberculosis infection. 
C57BL/6N mice were intra-gastrically challenged with 2x108 CFU of Y. pseudotuberculosis YPIII or YPIII ΔcnfY. 
The health status of the mice was monitored for 14 days. The presented data were combined from two experiments: 
YPIII n=10, YPIII ΔcnfY n=10. (A) Survival of C57BL/6N mice. Survival data were statistically analyzed with the 
log-rank (Mantel-Cox) test: *** p<0.001. (B) Body weight-loss curves. Mice that lost more than 20 % of their initial 
body weight or reached a health score lower than three were sacrificed and recorded as dead. The graphs represent 
the mean ±SEM. The data were statistically analyzed with multiple t-tests using Holm-Šídák’s correction:  
* p<0.001. 
mice were more resistant to Y. pseudotuberculosis infection compared to BALB/c mice (see 
Figure 3.7A, B), deletion of cnfY still rendered the bacteria avirulent. 
The increased resistance of C57BL/6N mice might possibly be due to decreased inflammation 
compared to BALB/c mice. Thus, Marina Pils of the Mouse Pathology, Animal Experimental 
Unit at the Helmholtz Center for Infection Research performed histopathologic analysis of the 
infected C57BL/6N mice. At 5 dpi in C57BL/6N mice, histopathologic analysis of the ileum 
demonstrated the same observations, as were made in BALB/c mice (Schweer et al., 2013): 
inflammation of YPIII ΔcnfY-infected ilea was restricted to multifocal areas accompanied by 
hyperplasia of the epithelium, whereas YPIII-infected ilea showed diffuse inflammation along 
the entire ileum (Figure 3.26A). 
In the spleen of YPIII infected animals, mild to severe depletion of the white pulp and severe 
depletion of the red pulp were detected, similar to spleens of YPIII-infected BALB/c mice. 
Moreover, spleens of YPIII ΔcnfY-infected C57BL/6N mice displayed mild hyperplasia of the 
white and red pulp (Figure 3.26B), which resembled the observations made in BALB/c mice 
(Schweer et al., 2013). As indicated by histopathologic analysis, depletion of the white and red 
pulp in the spleen led to decreased spleen sizes in C57BL/6N mice, whereas hyperplasia in the 
spleen of YPIII ΔcnfY-infected mice resulted in increased organ sizes (data not shown). This 
phenotype was also observed in BALB/c mice (Schweer et al., 2013). 
In summary, both YPIII and YPIII ΔcnfY elicit histopathologic phenotypes in the spleen and 
ileum of C57BL/6N mice comparable to BALB/c mice. 
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Figure 3.26 CNFY enhances inflammation and necrosis in C57BL/6N mice. 
C57BL/6N mice were intra-gastrically infected with 2x108 CFU of Y. pseudotuberculosis YPIII or YPIII ΔcnfY. At 
5 dpi mice were sacrificed, the small intestine and spleen were excised, fixed, and paraffin embedded. Sections were 
stained with H&E and analyzed with the light microscope. The shown pictures are representatives of multiple 
microscopic fields (>15) of groups of 5 mice. (A) Ileum. Bar: 200 µm. E: epithelial cells; *: mixed inflammatory 
infiltrate (B) Spleen. Bar: 100 µm. R: red pulp; W: white pulp; H: hyperplasia. 
Previously, CNFY was found to fine tune the immune response in the lymphatic organs (PPs, 
MLNs, and especially in the spleen) during Y. pseudotuberculosis YPIII infection of BALB/c 
mice (Schweer et al., 2013; Janina Schweer, PhD thesis). As infection in different mouse 
models and even using different infection conditions could greatly impact immune cell 
numbers (Figure S23), the relative abundance of immune cells in the PPs, MLNs and spleen at 
3 dpi were analyzed (Figure 3.27). Like in BALB/c mice, CNFY was found to modulate the 
immune cell composition in the PPs, MLNs and especially in the spleen during 
Y. pseudotuberculosis YPIII infection in C57BL/6N mice (Figure S24; Schweer et al., 2013; 
PhD thesis Janina Schweer). However, some differences between C57BL/6N mice and 
BALB/c mice during Yersinia infection were observed: in the PPs of Y. pseudotuberculosis-
infected C57BL/6N mice, the relative abundance of neutrophils was generally more 
pronounced compared to uninfected C57BL/6N and Yersinia infected BALB/c mice. As the 
intestine and its lumen are the largest reservoirs of Yersinia during infection, the increased 
relative abundance of neutrophils in the PPs of C57BL/6N mice compared to BALB/c mice 
(ca. 10% vs. ca. 3 %) might constitute an improved barrier defense against Yersinia infection, 
that might result in decreased susceptibility of C57BL/6N mice compared to BALB/c mice. 
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Moreover, the relative abundance of neutrophils in the spleens of YPIII infected C57BL/6N 
mice compared to uninfected mice was higher (2.6-fold) than during BALB/c infection (1.4-
fold). As mentioned previously, this might also result in increased resistance to 
Y. pseudotuberculosis YPIII infection in C57BL/6N mice in comparison with BALB/c mice. 
However, the relative abundance of neutrophils, and monocytes/macrophages upon 
YPIII ΔcnfY infection in the spleen of C57BL/6N mice was reduced compared to BALB/c 
mice, which might account for the reduced dissemination of YPIII ΔcnfY to the spleen in 
C57BL/6N mice at 3 dpi compared to BALB/c mice (3.6.2, Schweer et al., 2013). 
 
Figure 3.27 CNFY affects pro-inflammatory cytokine and chemokine circulation in the serum at 
3 dpi. 
C57BL/6N mice were intra-gastrically infected with 2x108 CFU of Y. pseudotuberculosis YPIII or YPIII ΔcnfY. At 
3 dpi, serum from heart blood of mice was isolated and analyzed for pro-inflammatory chemokine and cytokine 
levels. The bars represent the mean ±SEM. The data were combined from two independent experiment: uninfected 
n=4, YPIII n=10, YPIII ΔcnfY n=10. Statistical analysis was performed employing Fisher’s LSD test: * p<0.05,  
** p<0.01, * p<0.001. 
RESULTS 
93 
 
Although the histopathological analysis suggested similar inflammatory responses in 
C57BL/6N and BALB/c mice, immune cell composition analysis showed that there are some 
minor differences in the relative abundance of immune cells. Thus, it was interesting to assess 
the cytokine profiles of C57BL/6N mice after Y. pseudotuberculosis challenge (Figure 3.27). 
In order to analyze this, C57BL/6N mice were intra-gastrically infected with 2x10
8
 CFU of 
Y. pseudotuberculosis YPIII or YPIII ΔcnfY and the chemokine and cytokine levels of 32 
cytokines were determined in the serum at 3 dpi. 
As suggested by the slight differences in the immune cell composition in the assessed organs 
of C57BL/6N mice, the Yersinia-affected cytokine and chemokine levels in the serum differed 
between BALB/c and C57BL/6N mice. However, YPIII infection generally induced the 
production of more different types of cytokines and chemokines in the serum of mice than 
YPIII ΔcnfY infection (Figure 3.27; Pisano et al., 2014; unpublished data from Janina 
Schweer). Accordingly, the cytokine and chemokine levels affected by Yersinia infection were 
also generally higher in the serum of YPIII-infected mice by comparison to YPIII ΔcnfY, 
irrespective of the mouse strain (Figure 3.27; Pisano et al., 2014; unpublished data from Janina 
Schweer). This suggests that YPIII infection generally and independently of the mouse strain 
induces a stronger pro-inflammatory response than YPIII ΔcnfY infection. Moreover, 
Y. pseudotuberculosis infection in BALB/c mice increased the production of more different 
pro-inflammatory cytokines and chemokines than Y. pseudotuberculosis infection in 
C57BL/6N mice (data not shown), indicating that Y. pseudotuberculosis infection is less severe 
in C57BL/6N mice.  
The analysis of the cytokine levels in the serum of C57BL/6N mice also revealed that IL-6,  
G-CSF, GROα/KC, IL-1β, IL-18, IP-10, and MCP1 were differentially regulated during YPIII 
infection in comparison to YPIII ΔcnfY infection (Figure 3.27; data not shown), implicating 
that there is a strong induction of inflammasome activity, and recruitment/activation of 
leukocytes, especially neutrophils, in YPIII-infected C57BL/6N mice compared to 
YPIII ΔcnfY-infected wild type mice. On the other hand, IL-6, eotaxin, GM-CSF, and MIP-1β 
were more abundant during YPIII infection than during YPIII ΔcnfY infection of BALB/c mice 
(Pisano et al., 2014; PhD thesis of Janina Schweer), suggesting stronger phagocyte 
activation/maturation and eosinophil, neutrophil, DC, NK cell and monocyte recruitment in 
YPIII- compared to YPIII ΔcnfY-infected BALB/c mice. This data, together, indicates that 
C57BL/6N mice might elicit a stronger neutrophil-driven immunity in response to YPIII 
infection than BALB/c mice and thus are more resistant to YPIII infection, while YPIII 
infection of BALB/c mice triggers the recruitment of several immune cells. 
Although the Yersinia-affected cytokines and chemokines differ between C57BL/6N and 
BALB/c mice, the data propose that CNFY induces the production of pro-inflammatory 
chemokines and cytokines in C57BL/6N mice as it does in BALB/c mice. However, there are 
some differences in the abundance of the cytokines and chemokines in the serum of the mice 
that might contribute to C57BL/6N resistance and BALB/c susceptibility. 
In conclusion, C57BL/6N mice are more resistant to Y. pseudotuberculosis infection, which is 
possibly caused by an improved immune response in C57BL/6N compared to BALB/c mice, 
but C57BL/6N mice still display a pathophysiology resembling that of BALB/c mice. 
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3.6.2 Y. pseudotuberculosis YPIII ΔcnfY is defective in effective systemic 
organ colonization in C57BL/6N mice 
In the previous sections, it was found that C57BL/6N mice are more resistant to 
Y. pseudotuberculosis infection than BALB/c mice, which might be due to divergent 
inflammatory immune reactions (3.6.1). These differences might also impact the organ 
colonization abilities of both Yersinia strains. To study this, C57BL/6N mice were intra-
gastrically challenged with 2x10
8
 CFU of Y. pseudotuberculosis YPIII or YPIII ΔcnfY. After  
 
 
Figure 3.28 Deletion of cnfY results in colonization defects in the MLNs, spleen and liver during 
early infection stages. 
C57BL/6N mice were intra-gastrically infected with 2x108 CFU of Y. pseudotuberculosis YPIII or YPIII ΔcnfY. At 
indicated time points post infection, the Yersinia burden in (A) small intestine, (B) cecum, (C) PPs, (D) MLNs, (E) 
spleen, and (F) liver was determined. The data were combined from four (3 dpi) or two (5 dpi) independent 
experiments: YPIII, n=21 (3 dpi) n=7 (5 dpi); YPIII ΔcnfY, n=20 (3 dpi) n=9 (5 dpi). The bars represent the median. 
The data were statistically analyzed with t-tests (A-D) or Mann-Whitney U tests (E & F): * p<0.05, ** p<0.01, 
 *** p<0.001. 
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3 and 5 dpi the Yersinia burdens in the small intestine, cecum, PPs, MLNs, spleen and liver 
were determined (Figure 3.28). The obtained Yersinia burden data demonstrate that the 
colonization levels in the small intestine (Figure 3.28A), the cecum (Figure 3.28B), and the 
PPs (Figure 3.28C) of YPIII and YPIII ΔcnfY at 3 and 5 dpi were comparable to those obtained 
for BALB/c mice (Schweer et al., 2013). In the MLNs of the C57BL/6N mice, the colonization 
levels of YPIII and YPIII ΔcnfY were also comparable to those of BALB/c mice 
(Figure 3.28D, Schweer et al., 2013). However, YPIII loads in the MLNs of C57BL/6N mice 
did not increase at 5 dpi as they did in BALB/c mice, emphasizing that C57BL/6N mice are 
more resistant to Y. pseudotuberculosis YPIII infection (Figure 3.28D, Schweer et al., 2013). 
While 86 % and 81 % of the C57BL/6N spleens and livers were colonized by YPIII at 3 dpi, 
only 55 % and 60 % of C57BL/6N spleens and livers were populated by YPIII ΔcnfY at 3 dpi 
(Figure 3.28E, F). This colonization/dissemination defects during acute YPIII ∆cnfY infection 
were not observed in BALB/c mice at 3 dpi (Figure S10, Schweer et al., 2013), and were still 
somewhat present in the spleen and liver of C57BL/6N mice at 5 dpi. 
In conclusion, the gut-associated tissues of C57BL/6N mice, i.e. small intestine, cecum and 
PPs, were as highly colonized by YPIII and YPIII ΔcnfY as observed in BALB/c mice. During 
C57BL/6N infection, YPIII burdens did not increase in the MLNs at 5 dpi and YPIII ΔcnfY 
was defective in early systemic organ colonization (spleen and liver) in C57BL/6N mice 
compared to BALB/c mice, which was somewhat compensated at later infection stages. 
3.6.3 Y. pseudotuberculosis YPIII ΔcnfY is defective in systemic dissemina-
tion in C57BL/6N mice 
During intra-gastric Y. pseudotuberculosis infection in C57BL/6N mice, an early dissemination 
and/or colonization defect was detected, which could be due to bacterial elimination of 
YPIII ΔcnfY in comparison to the wild type. In order to dissect this, intra-venous infections 
with 5,000 CFU of Y. pseudotuberculosis YPIII or YPIII ΔcnfY were performed in C57BL/6N 
mice. Strikingly, YPIII ΔcnfY was also severely attenuated upon systemic infection, suggesting 
that there might also be differences in organ colonization abilities compared to YPIII 
(Figure S25). Organ colonization analysis of the spleen and liver at 1 dpi, when mice still 
shared the same relative body weight (Figure S25B), revealed that both, YPIII and 
YPIII ΔcnfY, efficiently colonize the organs to the same amounts (Figure 3.29A, B). During 
the ongoing infection (3 dpi), when the relative body weights of both infection groups differed 
by approximately 10 %, the Yersinia burdens in the spleen remained stable and increased to 
comparable levels in the liver (Figure 3.29A, B). Interestingly, the YPIII ΔcnfY levels in the 
spleen were slightly reduced and in the liver slightly increased compared to YPIII at 3 dpi 
(Figure 3.29A, B). The analysis of the bacterial loads in the blood at 3 dpi, revealed that 60 % 
of YPIII-infected mice suffered from bacteremia, while only 10 % of YPIII ΔcnfY-infected 
mice did (Figure 3.29C). 
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Figure 3.29 Deletion of cnfY does not impact Y. pseudotuberculosis colonization abilities during 
systemic infection. 
C57BL/6N mice were intra-venously infected with 5,000 CFU of Y. pseudotuberculosis YPIII or YPIII ΔcnfY. At 
indicated time points post infection, the Yersinia loads in the (A) spleen, (B) liver, and (C) blood were assessed. The 
data were combined from two independent experiments: YPIII n=10; YPIII ΔcnfY n=10. The bars indicate the 
median and the dashed line the detection limit (7 CFU/ml). The statistical analysis was performed with two-way 
ANOVA employing Holm-Šídák’s correction: * p<0.05, *** p<0.001; ns: not significant. 
These results suggest that YPIII ΔcnfY might primarily experience a dissemination defect to 
systemic organs during early infection, since initial systemic organ colonization after intra-
venous challenge is not affected by a loss of cnfY. This assumption is supported by detection of 
bacteremia, which is 6-fold higher in wild type Y. pseudotuberculosis expressing cnfY. 
Nevertheless, bacterial clearance from the organs, especially the spleen, might have a more 
important impact during later infection stages. 
3.6.4 The inflammasome network plays divergent roles in early 
Y. pseudotuberculosis dissemination and depends on CNFY 
In section 3.6, the modulation of the inflammasomes by Y. pseudotuberculosis was introduced. 
Although there are plenty of in vitro studies in bone marrow derived macrophages concerning 
the influence of Yops and the TTSS on the activity of the inflammasome, little is known about 
the impact during the oral infection route in vivo. Moreover, the CNFY toxin, which is known 
to constitutively activate small Rho GTPases, thereby increasing Yop translocation into 
immune cells, could impact inflammasome-dependent infection outcomes with 
Y. pseudotuberculosis. However, it has to be considered that YPIII and YPIII ΔcnfY elicit 
different immune responses and levels of inflammation during acute infection (3.4, 3.6.1), 
which proposes that the induction of the inflammasome could differently impact 
Y. pseudotuberculosis infection. Thus, the direct comparison of YPIII to YPIII ΔcnfY infection 
should carefully be drawn and the comparison should be focused on each strain’s colonization 
abilities in the different knockout mouse strains. 
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In order to analyze the impact of caspase-1 and caspase-11 on either Y. pseudotuberculosis 
YPIII or YPIII ΔcnfY infection after intra-gastric challenge, caspase-1, caspase-11 and 
caspase-1/11-knockout mice were infected with 2x10
8
 CFU of Y. pseudotuberculosis. The 
caspase-1- and caspase-1/11-knockout mice were as susceptible as C57BL/6N mice to YPIII 
infection (Figure S26), but the caspase-11-knockout mouse strain was slightly more resistant 
against YPIII infection. However, this difference was not significant. Upon YPIII ∆cnfY 
infection, the caspase-1-, caspase-11- and caspase-1/11-knockout mice were as resistant as 
wild type mice (C57BL/6N) (Figure S26). This data suggests that the inflammasome and/or 
pyroptosis have no/minor influence on resistance/susceptibility to Y. pseudotuberculosis 
infection by the oral infection route. 
 
Figure 3.30 The pro-inflammatory caspases modulate systemic Y. pseudotuberculosis dissemina-
tion depending on cnfY. 
C57BL/6N, caspase-1-, caspase-11- or caspase-1/11-knockout mice were intra-gastrically infected with 2x108 CFU 
of Y. pseudotuberculosis YPIII or YPIII ΔcnfY. At 3 dpi, spleen (A) and liver (B) were analyzed for Yersinia 
colonization levels. The data were combined from two to four independent experiments: C57BL/6N mice, YPIII 
n=21, YPIII ΔcnfY n=20; caspase-1-/- mice, YPIII n=9, YPIII ΔcnfY n=8; caspase-11-/- mice, YPIII n=15, 
YPIII ΔcnfY n=15; caspase-1-/-/11-/- mice, YPIII n=13, YPIII ΔcnfY n=13. The bar represents the median. The 
detection limit was at 300 CFU/g in the spleen and 50 CFU/g in the liver. The statistical analysis was performed 
with the Mann-Whitney U test: ns: not significant; * p<0.05. 
As cell death and the release of pro-inflammatory cytokines are associated with bacterial 
resistance and clearance (Lebeis et al., 2009; Aachoui et al., 2013; Barry et al., 2013; Lemon 
et al., 2015), the influence of caspase-1 and -11 on bacterial organ colonization during early 
infection stage was assessed. To this end, wild type mice or the respective caspase-knockout 
mutants were intra-gastrically challenged with 2x10
8
 CFU of Y. pseudotuberculosis YPIII or 
YPIII ΔcnfY. Bacterial burdens in the small intestine, cecum, PPs, and MLNs of the caspase-
knockout mutants did not differ from those in wild type mice (data not shown). In contrast, 
Yersinia dissemination and/or colonization of spleen and liver were slightly altered 
(Figure 3.30). Although the Y. pseudotuberculosis wild type and the isogenic cnfY mutant 
colonized caspase-1, caspase-11 and caspase-1/11- knockout mice to comparable amounts as 
C57BL/6N mice, the median colonization efficiency of Y. pseudotuberculosis was cnfY and 
caspase-dependent (Figure 3.30): while the bacterial loads in the spleen of the colonized mice 
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ranged between 10
2
 to 10
7
 CFU/g (Figure 3.30A) and in the liver between 1.5x10
1
 to 10
6
 
CFU/g (Figure 3.30B), YPIII colonization of caspase1/11-knockout mice was slightly reduced. 
In contrast, the median systemic colonization levels of YPIII in caspase-1- and caspase-11-
knockout mice were not altered (Figure 3.30). Moreover, the YPIII ∆cnfY bacterial load was 
reduced compared with YPIII in C57BL/6N mice but not when caspase-1 and/or -11 were 
absent, however these differences were not significant (Figure 3.30).  
Table 3.1 Comparison of dissemination/manifestation efficiency in systemic organs of caspase-1 
and caspase-11-knockout mice. 
Yersinia strain Mouse strain 
Relative dissemination/manifestation effectiveness 
at 3 dpi
11
 
spleen liver 
YPIII C57BL/6N 86 % (18/21) 81 % (17/21) 
Caspase-1
-/- 78 % (7/9) 89 % (8/9) 
Caspase-11
-/- 87 % (13/15) 87 % (13/15) 
Caspase-1/11
-/- 69 % (9/13) 62 % (8/13) 
YPIII ΔcnfY C57BL/6N 55 % (11/20) 60 % (12/20) 
Caspase-1
-/- 63 % (5/8) 63 % (5/8) 
Caspase-11
-/- 80 % (12/15) 73 % (11/15) 
Caspase-1/11
-/- 54 % (7/13) 46 % (6/13) 
 
As YPIII ∆cnfY is impaired in systemic dissemination (3.6.2 & 3.6.3), the dissemination 
efficiencies of YPIII or YPIII ∆cnfY to the spleen and liver between the different mouse strains 
were compared (Table 3.1). In line with the assumption at the top of the chapter, the caspases 
differently influenced the dissemination to the systemic organs. While YPIII was partly 
impaired in dissemination to the spleen and liver of caspase-1/11-knockout mice (69 %/62 % 
vs. 86 %/81 % in C57BL/6N mice), YPIII ΔcnfY was improved in systemic dissemination in 
caspase-11-knockout mice (80 %/73 % vs. 55 %/60 % in C57BL/6N mice) (Table 3.1). This 
proposes that pyroptosis-deficient caspase-1/-11-knockout mice are slightly more protected 
from systemic dissemination of YPIII, whereas caspase-1/11-sufficiency is not as important for 
YPIII ΔcnfY dissemination. Moreover, caspase-11 activity hinders systemic dissemination of 
YPIII ΔcnfY in wild type mice, while this is not important for YPIII infections. In conclusion, 
the data suggest different roles of the caspases during YPIII and YPIII ΔcnfY infection due to 
the induction of different immune reactions in response to each infection.  
The inflammasome not only mediates pyroptosis, but also facilitates pro-inflammatory 
cytokine production and release. Thus, the influence of IL-1α and IL-1β cytokines on bacterial 
colonization was tested (Figure 3.31). The Yersinia burden in the PPs, cecum and small 
intestine was not altered during the infection of IL-1-knockout mice compared to C57BL/6N 
wild type mice (data not shown). In the spleen and liver, YPIII was severely impaired in 
systemic dissemination and colonization of IL-1α knockout mice after intra-gastric challenge 
with 2x10
8
 CFU (Figure 3.31; Table 3.2): YPIII bacteria systemically disseminated to only  
 
                                                     
11
 relative proportion of colonized systemic organs among Y. pseudotuberculosis infected animals (total amount of colonized 
spleens or livers per the total amount of Y. pseudotuberculosis infected mice) 
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Figure 3.31 The pro-inflammatory cytokines IL-1α and IL-1β modulate systemic Y. pseudotu-
berculosis dissemination depending on cnfY. 
C57BL/6N, IL-1α-, or IL-1β-knockout mice were intra-gastrically infected with 2x108 CFU of 
Y. pseudotuberculosis YPIII or YPIII ΔcnfY. At 3 dpi, spleen (A) and liver (B) were analyzed for Yersinia burdens. 
The data were combined from two (IL-1-knockout mice) or four (C57BL/6N mice) independent experiments: 
C57BL/6N mice, YPIII n=21, YPIII ΔcnfY n=20; IL-1α-/- mice, YPIII n=10, YPIII ΔcnfY n=10; IL-1β-/- mice, YPIII 
n=8, YPIII ΔcnfY n=9. The bar represents the median. The detection limit was at approximately 300 CFU/g in the 
spleen and at ca. 50 CFU/g in the liver. The statistical analysis was performed with the Mann-Whitney U test: ns: 
not significant; * p<0.05, ** p<0.01. 
50 % of the spleens and 30 % of the livers of IL-1α-knockout mice (Table 3.2). This 
dissemination defect was even stronger than in caspase-1/11 knockout mice, indicating that IL-
1α is more crucial than caspase-1/11-sufficiency for YPIII dissemination. However, IL-1α did 
not influence systemic dissemination/colonization of YPIII ΔcnfY (Figure 3.31; Table 3.2).  
Interestingly, IL-1β-deficiency did not have a similar impact on systemic dissemination  
of YPIII, though IL-1β-deficiency caused slightly increased systemic dissemination of 
YPIII ΔcnfY to the spleen (78 % vs. 55 % in C57BL/6N mice) (Table 3.2; Figure 3.31A). This 
increase of YPIII ∆cnfY dissemination in IL-1β-knockout mice suggests that IL-1β secretion 
might prevent dissemination/manifestation of YPIII ∆cnfY in the spleen. However, IL-1β did 
not prevent YPIII ∆cnfY dissemination to/manifestation in the liver. These results again 
support the assumption that YPIII and YPIII ∆cnfY elicit different immune responses during 
the infection resulting in divergent influences of caspases and IL-1 cytokines on bacterial 
dissemination to systemic organs.  
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Table 3.2 Comparison of dissemination/manifestation efficiency in systemic organs of IL-1-
knockout mice. 
Yersinia strain Mouse strain 
Relative dissemination/manifestation effectiveness 
at 3 dpi
12
 
spleen liver 
YPIII C57BL/6N 86 % (18/21) 81 % (17/21) 
IL-1-/- 50 % (5/10) 30 % (3/10) 
IL-1-/- 75 % (6/8) 75 % (6/8) 
YPIII ΔcnfY C57BL/6N 55 % (11/20) 60 % (12/20) 
IL-1-/- 50 % (5/10) 70 % (7/10) 
IL-1-/- 78 % (7/9) 67 % (6/9) 
 
In order to test whether YPIII and YPIII ∆cnfY elicit different IL-1 cytokine responses in the 
infected tissues, C57BL/6N mice were intra-gastrically infected with 2x10
8
 CFU of 
Y. pseudotuberculosis YPIII or YPIII ∆cnfY. At 3 dpi, the cytokine responses of IL-1α, IL-1β 
and IL-12p70 (a caspase independent cytokine) were tested in the small intestine, MLNs, 
spleen and liver. As shown in Figure 3.32, the IL-1α level was ~10-fold higher in the MLNs of 
YPIII infected mice compared to uninfected and YPIII ∆cnfY-infected mice, suggesting that 
IL-1α secretion in the MLNs could ease bacterial spread to spleen and liver (Figure 3.32A). 
This is further supported by the observation that YPIII ∆cnfY does not elicit elevated IL-1α 
levels in the MLNs and is simultaneously impaired in systemic spread in C57BL/6N mice 
(3.6.2 & 3.6.3). The IL-1β levels were significantly increased upon YPIII infection in the 
MLNs and spleen in comparison to uninfected and YPIII ∆cnfY-infected C57BL/6N mice 
(Figure 3.32B). Moreover, YPIII ∆cnfY caused significantly increased IL-1β levels in the 
spleen compared to uninfected C57BL/6N mice (Figure 3.32B). Although the IL-1β level was 
slightly more induced during YPIII infection than upon YPIII ∆cnfY infection, IL-1β was 
dispensable for systemic dissemination of YPIII (Table 3.2). The IL-1β cytokine more likely 
prevents dissemination to/ colonization in the spleen of YPIII ∆cnfY infected mice and confers 
protection. Interestingly, Y. pseudotuberculosis-mediated IL-12p70 levels were unaffected by 
CNFY.  
Altogether, the data indicate that YPIII favors pyroptosis and IL-1α production in order to 
establish efficient systemic infections in early infection phase, whereas the activities of 
caspase-11 and IL-1β contribute to systemic dissemination-resistance during early YPIII ∆cnfY 
infection. 
                                                     
12
 relative proportion of colonized systemic organs among Y. pseudotuberculosis infected animals (total amount of colonized 
spleens or livers per the total amount of Y. pseudotuberculosis infected mice) 
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Figure 3.32 Y. pseudotuberculosis infection causes cnfY-dependent IL-1 production in C57BL/6N 
tissues. 
C57BL/6N mice were intra-gastrically challenged with 2x108 CFU of Y. pseudotuberculosis YPIII or YPIII ∆cnfY. 
At 3 dpi, small intestine, MLNs, spleen and liver were monitored for (A) IL-1α, (B) IL-1β and (C) IL-12p70 levels 
with ELISA. The data are combined from two independent experiments. The bar represents the mean ±SEM. The 
data were statistically analyzed with multiple t-tests employing Holm-Šídák’s correction: * p<0.05. 
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4 Discussion 
In the past, bacterial pathogens have been increasingly recognized to possess the ability of 
causing long-lasting infections that may lead to morbidity and mortality (1.4). 
Y. pseudotuberculosis is known to elicit gastrointestinal diseases but also holds the potential to 
cause relapsing and autoimmune diseases, i.e. erythema nodosum and reactive arthritis (1.2). 
Hoogkamp-Korstanje and colleagues demonstrated that Yersinia is able to persist in the colon 
and lymph nodes after initial infection in patients developing chronic arthritis and ileitis 
(Hoogkamp-Korstanje et al., 1988). Moreover, the prolonged presence of Yersinia-specific 
short-lived IgA antibodies indicates chronic stimulation by Yersinia-derived antigens in the 
gut-associated lymphoid tissue (Granfors and Toivanen, 1986; Hoogkamp-Korstanje et al., 
1988). The circulation of Yersinia-specific antigens in peripheral blood cells is detectable even 
years after Yersinia infection in reactive arthritis patients (Granfors et al., 1998). Recently, it 
was discovered that Y. pseudotuberculosis YPIII is able to persistently infect BALB/c and 
FVB/N mice, leading to asymptomatic infection in the cecum (Fahlgren et al., 2014). The 
importance of Yersinia virulence factors in the development and maintenance of persistence 
was not yet intensively studied. 
The virulence factor, CNFY, of the Y. pseudotuberculosis isolate YPIII is expressed during the 
infection of mice (Schweer et al., 2013). It significantly contributes to the pathogenesis of 
Y. pseudotuberculosis YPIII infection in BALB/c mice, since a cnfY mutant is attenuated in 
virulence and tissue colonization (Schweer et al., 2013). Furthermore, CNFY fosters increased 
inflammation and enhances the translocation of Yop effector proteins into host immune cells, 
especially neutrophils (Schweer et al., 2013).  
This study investigated the impact of cnfY on the pathogenesis of Y. pseudotuberculosis 
infections. In order to characterize its role in Yersinia persistence, the influence of cnfY on 
persistence establishment, host inflammation and host transcriptome alterations during the 
switch from acute to persistent asymptomatic gastrointestinal infection was studied. 
4.1 Relevance of CNFY for the development of persistent 
Y. pseudotuberculosis infection 
Bacterial pathogens that establish persistent infection encode for a variety of virulence and 
metabolic factors that influence and contribute to persistence ability. For this, these genes 
trigger or reduce the development of persistent infection. Studies to elucidate the mechanisms 
of bacterial persistence uncovered numerous genetic factors, which are involved in establishing 
colonization and persistence in the niche of the pathogen. The genetically highly variable 
H. pylori encodes several virulence factors that contribute to virulence and colonization, 
enabling the pathogen to establish long-lasting infections in the hostile environment of the 
stomach (Cellini et al., 2003; Kao et al., 2015): Urease activity, chemotaxis and motility are 
essential to establish infection by H. pylori since their inactivity led to the inability to establish 
long-lasting colonization of the gastric epithelium (Eaton et al., 1991; Eaton et al., 1996; 
Schoep et al., 2010; Howitt et al., 2011). VacA of H. pylori, which permeabilizes host 
membranes, induces apoptosis and triggers inflammation, is also necessary for long-term 
colonization of the stomach (Kao et al., 2015; Oertli et al., 2013). Interestingly, the natural 
competence of H. pylori that facilitates inter-strain genetic exchange, is dispensable for initial 
infection but important for long-term persistence in the murine infection model (Dorer et al., 
2013).  
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In contrast to H. pylori, S. Typhimurium normally does not persist in wild-type mice (Rhen et 
al., 2003). However, the analysis of several attenuated S. Typhimurium mutants demonstrated 
their ability to persist in systemic organs after oral and/or intra-peritoneal infection. Those 
attenuated S. Typhimurium strains include ompR (transcriptional regulator), aroAC (aromatic 
amino acid biosynthesis) agfA (fimbrium) and surA (chaperone) mutants (Dorman et al. 1989; 
Chatfield et al., 1992; Sukupolvi .et al., 1997; Sydenham et al., 2000). Moreover, 
S. Typhimurium persistence particularly requires the Salmonella pathogenicity islands (SPI) -1 
and SPI-2 for persistence. A S. Typhimurium clpXP protease mutant that produces increased 
amounts of SPI-1 proteins, was able to persistently colonize spleen and liver after intra-
peritoneal infection (Yamamoto et al., 2001; Kage et al., 2008). Likewise, PNPase mutants of 
S. Typhimurium show increased expression of SPI-1 and SPI-2, which leads to persistence of 
Salmonella in the spleen, liver and gall bladder after intra-gastric challenge (Clements et al., 
2002). A more direct link of SPI-1 and SPI-2 involvement in persistent Salmonella infection 
was shown in studies by Lawley et al. and McLaughlin et al. in Nramp1
+/+
 mice, which 
develop persistent infections with Salmonella wild type bacteria (Monack et al., 2004a; 
Johanns et al., 2010). In these studies, co-infection experiments demonstrated that SPI-1, some 
SPI-1 effectors, and the SPI-2 effector SseI are necessary for effective long-term colonization 
by Salmonella, thereby implicating that the pathogenicity islands and effectors are required to 
reinvade and modulate immunity to prevent clearance during persistence (Lawley et al., 2006; 
Lawley et al., 2008; McLaughlin et al., 2009). 
The virulence factor CNFY decreases Yersinia persistence 
This work demonstrates that deletion of cnfY enhances Y. pseudotuberculosis persistence 
events in the murine cecum after intra-gastric infection. Avican and co-workers showed that 
cnfY expression is down-regulated in Y. pseudotuberculosis YPIII during the persistent 
infection of FVB/N mice, suggesting that cnfY expression might impair or reduce persistence 
at later infection stages (Avican et al., 2015). This expression profile was confirmed during 
this study in BALB/c mice (3.4.4). Remarkably, the data in this study showed that cnfY 
expression was generally lower in vivo than in vitro, indicating the necessity to adjust cnfY 
expression to achieve ideal virulence and growth properties depending on the bacterial 
environment. Although there is little data on genetic factors of Y. pseudotuberculosis that 
influence the ability to establish and maintain infection, the impact of some virulence, 
regulator and metabolic genes on Yersinia persistence are described. Most of these genes were 
shown to reduce the ability of Y. pseudotuberculosis to either establish or maintain prolonged 
infection. Anaerobiosis and oxidative stress mutants of Y. pseudotuberculosis YPIII (i.e. 
ΔarcA, Δfnr, ΔfrdA and ΔwrbA) showed reduced ability to maintain prolonged infection after 
they passed the initial infection phase (Avican et al., 2015). Furthermore, YPIII ΔhdeB (acid 
stress protection) caused more severe disease than the wild type, leading to complete clearance 
and inability to establish long-lasting infections (Avican et al., 2015). The analysis of disease 
severity upon persistent Yersinia infection by survival, body weights and diarrhea scores also 
showed that YPIII ΔcnfY caused less severe disease during initial infection than YPIII (3.1). 
Altogether, this suggests that less severe forms of yersiniosis might assist the establishment of 
persistent infection, since most of the studies analyzing other persistent bacteria show that 
persistent pathogens harbor reduced virulence properties and emerged from virulent bacteria 
through gene loss (Dorman et al. 1989; Chatfield et al., 1992; Sukupolvi .et al., 1997; 
Sydenham et al., 2000; Zdziarski et al., 2007; Dobrindt et al., 2010). However, bacteria must 
retain virulence genes to guarantee long-term colonization, as shown for SPI-1 of 
S. Typhimurium (Lawley et al., 2006; Lawley et al., 2008). 
DISCUSSION 
104 
 
Studies on persistent bacterial infections regularly report on genes that are essential to facilitate 
persistent colonization (Zahrt, 2003; Monack, 2013). However, there are few publications that 
demonstrate enhanced bacterial persistence after gene mutagenesis, as described in this work. 
In P. aeruginosa, it was found that inactivation of hmgA (phenylalanine and tyrosine 
catabolism), which leads to hyperproduction of pyomelanin, increases persistence in the lungs 
of mice, most likely by increasing resistance to hydrogen peroxide (Rodríguez-Rojas et al., 
2009). This pyomelanin hyperproducing-phenotype is also frequently observed in isolates of 
cystic fibrosis and chronic obstructive pulmonary disease (COPD) patients (Rodríguez-Rojas 
et al., 2009). In Brucella suis, inactivation of the ATP-dependent Clp protease subunit A 
(ClpA) led to prolonged colonization of liver and spleen of infected mice. The authors 
suggested that the growth defect of the clpA mutant might contribute to enhanced persistence 
through delayed induction of an inflammatory response (Ekaza et al., 2000). However, the 
cnfY mutant of Y. pseudotuberculosis does not display a growth defect in vitro (3.2.2). 
Interestingly, deletion of the DNA-damage protecting gene uspA in Y. pseudotuberculosis 
strain YPIII, also caused increased persistence. Genomic mutations that are more frequent in 
uspA mutants may decrease bacterial fitness and thus induction of inflammation (Diez et al., 
2000; Avican et al., 2015). 
CNFY-dependent Yop secretion efficiency might modulate Yersinia persistence 
Fahlgren and co-workers showed that YopE and YopH are necessary to develop and maintain 
a persistent Y. pseudotuberculosis infection (Fahlgren et al., 2014). In the present work, it was 
also shown that persisting Y. pseudotuberculosis YPIII maintain the virulence plasmid during 
persistent infection, although it is the least stable virulence factor of Y. pseudotuberculosis 
(Fukushima et al., 1991; Eppinger et al., 2007; Ch’ng et al., 2011). While it was shown that 
Y. pseudotuberculosis increases its virulence plasmid copy numbers during the acute infection 
(Wang et al., 2016a), it can be speculated that Yersinia virulence plasmid copy numbers are 
down-regulated at the persistent infection stage compared to early infection. This is supported 
by the study of Avican and co-workers, who demonstrated that virulence plasmid encoded 
genes are expressed at lower levels during persistent Yersinia infection compared to acute 
infection (Avican et al., 2015), which is possibly accomplished by gene-dose reduction 
through decreased plasmid copy numbers. Whether Y. pseudotuberculosis harbors reduced 
plasmid copy numbers during persistent infection remains to be clarified. As the main function 
of CNFY appears to increase Yop translocation into host immune cells (Janina Schweer, PhD 
thesis; Schweer et al., 2013), fine-tuning of Yop translocation in vivo seems important for the 
development of a persistent infection.  
The evolutionary relevance of CNFY for infection and persistence 
In many Y. pestis and other Y. pseudotuberculosis isolates excluding YPIII and IP2666, the 
cnfY locus is truncated and therefore non-functional due to a deletion in the cnfY locus in HPI
-
 
strains or two deletions in HPI
+
 strains (Lockman et al., 2002). These data suggests that 
deletion of the cnfY gene may be beneficial. In this work, the deletion of the cnfY gene not only 
caused long-term colonization of a protected niche, it also conferred continuous shedding of 
the organisms into the environment. This potentially improves fecal-oral dissemination to other 
animals, and ensures host reservoir maintenance and zoonotic infections.  
Similar to Yersinia, not all UPEC isolates are cnf1 positive. A couple of studies analyzing the 
cnf1 prevalence in UTI caused by UPEC and uroseptic E. coli revealed that cnf1 was present in 
3-37 % of the isolates (Caprioli et al., 1987; Bingen-Bidois et al., 2002; Tarchouna et al., 
2013). In contrast, cnf1 positive E. coli strains were infrequently isolated from stool samples of 
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healthy people (Caprioli et al., 1987), indicating that cnf1 is specifically required during UTI. 
This is supported by a study of Rippere-Lampe and colleagues who showed that cnf1 permits 
UPEC to long-term colonize the urine, bladder and kidneys of mice (Rippere-Lampe et al., 
2001b). Moreover, the presence of cnf1 mediates apoptosis of cells in the bladder epithelium 
and bacterial invasion into bladder cells (Mills et al., 2000b; Doye et al., 2002; Bower et al., 
2005). This might provide UPEC access to deeper tissues, which is an important step to 
establish UPEC persistence (Hannan et al., 2012). These reports emphasize that homologous 
virulence factors, such as CNFY and CNF1, might confer different virulence abilities in distinct 
pathogens that are important to their evolution and access to different host niches. While the 
presence of cnfY facilitates systemic colonization during acute Yersinia infection (Schweer et 
al., 2013), it impairs persistent infection in the cecum. To further extend this hypothesis, it was 
shown that the Salmonella TTSS effector AvrA improves persistence in the cecal lumen of 
young chicken by improving bacterial invasion, yet persistence of an avrA mutant was 
decreased during murine infection (Lu et al., 2010; Arsenault et al., 2016), suggesting that 
persistence related genes might also depend on the host organism. 
4.2 The contribution of inflammation on pathogenesis and 
development of persistent Yersinia infection 
Some studies show that pathogens induce initial inflammation to initiate and establish effective 
colonization (Mahdavi et al., 2002; Stecher et al., 2007; Winter et al., 2010; Sasindran and 
Torrelles, 2011). However, bacterial pathogens have also evolved strategies to avoid extensive 
immune recognition and induction of inflammation to promote long-term infections. H. pylori 
has developed multiple strategies for this, for instance modification of lipid A via acetylation 
to avoid TLR4 recognition (Moran et al., 1997; Salama et al., 2013). This is important for 
H. pylori colonization in the long term, since increased inflammation was associated with 
increased clearance of the bacterium (Blanchard et al., 2003; Ismail et al., 2003). It is accepted 
that the presence of cnfY/1 enhances inflammation and tissue damage (Rippere-Lampe et al., 
2001a; Schweer et al., 2013). The histopathologic analysis of the cecal tissue during acute 
Yersinia infection in this work also showed increased inflammation of the lamina propria (LP) 
and the lymphoid tissue of the cecum with cnfY
+
 YPIII, yet YPIII ΔcnfY infected ceca still 
presented inflammation (3.2.1). Interestingly, presence of cnfY caused massive edema 
formation, which was also observed during infection with cnf1
+
 E. coli (Rippere-Lampe et al., 
2001; Smith et al., 2015). The exacerbated inflammation upon YPIII infection compared to the 
cnfY mutant might also be reinforced by dampened wound repair through secretion of CNFY, 
since CNF1 was described to impair wound healing in bladder, intestinal and fibroblast cell 
layers (Island et al., 1999; Brest et al., 2004). This might facilitate barrier breaching for 
systemic dissemination of Y. pseudotuberculosis YPIII, but the sustained inflammatory 
response during the infection might foster bacterial clearance. Thus, reduced inflammation by 
YPIII ΔcnfY might contribute to enhanced persistence. 
CNFY-mediated IL-6 production might foster tissue destruction and inflammation 
through neutrophils and bacterial clearance via the development of T cell immunity 
Acute YPIII infection triggered massive infiltration of lymphocytes into the LP of the cecum, 
whereas acute YPIII ΔcnfY infection caused diffuse infiltration of PMNs into the LP, 
indicating a dampened inflammatory response and a reduced immunogenicity of YPIII ΔcnfY. 
Necrosis was also more pronounced in the cecal lymphoid tissue of YPIII-infected mice 
compared to those infected with the cnfY mutant and infiltrating neutrophils surrounded 
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bacterial microcolonies. Cytokine analysis of the cecal tissue also revealed that IL-6 levels 
were more strongly elevated in the cecal tissue and serum of YPIII-infected mice than in mice 
infected with YPIII ΔcnfY (3.5). IL-6 contributes to neutrophil attraction during early infection, 
triggers monocyte recruitment at later stages, and regulates adaptive immunity by mediating 
lymphocyte recruitment (as observed in histopathologic sections), effector T cell 
differentiation and proliferation (Scheller et al., 2011; Araie-Kachoie et al., 2014; Hunter and 
Jones, 2015), suggesting a potential role in enhanced clearance of YPIII from the cecum. In 
line with that, a previous study showed that Y. pseudotuberculosis YPIII infection of BALB/c 
mice caused more enhanced infiltration of neutrophils into the PP than YPIII ΔcnfY (Schweer 
et al., 2013). The increased infiltration of neutrophils can lead to massive tissue destruction by 
conglomeration of secreted proteases and ROS (Borregaard et al., 2007; El-Benna et al., 
2016). Interestingly, CNF1 was also connected to enhanced ROS production from neutrophils 
(Davis et al., 2005). 
Mild inflammation during persistent Yersinia infection is independent of CNFY but 
dependent on the mouse strain 
Histopathologic analysis revealed cnfY-independent, low inflammation in the LP of the cecum 
during persistent Y. pseudotuberculosis infection, eliciting diffuse and isolated neutrophil 
infiltration into the LP of the cecum. One possible reason for the cnfY-independency might be 
that cnfY is only lowly expressed in the persistent infection stage compared to acute infection 
(Avican et al., 2015; this study). Notably, the clinical study of Hoogkamp-Korstanje presented 
Yersinia-driven, nonspecific inflammation of the colon during acute ileitis or colitis, which 
encompassed tissue destruction and recruitment of mononuclear cells, whereas colon biopsies 
of chronically Yersinia infected patients demonstrated no tissue destruction (Hoogkamp-
Korstanje et al., 1988). In contrast, persistently Y. pseudotuberculosis-infected FVB/N mice 
had disrupted epithelium and a profound influx of neutrophils that surrounded the 
Y. pseudotuberculosis foci (Fahlgren et al., 2014; Avican et al., 2015). This discrepancy 
compared to the results in this work might be due to genetic differences between FVB/N and 
BALB/c mice. The genetic backgrounds that cause these differences are still not fully 
understood, yet the myeloid transmembrane receptor Gpr84 is truncated in FVB/N mice, 
whereas it is functional in BALB/c mice (Perez et al., 2013). Moreover, BALB/c mice produce 
complement component C5, whereas FVB/N mice are deficient (Radovanovic et al., 2011). 
The MHC class I haplotypes of H-2 also differ between the two strains, which was associated 
with different susceptibilities to bacterial infection (Curtis et al., 1982; Goldmann et al., 2005). 
This proposes that the murine genetic background might be involved in controlling 
inflammation during persistent Y. pseudotuberculosis infection. 
Yersinia might exploit neutrophil transmigration to establish a bacterial reservoir in the 
lamina propria 
The histopathologic analysis showed neutrophil accumulation in the intestinal lumen during 
acute Yersinia infection, which is known to occur in the inflamed gut through neutrophil trans-
epithelial migration (Reaves et al., 2005). A sophisticated study by McCormick and colleagues 
with Y. pseudotuberculosis established that this event in particular disrupts barrier polarization, 
thereby exposing β1 integrins at the apical site. This enables Y. pseudotuberculosis to cross the 
epithelial layer by engaging InvA with the apical β1 integrins and thus colonizing the 
basolateral side (McCormick et al., 1997). Considering the obtained histopathologic and 
Yersinia-localization data, this mechanism explains (1) Yersinia colonization at the basal site 
of the epithelium and (2) that increased neutrophil infiltration and transmigration in YPIII-
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infected animals might lead to augmented invasion of YPIII into the lamina propria compared 
to YPIII ΔcnfY. In the persistent colonization state, Yersinia can exploit this basolateral 
localization to re-enter the lumen by engaging with β1 integrins at the basolateral site, allowing 
dissemination into the environment and re-invasion. This assumption proposes circulation of 
Yersinia in the cecum to maintain environmental shedding and reservoir colonization.  
Re-distributed colonization patterns of Y. pseudotuberculosis might protect the bacteria 
from elimination 
Analysis of the colonization patterns of Y. pseudotuberculosis during persistent infection 
revealed that the colonization pattern greatly differs from acute infection and the patterns 
observed during persistent Y. pseudotuberculosis infection in FVB/N mice (Fahlgren et al., 
2014; Avican et al., 2015). Yersinia was found to localize in small to large microcolonies in 
the cecal lymphoid tissue during acute BALB/c infection and persistent infection in FVB/N 
mice (3.2.3; Fahlgren et al., 2014; Avican et al., 2015), whereas Y. pseudotuberculosis was 
widely distributed as single to multiple-cell aggregates during persistent infection of BALB/c 
mice. 
M. tuberculosis, P. aeruginosa, H. pylori and UPEC are biofilm-forming bacteria that cause 
persisting infections (Singh et al., 2000; Anderson et al., 2004; Ojha et al., 2008; Percival and 
Suleman, 2014). The ability to form a biofilm and to undergo phenotypic switches is 
correlatable to bacterial persistence and important for reservoir maintenance (Balaban et al., 
2004; Chen and Wen, 2011). In Y. pseudotuberculosis, PhoP represses the production of 
Yersinia biofilms (Sun et al., 2009). However, Y. pseudotuberculosis YPIII carries naturally a 
non-functional phoP gene (Grabenstein et al., 2004), and was thus shown to be capable of 
forming biofilms at abiotic and biotic surfaces (Joshua et al., 2003; Sun et al., 2009). In the 
study by Avican et al., it was also shown that biofilm and quorum-sensing genes are up-
regulated during persistent infection (Avican et al., 2015). As biofilm formation is induced 
upon iron starvation in Y. pestis, iron limitation in the host during Y. pseudotuberculosis 
infection might also induce biofilm formation (3.4.3) (Perry and Fetherston, 1997; Liu et al., 
2009; Nuss et al., 2017). However, the localization studies of the cecal lymphoid tissue during 
persistent infection showed that Y. pseudotuberculosis was almost exclusively found in the 
intercellular space, and in close and dense association to lymphocytes. These results lead to the 
hypothesis that the bacteria adhere tightly as aggregates on the surface of lymphocytes and/or 
in the intracellular space. As bacterial adherence and the formation of aggregates protect 
pathogens from phagocytosis (Galdiero et al., 1988; Ribet and Cossart, 2015), the aggregation 
and/or adherence to cells might protect the bacteria from phagocytic elimination. 
The cytokine production is dependent on CNFY and might contribute to disease 
progression 
Cytokine profiling in the serum of Y. pseudotuberculosis-infected mice showed a mild 
systemic inflammation in both infection groups during acute infection (≤ 14 dpi), whereas 
almost no systemic cytokine response was observed during persistent Yersinia infection 
(≥ 21 dpi) (3.5). Only IL-12p40 was more abundant in the serum of persistently YPIII 
colonized mice, which enhances innate immune responses by recruiting macrophages, 
fostering activated dendritic cells migration and IFNγ production (Piccotti et al., 1997; Ha et 
al., 1999; Kahder et al., 2006; Cooper and Khader, 2007). In persistent Salmonella and 
Mycobacteria infection, IL-12 signaling is a key pathway to control the infection (Cooper et 
al., 1997; Lehmann et al., 2006). This suggests that replication of YPIII might be more easily 
controlled through long-term immune system stimulation. 
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Interestingly, pro-inflammatory cytokines such as IFNγ, GM-CSF, and IL-17A were more 
abundant in the serum of YPIII ΔcnfY infected mice during the late phase of acute infection 
(9 dpi), indicating that antigen presentation, pathogen elimination and defense mechanisms, 
e.g. phagocyte activation and antimicrobial peptides, against YPIII ΔcnfY infection are more 
active (Teixeira et al., 2005; Iwakura et al., 2008; Manni et al., 2014; Becher et al., 2016; Song 
et al., 2016). In contrast, YPIII induces a massive systemic inflammation, as indicated by a 
prolonged and/or elevated abundance of IL-22 and the pleiotropic cytokine IL-6 in the serum 
of mice (3.5). 
As shown in this study, acute Yersinia infection led to a pro-inflammatory cytokine response in 
the cecum by increased production of IL-6, Il-12 family cytokines (IL-12p40, IL-12p70, IL-
23), IL-1α and IL-33. These cytokines recruit leukocytes and lymphocytes, increase pro-
inflammatory cytokine production, induce acute phase response and act during T cell 
polarization/differentiation and tissue repair (Gee et al., 2009; Vignali and Kuchroo, 2012; 
Yazdi and Drexler, 2013; Rider et al., 2013; Ataie-Kachoie et al., 2014; Molofsky et al., 2015; 
Martin and Martin, 2016). The enhanced abundance of the alarmins IL-33 and IL-1α indicates 
increased cell destruction (Garlanda et al., 2013; Rider et al., 2013; Martin and Martin, 2016). 
Interestingly, IL-1α and IL-33 levels were slightly oppositionally produced between the two 
Y. pseudotuberculosis strains at 9 and 14 dpi, with higher levels of IL-33 in YPIII-infected 
mice and greater IL-1α production in YPIII ΔcnfY-infected animals. This suggests different 
cellular sources and/or activated pathways during infection. Epithelial cells constitutively 
express IL-33 and release it upon disruption (Moussion et al., 2008; Pichery et al., 2012). The 
more pronounced production of IL-33 during YPIII infection could indicate that more tissue 
destruction occurs, which is also supported by histopathology. Moreover, intracellular IL-33 
induces the expression of IL-6 (Shan et al., 2015), explaining that YPIII-infected mice more 
highly expressed IL-6 in the cecum (3.4.1). il-1α is constitutively expressed in epithelial cells, 
though expression of il-1α in myeloid cells requires TLR activation (Dinarello, 2009; Yazdi 
and Drexler, 2013). Furthermore, IL-1α release from myeloid cells requires the activation of 
either caspase-1 or caspase-11 (Viganò and Mortellaro, 2013), which, taken together, might 
imply different phagocyte-activation states during YPIII and YPIII ΔcnfY infection. Given 
these assumptions, it is noteworthy that caspase-1 seems to inactivate IL-33, thereby reducing 
the severity of inflammation (Madouri et al., 2015). This might indicate that caspase-1 
activation during YPIII ΔcnfY infection could also decrease IL-33 levels and thus IL-33-
mediated inflammation. 
The abundance of IL-7, IL-12p70, IL-23 and IL-6 during acute Yersinia infection further 
proposes the development of adaptive immune responses, i.e. recruitment of T cells, B cell 
maturation, and T cell survival, development and differentiation (Stetsko and Sauder, 2008; 
Ceredig and Rohlink, 2012; Kang and Coles, 2012; Hunter and Jones, 2015). The highly 
elevated IL-6 levels during YPIII infection compared to YPIII ΔcnfY infection indicate 
development of TH17 immunity and maturation of plasma blasts into antibody-secreting 
plasma cells in response to YPIII infection (Hunter and Jones, 2015). This supports the 
assumption that the strong inflammatory immune response during YPIII infection might trigger 
clearance and thereby impairs persistence. Additionally, the abundance of pro-inflammatory 
cytokines such as IL-6 IL-17A, IL-22, IL-1α, IL-7, IL-12, and IL-23, implicated the 
development of a TH1/TH17 dominated immune response in the cecum (Figure 1.3). Nuss and 
co-workers also observed increased expression of pro-inflammatory cytokines that contribute 
to TH1/TH17 development and TH1/TH17 immune responses in the PP of BALB/c mice after 
infection with Y. pseudotuberculosis IP32953 (Nuss et al., 2017). 
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Moreover, acute Yersinia infection triggered the production of cytokines involved in barrier 
defense (IL-17A, IL-22), maintenance (IL-22, IL-11) and regeneration (IL-22, IL-11, IL-33) 
(Iwakura et al., 2008; Garbers and Scheller, 2013; Dudakov et al., 2015; Molofsky et al., 2015; 
Parks et al., 2016), contributing to the restoration of tissue homeostasis after its disruption. The 
majority of affected and elevated cytokine levels decline after 14 dpi, suggesting restoration of 
tissue homeostasis, thereby allowing establishment of bacterial persistence. Interestingly, the 
anti-inflammatory cytokine levels, i.e. IL-10 and IL-13, were increased in the cecum of YPIII-
infected mice 3 dpi compared to uninfected and YPIII ΔcnfY infected mice. 
Y. pseudotuberculosis is known to stimulate anti-inflammatory cytokine production during 
early infection, which is important for virulence (McPhee et al., 2012). The lack of early anti-
inflammatory cytokine production in the cecum might lead to an accelerated onset of the 
immune response against YPIII ΔcnfY, thereby reducing virulence and improving persistence. 
CNFY-dependent inflammation during Yersinia infection triggers dysbiosis of the 
microbial community in the gut 
Inflammation due to invading pathogens is able to alter the composition of the symbiotic 
microbial community in the intestinal compartment, a mechanism named dysbiosis, and leads 
mostly to a bloom of Proteobacteria (Zeng et al., 2016). This Proteobacteria bloom is often 
associated with increased susceptibility to bacterial infection (Buffie et al., 2012; Ayres et al., 
2012; Dicksved et al., 2014). Furthermore, Citrobacter rodentium and Salmonella initiate 
inflammation in the gut to gain a growth advantage compared with the commensal microbiota 
(Lupp et al., 2007; Barman et al., 2008; Kamada et al., 2012). Upon Yersinia infection, Avican 
and colleagues detected a decrease in the relative abundance of Bacteroidetes during acute 
infection, however they did not observe the described bloom of Proteobacteria (Avican et al., 
2015). The data of this work show that YPIII-induced inflammation but not YPIII ΔcnfY-
triggered inflammatory reactions caused dysbiosis during late acute Yersinia infection with an 
associated increase of the relative abundance of Proteobacteria, i.e. Desulfovibrionales, and a 
massive decrease in the Bacteroidetes (S24-7). Kamdar et al. also observed an outgrowth of 
Desulfovibrionales upon Y. enterocolitica infection in TLR1
-/-
 mice. They revealed, that 
Y. enterocolitica, similar to S. Typhimurium, utilizes tetrathionate, which is generated through 
the reaction of ROS with intestinal thiosulfate in the inflamed gut, thereby mediating the 
outgrowth of Desulfovibrionales (Winter et al., 2010; Kamdar et al., 2016). It can be 
speculated that YPIII ΔcnfY-driven inflammation leads to no or decreased tetrathionate 
production in the inflamed gut, which prevents tetrathionate respiration of YPIII ΔcnfY and 
dysbiosis. Furthermore, outgrowth of Proteobacteria could also be reinforced by higher oxygen 
concentrations in the inflamed intestine, which inhibits growth of obligate anaerobes, such as 
Bacteroidetes, but fosters the growth of facultative aerobes, such as Proteobacteria (Zeng et al., 
2016). This might also indicate that the dampened inflammation during YPIII ΔcnfY infection 
might circumvent dysbiosis and clearance. 
Similar to the present study, the relative abundance of Lactobacillaceae was also decreased in 
the work of Kamdar and colleagues and therapy with Lactobacillus species prevented 
Desulfovibrionales outgrowth and improved Y. enterocolitica clearance (Kamdar et al., 2016). 
Whether this effect could be reproduced using the infection model described in this work and 
whether Lactobacillus transfer influences Y. pseudotuberculosis persistence remains to be 
determined.  
The gut-associated microbial genus Akkermansia belongs to the Verrucomicrobiota. 
Akkermansia was specifically associated with increased barrier integrity and protection upon 
administration as a probiotic, suggesting that it might protect against microbial encroachment 
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(Everard et al., 2013). However, upon S. Typhimurium infection, the presence of Akkermansia 
has been found to increase tissue inflammation. The same study also showed that Akkermansia 
degrades mucin, in response most likely enabling increased access of Salmonella to host tissue 
and its overgrowth (Ganesh et al., 2013). Thus, the increased abundance of the 
Verrucomicrobiota upon YPIII ΔcnfY infection might support colonization. 
Yersinia infection might trigger long-term gut dysfunction 
Interestingly, very mild diarrhea was still observed during persistent infection phase in both 
Y. pseudotuberculosis infection groups. The grade of inflammation and dysbiosis correlated 
with the severity of diarrhea during early infection, whereas sustained diarrhea during late 
infection was not associated with altered microbial community composition or pathologic 
tissue alterations. In a study by Fonseca and co-workers, it was demonstrated that 
Y. pseudotuberculosis is able to elicit long-term impairment of mucosal immune functions 
even after its clearance (Fonseca et al., 2015): They showed that the intestinal microbiota was 
able to infiltrate the deeper-lying tissue, thereby debilitating tolerance and immunity (Fonseca 
et al., 2015), indicating that not only Yersinia by itself but also dislocated microbiota might 
foster prolonged gut dysfunction. Infections with Yersinia spp. have also been linked to 
inflammatory complications after acute gastroenteritis, encompassing Crohn’s disease, 
ulcerative colitis, irritable bowel syndrome, intestinal malabsorption and non-infective colitis 
(Ternhag et al., 2008), suggesting that tissue impairment might contribute to the development 
of sequelae. In patients suffering from irritable bowel syndrome, only subtle changes in 
immune cell composition are observed: especially mast cells are significantly more abundant 
in the gut tissue (Weston et al., 1993; O’Sullivan et al., 2000; Bercik et al., 2005) and a higher 
abundance and/or an activation of mast cells are clearly connected with chronic diarrhea (Yen 
and Pardi, 2011). Moreover, the il-1β expression in tissue biopsies from patients suffering from 
irritable bowel disease is also significantly increased in comparison to healthy persons (Gwee 
et al., 2003). Similar to that, only mild inflammation was observed during persistent Yersinia 
infection visible by diffuse infiltration of neutrophils into the LP of the cecum (3.2.1). 
Additionally, up-regulation of mast cell proteases (mcpt1/2) and il-1β expression during 
persistent Yersinia infection (both YPIII and YPIII ΔcnfY) was observed (3.4.3). Together, this 
suggests that prolonged diarrhea after and during Y. pseudotuberculosis infection in BALB/c 
mice, might be due to subtle alterations in the gut tissue, which resembles those connected with 
irritable bowel syndrome. 
In conclusion, YPIII-driven inflammation results in severe pathogenesis encompassing 
dysbiosis, severe tissue pathology, and enhanced IL-6 production. This might result in 
development of adaptive immunity and bacterial clearance events. On the other hand, 
YPIII ΔcnfY elicits milder inflammation, which is associated with enhanced persistence, a lack 
of dysbiosis and decreased IL-6 levels in comparison to YPIII. Together these results suggest 
that acute inflammation and host immune responses to the respective Y. pseudotuberculosis 
infection influence the development of persistent infection.  
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4.3 Crosstalk of genomes - complex host-pathogen interactions 
Infection with a pathogen challenges the host to mount innate and adaptive immune responses 
against the invader. Also, the intruding pathogen is confronted with harsh and hostile 
conditions in the host and has to employ its virulence strategies. This demands readjustment of 
both, host and pathogen, transcriptional expression profiles, which are interconnected through 
complex host-pathogen interaction networks. Studies analyzing this issue in vivo are realized 
via different means, such as knockout mutant analysis or more global approaches, for instance 
proteome and transcriptome analysis. In this study, the global mRNA transcriptome of the host 
and the expression of important factors for Yersinia virulence and persistence during acute and 
persistent Y. pseudotuberculosis infection in BALB/c mice were assessed. The data are 
discussed in the following sections. 
4.3.1 CNFY sufficiency and deficiency shapes the host transcriptome during acute 
and persistent infection 
The deletion of a single virulence gene is generally not expected to strongly impact overall 
immune signaling. This is supported by the study of Arsenault and co-workers, who showed 
that the deletion of the kinase inhibitor AvrA of Salmonella caused similar phosphorylation 
patterns on immune signaling proteins as the wild type (Arsenault et al., 2016). This is 
reinforced by the work of Price and Abu Kwaik, who showed that AnkB, which confers 
intracellular Legionella pneumophila replication, does not alter the transcription profile of 
human macrophages (Price and Abu Kwaik, 2014). However, a study by Wang et al. analyzed 
the impact of SpeG of Salmonella on Caco-2 and M-cells. They found that SpeG alters 
immune signaling, resulting in different immune responses (Wang et al., 2016b). 
The virulence factor CNFY of Y. pseudotuberculosis mainly functions to enhance translocation 
of the Yop effectors into host immune cells (Wolters et al., 2013; Schweer et al., 2013; Janina 
Schweer, PhD thesis), which might manipulate Yop effector functions during the infection. 
Thus, it was not surprising that the transcriptional profiles differed between the 
Y. pseudotuberculosis strains YPIII and YPIII ΔcnfY. 
Analysis of the acute infection phase reveals regulation of inflammation and immune 
responses after challenge with Y. pseudotuberculosis 
It is well known that Y. pseudotuberculosis infection triggers inflammation. As expected 
several inflammatory modulators, acute phase proteins, metal ion sequestration, and proteins 
involved in bacterial killing and growth restriction were up-regulated during 
Y. pseudotuberculosis infection irrespective of the presence of CNFY. Almost all of these 
commonly up-regulated genes were also found to be most highly induced during 
Y. pseudotuberculosis IP32953 infection of the PP in BALB/c mice (Nuss et al., 2017). This 
suggests that a common core regulon is triggered by infection with Y. pseudotuberculosis in 
the gut associated tissues. Similar to the work of Nuss and colleagues, most of the detected, 
highly induced transcripts are specific for neutrophils (Nuss et al., 2017), emphasizing that the 
immune response to Y. pseudotuberculosis YPIII/YPIII ΔcnfY is also dominated by infiltrating 
neutrophils. 
YPIII triggers expression of IL-6-inducible genes 
The analysis of host genes that are cnfY-dependent, demonstrated distinct tissue and immune 
reactions. In accordance to the cytokine levels observed in the cecum, YPIII infection drove a 
stronger induction of il-6 gene expression and expression of genes related to IL-6-induced 
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pathways, for instance acute phase proteins, haptoglobin, matrix metalloproteinases, and 
angiogenesis (Heinrich et al., 1990; Cronstein, 2007; Nagasaki et al., 2014; Kelwick). 
Remarkably, the matrix metalloproteinase pathway is linked to tissue destruction (Birkedal-
Hansen, 1993; Elkington et al., 2005), which might also contribute to increased tissue 
pathology upon YPIII infection. Moreover, the acute phase proteins Chil3 and Cxcl2, which 
attract neutrophils, and the neutrophil derived matrix metalloproteinase MMP8 that facilitates 
chemokine gradients to attract neutrophils, were more strongly induced during YPIII than 
during YPIII ΔcnfY infection. This supports the assumption that YPIII drives massive 
neutrophil infiltration, which results in exacerbated immune responses and uncontrolled tissue 
destruction and reorganization (Figure 4.1). 
YPIII ΔcnfY drives expression of IL-22 and IFN-inducible genes 
In contrast to YPIII, an increased expression of IL-22-inducible genes, such as 
fucosyltransferase 2, dual oxidase 2, RegIII and other defensins, was observed during 
YPIII ΔcnfY infection (3.4.1; Mizoguchi, 2012; Grasberger et al., 2015; Parks et al., 2016). In 
Citrobacter intestinal infections, IL-22 was associated with reduction of colitis severity, while 
IL-22 is also necessary to avoid systemic inflammation and bacterial admittance to lymphatic 
tissues (Zheng et al., 2008; Sonnenberg et al., 2011; Sonnenberg et al., 2012; Grasberger et al., 
2015). A study on Y. pseudotuberculosis also demonstrated that RegIIIβ decreases Yersinia 
encroachment of the PP (Dessein et al., 2009). Hence, increased expression of IL-22-inducible 
genes during YPIII ΔcnfY infection might contribute to decreased disease severity and tissue 
invasion compared to YPIII infection (Figure 4.1). In addition, increased IFNγ production and 
enhanced expression of many interferon-inducible genes, such as genes for antigen 
presentation, the inducible nitric oxide synthase, and the interferon-inducible GTPases, were 
detected during YPIII ΔcnfY infection (3.4.1 & 3.5) (Boehm et al., 1997; MacMicking, 2012). 
The latter are associated with the control of bacterial infections involving antimicrobial 
activities, such as promotion of canonical and non-canonical inflammasome activation (Taylor 
et al., 2000; Tietzel et al., 2009; Al-Zeer et al., 2013; Meunier and Broz, 2015; Pilla et al., 
2014; Man et al., 2015; Finethy et al., 2015; Meunier et al., 2015). To foster inflammasome 
activation, the GTPases destabilize the phagosome or pathogen-containing vacuole, thereby 
releasing LPS into the host cytosol (Meunier et al., 2014). Caspase-11 directly binds the 
cytosolic LPS and becomes activated, triggering pyroptosis and release of pro-inflammatory 
cytokines, such as IL-1α (Yazdi and Drexler, 2012; Shi et al., 2014). The detected cytokines 
and RNA-profiles of the cecal samples support that YPIII ΔcnfY infection induces pyroptotic 
cell death of activated phagocytes, triggering increased amounts of IL-1α.  
Some pathogens exploit lytic host cell death to escape the host cell and to colonize the 
extracellular space (Traven and Naderer, 2014; Chow et al., 2016). Particularly, caspase-11-
mediated pyroptosis is able to trigger Salmonella proliferation and dissemination (Broz et al., 
2012). Moreover, S. Typhimurium and L. monocytogenes exploit the type I IFN pathway to 
establish infection (Auerbuch et al., 2004, Robinson et al., 2012). Previously, pathogenic 
yersiniae have also been detected inside phagocytes in vivo and in vitro (Rosqvist et al., 1988; 
Pujol and Bliska, 2003). Furthermore, decreased Yop translocation of YPIII ΔcnfY might 
impair the blockage of phagocytosis, allowing bacterial uptake and pro-inflammatory signaling 
(Rosqvist et al., 1988; Pha and Navarro, 2016; Zhang et al., 2016a) This, altogether, indicates 
that cell lysis and/or IFN-mediated signaling during YPIII ΔcnfY infection might similarly 
support bacterial colonization of the host (Figure 4.1). 
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Figure 4.1 CNFY-dependent cytokine signaling shapes the host transcriptional landscape during 
acute Yersinia infection. 
Prevalence of IL-6 levels during Y. pseudotuberculosis YPIII infection drives immunopathology, IFN signaling 
suppression and clearance of Yersinia (left site), whereas reduced IL-6 levels during YPIII ΔcnfY infection allow 
IFN pathway induction, tolerogenesis and decreased clearance of Yersinia. Induction of IL-22 associated genes 
might contribute to host barrier protection and decreased disease severity. 
IFN-induced ido1 expression might facilitate YPIII ΔcnfY persistence 
The IFN-inducible indoleamine 2,3-dioxygenase (ido1) was the most highly induced gene 
during YPIII ΔcnfY infection compared to YPIII infection. IDO1 is a multifaceted enzyme of 
the tryptophan catabolism that locally regulates immunity, thereby mediating either protection 
or disease (Zelante et al., 2009; Carlin et al., 1989). Through the depletion of tryptophan and 
the generation of kynurenine metabolites, IDO1 inhibits T cell proliferation, induces T cell 
apoptosis (Frumento et al., 2002; Murakami et al., 2013) and triggers the differentiation of 
Tregs, which inhibit effector T cells (Fallarino et al., 2006; von Boehmer, 2005). Moreover, 
induction of ido1 in DCs promotes immune tolerance and restricts immunity (Mellor and 
Munn, 2004; Romani et al., 2006), which benefits parasitic, viral and bacterial persistent 
infections (Sanchez and Yang, 2011; Mellor and Munn, 2008). Notably, ido1 expression was 
implicated in infections with pathogens causing persistent infections (Pantoja et al., 2001; 
Desvignes and Ernst, 2009; Loughman and Hunstad, 2012; Larussa et al., 2014). During 
human immunodeficiency virus (HIV) infection, ido1 over-expression is linked to the 
impairment of T cell immunity, which dampens HIV-specific immune responses (Favre et al., 
2010; Boasso et al., 2008). During bacteria-induced granulomatous disease, a significant 
amount of the ring structure cells are IDO1-positive, which possibly prevents clearance of the 
granulomas (Popov et al., 2006, Popov et al., 2008, Desvignes and Ernst 2009, Barth and 
Raghuraman, 2014). Moreover, IDO1 restricts pathology during C. difficile intestinal 
infections by inducing neutrophil apoptosis (El-Zaatari et al., 2014). As acute pathology in the 
YPIII ΔcnfY-infected cecum is less severe than during YPIII infection, these data propose a 
similar mechanism during YPIII ΔcnfY infection. In summary, IDO1 induced tolerogenesis is a 
possible mechanism that might foster YPIII ΔcnfY long-term infection and protection from the 
immune system (Figure 4.1). Whether IDO1 inhibition by administration of 1-methyl-D-
tryptophan prevents the development of persistent Yersinia infection should be addressed in 
the future.  
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Increased IL-6 levels might inhibit immune suppression 
It is noteworthy that the tolerogenic function of ido1-expressing DCs is abrogated by IL-6 
(Grohmann et al., 2001). A study on M. tuberculosis showed that IL-6 expression inhibits type 
I interferon signaling by down-regulating the expression of type I interferon-inducible genes, 
such as irg1 (Martinez et al., 2013), proposing that reduced IL-6 production during 
YPIII ΔcnfY infection might facilitate IFN signaling, whereas a high level of IL-6 prevents IFN 
signaling and immune regulation upon YPIII infection. As IL-6 protects against 
Y. enterocolitica infection and facilitates bacterial clearance (Dube et al., 2004), production of 
high IL-6 levels during YPIII infection might induce TH17 immunity and confer potent 
clearance, while impairing Treg differentiation (Kimura and Kishimoto, 2010) (Figure 4.1). 
Whether administration of IL-6 during YPIII ΔcnfY infection decreases persistence, should be 
addressed in the future. Interestingly, human IL-6 polymorphisms, that cause increased 
production of IL-6 are more prevalent in regions with a high pathogen burden, suggesting 
increased IL-6 levels are necessary to confer pathogen clearance (Napolioni and MacMurray, 
2016). 
Altogether, this data suggests, that CNFY-dependent cytokine responses drive the transcription 
of different signaling cascades, which favor either bacterial clearance or benefit bacterial long-
term colonization (Figure 4.1). 
Persistent Yersinia infection is marked by a mélange of immune suppression and 
infection control 
The comparison of the gene expression profiles of persistent Yersinia-infected mice to 
uninfected mice suggested that the infection triggers chronic gut dysfunction and diarrhea 
(discussed in 4.2). The persistent Yersinia infection induced expression of immunoglobins and 
mobilization of neutrophils by Cxcl2 expression (Day and Link, 2012), which resulted in the 
attraction of neutrophils and increased abundance of neutrophil associated genes, i.e. clec4d, il-
1β, hp, slpi, and trem1. This indicates that development of B cell immunity and recruitment of 
neutrophils are involved in the containment of persistent Yersinia infection (Figure 4.2). The 
induction of mmp3 expression during persistent Yersinia infection might also foster TH 
recruitment and infection control (Li et al., 2004). Interestingly, the secretory leukocyte 
protease inhibitor SLPI harbors not only antimicrobial activity (Hiemstra et al., 1996), but also 
suppresses immune signaling and responses, such as the NFκB pathway and the formation of 
neutrophil extracellular traps (Weldon and Taggart, 2007; Zabieglo et al., 2015). Thus, slpi 
expression might contribute to suppression of inflammation during persistent bacterial 
colonization, thereby preventing tissue damage but also enhancing bacterial persistence. In 
addition to slpi expression, the arginase-1 transcript, which is associated to the abundance of 
myeloid suppressor cells (Popovic et al., 2007), was induced during persistent Yersinia 
infection. Arginase-1 depletes arginine in the host environment and thereby impairs NO 
production and T cell immunity by inhibiting T cell proliferation, T cell receptor expression 
and T cell memory (Bronte et al., 2003). During chronic colitis, the induction of arginine 
metabolism is a protective mechanism against exacerbated T cell activities (Kurmaeva et al., 
2014). Moreover, activation of arginase-1 during viral and bacterial infections is connected 
with immune evasion and chronic infection (Lewis et al., 2011; Burrack et al., 2015; 
Knippenberg et al., 2015; Goh et al., 2016). Remarkably, H. pylori also actively evades T cell 
immunity in the host by expressing a Helicobacter-encoded arginase (Zabaleta et al., 2004). 
This indicates that Yersinia persistence might be fostered by arg1 expression, similar to IDO1 
induction during acute YPIII ΔcnfY infection. 
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Figure 4.2 Dampened host immunity benefits persistence of Y. pseudotuberculosis YPIII ΔcnfY. 
Yersinia persistence is a balance between immune responses that confer infection containment and suppression of 
immune responses (upper panel). The strong induction of immune responses during persistent YPIII infection shifts 
the balance towards pathogen clearance. In contrast, diminished immune responses to YPIII ∆cnfY infection prevent 
effective pathogen elimination (lower panel). 
Interestingly, chronic stimulation of the immune system with type I interferon and IL-1β is 
associated with the generation of myeloid suppressor cells, which are also more frequently 
observed in H. pylori-infected patients (Mesali et al., 2016; Tu et al., 2008; Taleb et al., 2017). 
The sequencing data of this thesis also indicated the presence of myeloid suppressor cells by 
detection of arginase-1 transcript, yet this remains to be verified. 
In summary, persistent Yersinia infection encompasses the balance between infection 
containment and inhibition of immunity that prevents pathology but also facilitates pathogen 
long-term infection (Figure 4.2). 
Presence of CNFY might stimulate clearance by the immune system 
Similar to acute Y. pseudotuberculosis infection, persistent YPIII infection triggered stronger 
and/or varying tissue and immune response reactions in the cecum, which are linked to host 
defense and pathogen clearance, e.g. the complement system, T cell immunity, antigen 
presentation and antibody maturation. This analysis supports the hypothesis that YPIII 
activates host immunity during persistent infection resulting in a shift of the balance between 
persistence and clearance towards pathogen elimination (Figure 4.2). In contrast, persistent 
DISCUSSION 
116 
 
YPIII ∆cnfY infection only very mildly induced expression of host immune response 
associated transcripts, which might impair YPIII ∆cnfY elimination (Figure 4.2). Persistence of 
other pathogens is also fostered by impaired or lacking immune responses (Gercken et al., 
1994; Stevens et al., 1994; Knipp et al., 1994; Molinari et al., 1998). The best studied among 
them is H. pylori that evolved several sophisticated mechanisms to avoid the development of 
effective immunity: Helicobacter secretes factors that impair IL-12 expression and release 
during infection, which avoids mounting of effective TH1-derived immunity, and prevents the 
proliferation of T cells (Ishii et al., 2008; Kao et al., 2006; Weiss et al., 2013). Moreover, 
H. pylori manipulates DC maturation and induces the development of tolerogenic DCs, which 
drives differentiation of immune-suppressive Tregs (Oertli et al., 2012; Zhang et al., 2010). 
Further experiments should address the adaptive immune evasion strategy of 
Y. pseudotuberculosis. Especially, the evasion strategy of YPIII ∆cnfY, which suppresses 
protective immune responses during persistent YPIII ∆cnfY infection, should be analyzed. 
4.3.2 The transcriptional adaptation strategy of Y. pseudotuberculosis during 
infection 
Studies on Yersinia transcription profiles during acute infection in vivo, showed that the 
transcriptional profile is distinct from virulence-relevant in vitro culture conditions, 
highlighting that the host environment confronts the bacterium with complex growth 
conditions that drive transcriptional adaptation programs that are either not or only partly 
experienced in an in vitro culture (Lathem et al., 2005; Avican et al., 2015; Nuss et al., 2017). 
The study of Avican and co-workers in 2015 on Y. pseudotuberculosis transcriptional 
programming during acute and persistent infection in FVB/N mice elucidated that Yersinia 
undergo a transcriptional adaptation process that reduces virulence traits, enhances overall 
stress resistance, and induces anaerobic growth (1.4.2; Avican et al., 2015). Although this 
transcriptional adaption process was mainly also detected during the infection in the present 
study, some differences in the gene transcription profiles of Y. pseudotuberculosis were 
observed compared to those detected in FVB/N mice. Unlike to FVB/N mice, fnr and cspC 
were not induced during persistent Yersinia infection. fnr mutants persist like the wild type 
Y. pseudotuberculosis in FVB/N mice (Avican et al., 2015), demonstrating that fnr is not 
necessarily needed for establishment of persistent infection. As the RNA chaperone CspC 
stabilizes the alternative sigma factor σS (rpoS), cspC expression is important for salt and acid 
induced stress responses (Cohen-Or et al., 2010; Derman et al., 2015). This suggests that 
Yersinia infection in FVB/N mice mounts other stresses, e.g. stronger neutrophil recruitment, 
that demand stable stress responses (Cohen-Or et al., 2010; Avican et al., 2015). 
Expression of yopJ, ail, cnfY and uspA might modulate Yersinia persistence and host 
immunity 
The expression of the virulence factors yopJ and ail was not down-regulated during persistent 
infection of BALB/c mice compared to the expression profile in FVB/N mice. YopJ was 
previously shown to be dispensable for the establishment of persistent infection in FVB/N 
mice (Fahlgren et al., 2014); nevertheless the results of the present work strongly indicate that 
YopJ might play a crucial role during persistent Y. pseudotuberculosis infection. As YopJ 
inhibits the MAPK and NFκB pathways, induces apoptosis, and is important for intestinal 
epithelium disruption and dissemination from the gut intestinal epithelium (Monack et al., 
1997; Monack et al., 1998; Meinzer et al., 2012; Zhang et al., 2016a), enhanced transcription 
of yopJ might confer (1) immune suppression and reduced clearance and (2) a possible 
mechanism to allow continuous dissemination and colonization of the cecum (Figure 4.3). 
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Together this suggests that yopJ might be crucial for persistent colonization of the cecum in 
BALB/c in contrast to FVB/N mice. The adhesin Ail is responsible for serum resistance, 
adherence to cells and autoaggregation of Yersinia (Biedzka-Sarek et al., 2005; Felek and 
Krukonis, 2009; Rebecca Geyer, PhD thesis), which proposes that ail expression during 
persistent infection, is important to defend against humoral immunity. Enhanced ail expression 
might also promote increased protection against phagocytosis and elimination by the formation 
of multi-cell aggregates. Moreover, increased expression of ail during persistent infection 
might support tight cellular adherence and dense bacterial packaging, as observed in cecal 
tissue preparations (3.2.3). 
 
Figure 4.3 Model of the Y. pseudotuberculosis gene expression strategy during acute and persistent 
infection. 
cnfY expression during the acute phase of the infection enhances translocation of Yop effectors into host immune 
cells (Schweer et al., 2013), thereby suppressing host-derived stresses and bacterial elimination. Inflammation-
driven recruitment of neutrophils stimulates ongoing virulence-gene expression. Deletion of CNFY provokes 
enhanced abundance of host-derived cues and stresses, which fosters transcriptional adaptation causing pre-
adaptation for transcriptional reprogramming. This enables transition to persistent infection compared to CNFY-
expressing Yersinia. The sustained expression of ail and yopJ during persistent Yersinia infection are likely to 
contribute to an anti-inflammatory environment, resistance against phagocytosis, and enables dissemination and re-
colonization. Increased uspA expression in the YPIII ΔcnfY population might indicate that at least a part of the 
bacteria reside in an altered metabolic state, as known for persister cells, while sustained secretion of CNFY might 
stimulate immune responses. 
Remarkably, the stress protein UspA was differentially expressed between the two 
Y. pseudotuberculosis strains during persistent infection. uspA expression is induced upon 
metabolic, oxidative, and temperature stress. Moreover, uspA is highly expressed in cells that 
enter stationary phase or are growth-arrested (Liu et al., 2007). As YPIII ΔcnfY is confronted 
with decreased host-derived stresses compared to YPIII, this suggests that at least a part of the 
YPIII ΔcnfY population could be in a different metabolic state than persistent YPIII bacteria 
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(Figure 4.3), allowing persistence over long periods of time with rare clearance events, as 
observed in this thesis. 
Although cnfY expression is down-regulated during persistent infection, low but sustained 
production of CNFY might stimulate the immune system to clear the infection (Figure 4.3, 
4.3.1). This hypothesis is supported by recent publications, which recognized CNFY and CNF1 
as potent immunogens and immunoadjuvants (Mou et al., 2012; Michel et al., 2016). 
YPIII ΔcnfY undergoes a transcriptional pre-adaption process during acute infection 
Recently, a study on S. aureus showed that a differential immune response of the host affects 
the transcriptional landscape of the bacterium (Thänert et al., 2017). Noteworthy, the 
expression profiles of important Yersinia persistence and virulence factors from YPIII ΔcnfY 
during acute infection were different to those observed during acute YPIII infection. In 
YPIII ΔcnfY, increased expression of anaerobiosis genes (arcA, frdA, napA), stress response 
genes (hdeB, rfaH, sodB, wrbA), virulence factors (i.e. ail and yopJ), crp and rovA was 
observed. This expression pattern suggested that host-derived environmental cues and stresses, 
which are discussed above, trigger a transcriptional pre-adaptation of YPIII ΔcnfY, which 
might ease the transition to persistent colonization of the host (Figure 4.3). One can speculate 
that this transcriptional pre-adaptation confers an advantage to YPIII ΔcnfY bacteria in 
comparison to YPIII: wild type Y. pseudotuberculosis has to undergo stronger transcriptional 
reprogramming, thereby impairing effective and accurately-timed transcriptional switches 
(Figure 4.3). This hypothesis is reinforced by the study by Avican and colleagues that showed 
that Y. pseudotuberculosis arcA, frdA, and wrbA mutants are somewhat impaired in the 
establishment of persistent infection (Avican et al., 2015). Increased expression of yopJ during 
the acute infection with YPIII ΔcnfY might further foster persistent infection by suppression of 
immune responses. 
4.4 CNFY-dependent host-pathogen interactions – a decision between 
immune suppression and clearance 
The results of this work provide a new understanding of the host-pathogen interactions during 
acute and persistent Y. pseudotuberculosis infection and illustrate the dominant role of CNFY 
in Y. pseudotuberculosis YPIII pathogenesis. Adapted from these data, a multifaceted model of 
the acute and persistent infection can be proposed (Figure 4.4). 
Consistent with the studies by Schweer and colleagues, secretion of CNFY during the acute 
stage of infection triggers a pro-inflammatory cascade that leads to a strong inflammatory 
reaction, which encompasses enhanced production of IL-6 and IL-6-dependent genes, 
enhanced neutrophil recruitment, dysbiosis and tissue destruction (Schweer et al., 2013; Janina 
Schweer, PhD thesis; 4.2; 4.3.1). This pro-inflammatory milieu supports the development of 
protective immunity by TH17 cells and impairs the differentiation of Tregs, which, together, 
mediate bacterial clearance (Figure 4.4 upper left). In the absence of CNFY, this 
proinflammatory cascade is less induced, which results in decreased IL-6 levels and the 
induction of interferon- and IL-22-dependent genes. This leads to a transcriptional pre-
adaptation of YPIII ΔcnfY and an IDO1-mediated suppression of effector T cells and induction 
of tolerogenesis. These events allow expedited transcriptional reprogramming in Yersinia and 
impair innate and adaptive immunity, thereby mediating enhanced bacterial persistence 
(Figure 4.4 upper right). 
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Figure 4.4 The decision between Y. pseudotuberculosis clearance and persistence is dependent on 
CNFY. 
Model of the CNFY-dependent host-pathogen interactions during acute and persistent infection. Bacterial and host-
derived genetic factors dictate immune response development or its suppression resulting in either enhancement of 
bacterial clearance/elimination or development/maintenance of bacterial persistence. 
At the persistent stage of the infection, the immune system is balanced between infection 
containment by the immune system and immune suppression through Arg1 and SLPI 
(Figure 4.4 lower panels). Moreover, Yersinia has reprogrammed its gene expression from 
virulent to a stress-adapted phenotype and the expression of yopJ and ail facilitates immune 
evasion (Figure 4.4 lower panels). However, YPIII is more strongly impaired in maintaining 
persistent infection of mice in comparison to YPIII ∆cnfY: persistent YPIII infection induces 
sustained activation of the immune system that is most likely triggered by the production of 
CNFY, causing decreased persistence and elimination of YPIII infection (Figure 4.4 lower left). 
In contrast, the stimulation of the immune system is decreased during persistent YPIII ∆cnfY 
infection, resulting in enhanced persistence of YPIII  ∆cnfY infection (Figure 4.4 lower right).  
DISCUSSION 
120 
 
4.5 Murine genetics and the inflammasome network influence 
systemic Y. pseudotuberculosis dissemination 
Host susceptibility is linked to genetic predispositions 
Resistance to an infection is not determined by the pathogen alone but also by the genetic 
predisposition of the host (Casanova, 2015a,b; Shukla et al., 2015; Wu and Holland, 2016; 
Thänert et al., 2017). Many studies have shown that C57BL/6 mice are more resistant against 
bacterial infections than BALB/c mice (Murphy et al., 2001; Hancock et al., 1986; Arko-
Mensah et al., 2009; Jiang et al., 2010). This is linked to the genetic background of these two 
mouse strains. C57BL/6 mice favor the development of TH1-dominated immune responses, 
whereas BALB/c mice develop TH2-dominated immunity (Hsieh et al., 1995; Mills et al., 
2000a). During Y. enterocolitica infections the major TH1-cytokine IFNγ determines 
susceptibility to the infection and is crucial for mediating bacterial clearance, thus explaining 
why BALB/c mice are more susceptible to Yersinia infection than C57BL/6 mice (Autenrieth 
et al., 1994). Moreover, the macrophages of C57BL/6 mice exhibit effective bactericidal 
activities and display M1 macrophage polarization, while BALB/c mice mount primarily M2 
macrophage polarization, which is associated with impairment in bacterial clearance and 
susceptibility to Yersinia infection (Mills et al., 2000a; Watanabe et al., 2004; van Erp et al., 
2006; Tumitan et al., 2007). The current study also confirms that C57BL/6N mice are more 
resistant against Y. pseudotuberculosis YPIII infection. However, the survival of C57BL/6N 
mice after Y. pseudotuberculosis YPIII ∆cnfY infection is still significantly increased compared 
to a Y. pseudotuberculosis YPIII infection, demonstrating a crucial role for CNFY in the 
pathogenicity in both mouse models. 
Decreased Yop translocation efficiencies might impair systemic dissemination through 
the action of neutrophils 
Similarly to BALB/c mice (Schweer et al., 2013; Janina Schweer, PhD thesis), the 
histopathology, cytokine levels and immune response were dependent on CNFY. The increased 
relative abundance of neutrophils in C57BL/6N mice compared to BALB/c mice might 
contribute to increased resistance against Y. pseudotuberculosis infection since neutrophils 
were found to protect against human pathogenic Yersinia infection (Conlan, 1997; Laws et al., 
2010; Westermark et al., 2014; Vagima et al., 2015). As a consequence, the human pathogenic 
Yersinia spp. successfully developed defense mechanisms against neutrophils and their 
functions. Via injection of Yop effectors into neutrophils, yersiniae prevent their recruitment, 
block degranulation, inhibit the respiratory burst, and avoid killing and phagocytosis by 
neutrophils (Ruckdeschel et al., 1996; Spinner et al., 2008; Laws et al., 2011; Dave et al., 
2016; Taheri et al., 2016). As neutrophils are preferentially targeted by Y. pseudotuberculosis 
TTSS in vivo (Schweer et al., 2013), it seems reasonable that impaired Yop effector 
translocation into neutrophils by the Y. pseudotuberculosis cnfY mutant might result in 
impaired escape from neutrophils and decreased dissemination. This assumption is reinforced 
by a study by Westermark and co-workers. They demonstrated that yopE and yopH mutants are 
impaired in early dissemination to the MLNs and that this effect is dependent on neutrophils 
(Westermark et al., 2014). Additionally, a functional TTSS and two other Yop effectors have 
been shown to be important for Yersinia dissemination after intra-gastric challenge: the TTSS 
is indispensable for systemic dissemination (Balada-Llasat and Mecsas, 2006), YopJ is 
important for barrier breaching, virulence and colonization of MLNs and spleen (Meinzer et 
al., 2012) and deletion of yopM is connected to impaired dissemination to systemic organs and 
reduced virulence (McPhee et al., 2010). This suggests that, overall, decreased Yop 
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translocation might be responsible for impaired dissemination in C57BL/6N mice. Moreover, 
YPIII ΔcnfY is able to colonize systemic organs after intra-venous administration but is less 
effective entering the blood stream during the progression of the disease as opposed to the wild 
type, which, supports this hypothesis. The observed inability of YPIII ΔcnfY to effectively 
cause bacteremia might be also a possible reason for its avirulence during intra-venous 
infection, since bacteremia could cause sepsis and/or colonization of multiple systemic organs 
leading to multi-organ failure (Schlag et al., 1991; Tsiotou et al., 2005; Shah and Reed, 2014). 
The inflammasome network is involved in the modulation of CNFY-dependent systemic 
Y. pseudotuberculosis dissemination  
During bacterial infections NLRs (NOD-and leucine-rich repeat-containing receptor) recognize 
bacterial derived molecular patterns (e.g. flagellin, LPS, secretion system proteins) and 
assemble together with ASC (apoptosis-associated speck-like protein containing CARD) and 
pro-caspase-1 to a multi-protein platform called the inflammasome (Man and Kanneganti, 
2016). After the assembly, activated caspase-1 is able to cleave pro-IL-1β, pro-IL-18, and 
gasdermin D that triggers pyroptosis (van de Veerdonk et al., 2011). Procaspase-11 is activated 
by cytosolic LPS that is released by guanylate-binding proteins (GBPs) from bacteria 
containing vacuoles (Meunier et al., 2014). Thereafter, activated caspase-11 drives non-
canonical inflammasome activation via NLRP3 as well as pyroptosis by cleaving gasdermin D 
(Broz and Dixit, 2016).  
At the molecular level, pathogens have evolved strategies to prevent the activation of the 
inflammasome, for instance IcaA of Coxiella burnetii, which inhibits caspase-11 and ExoU of 
P. aeruginosa, which prevents caspase-1 activation (Shin and Brodsky, 2015; Stewart and 
Cookson, 2016). In Yersinia, the TTSS and the Yops also interact with the inflammasome 
network (Auerbuch et al., 2009; Zheng et al., 2011; Casson et al., 2013; Zwack et al., 2015). 
While the formation of a translocation pore and/or the translocation of the translocon proteins 
YopB and YopD into the host cell cytosol activate the inflammasome (Auerbuch et al., 2009; 
Casson et al., 2013; Zwack et al., 2015), YopE/YopH coordinately inhibit integrin-mediated 
inflammasome activation in intestinal epithelial cells (Thinwa et al., 2014). Additionally, 
YopJ/YopM inhibit the activity of the caspase-1 inflammasome in phagocytes (LaRock and 
Cookson, 2012; Chung et al., 2014; Chung et al., 2016; Schoberle et al., 2016; Ratner et al., 
2016). Remarkably, YopJ also prevents pro-inflammatory NFκB and MAPK signaling, thereby 
favoring caspase-8 activation and apoptotic cell death (Philip and Brodsky, 2012). Activated 
caspase-8 in turn can also trigger caspase-1 activation in the targeted host cell, which initiates 
pro-inflammatory immune responses and pyroptosis (Weng et al., 2014; Philip et al., 2014). 
This mechanism is particularly important for dissemination from the intestinal compartment 
(Meinzer et al., 2012). In UPEC, CNF1 was also found to activate the inflammasome and 
induce the release of IL-1β, which elicits protective immune responses (Diabate et al., 2015). 
The cytokine data of the serum revealed that YPIII infection triggered the production of IL-1β 
and IL-18 and bacterial load determination showed that YPIII was more effectively 
disseminating to systemic organs compared to the cnfY mutant (3.6.1 & 3.6.2). This suggested 
that CNFY-enhanced Yop translocation and/or the CNFY toxin itself might facilitate bacterial 
dissemination, which might be influenced by the inflammasome activity. However, the 
inflammasome and caspase-1/-11 differently affected the Y. pseudotuberculosis dissemination. 
While coordinated caspase-1/-11 activity and IL-1α-sufficiency were important to foster 
systemic dissemination of Y. pseudotuberculosis YPIII, caspase-11 and IL-1β were important 
to restrict systemic dissemination of YPIII ∆cnfY (3.6.4). Interestingly, the transcriptional 
profiling in BALB/c mice also suggested that YPIII ∆cnfY infection is controlled by the 
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induction of the non-canonical caspase-11 inflammasome, supporting the assumption that 
caspase-11 activity might protect against the systemic dissemination of YPIII ∆cnfY. This is 
supported by studies with other pathogens such as Listeria monocytogenes, L. pneumophila, 
Burkholderia thailandensis, and Burkholderia pseudomallei, where the inflammasome activity 
assists pathogen elimination (Miao et al., 2010; Menu and Vince, 2011; Ceballos-Olvera et al., 
2011; Aachoui et al., 2013). Yet, YPIII ΔcnfY does not excessively activate IL-1β and IL-18 
production in the serum, indicating that diminished inflammasome activity during YPIII ΔcnfY 
infection might also protect against systemic Yersinia infections. In contrast, YPIII-induced 
inflammasome activities, namely pyroptosis and the production of IL-1α, support systemic 
dissemination. This is reinforced by previous work, which revealed that IL-1α is associated 
with intestinal inflammation, pathology development and bacterial dissemination upon 
Y. enterocolitica infection (Dube et al., 2001). Moreover, pyroptosis was previously 
connected to Salmonella dissemination (Broz et al., 2012; Knodler et al., 2010). Hence, the 
IL-1α/pyroptosis-axis might support systemic dissemination of YPIII. Interestingly, LPS 
induced sepsis requires caspase-11 (Wang et al., 1998; Kayagaki et al., 2011) and the survival 
experiments in the present work showed that the caspase-11-knockout mice were slightly more 
resistant against YPIII infection (3.6.4), indicating that caspase-11 might contribute to YPIII 
infection-mediated pathological consequences. Although epithelial and endothelial cell death 
are clearly connected with the progression of systemic infections, which presumably lead to 
sepsis, it is challenging to dissect this process since caspase-1 has several functions beyond 
pyroptosis and pro-inflammatory cytokine secretion (Labbé and Saleh, 2008; Denes et al., 
2012). Thus, further experiments in C57BL/6N wild type mice testing whether the 
administration of caspase inhibitors and/or anti-IL1α/β antibodies impact Y. pseudotubercu-
losis dissemination abilities are needed to verify these assumptions. 
Host genetic polymorphisms might contribute to disease progression after Y. pseudotu-
berculosis infection 
As IL-1β and inflammasome-associated polymorphisms in humans determine development of 
sepsis, severity of infectious disease, sequelae of infection (e.g. cancer development), and 
chronic disease/infection (Azad et al., 2012; Liu et al., 2013b; Opipari and Franchi, 2015; 
Hong et al., 2016; Jiménez-Sousa et al., 2017), genetic properties of the host are highly likely 
to determine the susceptibility to Yersinia infection. This is supported by a case report of 
chronic yersiniosis that was caused by defects in TLR5 and NOD2 recognition due to 
polymorphisms in these receptors (Netea et al., 2010). The present work further reinforces this 
hypothesis by showing that the bacterial and host genetic predispositions modulate 
inflammation and infection outcome during acute and persistent Y. pseudotuberculosis 
infection. It will be interesting to analyze whether there are additionally unidentified genetic 
predispositions that have an impact on disease severity and chronicity of yersiniosis 
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5 Perspectives 
In this work, it was demonstrated that CNFY-deficiency increases Y. pseudotuberculosis 
persistence in its preferred niche, the cecum of mice. This is due to altered host-pathogen 
interactions during acute Y. pseudotuberculosis YPIII ΔcnfY infection, which favor the switch 
for bacterial transcriptional reprogramming and host immune suppression. However, the 
initiating signals that induce the transcriptional re-adaptation in Y. pseudotuberculosis YPIII 
are still unknown. Next experiments should analyze the host’s transcriptional profile in a time 
series after the infection, to identify which host-derived signals drive transcriptional 
reprogramming of Y. pseudotuberculosis YPIII. This will help to identify more putative 
treatment targets that could be applied to avoid the development of chronic disease. Moreover, 
inhibitors against the putative treatment targets, IDO1 and Arginase-1, to treat persistent 
bacterial infections should be tested in the mouse model. 
The colonization-pattern analysis suggested that Y. pseudotuberculosis forms biofilms and/or 
aggregates as well as persister cells during persistent infection. To gain reliable data on this, 
the expression and presence of proteins known for biofilm, aggregate and persister cell 
formation should be analyzed. This is of particular interest for treatment strategies against 
persistent Yersinia infections, since all these colonization states potentially protect the bacteria 
against the host immune system and antimicrobial treatment (Mihai et al., 2015). The results of 
these analyses should provide new approaches to design treatment strategies against persistent 
Yersinia infection. 
It remains unclear whether persistent Y. pseudotuberculosis infection in the murine model also 
elicits development of reactive arthritis. To evaluate this model to study reactive arthritis, 
further experiments should assess whether bacterial antigens and Yersinia-specific IgA 
antibodies circulate in the blood stream of persistently infected mice and whether the persistent 
infection elicits a local inflammatory reaction in the joints of the mice. In this respect, it is also 
interesting to study whether reactive arthritis development is CNFY-dependent. 
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6 Summary 
The bacterial cytotoxic necrotizing factor toxin CNFY is important for Y. pseudotuberculosis 
virulence and modulates pathogenesis. This study set forth to characterize the complexity of 
the CNFY-dependent pathogenesis and host-pathogen interactions during acute and persistent 
Y. pseudotuberculosis infection. 
The results of this work demonstrated that presence of CNFY impaired the development of 
persistent Y. pseudotuberculosis infection. The enhanced persistence of the YPIII ∆cnfY was 
linked to decreased inflammatory tissue alterations, reduced production of IL-6, and lower 
disease severity during acute infection. Moreover, dysbiosis in the gut during late acute 
infection was CNFY-dependent but eliminated during persistent Y. pseudotuberculosis 
infections. 
Analysis of the bacterial colonization patterns using newly engineered, stable red-fluorescent 
Y. pseudotuberculosis enabled the detection of bacterial re-distribution in the cecal lymphoid 
tissue from acute to persistent infection. The re-distribution during the switch from acute to 
persistent infection stage was characterized by the absence of microcolonies and increased 
formation of dense bacterial aggregates during persistent Yersinia infection. Mild 
inflammatory responses in the cecum during persistent Y. pseudotuberculosis YPIII and 
YPIII ∆cnfY infection were accompanied by no- to low inflammatory cytokine production. 
The results of the host transcription profile analysis demonstrated that acute 
Y. pseudotuberculosis infection induced a common pro-inflammatory immune response in the 
cecum. However, YPIII infection resulted in the increased transcription of IL-6 induced genes, 
such as acute phase response proteins, and YPIII ∆cnfY infection triggered the transcription of 
interferon- and IL-22-induced genes, such as IDO1, GTPases and RegIII defensins. In 
comparison to uninfected cecal tissue, persistent Y. pseudotuberculosis infection caused 
sustained neutrophil recruitment and expression of il-1β, mast cell-associated proteases, and 
arginase-1. Although the acute inflammatory immune response was strongly down-regulated 
during persistent YPIII ∆cnfY infection, persistent YPIII infection fostered the expression of 
the complement system, antigen presentation and antibody maturation-associated genes. 
Transcriptional profiling of selected Y. pseudotuberculosis genes that are important for 
virulence and persistence showed that Y. pseudotuberculosis undergoes a transcriptional 
reprogramming from acute to persistent infection in BALB/c mice and retains the virulence 
plasmid during persistent infection. The analysis also revealed that the YPIII ∆cnfY gene 
expression profile upon acute infection was distinct from that of the wild type and strongly 
resembled the gene expression profile during persistent infection. 
Detailed analysis of Y. pseudotuberculosis CNFY-dependent pathogenesis in C57BL/6 mice 
revealed a similar modulation of virulence and disease progression compared to BALB/c  
mice. In this study it was also shown that systemic dissemination efficiency of Yersinia in 
C57BL/6N mice was CNFY-dependent. The dissemination of YPIII ∆cnfY was controlled by 
IL-1β and caspase-11, whereas YPIII systemic dissemination was supported by IL-1α and 
collective caspase-1/-11 activity. 
In conclusion, this study highlights CNFY as a crucial modulator during Y. pseudotuberculosis 
infection. It is a potent modulating factor of immune responses and inflammation that controls 
pathogenesis and infection outcome. Through its secretion, the toxin triggers strong pro-
inflammatory reactions that cause severe acute infection, while CNFY-deficiency reduces 
Yersinia virulence and pathology, but causes effective long-term infections that ensure 
environmental dissemination and reservoir maintenance. 
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Figure S1 Gating strategy of the “innate” panel. 
(A) Gating of living cells. (B-C) Gating of single cells. (D) Exclusion of small particles and cell debris. (E) Gating 
for “lineage negative” cells; exclusion of NK cells and lymphocytes. (F) Gating for macrophages (F4/80hi). (G) 
Exclusion of autofluorescent cells. (H) Remaining cells were gated for dendritic cells (CD11c+ Ly6G-). (I) The 
remaining cells were gated for Ly6G+PMNs. (J) The rest of the cells was gated for CD11b+ Ly6C- cells, denoted as 
monocytes. 
SUPPLEMENTARY INFORMATION 
171 
 
 
 
Figure S2 Gating strategy for the “adaptive” panel. 
(A) Gating of living cells. (B-C) Gating of single cells. (D) Exclusion of small particles and cell debris. (E) 
Exclusion of autofluorescent cells. (F) Gating for CD3- CD19+ B cells and CD3+ CD19- T cells. (G) CD3- CD19- 
cells were gated for NKp46+ NK cells.  
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Figure S3 Correlation of Yersinia loads in the cecum to luminal contents and feces. 
BALB/c mice were intra-gastrically infected with 1x106 CFU of Y. pseudotuberculosis YPIII ΔcnfY. At 40 dpi, 
egesta were assayed for Yersinia loads and bacterial burdens in the cecum or its luminal content at 42 days of 
infection. Yersinia burdens in the cecum of individual mice were plotted against the associated burdens in (A) the 
luminal content of the cecum and (B) the feces. Linear relationships were analyzed using Spearman’s correlation. 
The r-value specifies the correlation coefficient. 
 
Figure S4 Deletion of cnfY does not lead to increased persistent colonization of the small intestine. 
BALB/c mice were intra-gastrically infected with 1x106 CFU of Y. pseudotuberculosis YPIII ΔcnfY. The presented 
data were combined from two independent experiments: n=25. (A) Yersinia colonization in the feces at 40 dpi of 
mice analyzed for persisting Yersinia infection in the small intestine. (B) Yersinia loads in the PPs and the small 
intestine. Detection limits were: PPs ca. 227 CFU/g, small intestine ca. 25 CFU/g. (C) Yersinia burden in the 
luminal content of the small intestine (detection limit: 50 CFU). 
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Figure S5 Increased persistency rates due to cnfY absence are transferable to FVB/N mouse 
model. 
FVB/N mice were intra-gastrically infected with 1x106 CFU of Y. pseudotuberculosis YPIII or YPIII ΔcnfY. At 
42 dpi, Yersinia colonization rates were determined by bacterial burden assessment in the cecum. Colonization rates 
of the cecum were calculated using data from YPIII: n=7 and YPIII ΔcnfY: n=10 infected mice. 
 
Figure S6 The grade of inflammation in the cecum is independent of cnfY and differs between the 
infection phases. 
BALB/c mice were intra-gastrically infected with either 2x108 CFU (acute infection) or 1x106 CFU (persistent 
infection) of Y. pseudotuberculosis YPIII or YPIII ΔcnfY, respectively. After 3 dpi (acute infection) or 42 dpi 
(persistent infection) the inflammation grades were scored on the basis of H&E stained sections of the cecum. The 
data show the median scores of groups of 4 to 5 mice and was statistically analyzed with multiple t-tests employing 
Holm-Šídák’s correction: * p<0.01, ns: not significant. (A) Histopathology score of the lamina propria. (B) 
Histopathology score of the cecal lymphoid tissue.  
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Figure S7 Expression of chromosomally integrated PLtetO-1::mRuby2 is detectable during different 
growth phases at 25 °C. 
Stable mRuby2 labeled Y. pseudotuberculosis YPIII or YPIII ΔcnfY were grown to exponential (5 h, upper panel), 
early stationary (8 h, middle panel) or late stationary growth phase (24 h, lower panel) at 25 °C. Fixated bacteria 
were analyzed with the fluorescence microscope using the DIC and the mRuby2 channel. The microscopic pictures 
are representatives of 9 microscopic fields and were adjusted in brightness and exposure (mRuby2 channel) or in 
contrast (DIC channel). The bar indicates 20 µm. 
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Figure S8 Expression of chromosomally integrated PLtetO-1::mRuby2 is detectable during different 
growth phases at 37 °C. 
Stable mRuby2 labeled Y. pseudotuberculosis YPIII or YPIII ΔcnfY were grown to exponential (5 h, upper panel), 
early stationary (8 h, middle panel) or late stationary growth phase (24 h, lower panel) at 37 °C. The fixated bacteria 
were analyzed with the fluorescence microscope using the differential interference contrast (DIC) and the mRuby2 
channel. The microscopic pictures are representatives of 9 microscopic fields and were adjusted in brightness and 
exposure (mRuby2 channel) or in contrast (DIC channel). The bar indicates 20 µm. 
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Figure S9 Red fluorescence is specific for mRuby2 labeled Y. pseudotuberculosis strains. 
The unlabeled Y. pseudotuberculosis strains, YPIII and YPIII ΔcnfY, were grown to late stationary growth phase 
(24 h) at 25 °C or 37 °C, respectively. Fixated bacteria were analyzed with the fluorescence microscope using the 
DIC and the mRuby2 channel. The microscopic pictures are representatives of 9 microscopic fields and were 
adjusted in brightness and exposure (mRuby2 channel) or in contrast (DIC channel). The bar indicates 20 µm.  
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Figure S10 The integration of PLtetO-1::mRuby2 into the Y. pseudotuberculosis chromosome does not 
influence organ colonization traits. 
Groups of eight to ten BALB/c mice were intra-gastrically infected with 2x108 CFU of Y. pseudotuberculosis YPIII, 
YPIII ΔcnfY or the isogenic mRuby2 labeled strains. At the indicated time points (A) small intestine, (B) PPs, (C) 
mesenteric lymph nodes, (D) spleen and (E) liver were isolated and bacterial loads were determined. Detection 
limits were at ca. 330 CFU/g in the spleen and ca. 50 CFU/g in the liver. The data were combined from two 
independent experiments. Statistical analysis was performed using the Kruskal-Wallis test and Dunn’s correction: 
ns: not significant; ** p<0.01, *** p<0.001.  
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Figure S11 Chromosomal integration of PLtetO-1::mRuby2 does not affect Y. pseudotuberculosis 
persistence rates in the feces. 
Mice were intra-gastrically challenged with 1x106 CFU of Y. pseudotuberculosis YPIII, YPIII ΔcnfY or their 
respective mRuby2 labeled strains. The rate of mice positively tested for Yersinia colonization was determined after 
cold enrichment of the egesta at the indicated time points. The frequencies were calculated using data of (A) YPIII 
n=40 mice, YPIII (mRuby2) n=40 mice, and (B) YPIII ΔcnfY n=10 mice, YPIII ΔcnfY (mRuby2) n=20 mice. 
 
Figure S12 The integration of PLtetO-1::mRuby2 into the Yersinia chromosome does not impact the 
colonization characteristics in the cecum during persistency. 
BALB/c mice were intra-gastrically infected with 1x106 CFU of Y. pseudotuberculosis YPIII (mRuby2) or 
YPIII ΔcnfY (mRuby2). (A-B) At 42 dpi, bacterial colonization rates and burden in the cecal compartment were 
assessed: YPIII (mRuby2) n= 11, YPIII ΔcnfY (mRuby2) n=10. The bar represents the median. The data were 
statistically analyzed with the Mann-Whitney U test: * p<0.05. (A) Yersinia loads in the cecum. The detection limit 
was at ca. 125 CFU/g. (B) Yersinia burden in the luminal content of the cecum. The detection limit was at 50 CFU.  
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Figure S13 Microcolony caused lesion severity in the cecal lymphoid tissue is independent of cnfY. 
BALB/c mice were intra-gastrically infected with 2x108 CFU of Y. pseudotuberculosis YPIII (mRuby2) or 
YPIII cnfY (mRuby2). At 3 dpi (acute), sections of highly colonized ceca were prepared, fixated, stained and 
scored. The sections were scored for bacterial microcolony caused lesions in the cecal lymphoid tissue by the 
analyses of multiple sections of multiple fields (n): YPIII n=85, YPIII ΔcnfY n=165. The data show the mean scores 
±SEM combined from 3 mice per group. Statistical analyses were performed using the student’s t-test; ns, not 
significant. 
 
 
Figure S14 Principal coordinates analysis of the 16S rDNA sequencing from egesta of 
Y. pseudotuberculosis infected mice. 
Mice were intra-gastrically challenged with 1x106 CFU of Y. pseudotuberculosis YPIII or YPIII cnfY. At indicated 
time points post infection, fresh feces was sampled. Colonized samples were further analyzed for the relative 
abundance of commensal bacteria by 16S rDNA sequencing. The Plot shows the principal coordinates analysis of 
the sequenced samples. 
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Figure S15 The Yersinia colonization levels in the cecum are independent of the infection dose and 
infection stage. 
(A) RNA electropherograms of exemplary RNA pools from cecal tissue total RNA extracts. The RIN indicates the 
quality of the total RNA pools. (B) BALB/c mice were intra-gastrically challenged with the indicated infection 
doses of Y. pseudotuberculosis YPIII or YPIII ΔcnfY. At 5 dpi and 42 dpi highly colonized mice were sacrificed and 
the cecum was assayed for the Yersinia burdens. The individual data points represent single mice and the line the 
median. Statistical analysis was performed with One-way ANOVA employing Holm-Šídák’s correction. No 
significant differences were found.  
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Figure S16 Sequencing platform performance. 
Exemplary ERCC RNA Spike-In Control mixes analysis to determine the platform performance. (A) Dose response 
to determine the lower detection limit (LLD) and dynamic range. (B) Fold-change response to determine platform 
accuracy.  
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Figure S17 Replicate correlation of RNA-Sequencing data. 
RPKM normalized read counts for all detected genes are plotted for 3 biological replicates. The Pearson-coefficient 
(r) is given for each replicate. 
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Figure S18 Tissue repair genes are transcribed during persistent Y. pseudotuberculosis YPIII in-
fection. 
Heat map of a selection of more abundant transcripts associated with tissue repair ((-1 < log2 FC > 1; p<0.05) at 42 
dpi comparing YPIII to YPIII ΔcnfY infection (left column). The respective log2 FC of each gene compared to 
uninfected mice are displayed: YPIII infected mice 5 dpi compared to uninfected (middle column) and YPIII ΔcnfY 
infected mice 5 dpi compared to uninfected (right column). Grey fields indicate no significant changes (p ≥ 0.05) 
compared to uninfected mice. 
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Figure S19 In vitro characterization of anaerobiosis and stress gene expression in Y. pseudotuber-
culosis YPIII and YPIII ΔcnfY. 
Bacterial liquid cultures were grown to stationary phase (16 h) at 25 °C and 37 °C, respectively. Total RNA extracts 
were analyzed for the indicated relative transcript expression using qRT-PCR. The relative expression levels were 
normalized to sopB and if-3 expression levels and calculated relative to YPIII at 25 °C. (A) Anaerobiosis genes. (B) 
Stress genes reacting to environmental cues. The data show the mean ±SEM and was statistically analyzed with 
multiple t-tests employing Holm-Šídák’s correction: no significant differences between YPIII and YPIII ΔcnfY were 
found. ns: not significant. 
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Figure S20 In vitro characterization of virulence and regulator gene expression in Y. pseudotuber-
culosis YPIII and YPIII ΔcnfY. 
Bacterial liquid cultures were grown to stationary phase (16 h) at 25 °C and 37 °C, respectively. Total RNA extracts 
were analyzed for the indicated relative transcript expression using qRT-PCR. The relative expression levels were 
normalized to sopB and if-3 expression levels and calculated relative to YPIII at 25 °C. (A) Virulence genes. (B) 
Metabolic and virulence regulator genes. The data show the mean ±SEM and was statistically analyzed with 
multiple t-tests employing Holm-Šídák’s correction: no significant differences between YPIII and YPIII ΔcnfY were 
found. ns: not significant. 
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Figure S21 cnfY expression is down-regulated during acute and persistent Y. pseudotuberculosis 
YPIII infection compared to in vitro cultures. 
The cnfY expression levels of Y. pseudotuberculosis YPIII liquid cultures from stationary phase (16 h) at 25 °C and 
37 °C were compared to the total RNA extracts from YPIII infected ceca at 5 and 42 dpi employing qRT-PCR. The 
relative expression levels were normalized to sopB and if-3 expression levels and calculated relative to YPIII 
infection in the cecum 5 dpi. The data show the mean ±SEM and was statistically analyzed with one-way ANOVA 
using Holm-Šídák’s correction: *** p<0.001. 
 
Figure S22 Yersinia colonization levels in the cecal content of mice analyzed for the cytokine 
profiles in serum and cecum. 
BALB/c mice were intra-gastrically challenged with 1x106 CFU of Y. pseudotuberculosis YPIII or YPIII ΔcnfY. At 
indicated time points post infection ceca were excised and the cecal content was screened for Yersinia colonization 
levels. The presented data show the bacterial loads in the cecal content of the most highly colonized mice. The 
cytokine levels in the serum and the cecum of these mice were further characterized. The bars indicate the median 
CFU in the cecal content. The detection limit was at 25 CFU. The data were analyzed with multiple t-tests 
employing Holm-Šídák’s correction: no significant differences were found between YPIII and YPIII ΔcnfY.  
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Figure S23 Total cell numbers isolated from PPs, mesenteric lymph nodes and spleen at 3 dpi. 
C57BL/6N mice were intra-gastrically infected with 2x108 CFU of Y. pseudotuberculosis YPIII or YPIII ΔcnfY. At 
3 dpi, PP, MLNs and spleen were isolated, single cell suspensions were generated, and counted. The bar chart shows 
the absolute cell numbers obtained from the different organs. The bar represents the mean ±SEM. The data were 
combined from two independent experiments: YPIII n=10, YPIII ΔcnfY n=10. Statistical analysis was performed 
with multiple t-tests employing Holm-Šídák’s correction: +, comparison of infected to uninfected group; ++, 
p<0.01; +++, p<0.001. *, comparison of the YPIII to the YPIII ΔcnfY infected group; *, p<0.05; ***, p<0.001. 
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Figure S24 CNFY of Y. pseudotuberculosis modulates relative immune cell composition 
C57BL/6N mice were intra-gastrically challenged with 2x108 CFU of Y. pseudotuberculosis YPIII or YPIII ΔcnfY. 
At 3 dpi, PPs, MLNs and spleen were analyzed for their relative immune cell composition of neutrophils, 
macrophages, monocytes, DCs, NK cells, B cells, and T cells. The data were combined from two independent 
experiments, YPIII n=10; YPIII ΔcnfY n=10. Bars indicate mean  ±SEM. Statistical analysis was performed with 
multiple t-tests employing Holm-Šídák’s correction; + comparison between infected and uninfected mice, + p<0.05; 
++, p<0.01; +++, p<0.001. * comparison between YPIII and YPIII ΔcnfY infected mice: * p<0.05, ** p<0.01,  
*** p<0.001.  
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Figure S25 Y. pseudotuberculosis YPIII ΔcnfY is severely attenuated during intravenous challenge. 
C57BL/6N mice were intravenously infected with 5000 CFU of Y. pseudotuberculosis YPIII or YPIII ΔcnfY. The 
health status of the mice was monitored over a period of 10 days. The data were combined from two independent 
experiments: YPIII n=9; YPIII ΔcnfY n=9. (A) Survival of C57BL/6N mice. Statistical analysis was performed with 
the log-rank test (Mantel-Cox): *** p<0.001. (B) Body weight loss curves. The data shows the mean ±SEM and 
statistical analysis was performed with multiple t-tests using Holm-Šídák’s correction: * p<0.05. 
 
Figure S26 The inflammasome has no impact on C57BL/6N susceptibility. 
C57BL/6N mice and the respective caspase-1/-11 mutants were challenged with 2x108 CFU of 
Y. pseudotuberculosis YPIII (A & B) or YPIII ΔcnfY (C). The health status of the infected mice was monitored over 
a time period of 14 days. The data were combined from two independent experiments: C57BL/6N, YPIII/ 
YPIII ΔcnfY n=8; caspase-1-/-, YPIII n=10; caspase-11-/-, YPIII n=9, YPIII ΔcnfY n=8; caspase-1-/-/-11-/-, YPIII/ 
YPIII ΔcnfY n=10 (A) Survival of C57BL/6N mice in comparison to caspase-1-/-, caspase-11-/- and caspase-1-/-/-11-/- 
mice after YPIII challenge. Statistical analysis was performed with the log-rank test (Mantel-Cox): no significant 
differences of the caspase knock out mice compared to wild type mice were observed. (B) Body weight loss curves 
upon YPIII infection. (C) Body weight loss curves upon YPIII ΔcnfY infection. (B & C) The data shows the mean 
±SEM and was statistically analyzed with multiple t-tests employing Holm- Šídák’s correction. No significant 
differences were observed. ns: not significant. 
  
 
 
                  Table S1 Mapping statistics. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sample Replicate Read 
length 
Total reads Total mapped 
including ERCC 
Total mapped 
to genome 
Total mapped to 
genes 
Uninfected 5 dpi 1 51 22,047,027 20,430,012 14,669,574 11,138,040 
Uninfected 5 dpi 2 51 21,873,833 20,052,447 14,223,693 10,367,252 
Uninfected 5 dpi 3 51 22,107,361 20,344,484 12,210,972 8,657,003 
YPIII 5 dpi 1 51 18,014,829 16,589,782 10,540,510 7,211,779 
YPIII 5 dpi 2 51 23,817,131 21,771,321 15,347,411 10,181,473 
YPIII 5 dpi 3 51 26,875,039 24,533,224 13,632,231 8,654,807 
YPIII ΔcnfY 5 dpi 1 51 26,009,339 23,785,082 16,411,709 11,073,180 
YPIII ΔcnfY 5 dpi 2 51 19,350,404 17,666,055 11,466,580 8,342,268 
YPIII ΔcnfY 5 dpi 3 51 19,536,186 17,715,178 12,440,019 8,207,709 
Uninfected 42 dpi 1 51 24,908,621 22,820,056 17,182,363 12,736,288 
Uninfected 42 dpi 2 51 27,407,426 25,187,148 17,482,471 12,846,119 
Uninfected 42 dpi 3 51 27,665624 25,073,102 18,191,840 12,969,359 
YPIII 42 dpi 1 51 39,795,513 36,477,547 23,818,604 14,934,833 
YPIII 42 dpi 2 51 38,071,123 35,199,382 24,552,069 16,591,558 
YPIII 42 dpi 3 51 38,140,082 34,745,298 24,762,343 16,507,236 
YPIII ΔcnfY 42 dpi 1 51 25,239,634 22,980,418 13,956,701 10,008,228 
YPIII ΔcnfY 42 dpi 2 51 24,297,789 22,003,730 16,606,374 11,899,990 
YPIII ΔcnfY 42 dpi 3 51 27,823,321 25,326,423 16,275,006 11,698,916 
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Table S2 Differentially expressed genes of BALB/c (YPIII infected 5 dpi vs. uninfected 5 dpi) 
Ensembl ID Gene 
Symbol 
Gene name log2 fold 
change 
p-value 
ENSMUSG00000058427 Cxcl2 chemokine (C-X-C motif) ligand 2 4.37 9.51E-37 
ENSMUSG00000031722 Hp haptoglobin 3.97 4.15E-32 
ENSMUSG00000027398 Il1b interleukin 1 beta 3.68 1.85E-30 
ENSMUSG00000040809 Chil3 chitinase-like 3 3.64 2.70E-22 
ENSMUSG00000022126 Irg1 immunoresponsive gene 1 3.60 4.69E-31 
ENSMUSG00000026822 Lcn2 lipocalin 2 3.60 4.56E-28 
ENSMUSG00000005800 Mmp8 matrix metallopeptidase 8 3.51 6.58E-22 
ENSMUSG00000024087 Cyp1b1 cytochrome P450, family 1, subfamily b, polypeptide 1 3.46 2.46E-27 
ENSMUSG00000001131 Timp1 tissue inhibitor of metalloproteinase 1 3.44 1.09E-25 
ENSMUSG00000028859 Csf3r colony stimulating factor 3 receptor (granulocyte) 3.43 1.32E-31 
ENSMUSG00000064246 Chil1 chitinase-like 1 3.36 1.13E-25 
ENSMUSG00000006403 Adamts4 a disintegrin-like and metallopeptidase (reprolysin type) with 
thrombospondin type 1 motif, 4 
3.24 4.71E-25 
ENSMUSG00000021091 Serpina3n serine (or cysteine) peptidase inhibitor, clade A, member 3N 3.14 2.27E-44 
ENSMUSG00000029371 Cxcl5 chemokine (C-X-C motif) ligand 5 3.11 6.64E-16 
ENSMUSG00000042265 Trem1 triggering receptor expressed on myeloid cells 1 3.11 2.69E-17 
ENSMUSG00000043613 Mmp3 matrix metallopeptidase 3 3.07 1.21E-19 
ENSMUSG00000029380 Cxcl1 chemokine (C-X-C motif) ligand 1 3.04 2.16E-18 
ENSMUSG00000025746 Il6 interleukin 6 2.96 4.29E-16 
ENSMUSG00000030144 Clec4d C-type lectin domain family 4, member d 2.95 5.34E-16 
ENSMUSG00000056071 S100a9 S100 calcium binding protein A9 (calgranulin B) 2.92 6.33E-14 
ENSMUSG00000000204 Slfn4 schlafen 4 2.91 1.05E-28 
ENSMUSG00000027832 Ptx3 pentraxin related gene 2.90 1.06E-14 
ENSMUSG00000052270 Fpr2 formyl peptide receptor 2 2.89 2.24E-19 
ENSMUSG00000019987 Arg1 arginase, liver 2.85 1.12E-18 
ENSMUSG00000032691 Nlrp3 NLR family, pyrin domain containing 3 2.80 1.56E-19 
ENSMUSG00000079012 Serpina3m serine (or cysteine) peptidase inhibitor, clade A, member 3M 2.80 1.24E-18 
ENSMUSG00000030142 Clec4e C-type lectin domain family 4, member e 2.78 1.07E-13 
ENSMUSG00000048636  2.78 8.16E-14 
ENSMUSG00000024529 Lox lysyl oxidase 2.70 1.92E-17 
ENSMUSG00000044103 Il1f9 interleukin 1 family, member 9 2.69 1.11E-15 
ENSMUSG00000089672 Gp49a glycoprotein 49 A 2.67 4.34E-20 
ENSMUSG00000027399 Il1a interleukin 1 alpha 2.62 3.28E-16 
ENSMUSG00000031444 F10 coagulation factor X 2.58 3.74E-14 
ENSMUSG00000073530 Pappa2 pappalysin 2 2.56 7.54E-17 
ENSMUSG00000022651 Retnlg resistin like gamma 2.53 2.05E-15 
ENSMUSG00000027656 Wisp2 WNT1 inducible signaling pathway protein 2 2.50 2.87E-11 
ENSMUSG00000024697 Gna14 guanine nucleotide binding protein, alpha 14 2.46 1.11E-20 
ENSMUSG00000026180 Cxcr2 chemokine (C-X-C motif) receptor 2 2.46 1.86E-16 
ENSMUSG00000036040 Adamtsl2 ADAMTS-like 2 2.45 3.70E-19 
ENSMUSG00000047798 Cd300lf CD300 antigen like family member F 2.45 1.80E-15 
ENSMUSG00000047562 Mmp10 matrix metallopeptidase 10 2.43 2.50E-10 
ENSMUSG00000034855 Cxcl10 chemokine (C-X-C motif) ligand 10 2.41 1.32E-13 
ENSMUSG00000052749 Trim30b tripartite motif-containing 30B 2.39 1.44E-10 
ENSMUSG00000029379 Cxcl3 chemokine (C-X-C motif) ligand 3 2.39 4.03E-10 
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ENSMUSG00000056054 S100a8 S100 calcium binding protein A8 (calgranulin A) 2.38 6.97E-10 
ENSMUSG00000000182 Fgf23 fibroblast growth factor 23 2.36 5.62E-10 
ENSMUSG00000030732 Chrdl2 chordin-like 2 2.36 6.70E-11 
ENSMUSG00000026580 Selp selectin, platelet 2.35 4.72E-16 
ENSMUSG00000032068 Plet1 placenta expressed transcript 1 2.32 3.37E-14 
ENSMUSG00000021950 Anxa8 annexin A8 2.32 3.54E-11 
ENSMUSG00000027360 Hdc histidine decarboxylase 2.30 3.58E-10 
ENSMUSG00000044162 Tnip3 TNFAIP3 interacting protein 3 2.30 1.38E-19 
ENSMUSG00000035385 Ccl2 chemokine (C-C motif) ligand 2 2.29 3.02E-11 
ENSMUSG00000032796 Lama1 laminin, alpha 1 2.28 3.19E-18 
ENSMUSG00000041449  2.28 2.64E-14 
ENSMUSG00000000982 Ccl3 chemokine (C-C motif) ligand 3 2.26 2.21E-09 
ENSMUSG00000022548 Apod apolipoprotein D 2.25 1.79E-14 
ENSMUSG00000022181 C6 complement component 6 2.24 2.40E-16 
ENSMUSG00000028766 Alpl alkaline phosphatase, liver/bone/kidney 2.24 1.20E-21 
ENSMUSG00000030187 Klra2 killer cell lectin-like receptor, subfamily A, member 2 2.19 1.41E-12 
ENSMUSG00000074934 Grem1 gremlin 1 2.18 7.63E-21 
ENSMUSG00000000318 Clec10a C-type lectin domain family 10, member A 2.17 1.65E-14 
ENSMUSG00000059657 Stfa2l1 stefin A2 like 1 2.15 9.04E-09 
ENSMUSG00000027068 Dhrs9 dehydrogenase/reductase (SDR family) member 9 2.14 2.12E-19 
ENSMUSG00000062593 Lilrb4 leukocyte immunoglobulin-like receptor, subfamily B, member 4 2.12 2.83E-12 
ENSMUSG00000081665  2.12 8.31E-10 
ENSMUSG00000068196 Col8a1 collagen, type VIII, alpha 1 2.11 5.96E-17 
ENSMUSG00000040026 Saa3 serum amyloid A 3 2.09 7.53E-11 
ENSMUSG00000086320  2.09 6.06E-18 
ENSMUSG00000032690 Oas2 2'-5' oligoadenylate synthetase 2 2.06 9.91E-12 
ENSMUSG00000012428 Steap4 STEAP family member 4 2.04 3.90E-17 
ENSMUSG00000089942 Pira2 paired-Ig-like receptor A2 2.03 4.03E-10 
ENSMUSG00000053113 Socs3 suppressor of cytokine signaling 3 2.03 1.27E-10 
ENSMUSG00000078763 Slfn1 schlafen 1 2.02 6.00E-13 
ENSMUSG00000095788 Sirpb1a signal-regulatory protein beta 1A 2.02 8.19E-08 
ENSMUSG00000037095 Lrg1 leucine-rich alpha-2-glycoprotein 1 1.99 1.84E-10 
ENSMUSG00000026073 Il1r2 interleukin 1 receptor, type II 1.98 3.10E-09 
ENSMUSG00000060183 Cxcl11 chemokine (C-X-C motif) ligand 11 1.97 4.56E-08 
ENSMUSG00000056749 Nfil3 nuclear factor, interleukin 3, regulated 1.95 7.88E-14 
ENSMUSG00000025877 Hk3 hexokinase 3 1.95 2.88E-09 
ENSMUSG00000040264 Gbp2b guanylate binding protein 2b 1.94 3.61E-10 
ENSMUSG00000052353 Cemip cell migration inducing protein, hyaluronan binding 1.94 1.41E-07 
ENSMUSG00000059089 Fcgr4 Fc receptor, IgG, low affinity IV 1.94 1.42E-12 
ENSMUSG00000093916  1.93 3.84E-07 
ENSMUSG00000016024 Lbp lipopolysaccharide binding protein 1.93 3.48E-17 
ENSMUSG00000067780 Pi15 peptidase inhibitor 15 1.93 1.46E-16 
ENSMUSG00000066363 Serpina3f serine (or cysteine) peptidase inhibitor, clade A, member 3F 1.92 1.30E-10 
ENSMUSG00000049103 Ccr2 chemokine (C-C motif) receptor 2 1.92 7.86E-16 
ENSMUSG00000029675 Eln elastin 1.91 1.91E-12 
ENSMUSG00000037411 Serpine1 serine (or cysteine) peptidase inhibitor, clade E, member 1 1.90 8.62E-15 
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ENSMUSG00000064147 Rab44 RAB44, member RAS oncogene family 1.90 2.78E-07 
ENSMUSG00000054072 Iigp1 interferon inducible GTPase 1 1.90 1.99E-08 
ENSMUSG00000075602 Ly6a lymphocyte antigen 6 complex, locus A 1.89 2.26E-14 
ENSMUSG00000015947 Fcgr1 Fc receptor, IgG, high affinity I 1.86 5.39E-12 
ENSMUSG00000013974 Mcemp1 mast cell expressed membrane protein 1 1.86 4.81E-07 
ENSMUSG00000020826 Nos2 nitric oxide synthase 2, inducible 1.85 2.45E-09 
ENSMUSG00000002289 Angptl4 angiopoietin-like 4 1.85 1.78E-10 
ENSMUSG00000026981 Il1rn interleukin 1 receptor antagonist 1.83 4.31E-12 
ENSMUSG00000079227 Ccr5 chemokine (C-C motif) receptor 5 1.82 1.58E-15 
ENSMUSG00000000031  1.79 3.69E-06 
ENSMUSG00000024679 Ms4a6d membrane-spanning 4-domains, subfamily A, member 6D 1.79 7.08E-13 
ENSMUSG00000028111 Ctsk cathepsin K 1.79 1.01E-11 
ENSMUSG00000028655 Mfsd2a major facilitator superfamily domain containing 2A 1.78 1.52E-06 
ENSMUSG00000026249 Serpine2 serine (or cysteine) peptidase inhibitor, clade E, member 2 1.78 5.50E-13 
ENSMUSG00000069792 Wfdc17 WAP four-disulfide core domain 17 1.78 5.43E-07 
ENSMUSG00000074677 LOC10003894
7 
signal-regulatory protein beta 1-like 1.77 4.17E-06 
ENSMUSG00000024810 Il33 interleukin 33 1.77 4.48E-15 
ENSMUSG00000090307 1700071M16
Rik 
RIKEN cDNA 1700071M16 gene 1.77 2.70E-08 
ENSMUSG00000054555 Adam12 a disintegrin and metallopeptidase domain 12 (meltrin alpha) 1.76 4.00E-09 
ENSMUSG00000024053 Emilin2 elastin microfibril interfacer 2 1.76 1.80E-14 
ENSMUSG00000016194 Hsd11b1 hydroxysteroid 11-beta dehydrogenase 1 1.75 8.08E-11 
ENSMUSG00000043832 Clec4a3 C-type lectin domain family 4, member a3 1.75 7.13E-12 
ENSMUSG00000025161 Slc16a3 solute carrier family 16 (monocarboxylic acid transporters), member 
3 
1.74 4.02E-09 
ENSMUSG00000030474 Siglece sialic acid binding Ig-like lectin E 1.74 2.70E-06 
ENSMUSG00000007682 Dio2 deiodinase, iodothyronine, type II 1.74 1.07E-06 
ENSMUSG00000073555 Gm4951 predicted gene 4951 1.74 2.20E-10 
ENSMUSG00000029553 Tfec transcription factor EC 1.72 1.58E-06 
ENSMUSG00000030022 Adamts9 a disintegrin-like and metallopeptidase (reprolysin type) with 
thrombospondin type 1 motif, 9 
1.72 2.14E-13 
ENSMUSG00000022534 Mefv Mediterranean fever 1.71 9.04E-09 
ENSMUSG00000008845 Cd163 CD163 antigen 1.71 5.47E-14 
ENSMUSG00000096528 G430049J08R
ik 
RIKEN cDNA G430049J08 gene 1.71 7.11E-12 
ENSMUSG00000040152 Thbs1 thrombospondin 1 1.70 3.24E-20 
ENSMUSG00000074151 Nlrc5 NLR family, CARD domain containing 5 1.70 1.09E-10 
ENSMUSG00000050578 Mmp13 matrix metallopeptidase 13 1.69 4.84E-06 
ENSMUSG00000051748 Wfdc21 WAP four-disulfide core domain 21 1.68 1.29E-05 
ENSMUSG00000037035 Inhbb inhibin beta-B 1.68 2.75E-07 
ENSMUSG00000090942 F830016B08R
ik 
RIKEN cDNA F830016B08 gene 1.68 1.60E-08 
ENSMUSG00000022860 Chodl chondrolectin 1.68 4.33E-08 
ENSMUSG00000041193 Pla2g5 phospholipase A2, group V 1.67 1.99E-10 
ENSMUSG00000085977  1.66 3.61E-06 
ENSMUSG00000029484 Anxa3 annexin A3 1.66 2.34E-14 
ENSMUSG00000009185 Ccl8 chemokine (C-C motif) ligand 8 1.65 2.63E-09 
ENSMUSG00000047330 Kcne4 potassium voltage-gated channel, Isk-related subfamily, gene 4 1.65 7.36E-11 
ENSMUSG00000038156 Spon1 spondin 1, (f-spondin) extracellular matrix protein 1.65 9.11E-16 
ENSMUSG00000028583 Pdpn podoplanin 1.64 7.24E-15 
ENSMUSG00000074415 2610203C20R
ik 
RIKEN cDNA 2610203C20 gene 1.64 1.17E-11 
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ENSMUSG00000030786 Itgam integrin alpha M 1.64 3.03E-15 
ENSMUSG00000058818 Pirb paired Ig-like receptor B 1.63 1.21E-10 
ENSMUSG00000046402 Rbp1 retinol binding protein 1, cellular 1.63 4.24E-09 
ENSMUSG00000079419 Ms4a6c membrane-spanning 4-domains, subfamily A, member 6C 1.63 8.95E-13 
ENSMUSG00000041481  1.62 5.25E-11 
ENSMUSG00000035373 Ccl7 chemokine (C-C motif) ligand 7 1.62 1.27E-05 
ENSMUSG00000021614 Vcan versican 1.62 1.16E-15 
ENSMUSG00000018930 Ccl4 chemokine (C-C motif) ligand 4 1.61 2.89E-05 
ENSMUSG00000029417 Cxcl9 chemokine (C-X-C motif) ligand 9 1.59 2.23E-06 
ENSMUSG00000046688 Tifa TRAF-interacting protein with forkhead-associated domain 1.58 2.16E-10 
ENSMUSG00000085786  1.58 4.73E-09 
ENSMUSG00000022582 Ly6g lymphocyte antigen 6 complex, locus G 1.57 2.97E-07 
ENSMUSG00000055978 Fut2 fucosyltransferase 2 1.57 1.15E-10 
ENSMUSG00000081448  1.57 5.37E-07 
ENSMUSG00000079014 Serpina3i serine (or cysteine) peptidase inhibitor, clade A, member 3I 1.57 5.26E-06 
ENSMUSG00000096768 Erdr1 erythroid differentiation regulator 1 1.57 2.07E-06 
ENSMUSG00000025044 Msr1 macrophage scavenger receptor 1 1.56 1.64E-08 
ENSMUSG00000051439 Cd14 CD14 antigen 1.56 4.09E-09 
ENSMUSG00000021281 Tnfaip2 tumor necrosis factor, alpha-induced protein 2 1.56 1.31E-10 
ENSMUSG00000074417 Pira11 paired-Ig-like receptor A11 1.56 4.95E-07 
ENSMUSG00000058755 Osm oncostatin M 1.54 6.31E-05 
ENSMUSG00000042759 Apobr apolipoprotein B receptor 1.54 6.57E-08 
ENSMUSG00000075270 Pde11a phosphodiesterase 11A 1.53 7.44E-06 
ENSMUSG00000079363 Gbp4 guanylate binding protein 4 1.53 9.25E-07 
ENSMUSG00000019997 Ctgf connective tissue growth factor 1.53 6.31E-10 
ENSMUSG00000026185 Igfbp5 insulin-like growth factor binding protein 5 1.53 5.66E-13 
ENSMUSG00000078921 Tgtp2 T cell specific GTPase 2 1.53 1.98E-07 
ENSMUSG00000031972 Acta1 actin, alpha 1, skeletal muscle 1.52 5.73E-06 
ENSMUSG00000053101 Gpr141 G protein-coupled receptor 141 1.52 1.84E-07 
ENSMUSG00000041695 Kcnj2 potassium inwardly-rectifying channel, subfamily J, member 2 1.51 3.22E-06 
ENSMUSG00000044254 Pcsk9 proprotein convertase subtilisin/kexin type 9 1.51 3.67E-10 
ENSMUSG00000018339 Gpx3 glutathione peroxidase 3 1.51 7.40E-11 
ENSMUSG00000079362 Gbp6 guanylate binding protein 6 1.51 3.14E-07 
ENSMUSG00000025330 Padi4 peptidyl arginine deiminase, type IV 1.50 6.33E-05 
ENSMUSG00000003665 Has1 hyaluronan synthase1 1.50 1.09E-04 
ENSMUSG00000060063 Alox5ap arachidonate 5-lipoxygenase activating protein 1.49 1.14E-09 
ENSMUSG00000054588  1.49 4.76E-05 
ENSMUSG00000068452 Duox2 dual oxidase 2 1.49 2.95E-09 
ENSMUSG00000041347 Bdkrb1 bradykinin receptor, beta 1 1.49 1.09E-04 
ENSMUSG00000031963 Bmper BMP-binding endothelial regulator 1.48 6.83E-08 
ENSMUSG00000040133 Gpr176 G protein-coupled receptor 176 1.48 5.96E-05 
ENSMUSG00000025804 Ccr1 chemokine (C-C motif) receptor 1 1.47 3.96E-10 
ENSMUSG00000022367 Has2 hyaluronan synthase 2 1.47 5.35E-06 
ENSMUSG00000001435 Col18a1 collagen, type XVIII, alpha 1 1.47 4.71E-12 
ENSMUSG00000073489 Ifi204 interferon activated gene 204 1.47 3.18E-09 
ENSMUSG00000024481 Lvrn laeverin 1.47 1.65E-05 
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ENSMUSG00000028370 Pappa pregnancy-associated plasma protein A 1.46 5.75E-13 
ENSMUSG00000024411 Aqp4 aquaporin 4 1.46 2.46E-06 
ENSMUSG00000050747 Trim15 tripartite motif-containing 15 1.46 1.08E-04 
ENSMUSG00000022146 Osmr oncostatin M receptor 1.46 1.14E-11 
ENSMUSG00000029082 Bst1 bone marrow stromal cell antigen 1 1.45 3.10E-07 
ENSMUSG00000056025 Clca3a1 chloride channel calcium activated 3A1 1.45 5.55E-08 
ENSMUSG00000027460 Angpt4 angiopoietin 4 1.45 1.56E-04 
ENSMUSG00000027737 Slc7a11 solute carrier family 7 (cationic amino acid transporter, y+ system), 
member 11 
1.44 3.08E-10 
ENSMUSG00000028874 Fgr Gardner-Rasheed feline sarcoma viral (Fgr) oncogene homolog 1.44 1.28E-08 
ENSMUSG00000071714 Csf2rb2 colony stimulating factor 2 receptor, beta 2, low-affinity 
(granulocyte-macrophage) 
1.44 2.39E-08 
ENSMUSG00000046223 Plaur plasminogen activator, urokinase receptor 1.44 4.39E-06 
ENSMUSG00000063388  1.44 1.76E-04 
ENSMUSG00000029915 Clec5a C-type lectin domain family 5, member a 1.43 1.28E-05 
ENSMUSG00000035004 Igsf6 immunoglobulin superfamily, member 6 1.42 6.71E-09 
ENSMUSG00000028633 Ctps cytidine 5'-triphosphate synthase 1.42 6.14E-11 
ENSMUSG00000062345 Serpinb2 serine (or cysteine) peptidase inhibitor, clade B, member 2 1.41 2.56E-04 
ENSMUSG00000079445 B3gnt7 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 7 1.41 7.34E-06 
ENSMUSG00000024640 Psat1 phosphoserine aminotransferase 1 1.40 1.56E-06 
ENSMUSG00000030353 Tead4 TEA domain family member 4 1.40 1.17E-04 
ENSMUSG00000041324 Inhba inhibin beta-A 1.39 4.22E-05 
ENSMUSG00000042808 Gpx2 glutathione peroxidase 2 1.39 7.62E-09 
ENSMUSG00000030077 Chl1 cell adhesion molecule with homology to L1CAM 1.39 5.05E-09 
ENSMUSG00000027323 Rad51 RAD51 homolog 1.39 9.17E-07 
ENSMUSG00000033508 Asprv1 aspartic peptidase, retroviral-like 1 1.39 1.40E-04 
ENSMUSG00000045551 Fpr1 formyl peptide receptor 1 1.38 3.39E-04 
ENSMUSG00000029084 Cd38 CD38 antigen 1.38 1.13E-06 
ENSMUSG00000047230 Cldn2 claudin 2 1.38 7.59E-06 
ENSMUSG00000097815  1.38 3.05E-11 
ENSMUSG00000025473 Adam8 a disintegrin and metallopeptidase domain 8 1.37 3.44E-07 
ENSMUSG00000022440 C1qtnf6 C1q and tumor necrosis factor related protein 6 1.37 1.78E-04 
ENSMUSG00000037613 Tnfrsf23 tumor necrosis factor receptor superfamily, member 23 1.36 2.96E-05 
ENSMUSG00000034438 Gbp8 guanylate-binding protein 8 1.35 1.37E-06 
ENSMUSG00000036356 Csgalnact1 chondroitin sulfate N-acetylgalactosaminyltransferase 1 1.35 7.94E-07 
ENSMUSG00000039252 Lgi2 leucine-rich repeat LGI family, member 2 1.35 5.91E-06 
ENSMUSG00000086653 9130015L21R
ik 
RIKEN cDNA 9130015L21 gene 1.34 4.54E-04 
ENSMUSG00000024235 Map3k8 mitogen-activated protein kinase kinase kinase 8 1.34 1.86E-08 
ENSMUSG00000020256 Aldh1l2 aldehyde dehydrogenase 1 family, member L2 1.34 7.46E-06 
ENSMUSG00000021647 Cartpt CART prepropeptide 1.34 3.33E-05 
ENSMUSG00000029659 Medag mesenteric estrogen dependent adipogenesis 1.34 2.00E-07 
ENSMUSG00000071713 Csf2rb colony stimulating factor 2 receptor, beta, low-affinity (granulocyte-
macrophage) 
1.33 5.06E-09 
ENSMUSG00000004371 Il11 interleukin 11 1.33 5.18E-04 
ENSMUSG00000076694  1.33 5.98E-04 
ENSMUSG00000005824 Tnfsf14 tumor necrosis factor (ligand) superfamily, member 14 1.33 5.08E-04 
ENSMUSG00000078922 Tgtp1 T cell specific GTPase 1 1.32 1.11E-04 
ENSMUSG00000058794 Nfe2 nuclear factor, erythroid derived 2 1.32 6.00E-04 
ENSMUSG00000035448 Ccr3 chemokine (C-C motif) receptor 3 1.32 6.27E-04 
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ENSMUSG00000028262 Clca3a2 chloride channel calcium activated 3A2 1.32 4.09E-05 
ENSMUSG00000092274  1.32 7.38E-09 
ENSMUSG00000037440 Vnn1 vanin 1 1.31 1.76E-05 
ENSMUSG00000060445 Sycp2 synaptonemal complex protein 2 1.31 7.05E-04 
ENSMUSG00000024349 Tmem173 transmembrane protein 173 1.31 1.74E-07 
ENSMUSG00000082292  1.31 4.52E-05 
ENSMUSG00000056501 Cebpb CCAAT/enhancer binding protein (C/EBP), beta 1.31 5.29E-06 
ENSMUSG00000028613 Lrp8 low density lipoprotein receptor-related protein 8, apolipoprotein e 
receptor 
1.30 1.40E-06 
ENSMUSG00000004668 Abca13 ATP-binding cassette, sub-family A (ABC1), member 13 1.30 2.25E-04 
ENSMUSG00000057596 Trim30d tripartite motif-containing 30D 1.30 3.37E-05 
ENSMUSG00000053675 Tgm5 transglutaminase 5 1.30 7.49E-04 
ENSMUSG00000048852 Gm12185 predicted gene 12185 1.30 6.48E-05 
ENSMUSG00000052125 F730043M19
Rik 
RIKEN cDNA F730043M19 gene 1.30 5.90E-05 
ENSMUSG00000060131 Atp8b4 ATPase, class I, type 8B, member 4 1.29 7.29E-06 
ENSMUSG00000073492  1.29 5.29E-04 
ENSMUSG00000056427 Slit3 slit homolog 3 (Drosophila) 1.29 1.71E-09 
ENSMUSG00000042943  1.29 3.89E-04 
ENSMUSG00000003617 Cp ceruloplasmin 1.28 8.31E-11 
ENSMUSG00000023886 Smoc2 SPARC related modular calcium binding 2 1.28 3.83E-10 
ENSMUSG00000085363  1.28 8.02E-04 
ENSMUSG00000034206 Polq polymerase (DNA directed), theta 1.28 5.25E-08 
ENSMUSG00000084956  1.28 8.27E-04 
ENSMUSG00000078606 Gm4070 predicted gene 4070 1.28 5.00E-06 
ENSMUSG00000030043 Tacr1 tachykinin receptor 1 1.28 6.08E-07 
ENSMUSG00000020363 Gfpt2 glutamine fructose-6-phosphate transaminase 2 1.28 1.18E-06 
ENSMUSG00000026787 Gad2 glutamic acid decarboxylase 2 1.28 3.25E-04 
ENSMUSG00000074892 B3galt5 UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, polypeptide 5 1.28 1.66E-07 
ENSMUSG00000080917  1.27 3.99E-04 
ENSMUSG00000017493 Igfbp4 insulin-like growth factor binding protein 4 1.27 2.26E-10 
ENSMUSG00000026536 Mnda myeloid cell nuclear differentiation antigen 1.27 7.71E-06 
ENSMUSG00000059108 Ifitm6 interferon induced transmembrane protein 6 1.27 1.08E-03 
ENSMUSG00000028527 Ak4 adenylate kinase 4 1.27 3.52E-05 
ENSMUSG00000029299 Abcg3 ATP-binding cassette, sub-family G (WHITE), member 3 1.26 1.72E-06 
ENSMUSG00000000628 Hk2 hexokinase 2 1.26 1.22E-07 
ENSMUSG00000036596 Cpz carboxypeptidase Z 1.26 1.15E-03 
ENSMUSG00000038751 Ptk6 PTK6 protein tyrosine kinase 6 1.26 1.73E-07 
ENSMUSG00000049436 Upk1b uroplakin 1B 1.26 9.03E-04 
ENSMUSG00000063286  1.25 6.56E-09 
ENSMUSG00000058715 Fcer1g Fc receptor, IgE, high affinity I, gamma polypeptide 1.25 1.10E-05 
ENSMUSG00000087070 Gm12505 predicted gene 12505 1.25 6.14E-06 
ENSMUSG00000074813  1.25 2.94E-04 
ENSMUSG00000022220 Adcy4 adenylate cyclase 4 1.25 2.11E-05 
ENSMUSG00000068606 Gm4841 predicted gene 4841 1.25 9.80E-05 
ENSMUSG00000018924 Alox15 arachidonate 15-lipoxygenase 1.24 8.63E-04 
ENSMUSG00000028864 Hgf hepatocyte growth factor 1.24 3.25E-06 
ENSMUSG00000053338 Tarm1 T cell-interacting, activating receptor on myeloid cells 1 1.24 1.32E-03 
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ENSMUSG00000058099 Nfam1 Nfat activating molecule with ITAM motif 1 1.24 3.14E-06 
ENSMUSG00000044041 Krt13 keratin 13 1.24 9.68E-04 
ENSMUSG00000002847 Pla1a phospholipase A1 member A 1.24 9.54E-04 
ENSMUSG00000097423  1.23 7.39E-05 
ENSMUSG00000046295 Ankle1 ankyrin repeat and LEM domain containing 1 1.23 3.06E-04 
ENSMUSG00000022894 Adamts5 a disintegrin-like and metallopeptidase (reprolysin type) with 
thrombospondin type 1 motif, 5 (aggrecanase-2) 
1.23 2.39E-09 
ENSMUSG00000020676 Ccl11 chemokine (C-C motif) ligand 11 1.23 3.50E-09 
ENSMUSG00000017737 Mmp9 matrix metallopeptidase 9 1.22 1.39E-05 
ENSMUSG00000024066 Xdh xanthine dehydrogenase 1.22 1.12E-08 
ENSMUSG00000090665  1.22 1.57E-03 
ENSMUSG00000049130 C5ar1 complement component 5a receptor 1 1.22 1.33E-04 
ENSMUSG00000038011 Dnah10 dynein, axonemal, heavy chain 10 1.22 1.32E-03 
ENSMUSG00000001670 Tat tyrosine aminotransferase 1.21 2.88E-07 
ENSMUSG00000057191 AB124611 cDNA sequence AB124611 1.21 1.44E-05 
ENSMUSG00000025491 Ifitm1 interferon induced transmembrane protein 1 1.21 7.72E-07 
ENSMUSG00000061540 Orm2 orosomucoid 2 1.21 1.50E-03 
ENSMUSG00000020932 Gfap glial fibrillary acidic protein 1.20 7.77E-06 
ENSMUSG00000041293 Gpr110 G protein-coupled receptor 110 1.20 1.65E-03 
ENSMUSG00000055541 Lair1 leukocyte-associated Ig-like receptor 1 1.20 3.90E-07 
ENSMUSG00000039109 F13a1 coagulation factor XIII, A1 subunit 1.20 4.64E-08 
ENSMUSG00000081723  1.20 1.16E-03 
ENSMUSG00000000957 Mmp14 matrix metallopeptidase 14 (membrane-inserted) 1.20 2.50E-11 
ENSMUSG00000020649 Rrm2 ribonucleotide reductase M2 1.20 8.69E-09 
ENSMUSG00000073902  1.19 8.84E-06 
ENSMUSG00000046718 Bst2 bone marrow stromal cell antigen 2 1.19 8.92E-05 
ENSMUSG00000041734 Kirrel kin of IRRE like (Drosophila) 1.19 2.32E-07 
ENSMUSG00000024401 Tnf tumor necrosis factor 1.19 3.09E-05 
ENSMUSG00000003355 Fkbp11 FK506 binding protein 11 1.19 2.74E-06 
ENSMUSG00000078122 F630028O10R
ik 
RIKEN cDNA F630028O10 gene 1.19 2.11E-06 
ENSMUSG00000079553 Kifc1 kinesin family member C1 1.19 4.51E-04 
ENSMUSG00000057604 Lmcd1 LIM and cysteine-rich domains 1 1.19 1.36E-05 
ENSMUSG00000033777 Tlr13 toll-like receptor 13 1.18 1.39E-07 
ENSMUSG00000056018 1700008F21Ri
k 
RIKEN cDNA 1700008F21 gene 1.18 1.56E-04 
ENSMUSG00000032586 Traip TRAF-interacting protein 1.18 5.67E-05 
ENSMUSG00000005124 Wisp1 WNT1 inducible signaling pathway protein 1 1.18 4.86E-06 
ENSMUSG00000045502 Hcar2 hydroxycarboxylic acid receptor 2 1.18 4.70E-04 
ENSMUSG00000070315 4930581F22Ri
k 
RIKEN cDNA 4930581F22 gene 1.17 9.47E-04 
ENSMUSG00000040522 Tlr8 toll-like receptor 8 1.17 8.41E-06 
ENSMUSG00000078780 Gm5150 predicted gene 5150 1.17 1.86E-03 
ENSMUSG00000091956 C2cd4b C2 calcium-dependent domain containing 4B 1.17 1.90E-03 
ENSMUSG00000097344  1.17 5.94E-04 
ENSMUSG00000022237 Ankrd33b ankyrin repeat domain 33B 1.16 5.36E-04 
ENSMUSG00000085913  1.16 1.36E-03 
ENSMUSG00000059498 Fcgr3 Fc receptor, IgG, low affinity III 1.16 1.85E-07 
ENSMUSG00000075611  1.16 6.88E-06 
ENSMUSG00000028195 Cyr61 cysteine rich protein 61 1.16 3.52E-05 
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ENSMUSG00000093846  1.16 2.36E-03 
ENSMUSG00000043740 B430306N03
Rik 
RIKEN cDNA B430306N03 gene 1.15 3.11E-05 
ENSMUSG00000029641 Rasl11a RAS-like, family 11, member A 1.15 1.26E-03 
ENSMUSG00000049281 Scn3b sodium channel, voltage-gated, type III, beta 1.15 2.03E-04 
ENSMUSG00000051279 Gdf6 growth differentiation factor 6 1.15 2.69E-03 
ENSMUSG00000061878 Sphk1 sphingosine kinase 1 1.15 2.06E-04 
ENSMUSG00000022032 Scara5 scavenger receptor class A, member 5 (putative) 1.15 1.83E-07 
ENSMUSG00000047728 BC025446 cDNA sequence BC025446 1.14 1.05E-03 
ENSMUSG00000078853 Igtp interferon gamma induced GTPase 1.14 4.46E-04 
ENSMUSG00000030428 Ttyh1 tweety homolog 1 (Drosophila) 1.14 1.08E-06 
ENSMUSG00000011171 Vipr2 vasoactive intestinal peptide receptor 2 1.14 4.59E-05 
ENSMUSG00000029377 Ereg epiregulin 1.14 2.22E-06 
ENSMUSG00000031502 Col4a1 collagen, type IV, alpha 1 1.13 1.16E-09 
ENSMUSG00000032915 Emr4 EGF-like module containing, mucin-like, hormone receptor-like 
sequence 4 
1.13 8.11E-04 
ENSMUSG00000031825 Crispld2 cysteine-rich secretory protein LCCL domain containing 2 1.13 8.30E-09 
ENSMUSG00000044017 Gpr133 G protein-coupled receptor 133 1.13 3.01E-07 
ENSMUSG00000028037 Ifi44 interferon-induced protein 44 1.13 1.40E-05 
ENSMUSG00000048699 4732456N10R
ik 
RIKEN cDNA 4732456N10 gene 1.13 3.07E-03 
ENSMUSG00000026605 Cenpf centromere protein F 1.13 3.08E-06 
ENSMUSG00000039146 Ifi44l interferon-induced protein 44 like 1.12 9.33E-04 
ENSMUSG00000003484 Cyp4f18 cytochrome P450, family 4, subfamily f, polypeptide 18 1.12 3.55E-03 
ENSMUSG00000032204 Aqp9 aquaporin 9 1.12 3.95E-03 
ENSMUSG00000025492 Ifitm3 interferon induced transmembrane protein 3 1.12 4.01E-08 
ENSMUSG00000078817 Nlrp12 NLR family, pyrin domain containing 12 1.12 3.22E-03 
ENSMUSG00000066755 Tnfsf18 tumor necrosis factor (ligand) superfamily, member 18 1.11 3.96E-03 
ENSMUSG00000022221 Ripk3 receptor-interacting serine-threonine kinase 3 1.11 3.42E-06 
ENSMUSG00000030748 Il4ra interleukin 4 receptor, alpha 1.11 1.99E-08 
ENSMUSG00000026535 Ifi202b interferon activated gene 202B 1.11 1.49E-05 
ENSMUSG00000027224 Duoxa1 dual oxidase maturation factor 1 1.11 9.71E-04 
ENSMUSG00000028539 Artn artemin 1.11 3.91E-03 
ENSMUSG00000016496 Cd274 CD274 antigen 1.11 5.47E-06 
ENSMUSG00000044574  1.10 3.86E-03 
ENSMUSG00000040253 Gbp7 guanylate binding protein 7 1.10 1.84E-04 
ENSMUSG00000037243 Zfp692 zinc finger protein 692 1.10 1.65E-04 
ENSMUSG00000040711 Sh3pxd2b SH3 and PX domains 2B 1.09 2.55E-07 
ENSMUSG00000001506 Col1a1 collagen, type I, alpha 1 1.09 2.72E-07 
ENSMUSG00000028871 Rspo1 R-spondin homolog (Xenopus laevis) 1.09 3.46E-03 
ENSMUSG00000023913 Pla2g7 phospholipase A2, group VII (platelet-activating factor 
acetylhydrolase, plasma) 
1.09 2.58E-07 
ENSMUSG00000026177 Slc11a1 solute carrier family 11 (proton-coupled divalent metal ion 
transporters), member 1 
1.09 2.96E-05 
ENSMUSG00000070390 Nlrp1b NLR family, pyrin domain containing 1B 1.09 9.60E-04 
ENSMUSG00000032487 Ptgs2 prostaglandin-endoperoxide synthase 2 1.08 7.09E-04 
ENSMUSG00000041707 1810011H11R
ik 
RIKEN cDNA 1810011H11 gene 1.08 4.29E-03 
ENSMUSG00000073565 Prr16 proline rich 16 1.08 2.82E-03 
ENSMUSG00000058624 Gda guanine deaminase 1.08 2.70E-04 
ENSMUSG00000086311  1.08 1.75E-03 
ENSMUSG00000025986 Slc39a10 solute carrier family 39 (zinc transporter), member 10 1.08 1.11E-06 
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ENSMUSG00000078161 Erich3 glutamate rich 3 1.08 3.34E-03 
ENSMUSG00000063193 Cd300lb CD300 antigen like family member B 1.08 3.79E-03 
ENSMUSG00000084213  1.08 3.23E-03 
ENSMUSG00000024989 Cep55 centrosomal protein 55 1.08 5.40E-07 
ENSMUSG00000003283 Hck hemopoietic cell kinase 1.08 5.07E-06 
ENSMUSG00000073490 AI607873 expressed sequence AI607873 1.08 2.86E-05 
ENSMUSG00000093800  1.08 5.28E-03 
ENSMUSG00000055491 Pprc1 peroxisome proliferative activated receptor, gamma, coactivator-
related 1 
1.07 5.56E-06 
ENSMUSG00000027907 S100a11 S100 calcium binding protein A11 (calgizzarin) 1.07 3.14E-06 
ENSMUSG00000001517 Foxm1 forkhead box M1 1.07 1.50E-05 
ENSMUSG00000040658 Dnph1 2'-deoxynucleoside 5'-phosphate N-hydrolase 1 1.07 2.54E-03 
ENSMUSG00000044258 Ctla2a cytotoxic T lymphocyte-associated protein 2 alpha 1.07 2.46E-06 
ENSMUSG00000036777 Anln anillin, actin binding protein 1.07 2.94E-07 
ENSMUSG00000032254 Kif23 kinesin family member 23 1.06 1.29E-07 
ENSMUSG00000024798 Htr7 5-hydroxytryptamine (serotonin) receptor 7 1.06 2.71E-03 
ENSMUSG00000033453 Adamts15 a disintegrin-like and metallopeptidase (reprolysin type) with 
thrombospondin type 1 motif, 15 
1.06 8.35E-06 
ENSMUSG00000025665 Rps6ka6 ribosomal protein S6 kinase polypeptide 6 1.06 1.47E-04 
ENSMUSG00000006522 Itih3 inter-alpha trypsin inhibitor, heavy chain 3 1.06 7.96E-04 
ENSMUSG00000089950  1.06 2.21E-03 
ENSMUSG00000027514 Zbp1 Z-DNA binding protein 1 1.06 3.65E-05 
ENSMUSG00000020916 Krt36 keratin 36 1.06 6.01E-03 
ENSMUSG00000084390  1.06 6.31E-03 
ENSMUSG00000017861 Mybl2 myeloblastosis oncogene-like 2 1.06 2.38E-05 
ENSMUSG00000086479  1.06 3.77E-03 
ENSMUSG00000031380 Figf c-fos induced growth factor 1.05 1.87E-04 
ENSMUSG00000046841 Ckap4 cytoskeleton-associated protein 4 1.05 5.32E-07 
ENSMUSG00000071547 Nt5dc2 5'-nucleotidase domain containing 2 1.05 3.30E-04 
ENSMUSG00000097814  1.05 6.45E-03 
ENSMUSG00000073821  1.05 6.33E-03 
ENSMUSG00000027322 Siglec1 sialic acid binding Ig-like lectin 1, sialoadhesin 1.05 4.46E-06 
ENSMUSG00000026068 Il18rap interleukin 18 receptor accessory protein 1.05 1.53E-04 
ENSMUSG00000022893 Adamts1 a disintegrin-like and metallopeptidase (reprolysin type) with 
thrombospondin type 1 motif, 1 
1.05 2.78E-06 
ENSMUSG00000035105 Egln3 egl-9 family hypoxia-inducible factor 3 1.05 3.03E-05 
ENSMUSG00000029752 Asns asparagine synthetase 1.05 7.62E-06 
ENSMUSG00000022372 Sla src-like adaptor 1.05 6.43E-08 
ENSMUSG00000006958 Chrd chordin 1.05 3.98E-03 
ENSMUSG00000026646 Suv39h2 suppressor of variegation 3-9 homolog 2 (Drosophila) 1.05 2.59E-04 
ENSMUSG00000049939 Lrrc4 leucine rich repeat containing 4 1.04 8.32E-04 
ENSMUSG00000026786 Apbb1ip amyloid beta (A4) precursor protein-binding, family B, member 1 
interacting protein 
1.04 3.40E-06 
ENSMUSG00000031821 Gins2 GINS complex subunit 2 (Psf2 homolog) 1.04 7.20E-05 
ENSMUSG00000046006 Gapt Grb2-binding adaptor, transmembrane 1.04 5.87E-03 
ENSMUSG00000031450 Grk1 G protein-coupled receptor kinase 1 1.04 8.32E-04 
ENSMUSG00000036036 Zfp57 zinc finger protein 57 1.04 1.73E-03 
ENSMUSG00000046245 Pilra paired immunoglobin-like type 2 receptor alpha 1.04 2.18E-04 
ENSMUSG00000040165 Cd209c CD209c antigen 1.04 3.90E-05 
ENSMUSG00000086451  1.04 6.45E-03 
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ENSMUSG00000034652 Cd300a CD300A antigen 1.03 2.87E-05 
ENSMUSG00000021260 Hhipl1 hedgehog interacting protein-like 1 1.03 3.91E-03 
ENSMUSG00000037185 Krt80 keratin 80 1.03 5.17E-03 
ENSMUSG00000027004 Frzb frizzled-related protein 1.03 4.17E-04 
ENSMUSG00000090293  1.03 5.88E-03 
ENSMUSG00000022021 Diap3 diaphanous homolog 3 (Drosophila) 1.03 5.22E-06 
ENSMUSG00000073274  1.03 1.02E-03 
ENSMUSG00000092500  1.03 3.92E-04 
ENSMUSG00000021728 Emb embigin 1.03 2.32E-05 
ENSMUSG00000079339 Gm14446 predicted gene 14446 1.03 4.07E-04 
ENSMUSG00000041498 Kif14 kinesin family member 14 1.03 6.30E-08 
ENSMUSG00000022148 Fyb FYN binding protein 1.02 3.71E-07 
ENSMUSG00000081305  1.02 3.91E-03 
ENSMUSG00000046179 E2f8 E2F transcription factor 8 1.02 6.57E-06 
ENSMUSG00000029414 Kntc1 kinetochore associated 1 1.02 3.23E-06 
ENSMUSG00000027248 Pdia3 protein disulfide isomerase associated 3 1.02 8.08E-07 
ENSMUSG00000030560 Ctsc cathepsin C 1.02 2.42E-06 
ENSMUSG00000029321 Slc10a6 solute carrier family 10 (sodium/bile acid cotransporter family), 
member 6 
1.01 5.18E-03 
ENSMUSG00000032115 Hyou1 hypoxia up-regulated 1 1.01 6.27E-06 
ENSMUSG00000026566 Mpzl1 myelin protein zero-like 1 1.01 2.24E-06 
ENSMUSG00000034311 Kif4 kinesin family member 4 1.01 2.27E-08 
ENSMUSG00000023903 Mmp25 matrix metallopeptidase 25 1.01 2.71E-03 
ENSMUSG00000021187 Tc2n tandem C2 domains, nuclear 1.01 8.37E-06 
ENSMUSG00000043939 A530064D06
Rik 
RIKEN cDNA A530064D06 gene 1.01 9.19E-03 
ENSMUSG00000031596 Slc7a2 solute carrier family 7 (cationic amino acid transporter, y+ system), 
member 2 
1.00 3.76E-04 
ENSMUSG00000000386 Mx1 MX dynamin-like GTPase 1 1.00 8.62E-04 
ENSMUSG00000022797 Tfrc transferrin receptor 1.00 5.13E-06 
ENSMUSG00000028010 Gar1 GAR1 ribonucleoprotein homolog (yeast) 1.00 3.50E-03 
ENSMUSG00000034394 Lif leukemia inhibitory factor 1.00 3.06E-03 
ENSMUSG00000027670 Ocstamp osteoclast stimulatory transmembrane protein 1.00 3.00E-03 
ENSMUSG00000069540  1.00 7.84E-03 
ENSMUSG00000024300 Myo1f myosin IF 1.00 1.16E-05 
ENSMUSG00000026950 Neb nebulin 1.00 2.61E-04 
ENSMUSG00000027225 Duoxa2 dual oxidase maturation factor 2 1.00 3.18E-03 
ENSMUSG00000035673 Sbno2 strawberry notch homolog 2 (Drosophila) 1.00 2.75E-06 
ENSMUSG00000041754 Trem3 triggering receptor expressed on myeloid cells 3 1.00 9.20E-03 
ENSMUSG00000022836 Mylk myosin, light polypeptide kinase -1.00 1.40E-09 
ENSMUSG00000068299 1700019G17R
ik 
RIKEN cDNA 1700019G17 gene -1.00 1.59E-03 
ENSMUSG00000040420 Cdh18 cadherin 18 -1.00 9.53E-03 
ENSMUSG00000061531 Tmem236 transmembrane protein 236 -1.00 8.02E-05 
ENSMUSG00000028307 Aldob aldolase B, fructose-bisphosphate -1.00 3.49E-06 
ENSMUSG00000085942  -1.00 9.04E-03 
ENSMUSG00000031376 Atp2b3 ATPase, Ca++ transporting, plasma membrane 3 -1.00 6.71E-03 
ENSMUSG00000021376 Tpmt thiopurine methyltransferase -1.00 3.15E-06 
ENSMUSG00000020183 Cpm carboxypeptidase M -1.00 5.15E-06 
ENSMUSG00000021336 Slc17a4 solute carrier family 17 (sodium phosphate), member 4 -1.00 2.59E-05 
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ENSMUSG00000032727 Mier3 mesoderm induction early response 1, family member 3 -1.00 1.07E-05 
ENSMUSG00000035473 Galm galactose mutarotase -1.01 9.42E-07 
ENSMUSG00000031613 Hpgd hydroxyprostaglandin dehydrogenase 15 (NAD) -1.01 1.95E-05 
ENSMUSG00000085121  -1.01 8.99E-03 
ENSMUSG00000096410  -1.01 9.35E-03 
ENSMUSG00000058806 Col13a1 collagen, type XIII, alpha 1 -1.01 1.68E-03 
ENSMUSG00000002032 Tmem25 transmembrane protein 25 -1.01 4.09E-03 
ENSMUSG00000090124 Ugt1a7c UDP glucuronosyltransferase 1 family, polypeptide A7C -1.01 4.73E-08 
ENSMUSG00000041986 Elmod1 ELMO/CED-12 domain containing 1 -1.01 6.81E-03 
ENSMUSG00000034918 Cdhr2 cadherin-related family member 2 -1.01 2.95E-08 
ENSMUSG00000025467 Prap1 proline-rich acidic protein 1 -1.01 2.42E-04 
ENSMUSG00000019775 Rgs17 regulator of G-protein signaling 17 -1.01 3.16E-04 
ENSMUSG00000023122 Sult1c2 sulfotransferase family, cytosolic, 1C, member 2 -1.01 5.66E-06 
ENSMUSG00000074261 Erich4 glutamate rich 4 -1.01 6.17E-03 
ENSMUSG00000051243 Islr2 immunoglobulin superfamily containing leucine-rich repeat 2 -1.01 7.65E-03 
ENSMUSG00000042834 Nrep neuronal regeneration related protein -1.01 5.14E-04 
ENSMUSG00000048337 Npy4r neuropeptide Y receptor Y4 -1.01 1.03E-03 
ENSMUSG00000003273 Car11 carbonic anhydrase 11 -1.01 8.75E-03 
ENSMUSG00000049536 Tceal1 transcription elongation factor A (SII)-like 1 -1.01 4.51E-04 
ENSMUSG00000027861 Casq2 calsequestrin 2 -1.01 9.14E-04 
ENSMUSG00000022758 P2rx6 purinergic receptor P2X, ligand-gated ion channel, 6 -1.01 6.44E-03 
ENSMUSG00000045871 Slitrk6 SLIT and NTRK-like family, member 6 -1.02 1.73E-04 
ENSMUSG00000021684 Pde8b phosphodiesterase 8B -1.02 1.18E-06 
ENSMUSG00000022474 Pmm1 phosphomannomutase 1 -1.02 7.43E-06 
ENSMUSG00000039364 Sectm1b secreted and transmembrane 1B -1.02 6.29E-06 
ENSMUSG00000020620 Abca8b ATP-binding cassette, sub-family A (ABC1), member 8b -1.02 4.22E-05 
ENSMUSG00000071711 Mpst mercaptopyruvate sulfurtransferase -1.02 1.71E-07 
ENSMUSG00000048388 Fam171b family with sequence similarity 171, member B -1.02 2.26E-04 
ENSMUSG00000042498 D330045A20
Rik 
RIKEN cDNA D330045A20 gene -1.02 1.23E-03 
ENSMUSG00000043088 Il17re interleukin 17 receptor E -1.02 5.77E-04 
ENSMUSG00000031647 Mfap3l microfibrillar-associated protein 3-like -1.02 7.32E-05 
ENSMUSG00000021943 Gdf10 growth differentiation factor 10 -1.02 7.84E-03 
ENSMUSG00000097184 4632428C04R
ik 
RIKEN cDNA 4632428C04 gene -1.02 7.05E-03 
ENSMUSG00000018796 Acsl1 acyl-CoA synthetase long-chain family member 1 -1.02 3.32E-06 
ENSMUSG00000030321 Efcab12 EF-hand calcium binding domain 12 -1.03 8.19E-03 
ENSMUSG00000044550 Tceal3 transcription elongation factor A (SII)-like 3 -1.03 6.38E-03 
ENSMUSG00000055675 Kbtbd11 kelch repeat and BTB (POZ) domain containing 11 -1.03 1.59E-06 
ENSMUSG00000032548 Slco2a1 solute carrier organic anion transporter family, member 2a1 -1.03 8.22E-06 
ENSMUSG00000036390 Gadd45a growth arrest and DNA-damage-inducible 45 alpha -1.03 1.18E-04 
ENSMUSG00000046589 Lrrc8e leucine rich repeat containing 8 family, member E -1.03 2.66E-05 
ENSMUSG00000023046 Igfbp6 insulin-like growth factor binding protein 6 -1.03 6.56E-05 
ENSMUSG00000021719 Rgs7bp regulator of G-protein signalling 7 binding protein -1.03 3.21E-05 
ENSMUSG00000020774 Aspa aspartoacylase -1.03 3.30E-04 
ENSMUSG00000070000 Fcho1 FCH domain only 1 -1.03 1.51E-04 
ENSMUSG00000018861 Fdxr ferredoxin reductase -1.03 1.16E-05 
ENSMUSG00000090626 Tex9 testis expressed gene 9 -1.03 6.61E-06 
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ENSMUSG00000030605 Mfge8 milk fat globule-EGF factor 8 protein -1.04 6.21E-09 
ENSMUSG00000048031 Fcrl5 Fc receptor-like 5 -1.04 5.78E-03 
ENSMUSG00000037493 Cib2 calcium and integrin binding family member 2 -1.04 2.93E-03 
ENSMUSG00000034308 Sdr42e1 short chain dehydrogenase/reductase family 42E, member 1 -1.04 3.00E-06 
ENSMUSG00000019359 Gdpd2 glycerophosphodiester phosphodiesterase domain containing 2 -1.04 7.71E-04 
ENSMUSG00000073557 Ppp1r12b protein phosphatase 1, regulatory (inhibitor) subunit 12B -1.04 1.00E-09 
ENSMUSG00000016495 Plgrkt plasminogen receptor, C-terminal lysine transmembrane protein -1.04 2.26E-07 
ENSMUSG00000019943 Atp2b1 ATPase, Ca++ transporting, plasma membrane 1 -1.04 3.30E-06 
ENSMUSG00000083282 Ctsf cathepsin F -1.04 8.41E-06 
ENSMUSG00000054477 Kcnn2 potassium intermediate/small conductance calcium-activated channel, 
subfamily N, member 2 
-1.04 6.71E-03 
ENSMUSG00000022445 Cyp2d26 cytochrome P450, family 2, subfamily d, polypeptide 26 -1.04 1.36E-05 
ENSMUSG00000039329 Tex19.1 testis expressed gene 19.1 -1.05 7.09E-03 
ENSMUSG00000076522  -1.05 3.48E-03 
ENSMUSG00000026840 Lamc3 laminin gamma 3 -1.05 1.14E-03 
ENSMUSG00000049086 Bmyc brain expressed myelocytomatosis oncogene -1.05 6.68E-03 
ENSMUSG00000055546 Timd4 T cell immunoglobulin and mucin domain containing 4 -1.05 4.06E-05 
ENSMUSG00000053963 6330403A02R
ik 
RIKEN cDNA 6330403A02 gene -1.05 2.05E-06 
ENSMUSG00000023829 Slc22a1 solute carrier family 22 (organic cation transporter), member 1 -1.05 7.71E-07 
ENSMUSG00000037126 Psd pleckstrin and Sec7 domain containing -1.05 1.23E-06 
ENSMUSG00000076670  -1.05 6.72E-03 
ENSMUSG00000048096 Lmod1 leiomodin 1 (smooth muscle) -1.06 6.01E-08 
ENSMUSG00000017639 Rab11fip4 RAB11 family interacting protein 4 (class II) -1.06 1.09E-06 
ENSMUSG00000063529 Stmnd1 stathmin domain containing 1 -1.06 5.89E-03 
ENSMUSG00000079507 H2-Q1 histocompatibility 2, Q region locus 1 -1.06 3.88E-05 
ENSMUSG00000062496  -1.06 4.17E-03 
ENSMUSG00000027359 Slc27a2 solute carrier family 27 (fatty acid transporter), member 2 -1.06 9.02E-06 
ENSMUSG00000064351 COX1 cytochrome c oxidase subunit I -1.06 8.88E-06 
ENSMUSG00000020963 Tshr thyroid stimulating hormone receptor -1.06 5.25E-03 
ENSMUSG00000032006 Pdgfd platelet-derived growth factor, D polypeptide -1.06 3.67E-05 
ENSMUSG00000087528  -1.06 3.26E-03 
ENSMUSG00000037855 Zfp365 zinc finger protein 365 -1.06 4.44E-03 
ENSMUSG00000029821 Dfna5 deafness, autosomal dominant 5 (human) -1.06 6.94E-06 
ENSMUSG00000030724 Cd19 CD19 antigen -1.06 1.58E-05 
ENSMUSG00000078157 4931440F15Ri
k 
RIKEN cDNA 4931440F15 gene -1.07 5.99E-04 
ENSMUSG00000036334 Igsf10 immunoglobulin superfamily, member 10 -1.07 3.48E-08 
ENSMUSG00000004035 Gstm7 glutathione S-transferase, mu 7 -1.07 8.46E-05 
ENSMUSG00000026012 Cd28 CD28 antigen -1.07 1.40E-05 
ENSMUSG00000061080 Lsamp limbic system-associated membrane protein -1.07 8.51E-04 
ENSMUSG00000021379 Id4 inhibitor of DNA binding 4 -1.07 1.20E-05 
ENSMUSG00000020607 Fam84a family with sequence similarity 84, member A -1.07 2.14E-03 
ENSMUSG00000022389 Tef thyrotroph embryonic factor -1.07 2.62E-05 
ENSMUSG00000022309 Angpt1 angiopoietin 1 -1.07 1.22E-04 
ENSMUSG00000039956 Mrap melanocortin 2 receptor accessory protein -1.08 5.62E-03 
ENSMUSG00000003477 Inmt indolethylamine N-methyltransferase -1.08 5.44E-03 
ENSMUSG00000064778  -1.08 5.16E-03 
ENSMUSG00000027792 Bche butyrylcholinesterase -1.08 6.09E-06 
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ENSMUSG00000001943 Vsig2 V-set and immunoglobulin domain containing 2 -1.08 6.59E-07 
ENSMUSG00000028138 Adh5 alcohol dehydrogenase 5 (class III), chi polypeptide -1.08 2.68E-07 
ENSMUSG00000053519 Kcnip1 Kv channel-interacting protein 1 -1.08 8.35E-04 
ENSMUSG00000015396 Cd83 CD83 antigen -1.08 2.55E-07 
ENSMUSG00000024600 Slc27a6 solute carrier family 27 (fatty acid transporter), member 6 -1.08 4.65E-03 
ENSMUSG00000052957 Gas1 growth arrest specific 1 -1.08 1.87E-05 
ENSMUSG00000024892 Pcx pyruvate carboxylase -1.08 7.96E-07 
ENSMUSG00000020019 Ntn4 netrin 4 -1.09 5.76E-07 
ENSMUSG00000030351 Tspan11 tetraspanin 11 -1.09 4.67E-03 
ENSMUSG00000074004 B3gnt6 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 6 
(core 3 synthase) 
-1.09 2.26E-04 
ENSMUSG00000053199 Arhgap20 Rho GTPase activating protein 20 -1.09 4.47E-07 
ENSMUSG00000029333 Rasgef1b RasGEF domain family, member 1B -1.09 3.44E-06 
ENSMUSG00000027282 Mtch2 mitochondrial carrier homolog 2 (C. elegans) -1.09 8.71E-09 
ENSMUSG00000086596 Susd5 sushi domain containing 5 -1.09 4.76E-03 
ENSMUSG00000016283 H2-M2 histocompatibility 2, M region locus 2 -1.10 2.31E-03 
ENSMUSG00000029630 Cyp3a25 cytochrome P450, family 3, subfamily a, polypeptide 25 -1.10 4.08E-03 
ENSMUSG00000025498 Irf7 interferon regulatory factor 7 -1.10 8.03E-10 
ENSMUSG00000074736 Syndig1 synapse differentiation inducing 1 -1.10 1.67E-04 
ENSMUSG00000035811 Ugt2b35 UDP glucuronosyltransferase 2 family, polypeptide B35 -1.10 3.33E-07 
ENSMUSG00000028919 Arhgef19 Rho guanine nucleotide exchange factor (GEF) 19 -1.10 6.90E-05 
ENSMUSG00000089960 Ugt1a1 UDP glucuronosyltransferase 1 family, polypeptide A1 -1.10 4.79E-05 
ENSMUSG00000022265 Ank progressive ankylosis -1.11 1.11E-08 
ENSMUSG00000028039 Efna3 ephrin A3 -1.11 1.21E-03 
ENSMUSG00000002308 Cd320 CD320 antigen -1.11 4.44E-07 
ENSMUSG00000017868 Sgk2 serum/glucocorticoid regulated kinase 2 -1.11 2.57E-04 
ENSMUSG00000061356 Nuggc nuclear GTPase, germinal center associated -1.11 1.43E-04 
ENSMUSG00000022853 Ehhadh enoyl-Coenzyme A, hydratase/3-hydroxyacyl Coenzyme A 
dehydrogenase 
-1.11 3.46E-09 
ENSMUSG00000054545 Ugt1a6a UDP glucuronosyltransferase 1 family, polypeptide A6A -1.11 5.10E-06 
ENSMUSG00000043631 Ecm2 extracellular matrix protein 2, female organ and adipocyte specific -1.11 1.27E-06 
ENSMUSG00000031886 Ces2e carboxylesterase 2E -1.11 2.94E-07 
ENSMUSG00000027858 Tspan2 tetraspanin 2 -1.11 3.44E-06 
ENSMUSG00000049336 Tenm2 teneurin transmembrane protein 2 -1.11 3.47E-04 
ENSMUSG00000033152 Podxl2 podocalyxin-like 2 -1.11 1.20E-03 
ENSMUSG00000023914 Mep1a meprin 1 alpha -1.11 3.19E-07 
ENSMUSG00000023243 Kcnk5 potassium channel, subfamily K, member 5 -1.12 1.36E-06 
ENSMUSG00000031712 Il15 interleukin 15 -1.12 1.50E-06 
ENSMUSG00000028545 Bend5 BEN domain containing 5 -1.12 8.07E-05 
ENSMUSG00000040289 Hey1 hairy/enhancer-of-split related with YRPW motif 1 -1.12 1.18E-03 
ENSMUSG00000099215  -1.12 3.40E-03 
ENSMUSG00000000903 Vpreb3 pre-B lymphocyte gene 3 -1.12 1.09E-03 
ENSMUSG00000042155 Klhl23 kelch-like 23 -1.12 4.98E-08 
ENSMUSG00000032064 Dixdc1 DIX domain containing 1 -1.12 1.34E-06 
ENSMUSG00000058070 Eml1 echinoderm microtubule associated protein like 1 -1.12 2.15E-10 
ENSMUSG00000078794 Dact3 dapper homolog 3, antagonist of beta-catenin (xenopus) -1.12 5.21E-05 
ENSMUSG00000046027 Stard5 StAR-related lipid transfer (START) domain containing 5 -1.13 4.96E-09 
ENSMUSG00000029644 Pdx1 pancreatic and duodenal homeobox 1 -1.13 3.72E-03 
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ENSMUSG00000023094 Msrb2 methionine sulfoxide reductase B2 -1.13 5.63E-04 
ENSMUSG00000055632 Hmcn2 hemicentin 2 -1.13 3.12E-09 
ENSMUSG00000034528 Hsd17b13 hydroxysteroid (17-beta) dehydrogenase 13 -1.13 4.66E-05 
ENSMUSG00000028033 Kcnq5 potassium voltage-gated channel, subfamily Q, member 5 -1.13 3.90E-04 
ENSMUSG00000029811 Aoc1 amine oxidase, copper-containing 1 -1.13 1.68E-09 
ENSMUSG00000055022 Cntn1 contactin 1 -1.13 1.28E-05 
ENSMUSG00000030278 Cidec cell death-inducing DFFA-like effector c -1.13 5.32E-06 
ENSMUSG00000024670 Cd6 CD6 antigen -1.13 1.11E-03 
ENSMUSG00000026574 Dpt dermatopontin -1.13 1.51E-08 
ENSMUSG00000046329 Slc25a23 solute carrier family 25 (mitochondrial carrier; phosphate carrier), 
member 23 
-1.13 4.96E-08 
ENSMUSG00000068614 Actc1 actin, alpha, cardiac muscle 1 -1.14 6.05E-07 
ENSMUSG00000001827 Folr1 folate receptor 1 (adult) -1.14 3.44E-03 
ENSMUSG00000045316 Fahd1 fumarylacetoacetate hydrolase domain containing 1 -1.14 2.77E-06 
ENSMUSG00000034449 Dhrs11 dehydrogenase/reductase (SDR family) member 11 -1.14 1.31E-10 
ENSMUSG00000030643 Rab30 RAB30, member RAS oncogene family -1.14 1.01E-04 
ENSMUSG00000060181 Slc35e3 solute carrier family 35, member E3 -1.14 7.77E-07 
ENSMUSG00000033308 Dpyd dihydropyrimidine dehydrogenase -1.14 4.87E-07 
ENSMUSG00000020439 Smtn smoothelin -1.14 1.26E-09 
ENSMUSG00000024924 Vldlr very low density lipoprotein receptor -1.14 3.65E-06 
ENSMUSG00000079470 Utp14b UTP14, U3 small nucleolar ribonucleoprotein, homolog B (yeast) -1.14 9.30E-07 
ENSMUSG00000027863 Cd2 CD2 antigen -1.14 3.52E-07 
ENSMUSG00000028020 Glrb glycine receptor, beta subunit -1.14 2.47E-03 
ENSMUSG00000029130 Rnf32 ring finger protein 32 -1.14 8.19E-05 
ENSMUSG00000020672 Sntg2 syntrophin, gamma 2 -1.15 8.83E-07 
ENSMUSG00000036278 Macrod1 MACRO domain containing 1 -1.15 5.00E-06 
ENSMUSG00000021390 Ogn osteoglycin -1.15 1.81E-06 
ENSMUSG00000014846 Tppp3 tubulin polymerization-promoting protein family member 3 -1.15 6.34E-07 
ENSMUSG00000040896 Kcnd3 potassium voltage-gated channel, Shal-related family, member 3 -1.15 2.10E-08 
ENSMUSG00000053783 1700016K19R
ik 
RIKEN cDNA 1700016K19 gene -1.15 2.11E-03 
ENSMUSG00000041378 Cldn5 claudin 5 -1.15 2.59E-04 
ENSMUSG00000044986 Tst thiosulfate sulfurtransferase, mitochondrial -1.15 8.20E-10 
ENSMUSG00000045441 Gprin3 GPRIN family member 3 -1.15 1.33E-05 
ENSMUSG00000026415 Fcamr Fc receptor, IgA, IgM, high affinity -1.16 4.73E-05 
ENSMUSG00000033342 Lppr5 lipid phosphate phosphatase-related protein type 5 -1.16 2.57E-03 
ENSMUSG00000026062 Slc9a2 solute carrier family 9 (sodium/hydrogen exchanger), member 2 -1.16 2.03E-08 
ENSMUSG00000025347 Mettl7b methyltransferase like 7B -1.16 1.04E-08 
ENSMUSG00000032324 Tspan3 tetraspanin 3 -1.16 3.43E-07 
ENSMUSG00000069814 E130309D14R
ik 
RIKEN cDNA E130309D14 gene -1.16 1.55E-03 
ENSMUSG00000025504 Eps8l2 EPS8-like 2 -1.16 1.83E-10 
ENSMUSG00000046743 Fat4 FAT tumor suppressor homolog 4 (Drosophila) -1.16 2.04E-11 
ENSMUSG00000029499 Pxmp2 peroxisomal membrane protein 2 -1.16 2.67E-04 
ENSMUSG00000001604 Tcea3 transcription elongation factor A (SII), 3 -1.16 1.86E-07 
ENSMUSG00000063430 Wscd2 WSC domain containing 2 -1.16 4.11E-07 
ENSMUSG00000059201 Lep leptin -1.17 1.84E-03 
ENSMUSG00000057378 Ryr3 ryanodine receptor 3 -1.17 6.89E-07 
ENSMUSG00000044749 Abca6 ATP-binding cassette, sub-family A (ABC1), member 6 -1.17 8.39E-05 
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ENSMUSG00000086706  -1.17 6.55E-04 
ENSMUSG00000061728  -1.17 4.81E-05 
ENSMUSG00000087291 Gm11946 predicted gene 11946 -1.18 1.01E-04 
ENSMUSG00000019989 Enpp3 ectonucleotide pyrophosphatase/phosphodiesterase 3 -1.18 1.31E-06 
ENSMUSG00000063873 Slc24a3 solute carrier family 24 (sodium/potassium/calcium exchanger), 
member 3 
-1.18 1.35E-11 
ENSMUSG00000095120  -1.18 1.92E-03 
ENSMUSG00000033715 Akr1c14 aldo-keto reductase family 1, member C14 -1.18 6.22E-05 
ENSMUSG00000005763 Cd247 CD247 antigen -1.18 8.18E-05 
ENSMUSG00000040703 Cyp2s1 cytochrome P450, family 2, subfamily s, polypeptide 1 -1.18 2.45E-09 
ENSMUSG00000062257 Opcml opioid binding protein/cell adhesion molecule-like -1.19 3.96E-06 
ENSMUSG00000019326 Aoc3 amine oxidase, copper containing 3 -1.19 6.00E-11 
ENSMUSG00000038393 Txnip thioredoxin interacting protein -1.19 6.66E-11 
ENSMUSG00000007038 Neu1 neuraminidase 1 -1.19 9.08E-09 
ENSMUSG00000017453 Pipox pipecolic acid oxidase -1.19 2.20E-03 
ENSMUSG00000020889 Nr1d1 nuclear receptor subfamily 1, group D, member 1 -1.19 8.23E-05 
ENSMUSG00000004360 9330159F19Ri
k 
RIKEN cDNA 9330159F19 gene -1.19 3.52E-05 
ENSMUSG00000023960 Enpp5 ectonucleotide pyrophosphatase/phosphodiesterase 5 -1.19 4.04E-10 
ENSMUSG00000036218 Pdzrn4 PDZ domain containing RING finger 4 -1.19 7.67E-04 
ENSMUSG00000042476 Abcb4 ATP-binding cassette, sub-family B (MDR/TAP), member 4 -1.19 1.98E-03 
ENSMUSG00000050751 Pgbd5 piggyBac transposable element derived 5 -1.20 1.56E-04 
ENSMUSG00000020811 Wscd1 WSC domain containing 1 -1.20 1.71E-03 
ENSMUSG00000008193 Spib Spi-B transcription factor (Spi-1/PU.1 related) -1.20 6.64E-08 
ENSMUSG00000004105 Angptl2 angiopoietin-like 2 -1.20 4.06E-08 
ENSMUSG00000020431 Adcy1 adenylate cyclase 1 -1.20 2.44E-04 
ENSMUSG00000079037 Prnp prion protein -1.20 4.97E-10 
ENSMUSG00000020251 Glt8d2 glycosyltransferase 8 domain containing 2 -1.21 4.00E-04 
ENSMUSG00000079355 Ackr4 atypical chemokine receptor 4 -1.21 5.98E-07 
ENSMUSG00000074971 Fibin fin bud initiation factor homolog (zebrafish) -1.21 1.32E-05 
ENSMUSG00000022479 Vdr vitamin D receptor -1.21 1.76E-09 
ENSMUSG00000030409 Dmpk dystrophia myotonica-protein kinase -1.21 1.49E-11 
ENSMUSG00000041660 Bbox1 butyrobetaine (gamma), 2-oxoglutarate dioxygenase 1 (gamma-
butyrobetaine hydroxylase) 
-1.21 1.78E-03 
ENSMUSG00000028461 Ccdc107 coiled-coil domain containing 107 -1.21 2.94E-08 
ENSMUSG00000027875 Hmgcs2 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2 -1.21 9.72E-10 
ENSMUSG00000057123 Gja5 gap junction protein, alpha 5 -1.21 4.50E-05 
ENSMUSG00000030092 Cntn6 contactin 6 -1.22 1.21E-03 
ENSMUSG00000051079 Rgs13 regulator of G-protein signaling 13 -1.22 6.26E-04 
ENSMUSG00000032134 Muc16 mucin 16 -1.22 4.20E-04 
ENSMUSG00000002475 Abhd3 abhydrolase domain containing 3 -1.22 4.27E-05 
ENSMUSG00000031938 4931406C07R
ik 
RIKEN cDNA 4931406C07 gene -1.22 1.65E-08 
ENSMUSG00000023959 Clic5 chloride intracellular channel 5 -1.22 1.61E-07 
ENSMUSG00000073802 Cdkn2b cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4) -1.22 4.06E-08 
ENSMUSG00000075318 Scn2a1 sodium channel, voltage-gated, type II, alpha 1 -1.23 5.24E-05 
ENSMUSG00000032648 Pygm muscle glycogen phosphorylase -1.23 1.65E-07 
ENSMUSG00000027894 Slc6a17 solute carrier family 6 (neurotransmitter transporter), member 17 -1.23 1.07E-05 
ENSMUSG00000032883 Acsl3 acyl-CoA synthetase long-chain family member 3 -1.23 4.71E-08 
ENSMUSG00000038967 Pdk2 pyruvate dehydrogenase kinase, isoenzyme 2 -1.23 1.46E-07 
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ENSMUSG00000005951 Shpk sedoheptulokinase -1.23 9.19E-07 
ENSMUSG00000047462 A530099J19R
ik 
RIKEN cDNA A530099J19 gene -1.23 3.50E-05 
ENSMUSG00000032482 Cspg5 chondroitin sulfate proteoglycan 5 -1.23 1.15E-03 
ENSMUSG00000027698 Nceh1 neutral cholesterol ester hydrolase 1 -1.23 5.88E-09 
ENSMUSG00000024049 Myom1 myomesin 1 -1.23 2.63E-09 
ENSMUSG00000003271 Sult2b1 sulfotransferase family, cytosolic, 2B, member 1 -1.24 6.82E-08 
ENSMUSG00000027562 Car2 carbonic anhydrase 2 -1.24 8.35E-09 
ENSMUSG00000022018 Rgcc regulator of cell cycle -1.24 3.03E-07 
ENSMUSG00000076435 Acsf2 acyl-CoA synthetase family member 2 -1.24 8.04E-12 
ENSMUSG00000018566 Slc2a4 solute carrier family 2 (facilitated glucose transporter), member 4 -1.24 4.67E-08 
ENSMUSG00000071540 3425401B19R
ik 
RIKEN cDNA 3425401B19 gene -1.24 1.40E-03 
ENSMUSG00000084092  -1.24 1.26E-03 
ENSMUSG00000063296 Tmem117 transmembrane protein 117 -1.24 7.35E-08 
ENSMUSG00000021200 Asb2 ankyrin repeat and SOCS box-containing 2 -1.24 3.94E-09 
ENSMUSG00000071604 Fam189a2 family with sequence similarity 189, member A2 -1.24 1.54E-11 
ENSMUSG00000029134 Plb1 phospholipase B1 -1.24 3.93E-04 
ENSMUSG00000056091 St3gal5 ST3 beta-galactoside alpha-2,3-sialyltransferase 5 -1.24 7.09E-07 
ENSMUSG00000050103 Agmo alkylglycerol monooxygenase -1.25 1.61E-06 
ENSMUSG00000032607 Amt aminomethyltransferase -1.25 2.73E-07 
ENSMUSG00000037904 Ankrd9 ankyrin repeat domain 9 -1.25 3.99E-06 
ENSMUSG00000038555 Reep2 receptor accessory protein 2 -1.25 1.54E-04 
ENSMUSG00000027358 Bmp2 bone morphogenetic protein 2 -1.25 1.29E-08 
ENSMUSG00000031636 Pdlim3 PDZ and LIM domain 3 -1.25 5.78E-11 
ENSMUSG00000049811 Fam161a family with sequence similarity 161, member A -1.25 1.37E-05 
ENSMUSG00000030577 Cd22 CD22 antigen -1.25 1.74E-09 
ENSMUSG00000031844 Hsd17b2 hydroxysteroid (17-beta) dehydrogenase 2 -1.25 5.22E-11 
ENSMUSG00000060843 Ctnna3 catenin (cadherin associated protein), alpha 3 -1.25 2.70E-07 
ENSMUSG00000061959 Ces1e carboxylesterase 1E -1.25 3.59E-07 
ENSMUSG00000016552 Foxred2 FAD-dependent oxidoreductase domain containing 2 -1.26 3.97E-05 
ENSMUSG00000031933 Izumo1r IZUMO1 receptor, JUNO -1.26 4.82E-04 
ENSMUSG00000031173 Otc ornithine transcarbamylase -1.26 1.04E-06 
ENSMUSG00000055653 Gpc3 glypican 3 -1.26 1.75E-08 
ENSMUSG00000030865 Chp2 calcineurin-like EF hand protein 2 -1.27 3.37E-09 
ENSMUSG00000038756 Ttll6 tubulin tyrosine ligase-like family, member 6 -1.27 7.98E-04 
ENSMUSG00000024747 Aldh1a7 aldehyde dehydrogenase family 1, subfamily A7 -1.27 3.28E-07 
ENSMUSG00000021792 Fam213a family with sequence similarity 213, member A -1.27 2.13E-09 
ENSMUSG00000035184 Fam124a family with sequence similarity 124, member A -1.27 5.75E-06 
ENSMUSG00000029838 Ptn pleiotrophin -1.27 1.34E-07 
ENSMUSG00000041845 Rhod ras homolog gene family, member D -1.27 8.52E-06 
ENSMUSG00000007097 Atp1a2 ATPase, Na+/K+ transporting, alpha 2 polypeptide -1.27 4.04E-09 
ENSMUSG00000029162 Khk ketohexokinase -1.28 3.28E-07 
ENSMUSG00000061013 Mkx mohawk homeobox -1.28 6.54E-07 
ENSMUSG00000097960 A330074K22
Rik 
RIKEN cDNA A330074K22 gene -1.28 7.06E-04 
ENSMUSG00000069601 Ank3 ankyrin 3, epithelial -1.28 5.62E-09 
ENSMUSG00000044860 Gm1123 predicted gene 1123 -1.28 8.33E-09 
ENSMUSG00000092008 Cyp2c69 cytochrome P450, family 2, subfamily c, polypeptide 69 -1.28 9.04E-04 
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ENSMUSG00000058135 Gstm1 glutathione S-transferase, mu 1 -1.29 2.59E-10 
ENSMUSG00000020182 Ddc dopa decarboxylase -1.29 2.24E-09 
ENSMUSG00000052485 Tmem171 transmembrane protein 171 -1.29 1.62E-09 
ENSMUSG00000004110 Cacna1e calcium channel, voltage-dependent, R type, alpha 1E subunit -1.29 1.82E-07 
ENSMUSG00000055333 Fat2 FAT tumor suppressor homolog 2 (Drosophila) -1.29 1.35E-04 
ENSMUSG00000038526 Car14 carbonic anhydrase 14 -1.29 5.57E-04 
ENSMUSG00000040147 Maob monoamine oxidase B -1.29 1.14E-09 
ENSMUSG00000048498 Cd300e CD300e antigen -1.29 6.37E-04 
ENSMUSG00000032085 Tagln transgelin -1.30 2.20E-14 
ENSMUSG00000023336 Wfdc1 WAP four-disulfide core domain 1 -1.30 7.72E-08 
ENSMUSG00000023073 Slc10a2 solute carrier family 10, member 2 -1.30 2.21E-04 
ENSMUSG00000028255 Clca1 chloride channel calcium activated 1 -1.30 2.70E-13 
ENSMUSG00000022383  -1.30 3.65E-10 
ENSMUSG00000003849 Nqo1 NAD(P)H dehydrogenase, quinone 1 -1.30 1.52E-10 
ENSMUSG00000042751 Nmnat2 nicotinamide nucleotide adenylyltransferase 2 -1.30 7.72E-07 
ENSMUSG00000025037 Maoa monoamine oxidase A -1.30 4.03E-10 
ENSMUSG00000023800 Tiam2 T cell lymphoma invasion and metastasis 2 -1.30 2.02E-09 
ENSMUSG00000025780 Itih5 inter-alpha (globulin) inhibitor H5 -1.30 1.96E-11 
ENSMUSG00000041828 Abca8a ATP-binding cassette, sub-family A (ABC1), member 8a -1.30 1.79E-09 
ENSMUSG00000048304 Slitrk3 SLIT and NTRK-like family, member 3 -1.31 1.89E-04 
ENSMUSG00000069919 Hba-a1 hemoglobin alpha, adult chain 1 -1.31 2.24E-06 
ENSMUSG00000029273 Sult1d1 sulfotransferase family 1D, member 1 -1.31 1.67E-05 
ENSMUSG00000039063 Echdc3 enoyl Coenzyme A hydratase domain containing 3 -1.31 3.74E-06 
ENSMUSG00000029260 Ugt2b34 UDP glucuronosyltransferase 2 family, polypeptide B34 -1.31 1.17E-08 
ENSMUSG00000064202 4430402I18Ri
k 
RIKEN cDNA 4430402I18 gene -1.31 5.11E-04 
ENSMUSG00000038421 Fcrla Fc receptor-like A -1.31 6.55E-08 
ENSMUSG00000020081 Tacr2 tachykinin receptor 2 -1.31 2.36E-09 
ENSMUSG00000025731 0610011F06Ri
k 
RIKEN cDNA 0610011F06 gene -1.32 1.08E-10 
ENSMUSG00000059994 Fcrl1 Fc receptor-like 1 -1.32 5.22E-08 
ENSMUSG00000020839 Tmigd1 transmembrane and immunoglobulin domain containing 1 -1.32 3.97E-05 
ENSMUSG00000032902 Slc16a1 solute carrier family 16 (monocarboxylic acid transporters), member 
1 
-1.32 7.89E-12 
ENSMUSG00000029727 Cyp3a13 cytochrome P450, family 3, subfamily a, polypeptide 13 -1.32 1.13E-09 
ENSMUSG00000055730 Ces2a carboxylesterase 2A -1.32 3.87E-04 
ENSMUSG00000027820 Mme membrane metallo endopeptidase -1.32 4.90E-05 
ENSMUSG00000046959 Slc26a1 solute carrier family 26 (sulfate transporter), member 1 -1.32 1.15E-09 
ENSMUSG00000018659 Pnpo pyridoxine 5'-phosphate oxidase -1.33 8.86E-11 
ENSMUSG00000040543 Pitpnm3 PITPNM family member 3 -1.33 1.45E-08 
ENSMUSG00000006345 Ggt1 gamma-glutamyltransferase 1 -1.33 3.47E-07 
ENSMUSG00000020732 Rab37 RAB37, member RAS oncogene family -1.33 3.38E-06 
ENSMUSG00000050505 Pcdh20 protocadherin 20 -1.33 4.95E-04 
ENSMUSG00000026452 Syt2 synaptotagmin II -1.33 1.18E-04 
ENSMUSG00000034842 Art3 ADP-ribosyltransferase 3 -1.33 6.48E-08 
ENSMUSG00000031700 Gpt2 glutamic pyruvate transaminase (alanine aminotransferase) 2 -1.33 3.76E-10 
ENSMUSG00000061100 Retnla resistin like alpha -1.34 4.25E-04 
ENSMUSG00000061808 Ttr transthyretin -1.34 7.98E-08 
ENSMUSG00000026463 Atp2b4 ATPase, Ca++ transporting, plasma membrane 4 -1.34 1.91E-15 
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ENSMUSG00000039323 Igfbp2 insulin-like growth factor binding protein 2 -1.34 1.87E-05 
ENSMUSG00000064267 Hvcn1 hydrogen voltage-gated channel 1 -1.34 6.02E-10 
ENSMUSG00000040413 Timd2 T cell immunoglobulin and mucin domain containing 2 -1.34 5.05E-04 
ENSMUSG00000014030 Pax5 paired box 5 -1.35 1.05E-07 
ENSMUSG00000039691 Tspan10 tetraspanin 10 -1.35 4.83E-04 
ENSMUSG00000001334 Fndc5 fibronectin type III domain containing 5 -1.35 3.80E-06 
ENSMUSG00000018570 2810408A11R
ik 
RIKEN cDNA 2810408A11 gene -1.35 4.64E-06 
ENSMUSG00000042474 Faim3 Fas apoptotic inhibitory molecule 3 -1.36 2.73E-09 
ENSMUSG00000026208 Des desmin -1.36 1.96E-16 
ENSMUSG00000074210  -1.36 1.74E-04 
ENSMUSG00000020080 Hkdc1 hexokinase domain containing 1 -1.36 2.19E-08 
ENSMUSG00000038209 Itln1 intelectin 1 (galactofuranose binding) -1.36 6.99E-11 
ENSMUSG00000004038 Gstm3 glutathione S-transferase, mu 3 -1.37 3.59E-05 
ENSMUSG00000003949 Hlf hepatic leukemia factor -1.37 6.61E-08 
ENSMUSG00000034687 Fras1 Fraser syndrome 1 homolog (human) -1.37 2.15E-06 
ENSMUSG00000068762 Gstm6 glutathione S-transferase, mu 6 -1.37 4.33E-07 
ENSMUSG00000024978 Gpam glycerol-3-phosphate acyltransferase, mitochondrial -1.37 4.09E-12 
ENSMUSG00000024076 Vit vitrin -1.37 4.81E-05 
ENSMUSG00000062410 Hsd3b3 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-
isomerase 3 
-1.37 4.07E-11 
ENSMUSG00000028976 Slc2a5 solute carrier family 2 (facilitated glucose transporter), member 5 -1.38 2.15E-05 
ENSMUSG00000070498 Tmem132b transmembrane protein 132B -1.38 2.77E-04 
ENSMUSG00000079440 Alpi alkaline phosphatase, intestinal -1.38 8.51E-09 
ENSMUSG00000028737 Aldh4a1 aldehyde dehydrogenase 4 family, member A1 -1.38 2.06E-06 
ENSMUSG00000026616 Cr2 complement receptor 2 -1.38 1.73E-10 
ENSMUSG00000024292 Cyp4f14 cytochrome P450, family 4, subfamily f, polypeptide 14 -1.38 4.97E-09 
ENSMUSG00000034324 Tmem132c transmembrane protein 132C -1.38 2.98E-05 
ENSMUSG00000038591 Colec10 collectin sub-family member 10 -1.38 1.11E-07 
ENSMUSG00000040812 Agbl2 ATP/GTP binding protein-like 2 -1.39 7.53E-07 
ENSMUSG00000038167 Plekhg6 pleckstrin homology domain containing, family G (with RhoGef 
domain) member 6 
-1.39 5.54E-09 
ENSMUSG00000032010 Usp2 ubiquitin specific peptidase 2 -1.39 3.09E-07 
ENSMUSG00000038370 Pcp4l1 Purkinje cell protein 4-like 1 -1.39 9.46E-12 
ENSMUSG00000042254 Cilp cartilage intermediate layer protein, nucleotide 
pyrophosphohydrolase 
-1.40 1.75E-10 
ENSMUSG00000094091 Gm21885 predicted gene, 21885 -1.40 2.12E-07 
ENSMUSG00000068877 Selenbp2 selenium binding protein 2 -1.41 3.89E-10 
ENSMUSG00000094924  -1.41 2.46E-05 
ENSMUSG00000020068  -1.41 8.10E-07 
ENSMUSG00000029095 Ablim2 actin-binding LIM protein 2 -1.41 3.67E-06 
ENSMUSG00000050315 Synpo2 synaptopodin 2 -1.41 3.16E-18 
ENSMUSG00000034936 Arl4d ADP-ribosylation factor-like 4D -1.41 3.26E-07 
ENSMUSG00000026676 Ccdc3 coiled-coil domain containing 3 -1.42 2.51E-08 
ENSMUSG00000029772 Ahcyl2 S-adenosylhomocysteine hydrolase-like 2 -1.42 6.34E-13 
ENSMUSG00000047880 Cxcr5 chemokine (C-X-C motif) receptor 5 -1.42 4.43E-09 
ENSMUSG00000040666 Sh3bgr SH3-binding domain glutamic acid-rich protein -1.42 5.46E-08 
ENSMUSG00000028088 Fmo5 flavin containing monooxygenase 5 -1.42 1.69E-09 
ENSMUSG00000057346 Apol9a apolipoprotein L 9a -1.43 1.56E-04 
ENSMUSG00000087582  -1.43 1.20E-04 
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ENSMUSG00000034157 Cipc CLOCK interacting protein, circadian -1.43 9.09E-10 
ENSMUSG00000038173 Enpp6 ectonucleotide pyrophosphatase/phosphodiesterase 6 -1.43 4.64E-05 
ENSMUSG00000026489 Adck3 aarF domain containing kinase 3 -1.43 2.15E-09 
ENSMUSG00000090223 Pcp4 Purkinje cell protein 4 -1.43 4.69E-05 
ENSMUSG00000028179 Cth cystathionase (cystathionine gamma-lyase) -1.44 8.14E-12 
ENSMUSG00000015354 Pcolce2 procollagen C-endopeptidase enhancer 2 -1.45 3.13E-07 
ENSMUSG00000047496 Rnf152 ring finger protein 152 -1.45 1.32E-10 
ENSMUSG00000001663 Gstt1 glutathione S-transferase, theta 1 -1.45 1.80E-09 
ENSMUSG00000047146 Tet1 tet methylcytosine dioxygenase 1 -1.46 1.07E-08 
ENSMUSG00000005540 Fcer2a Fc receptor, IgE, low affinity II, alpha polypeptide -1.46 3.78E-09 
ENSMUSG00000025528 2010106E10R
ik 
RIKEN cDNA 2010106E10 gene -1.46 8.13E-05 
ENSMUSG00000019945 1700040L02R
ik 
RIKEN cDNA 1700040L02 gene -1.46 1.25E-06 
ENSMUSG00000029201 Ugdh UDP-glucose dehydrogenase -1.46 1.54E-12 
ENSMUSG00000029603 Dtx1 deltex 1 homolog (Drosophila) -1.46 1.97E-09 
ENSMUSG00000074207 Adh1 alcohol dehydrogenase 1 (class I) -1.46 1.86E-11 
ENSMUSG00000047394 Odf3b outer dense fiber of sperm tails 3B -1.47 1.44E-04 
ENSMUSG00000029309 Sparcl1 SPARC-like 1 -1.47 5.69E-17 
ENSMUSG00000025545 Clybl citrate lyase beta like -1.47 2.26E-10 
ENSMUSG00000013415 Igf2bp1 insulin-like growth factor 2 mRNA binding protein 1 -1.48 7.64E-07 
ENSMUSG00000001225 Slc26a3 solute carrier family 26, member 3 -1.48 9.42E-10 
ENSMUSG00000041073 Nacad NAC alpha domain containing -1.48 1.47E-09 
ENSMUSG00000028464 Tpm2 tropomyosin 2, beta -1.48 1.58E-17 
ENSMUSG00000057880 Abat 4-aminobutyrate aminotransferase -1.48 1.14E-12 
ENSMUSG00000025213 Kazald1 Kazal-type serine peptidase inhibitor domain 1 -1.48 6.26E-05 
ENSMUSG00000050860 Phospho1 phosphatase, orphan 1 -1.49 8.39E-05 
ENSMUSG00000021319 Sfrp4 secreted frizzled-related protein 4 -1.50 8.68E-07 
ENSMUSG00000022425 Enpp2 ectonucleotide pyrophosphatase/phosphodiesterase 2 -1.50 4.55E-16 
ENSMUSG00000024899 Papss2 3'-phosphoadenosine 5'-phosphosulfate synthase 2 -1.50 8.21E-11 
ENSMUSG00000094651 Gal3st2 galactose-3-O-sulfotransferase 2 -1.50 3.95E-10 
ENSMUSG00000068748 Ptprz1 protein tyrosine phosphatase, receptor type Z, polypeptide 1 -1.50 1.11E-06 
ENSMUSG00000045725 Prr15 proline rich 15 -1.50 1.31E-11 
ENSMUSG00000054630 Ugt2b5 UDP glucuronosyltransferase 2 family, polypeptide B5 -1.51 2.26E-10 
ENSMUSG00000006360 Crip1 cysteine-rich protein 1 (intestinal) -1.51 6.69E-13 
ENSMUSG00000025176 Hoga1 4-hydroxy-2-oxoglutarate aldolase 1 -1.51 2.79E-07 
ENSMUSG00000067818 Myl9 myosin, light polypeptide 9, regulatory -1.51 6.31E-20 
ENSMUSG00000041559 Fmod fibromodulin -1.52 3.67E-06 
ENSMUSG00000059430 Actg2 actin, gamma 2, smooth muscle, enteric -1.53 5.60E-14 
ENSMUSG00000026614 Slc30a10 solute carrier family 30, member 10 -1.53 1.13E-05 
ENSMUSG00000022040 Ephx2 epoxide hydrolase 2, cytoplasmic -1.53 3.39E-11 
ENSMUSG00000040627 Aicda activation-induced cytidine deaminase -1.53 7.67E-06 
ENSMUSG00000023057 Fabp2 fatty acid binding protein 2, intestinal -1.53 6.13E-06 
ENSMUSG00000070704 Ugt2b36 UDP glucuronosyltransferase 2 family, polypeptide B36 -1.54 1.60E-05 
ENSMUSG00000026418 Tnni1 troponin I, skeletal, slow 1 -1.54 9.60E-06 
ENSMUSG00000038776 Ephx1 epoxide hydrolase 1, microsomal -1.54 2.43E-14 
ENSMUSG00000049971 Glt1d1 glycosyltransferase 1 domain containing 1 -1.54 4.49E-08 
ENSMUSG00000025196 Cpn1 carboxypeptidase N, polypeptide 1 -1.54 8.33E-10 
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ENSMUSG00000074218 Cox7a1 cytochrome c oxidase subunit VIIa 1 -1.55 7.85E-13 
ENSMUSG00000035557 Krt17 keratin 17 -1.56 2.65E-08 
ENSMUSG00000018830 Myh11 myosin, heavy polypeptide 11, smooth muscle -1.56 3.93E-20 
ENSMUSG00000059898 Dsc3 desmocollin 3 -1.57 5.72E-07 
ENSMUSG00000044309 Apol7c apolipoprotein L 7c -1.57 1.44E-07 
ENSMUSG00000040592 Cd79b CD79B antigen -1.58 8.44E-13 
ENSMUSG00000009075 Cabp7 calcium binding protein 7 -1.59 3.00E-05 
ENSMUSG00000032854 Ugt8a UDP galactosyltransferase 8A -1.60 1.56E-05 
ENSMUSG00000045348 Nyap1 neuronal tyrosine-phosphorylated phosphoinositide 3-kinase adaptor 
1 
-1.60 1.30E-08 
ENSMUSG00000051228 Nyx nyctalopin -1.61 6.80E-06 
ENSMUSG00000021573 Tppp tubulin polymerization promoting protein -1.61 9.59E-13 
ENSMUSG00000028713 Cyp4b1 cytochrome P450, family 4, subfamily b, polypeptide 1 -1.61 2.61E-07 
ENSMUSG00000030554 Synm synemin, intermediate filament protein -1.62 2.14E-20 
ENSMUSG00000027513 Pck1 phosphoenolpyruvate carboxykinase 1, cytosolic -1.62 2.70E-14 
ENSMUSG00000036123 Slc9a3 solute carrier family 9 (sodium/hydrogen exchanger), member 3 -1.62 6.72E-07 
ENSMUSG00000019278 Dpep1 dipeptidase 1 (renal) -1.62 5.17E-16 
ENSMUSG00000026166 Ccl20 chemokine (C-C motif) ligand 20 -1.64 9.44E-07 
ENSMUSG00000038550 Ciart circadian associated repressor of transcription -1.64 6.38E-08 
ENSMUSG00000053399 Adamts18 a disintegrin-like and metallopeptidase (reprolysin type) with 
thrombospondin type 1 motif, 18 
-1.64 1.50E-05 
ENSMUSG00000003379 Cd79a CD79A antigen (immunoglobulin-associated alpha) -1.64 7.90E-13 
ENSMUSG00000081169  -1.66 1.14E-06 
ENSMUSG00000074882 Cyp2c68 cytochrome P450, family 2, subfamily c, polypeptide 68 -1.67 6.22E-07 
ENSMUSG00000002565 Scin scinderin -1.67 2.99E-14 
ENSMUSG00000027761 Aadac arylacetamide deacetylase (esterase) -1.67 6.40E-09 
ENSMUSG00000030546 Plin1 perilipin 1 -1.67 9.42E-08 
ENSMUSG00000030256 Bhlhe41 basic helix-loop-helix family, member e41 -1.67 4.21E-10 
ENSMUSG00000025479 Cyp2e1 cytochrome P450, family 2, subfamily e, polypeptide 1 -1.67 1.15E-07 
ENSMUSG00000025658 Cnksr2 connector enhancer of kinase suppressor of Ras 2 -1.67 4.31E-08 
ENSMUSG00000061780 Cfd complement factor D (adipsin) -1.68 5.85E-10 
ENSMUSG00000068105 Tnfrsf13c tumor necrosis factor receptor superfamily, member 13c -1.69 3.80E-13 
ENSMUSG00000041012 Cmtm8 CKLF-like MARVEL transmembrane domain containing 8 -1.69 6.17E-10 
ENSMUSG00000021236 Entpd5 ectonucleoside triphosphate diphosphohydrolase 5 -1.70 7.66E-16 
ENSMUSG00000028755 Cda cytidine deaminase -1.70 4.46E-12 
ENSMUSG00000034579 Pla2g3 phospholipase A2, group III -1.70 1.00E-11 
ENSMUSG00000098132 Rassf10 Ras association (RalGDS/AF-6) domain family (N-terminal) member 
10 
-1.71 1.23E-07 
ENSMUSG00000019890 Nts neurotensin -1.71 1.27E-14 
ENSMUSG00000019970 Sgk1 serum/glucocorticoid regulated kinase 1 -1.72 2.71E-09 
ENSMUSG00000034785 Dio1 deiodinase, iodothyronine, type I -1.72 2.31E-13 
ENSMUSG00000052131 Akr1b7 aldo-keto reductase family 1, member B7 -1.72 2.39E-06 
ENSMUSG00000068874 Selenbp1 selenium binding protein 1 -1.72 4.90E-14 
ENSMUSG00000060548 Tnfrsf19 tumor necrosis factor receptor superfamily, member 19 -1.73 1.13E-08 
ENSMUSG00000051726 Kcnf1 potassium voltage-gated channel, subfamily F, member 1 -1.74 2.36E-09 
ENSMUSG00000041202 Pla2g2d phospholipase A2, group IID -1.74 1.56E-14 
ENSMUSG00000029369 Afm afamin -1.74 3.77E-13 
ENSMUSG00000040584 Abcb1a ATP-binding cassette, sub-family B (MDR/TAP), member 1A -1.75 1.48E-07 
ENSMUSG00000033207 Mamdc2 MAM domain containing 2 -1.75 1.02E-13 
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ENSMUSG00000051295 9630028B13R
ik 
RIKEN cDNA 9630028B13 gene -1.75 1.95E-11 
ENSMUSG00000024673 Ms4a1 membrane-spanning 4-domains, subfamily A, member 1 -1.77 1.11E-15 
ENSMUSG00000060780 Lrrtm1 leucine rich repeat transmembrane neuronal 1 -1.77 2.90E-06 
ENSMUSG00000027559 Car3 carbonic anhydrase 3 -1.78 2.38E-09 
ENSMUSG00000017607 Tns4 tensin 4 -1.78 3.68E-14 
ENSMUSG00000022878 Adipoq adiponectin, C1Q and collagen domain containing -1.79 6.04E-12 
ENSMUSG00000073608 Gm6086 predicted gene 6086 -1.79 1.82E-08 
ENSMUSG00000095385 D630033O11
Rik 
RIKEN cDNA D630033O11 gene -1.81 1.82E-06 
ENSMUSG00000027556 Car1 carbonic anhydrase 1 -1.81 7.67E-17 
ENSMUSG00000053279 Aldh1a1 aldehyde dehydrogenase family 1, subfamily A1 -1.81 8.60E-16 
ENSMUSG00000001349 Cnn1 calponin 1 -1.81 7.98E-26 
ENSMUSG00000069917 Hba-a2 hemoglobin alpha, adult chain 2 -1.81 5.54E-10 
ENSMUSG00000022546 Gpt glutamic pyruvic transaminase, soluble -1.82 7.99E-13 
ENSMUSG00000027401 Tgm3 transglutaminase 3, E polypeptide -1.84 1.86E-06 
ENSMUSG00000039760 Il22ra2 interleukin 22 receptor, alpha 2 -1.84 8.30E-13 
ENSMUSG00000073424 Cyp4f15 cytochrome P450, family 4, subfamily f, polypeptide 15 -1.84 6.43E-07 
ENSMUSG00000019762 Iyd iodotyrosine deiodinase -1.84 3.35E-08 
ENSMUSG00000061825 Ces2c carboxylesterase 2C -1.86 1.36E-14 
ENSMUSG00000027870 Hao2 hydroxyacid oxidase 2 -1.87 1.64E-15 
ENSMUSG00000024727 Trpm6 transient receptor potential cation channel, subfamily M, member 6 -1.88 9.73E-09 
ENSMUSG00000054619 Mettl7a1 methyltransferase like 7A1 -1.88 2.83E-18 
ENSMUSG00000025002 Cyp2c55 cytochrome P450, family 2, subfamily c, polypeptide 55 -1.88 9.75E-07 
ENSMUSG00000060600 Eno3 enolase 3, beta muscle -1.90 2.16E-14 
ENSMUSG00000062760 1810041L15R
ik 
RIKEN cDNA 1810041L15 gene -1.90 2.20E-10 
ENSMUSG00000030762 Aqp8 aquaporin 8 -1.91 3.29E-08 
ENSMUSG00000026701 Prdx6 peroxiredoxin 6 -1.95 6.57E-17 
ENSMUSG00000040405 Havcr1 hepatitis A virus cellular receptor 1 -1.97 1.68E-07 
ENSMUSG00000031937 Vstm5 V-set and transmembrane domain containing 5 -1.98 1.46E-09 
ENSMUSG00000060615 Ang4 angiogenin, ribonuclease A family, member 4 -1.99 6.99E-10 
ENSMUSG00000043439 E130012A19R
ik 
RIKEN cDNA E130012A19 gene -2.00 2.29E-15 
ENSMUSG00000020334 Slc22a4 solute carrier family 22 (organic cation transporter), member 4 -2.00 1.57E-10 
ENSMUSG00000084174 Sycn syncollin -2.04 4.10E-15 
ENSMUSG00000031725 Ces1f carboxylesterase 1F -2.04 8.44E-21 
ENSMUSG00000056973 Ces1d carboxylesterase 1D -2.06 3.08E-20 
ENSMUSG00000099065  -2.07 3.71E-16 
ENSMUSG00000030711 Sult1a1 sulfotransferase family 1A, phenol-preferring, member 1 -2.08 8.95E-13 
ENSMUSG00000027397 Slc20a1 solute carrier family 20, member 1 -2.09 3.90E-18 
ENSMUSG00000090136 Gm10177 predicted gene 10177 -2.14 3.04E-09 
ENSMUSG00000049580 Tsku tsukushi -2.16 1.11E-17 
ENSMUSG00000081488  -2.18 3.17E-14 
ENSMUSG00000000805 Car4 carbonic anhydrase 4 -2.18 3.96E-24 
ENSMUSG00000020793 Galr2 galanin receptor 2 -2.23 1.24E-11 
ENSMUSG00000059824 Dbp D site albumin promoter binding protein -2.25 2.95E-14 
ENSMUSG00000037762 Slc16a9 solute carrier family 16 (monocarboxylic acid transporters), member 
9 
-2.25 1.05E-24 
ENSMUSG00000092586 Ly6g6c lymphocyte antigen 6 complex, locus G6C -2.26 2.27E-09 
ENSMUSG00000024575 Pde6a phosphodiesterase 6A, cGMP-specific, rod, alpha -2.28 1.37E-13 
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ENSMUSG00000037071 Scd1 stearoyl-Coenzyme A desaturase 1 -2.31 1.06E-12 
ENSMUSG00000035686 Thrsp thyroid hormone responsive -2.31 4.06E-11 
ENSMUSG00000085375  -2.31 1.72E-12 
ENSMUSG00000030399 Ckm creatine kinase, muscle -2.32 1.73E-25 
ENSMUSG00000012705 Retn resistin -2.35 1.07E-12 
ENSMUSG00000010311 Optc opticin -2.76 1.20E-26 
ENSMUSG00000032122 Slc37a2 solute carrier family 37 (glycerol-3-phosphate transporter), member 2 -3.00 3.32E-24 
ENSMUSG00000057074 Ces1g carboxylesterase 1G -3.01 7.47E-21 
ENSMUSG00000022491 Glycam1 glycosylation dependent cell adhesion molecule 1 -3.17 3.85E-44 
 
Table S3 Differentially expressed genes of BALB/c (YPIII Δcnfy infected 5 dpi vs. uninfected 
5 dpi) 
Ensembl ID Gene-symbol Gene name lo2 fold 
change 
p-value 
ENSMUSG00000032068 Plet1 placenta expressed transcript 1 4.17 1.64E-42 
ENSMUSG00000027398 Il1b interleukin 1 beta 3.99 1.53E-35 
ENSMUSG00000022126 Irg1 immunoresponsive gene 1 3.82 9.40E-35 
ENSMUSG00000026822 Lcn2 lipocalin 2 3.77 1.09E-30 
ENSMUSG00000020826 Nos2 nitric oxide synthase 2, inducible 3.69 7.60E-33 
ENSMUSG00000029417 Cxcl9 chemokine (C-X-C motif) ligand 9 3.57 2.06E-26 
ENSMUSG00000043613 Mmp3 matrix metallopeptidase 3 3.40 1.22E-23 
ENSMUSG00000028859 Csf3r colony stimulating factor 3 receptor (granulocyte) 3.38 1.04E-30 
ENSMUSG00000064246 Chil1 chitinase-like 1 3.31 7.68E-25 
ENSMUSG00000044162 Tnip3 TNFAIP3 interacting protein 3 3.30 1.53E-39 
ENSMUSG00000052270 Fpr2 formyl peptide receptor 2 3.28 1.50E-24 
ENSMUSG00000034855 Cxcl10 chemokine (C-X-C motif) ligand 10 3.27 4.14E-24 
ENSMUSG00000075602 Ly6a lymphocyte antigen 6 complex, locus A 3.26 6.72E-40 
ENSMUSG00000058427 Cxcl2 chemokine (C-X-C motif) ligand 2 3.21 5.75E-20 
ENSMUSG00000030142 Clec4e C-type lectin domain family 4, member e 3.21 8.54E-18 
ENSMUSG00000029371 Cxcl5 chemokine (C-X-C motif) ligand 5 3.16 2.34E-16 
ENSMUSG00000031444 F10 coagulation factor X 3.09 7.57E-20 
ENSMUSG00000054072 Iigp1 interferon inducible GTPase 1 3.09 7.99E-20 
ENSMUSG00000040264 Gbp2b guanylate binding protein 2b 3.02 1.50E-22 
ENSMUSG00000031551 Ido1 indoleamine 2,3-dioxygenase 1 2.97 2.82E-29 
ENSMUSG00000024697 Gna14 guanine nucleotide binding protein, alpha 14 2.97 1.79E-29 
ENSMUSG00000041481  2.96 3.86E-34 
ENSMUSG00000027399 Il1a interleukin 1 alpha 2.95 4.38E-20 
ENSMUSG00000029380 Cxcl1 chemokine (C-X-C motif) ligand 1 2.86 2.27E-16 
ENSMUSG00000001131 Timp1 tissue inhibitor of metalloproteinase 1 2.86 7.76E-18 
ENSMUSG00000079363 Gbp4 guanylate binding protein 4 2.85 7.24E-20 
ENSMUSG00000000204 Slfn4 schlafen 4 2.84 2.68E-27 
ENSMUSG00000042265 Trem1 triggering receptor expressed on myeloid cells 1 2.84 1.64E-14 
ENSMUSG00000030144 Clec4d C-type lectin domain family 4, member d 2.81 1.42E-14 
ENSMUSG00000041193 Pla2g5 phospholipase A2, group V 2.81 2.18E-27 
ENSMUSG00000031722 Hp haptoglobin 2.81 1.02E-16 
ENSMUSG00000074195 Clca4b chloride channel calcium activated 4B 2.81 1.86E-15 
ENSMUSG00000028527 Ak4 adenylate kinase 4 2.80 3.55E-20 
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ENSMUSG00000040026 Saa3 serum amyloid A 3 2.79 3.41E-18 
ENSMUSG00000073555 Gm4951 predicted gene 4951 2.78 9.94E-25 
ENSMUSG00000090942 F830016B08Ri
k 
RIKEN cDNA F830016B08 gene 2.77 4.47E-21 
ENSMUSG00000066363 Serpina3f serine (or cysteine) peptidase inhibitor, clade A, member 3F 2.77 9.55E-21 
ENSMUSG00000082976 Gm15056 predicted gene 15056 2.77 1.11E-13 
ENSMUSG00000078922 Tgtp1 T cell specific GTPase 1 2.75 1.39E-16 
ENSMUSG00000024411 Aqp4 aquaporin 4 2.74 7.94E-19 
ENSMUSG00000079362 Gbp6 guanylate binding protein 6 2.74 6.97E-21 
ENSMUSG00000060183 Cxcl11 chemokine (C-X-C motif) ligand 11 2.72 3.27E-14 
ENSMUSG00000047562 Mmp10 matrix metallopeptidase 10 2.72 1.56E-12 
ENSMUSG00000025877 Hk3 hexokinase 3 2.70 1.14E-16 
ENSMUSG00000012428 Steap4 STEAP family member 4 2.67 2.02E-28 
ENSMUSG00000056071 S100a9 S100 calcium binding protein A9 (calgranulin B) 2.67 6.72E-12 
ENSMUSG00000054588  2.67 2.64E-13 
ENSMUSG00000032691 Nlrp3 NLR family, pyrin domain containing 3 2.65 1.97E-17 
ENSMUSG00000022582 Ly6g lymphocyte antigen 6 complex, locus G 2.64 1.97E-18 
ENSMUSG00000030187 Klra2 killer cell lectin-like receptor, subfamily A, member 2 2.63 1.42E-17 
ENSMUSG00000047728 BC025446 cDNA sequence BC025446 2.63 7.89E-15 
ENSMUSG00000049281 Scn3b sodium channel, voltage-gated, type III, beta 2.59 1.70E-17 
ENSMUSG00000034438 Gbp8 guanylate-binding protein 8 2.55 1.73E-20 
ENSMUSG00000085977  2.55 6.24E-13 
ENSMUSG00000005800 Mmp8 matrix metallopeptidase 8 2.55 5.66E-12 
ENSMUSG00000028655 Mfsd2a major facilitator superfamily domain containing 2A 2.54 6.39E-12 
ENSMUSG00000078921 Tgtp2 T cell specific GTPase 2 2.53 2.69E-18 
ENSMUSG00000055978 Fut2 fucosyltransferase 2 2.50 8.08E-25 
ENSMUSG00000027068 Dhrs9 dehydrogenase/reductase (SDR family) member 9 2.50 7.15E-26 
ENSMUSG00000059089 Fcgr4 Fc receptor, IgG, low affinity IV 2.49 4.22E-20 
ENSMUSG00000068452 Duox2 dual oxidase 2 2.49 3.32E-23 
ENSMUSG00000048852 Gm12185 predicted gene 12185 2.41 4.40E-14 
ENSMUSG00000053113 Socs3 suppressor of cytokine signaling 3 2.41 2.17E-14 
ENSMUSG00000068606 Gm4841 predicted gene 4841 2.41 2.48E-14 
ENSMUSG00000009185 Ccl8 chemokine (C-C motif) ligand 8 2.36 1.07E-17 
ENSMUSG00000021091 Serpina3n serine (or cysteine) peptidase inhibitor, clade A, member 3N 2.35 2.28E-25 
ENSMUSG00000089672 Gp49a glycoprotein 49 A 2.33 1.53E-15 
ENSMUSG00000042943  2.32 6.13E-11 
ENSMUSG00000047798 Cd300lf CD300 antigen like family member F 2.32 6.01E-14 
ENSMUSG00000041293 Gpr110 G protein-coupled receptor 110 2.32 1.38E-09 
ENSMUSG00000074151 Nlrc5 NLR family, CARD domain containing 5 2.32 8.82E-19 
ENSMUSG00000057465 Saa2 serum amyloid A 2 2.31 6.06E-18 
ENSMUSG00000082292  2.31 5.72E-13 
ENSMUSG00000078853 Igtp interferon gamma induced GTPase 2.29 1.49E-12 
ENSMUSG00000087070 Gm12505 predicted gene 12505 2.28 9.64E-17 
ENSMUSG00000095788 Sirpb1a signal-regulatory protein beta 1A 2.26 1.76E-09 
ENSMUSG00000029084 Cd38 CD38 antigen 2.26 1.85E-15 
ENSMUSG00000038751 Ptk6 PTK6 protein tyrosine kinase 6 2.25 3.98E-21 
ENSMUSG00000029915 Clec5a C-type lectin domain family 5, member a 2.24 4.88E-12 
SUPPLEMENTARY INFORMATION 
 
214 
 
ENSMUSG00000053101 Gpr141 G protein-coupled receptor 141 2.24 8.20E-15 
ENSMUSG00000027360 Hdc histidine decarboxylase 2.20 1.98E-09 
ENSMUSG00000026180 Cxcr2 chemokine (C-X-C motif) receptor 2 2.20 2.73E-13 
ENSMUSG00000019987 Arg1 arginase, liver 2.20 2.17E-11 
ENSMUSG00000079227 Ccr5 chemokine (C-C motif) receptor 5 2.19 5.28E-22 
ENSMUSG00000056054 S100a8 S100 calcium binding protein A8 (calgranulin A) 2.19 1.51E-08 
ENSMUSG00000037095 Lrg1 leucine-rich alpha-2-glycoprotein 1 2.18 2.96E-12 
ENSMUSG00000027225 Duoxa2 dual oxidase maturation factor 2 2.17 1.42E-10 
ENSMUSG00000035385 Ccl2 chemokine (C-C motif) ligand 2 2.17 3.67E-10 
ENSMUSG00000046688 Tifa TRAF-interacting protein with forkhead-associated domain 2.17 2.69E-18 
ENSMUSG00000096528 G430049J08Rik RIKEN cDNA G430049J08 gene 2.14 4.77E-18 
ENSMUSG00000022534 Mefv Mediterranean fever 2.14 5.99E-13 
ENSMUSG00000071356 Reg3b regenerating islet-derived 3 beta 2.13 9.08E-10 
ENSMUSG00000052749 Trim30b tripartite motif-containing 30B 2.12 1.47E-08 
ENSMUSG00000021214 Akr1c18 aldo-keto reductase family 1, member C18 2.12 6.59E-09 
ENSMUSG00000021281 Tnfaip2 tumor necrosis factor, alpha-induced protein 2 2.12 2.26E-18 
ENSMUSG00000085786  2.12 2.67E-15 
ENSMUSG00000024087 Cyp1b1 cytochrome P450, family 1, subfamily b, polypeptide 1 2.11 1.24E-10 
ENSMUSG00000013974 Mcemp1 mast cell expressed membrane protein 1 2.11 1.03E-08 
ENSMUSG00000079014 Serpina3i serine (or cysteine) peptidase inhibitor, clade A, member 3I 2.11 6.59E-10 
ENSMUSG00000025161 Slc16a3 solute carrier family 16 (monocarboxylic acid transporters), member 
3 
2.11 1.01E-12 
ENSMUSG00000025746 Il6 interleukin 6 2.11 1.28E-08 
ENSMUSG00000079012 Serpina3m serine (or cysteine) peptidase inhibitor, clade A, member 3M 2.11 7.10E-11 
ENSMUSG00000052353 Cemip cell migration inducing protein, hyaluronan binding 2.10 1.13E-08 
ENSMUSG00000050747 Trim15 tripartite motif-containing 15 2.10 2.21E-08 
ENSMUSG00000028269  2.09 7.89E-11 
ENSMUSG00000078763 Slfn1 schlafen 1 2.08 1.31E-13 
ENSMUSG00000078161 Erich3 glutamate rich 3 2.08 9.62E-09 
ENSMUSG00000044254 Pcsk9 proprotein convertase subtilisin/kexin type 9 2.07 7.41E-18 
ENSMUSG00000074892 B3galt5 UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, polypeptide 5 2.07 2.27E-17 
ENSMUSG00000016496 Cd274 CD274 antigen 2.06 1.07E-17 
ENSMUSG00000029082 Bst1 bone marrow stromal cell antigen 1 2.06 1.98E-13 
ENSMUSG00000044103 Il1f9 interleukin 1 family, member 9 2.05 1.67E-09 
ENSMUSG00000029553 Tfec transcription factor EC 2.05 9.54E-09 
ENSMUSG00000027514 Zbp1 Z-DNA binding protein 1 2.04 1.24E-15 
ENSMUSG00000000628 Hk2 hexokinase 2 2.04 1.30E-17 
ENSMUSG00000028270 Gbp2 guanylate binding protein 2 2.03 3.21E-16 
ENSMUSG00000029379 Cxcl3 chemokine (C-X-C motif) ligand 3 2.03 1.14E-07 
ENSMUSG00000021950 Anxa8 annexin A8 2.02 7.87E-09 
ENSMUSG00000056749 Nfil3 nuclear factor, interleukin 3, regulated 2.02 1.19E-14 
ENSMUSG00000035004 Igsf6 immunoglobulin superfamily, member 6 2.01 1.36E-16 
ENSMUSG00000024401 Tnf tumor necrosis factor 1.99 1.52E-12 
ENSMUSG00000040253 Gbp7 guanylate binding protein 7 1.99 1.52E-11 
ENSMUSG00000049103 Ccr2 chemokine (C-C motif) receptor 2 1.98 1.09E-16 
ENSMUSG00000043832 Clec4a3 C-type lectin domain family 4, member a3 1.97 1.42E-14 
ENSMUSG00000030017 Reg3g regenerating islet-derived 3 gamma 1.97 3.12E-08 
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ENSMUSG00000027224 Duoxa1 dual oxidase maturation factor 1 1.96 2.97E-09 
ENSMUSG00000022181 C6 complement component 6 1.96 1.31E-12 
ENSMUSG00000064346  1.94 4.49E-08 
ENSMUSG00000006403 Adamts4 a disintegrin-like and metallopeptidase (reprolysin type) with 
thrombospondin type 1 motif, 4 
1.93 1.95E-09 
ENSMUSG00000078606 Gm4070 predicted gene 4070 1.93 3.71E-12 
ENSMUSG00000089942 Pira2 paired-Ig-like receptor A2 1.92 4.06E-09 
ENSMUSG00000079445 B3gnt7 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 7 1.92 7.23E-10 
ENSMUSG00000026580 Selp selectin, platelet 1.92 5.35E-11 
ENSMUSG00000024679 Ms4a6d membrane-spanning 4-domains, subfamily A, member 6D 1.92 1.52E-14 
ENSMUSG00000097423  1.91 4.83E-10 
ENSMUSG00000062593 Lilrb4 leukocyte immunoglobulin-like receptor, subfamily B, member 4 1.91 3.91E-10 
ENSMUSG00000004668 Abca13 ATP-binding cassette, sub-family A (ABC1), member 13 1.91 5.03E-08 
ENSMUSG00000046031 Fam26f family with sequence similarity 26, member F 1.90 3.12E-08 
ENSMUSG00000026981 Il1rn interleukin 1 receptor antagonist 1.89 9.17E-13 
ENSMUSG00000079293 Clec7a C-type lectin domain family 7, member a 1.89 5.09E-15 
ENSMUSG00000027737 Slc7a11 solute carrier family 7 (cationic amino acid transporter, y+ system), 
member 11 
1.88 1.64E-16 
ENSMUSG00000000982 Ccl3 chemokine (C-C motif) ligand 3 1.87 8.98E-07 
ENSMUSG00000026073 Il1r2 interleukin 1 receptor, type II 1.87 2.54E-08 
ENSMUSG00000026880 Stom stomatin 1.85 1.20E-19 
ENSMUSG00000032690 Oas2 2'-5' oligoadenylate synthetase 2 1.85 1.33E-09 
ENSMUSG00000079339 Gm14446 predicted gene 14446 1.84 2.27E-10 
ENSMUSG00000075270 Pde11a phosphodiesterase 11A 1.84 6.98E-08 
ENSMUSG00000074115 Saa1 serum amyloid A 1 1.84 2.28E-08 
ENSMUSG00000073489 Ifi204 interferon activated gene 204 1.81 2.44E-13 
ENSMUSG00000037321 Tap1 transporter 1, ATP-binding cassette, sub-family B (MDR/TAP) 1.81 2.54E-17 
ENSMUSG00000048699 4732456N10Ri
k 
RIKEN cDNA 4732456N10 gene 1.80 1.83E-06 
ENSMUSG00000073902  1.78 2.50E-11 
ENSMUSG00000063286  1.78 2.02E-16 
ENSMUSG00000007989 Fzd3 frizzled homolog 3 (Drosophila) 1.77 1.16E-10 
ENSMUSG00000031596 Slc7a2 solute carrier family 7 (cationic amino acid transporter, y+ system), 
member 2 
1.76 2.15E-10 
ENSMUSG00000001670 Tat tyrosine aminotransferase 1.76 7.85E-14 
ENSMUSG00000058715 Fcer1g Fc receptor, IgE, high affinity I, gamma polypeptide 1.75 6.24E-10 
ENSMUSG00000042102 Dmgdh dimethylglycine dehydrogenase precursor 1.75 4.58E-06 
ENSMUSG00000046245 Pilra paired immunoglobin-like type 2 receptor alpha 1.74 2.69E-10 
ENSMUSG00000026104 Stat1 signal transducer and activator of transcription 1 1.74 2.73E-14 
ENSMUSG00000075010 AW112010 expressed sequence AW112010 1.74 1.91E-14 
ENSMUSG00000035105 Egln3 egl-9 family hypoxia-inducible factor 3 1.73 5.85E-12 
ENSMUSG00000079516 Reg3a regenerating islet-derived 3 alpha 1.72 3.96E-06 
ENSMUSG00000069874 Irgm2 immunity-related GTPase family M member 2 1.72 4.11E-09 
ENSMUSG00000032796 Lama1 laminin, alpha 1 1.72 9.02E-11 
ENSMUSG00000024640 Psat1 phosphoserine aminotransferase 1 1.71 3.84E-09 
ENSMUSG00000053398 Phgdh 3-phosphoglycerate dehydrogenase 1.71 9.91E-13 
ENSMUSG00000040809 Chil3 chitinase-like 3 1.71 8.36E-06 
ENSMUSG00000029484 Anxa3 annexin A3 1.70 7.23E-15 
ENSMUSG00000039304 Tnfsf10 tumor necrosis factor (ligand) superfamily, member 10 1.69 2.34E-11 
ENSMUSG00000024529 Lox lysyl oxidase 1.69 1.13E-07 
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ENSMUSG00000022221 Ripk3 receptor-interacting serine-threonine kinase 3 1.69 1.53E-12 
ENSMUSG00000081665  1.69 1.46E-06 
ENSMUSG00000041449  1.68 3.90E-08 
ENSMUSG00000030111 A2m alpha-2-macroglobulin 1.68 1.05E-05 
ENSMUSG00000036040 Adamtsl2 ADAMTS-like 2 1.67 2.34E-09 
ENSMUSG00000061947 Serpina10 serine (or cysteine) peptidase inhibitor, clade A (alpha-1 
antiproteinase, antitrypsin), member 10 
1.67 5.63E-06 
ENSMUSG00000028544 Slc5a9 solute carrier family 5 (sodium/glucose cotransporter), member 9 1.67 9.92E-09 
ENSMUSG00000015947 Fcgr1 Fc receptor, IgG, high affinity I 1.66 9.75E-10 
ENSMUSG00000046879 Irgm1 immunity-related GTPase family M member 1 1.66 6.66E-09 
ENSMUSG00000028268 Gbp3 guanylate binding protein 3 1.66 2.65E-07 
ENSMUSG00000073530 Pappa2 pappalysin 2 1.66 1.19E-07 
ENSMUSG00000024675 Ms4a4c membrane-spanning 4-domains, subfamily A, member 4C 1.65 1.79E-09 
ENSMUSG00000029752 Asns asparagine synthetase 1.65 1.73E-12 
ENSMUSG00000051439 Cd14 CD14 antigen 1.65 5.97E-10 
ENSMUSG00000026536 Mnda myeloid cell nuclear differentiation antigen 1.63 7.73E-09 
ENSMUSG00000022797 Tfrc transferrin receptor 1.63 1.49E-13 
ENSMUSG00000081467  1.62 2.74E-07 
ENSMUSG00000079298 Klrb1b killer cell lectin-like receptor subfamily B member 1B 1.62 2.33E-05 
ENSMUSG00000060550 H2-Q7 histocompatibility 2, Q region locus 7 1.61 1.04E-11 
ENSMUSG00000058908 Pla2g2a phospholipase A2, group IIA (platelets, synovial fluid) 1.61 6.67E-07 
ENSMUSG00000078920 Ifi47 interferon gamma inducible protein 47 1.61 2.21E-10 
ENSMUSG00000024066 Xdh xanthine dehydrogenase 1.59 1.12E-13 
ENSMUSG00000029298 Gbp9 guanylate-binding protein 9 1.58 4.73E-11 
ENSMUSG00000060131 Atp8b4 ATPase, class I, type 8B, member 4 1.58 3.11E-08 
ENSMUSG00000024349 Tmem173 transmembrane protein 173 1.58 2.47E-10 
ENSMUSG00000046718 Bst2 bone marrow stromal cell antigen 2 1.57 2.00E-07 
ENSMUSG00000057596 Trim30d tripartite motif-containing 30D 1.57 5.30E-07 
ENSMUSG00000037820 Tgm2 transglutaminase 2, C polypeptide 1.57 9.56E-15 
ENSMUSG00000028037 Ifi44 interferon-induced protein 44 1.57 1.44E-09 
ENSMUSG00000024798 Htr7 5-hydroxytryptamine (serotonin) receptor 7 1.56 9.66E-06 
ENSMUSG00000057191 AB124611 cDNA sequence AB124611 1.55 2.17E-08 
ENSMUSG00000016024 Lbp lipopolysaccharide binding protein 1.55 1.89E-11 
ENSMUSG00000050578 Mmp13 matrix metallopeptidase 13 1.55 2.70E-05 
ENSMUSG00000079018 Ly6c1 lymphocyte antigen 6 complex, locus C1 1.55 1.30E-09 
ENSMUSG00000052212 Cd177 CD177 antigen 1.54 3.57E-14 
ENSMUSG00000071713 Csf2rb colony stimulating factor 2 receptor, beta, low-affinity (granulocyte-
macrophage) 
1.54 1.41E-11 
ENSMUSG00000034206 Polq polymerase (DNA directed), theta 1.53 7.56E-11 
ENSMUSG00000038037 Socs1 suppressor of cytokine signaling 1 1.53 7.01E-06 
ENSMUSG00000038301 Snx10 sorting nexin 10 1.53 1.26E-11 
ENSMUSG00000027639 Samhd1 SAM domain and HD domain, 1 1.53 3.90E-13 
ENSMUSG00000073399 Trim40 tripartite motif-containing 40 1.53 2.89E-11 
ENSMUSG00000033508 Asprv1 aspartic peptidase, retroviral-like 1 1.52 3.11E-05 
ENSMUSG00000028613 Lrp8 low density lipoprotein receptor-related protein 8, apolipoprotein e 
receptor 
1.52 2.00E-08 
ENSMUSG00000045932 Ifit2 interferon-induced protein with tetratricopeptide repeats 2 1.51 9.10E-10 
ENSMUSG00000045502 Hcar2 hydroxycarboxylic acid receptor 2 1.51 6.48E-06 
ENSMUSG00000020649 Rrm2 ribonucleotide reductase M2 1.51 3.55E-13 
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ENSMUSG00000027323 Rad51 RAD51 homolog 1.50 1.19E-07 
ENSMUSG00000058624 Gda guanine deaminase 1.50 4.62E-07 
ENSMUSG00000065629  1.50 9.55E-05 
ENSMUSG00000064400  1.49 1.05E-04 
ENSMUSG00000035186 Ubd ubiquitin D 1.49 2.46E-10 
ENSMUSG00000087700  1.49 1.03E-05 
ENSMUSG00000024810 Il33 interleukin 33 1.48 7.07E-11 
ENSMUSG00000024053 Emilin2 elastin microfibril interfacer 2 1.48 1.49E-10 
ENSMUSG00000090293  1.48 7.25E-05 
ENSMUSG00000079419 Ms4a6c membrane-spanning 4-domains, subfamily A, member 6C 1.48 1.10E-10 
ENSMUSG00000030732 Chrdl2 chordin-like 2 1.47 6.35E-05 
ENSMUSG00000004371 Il11 interleukin 11 1.47 1.27E-04 
ENSMUSG00000024164 C3 complement component 3 1.47 8.55E-15 
ENSMUSG00000096727 Psmb9 proteasome (prosome, macropain) subunit, beta type 9 (large 
multifunctional peptidase 2) 
1.46 8.70E-10 
ENSMUSG00000035373 Ccl7 chemokine (C-C motif) ligand 7 1.46 8.45E-05 
ENSMUSG00000039699 Batf2 basic leucine zipper transcription factor, ATF-like 2 1.46 6.86E-10 
ENSMUSG00000025491 Ifitm1 interferon induced transmembrane protein 1 1.46 2.27E-09 
ENSMUSG00000017861 Mybl2 myeloblastosis oncogene-like 2 1.45 5.22E-09 
ENSMUSG00000023272 Creld2 cysteine-rich with EGF-like domains 2 1.45 1.05E-08 
ENSMUSG00000001095 Slc13a2 solute carrier family 13 (sodium-dependent dicarboxylate 
transporter), member 2 
1.45 4.15E-11 
ENSMUSG00000071714 Csf2rb2 colony stimulating factor 2 receptor, beta 2, low-affinity 
(granulocyte-macrophage) 
1.44 2.37E-08 
ENSMUSG00000042808 Gpx2 glutathione peroxidase 2 1.44 2.21E-09 
ENSMUSG00000030353 Tead4 TEA domain family member 4 1.44 7.95E-05 
ENSMUSG00000058818 Pirb paired Ig-like receptor B 1.43 1.91E-08 
ENSMUSG00000030560 Ctsc cathepsin C 1.43 2.99E-11 
ENSMUSG00000025044 Msr1 macrophage scavenger receptor 1 1.43 2.61E-07 
ENSMUSG00000024737 Slc15a3 solute carrier family 15, member 3 1.42 3.67E-07 
ENSMUSG00000024397 Aif1 allograft inflammatory factor 1 1.42 6.62E-10 
ENSMUSG00000056148 Rdh9 retinol dehydrogenase 9 1.41 1.68E-05 
ENSMUSG00000074934 Grem1 gremlin 1 1.41 1.36E-09 
ENSMUSG00000026535 Ifi202b interferon activated gene 202B 1.40 4.24E-08 
ENSMUSG00000022686 B3gnt5 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 5 1.40 1.77E-08 
ENSMUSG00000037679 Inf2 inverted formin, FH2 and WH2 domain containing 1.40 2.91E-09 
ENSMUSG00000046402 Rbp1 retinol binding protein 1, cellular 1.40 6.18E-07 
ENSMUSG00000026605 Cenpf centromere protein F 1.39 7.46E-09 
ENSMUSG00000074417 Pira11 paired-Ig-like receptor A11 1.39 8.30E-06 
ENSMUSG00000032496 Ltf lactotransferrin 1.39 3.12E-04 
ENSMUSG00000056025 Clca3a1 chloride channel calcium activated 3A1 1.38 2.59E-07 
ENSMUSG00000076534  1.38 5.42E-06 
ENSMUSG00000028874 Fgr Gardner-Rasheed feline sarcoma viral (Fgr) oncogene homolog 1.38 6.25E-08 
ENSMUSG00000021266 Wars tryptophanyl-tRNA synthetase 1.37 3.39E-10 
ENSMUSG00000049939 Lrrc4 leucine rich repeat containing 4 1.37 1.05E-05 
ENSMUSG00000059498 Fcgr3 Fc receptor, IgG, low affinity III 1.37 6.60E-10 
ENSMUSG00000058163 Gm5431 predicted gene 5431 1.36 6.58E-09 
ENSMUSG00000070427 Il18bp interleukin 18 binding protein 1.36 1.59E-07 
ENSMUSG00000097194 9330175E14Rik RIKEN cDNA 9330175E14 gene 1.36 9.01E-05 
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ENSMUSG00000075611  1.36 1.29E-07 
ENSMUSG00000030786 Itgam integrin alpha M 1.35 9.34E-11 
ENSMUSG00000032487 Ptgs2 prostaglandin-endoperoxide synthase 2 1.34 2.71E-05 
ENSMUSG00000046179 E2f8 E2F transcription factor 8 1.34 2.91E-09 
ENSMUSG00000043263 Pyhin1 pyrin and HIN domain family, member 1 1.34 2.39E-06 
ENSMUSG00000041324 Inhba inhibin beta-A 1.34 8.82E-05 
ENSMUSG00000028599 Tnfrsf1b tumor necrosis factor receptor superfamily, member 1b 1.34 5.11E-11 
ENSMUSG00000035208 Slfn8 schlafen 8 1.33 2.01E-09 
ENSMUSG00000021322 Aoah acyloxyacyl hydrolase 1.33 4.66E-05 
ENSMUSG00000032109 Nlrx1 NLR family member X1 1.33 4.20E-08 
ENSMUSG00000050014 Apol10b apolipoprotein L 10B 1.32 4.86E-07 
ENSMUSG00000042129 Rassf4 Ras association (RalGDS/AF-6) domain family member 4 1.32 1.03E-09 
ENSMUSG00000057610  1.31 6.22E-04 
ENSMUSG00000025804 Ccr1 chemokine (C-C motif) receptor 1 1.31 2.91E-08 
ENSMUSG00000092500  1.31 5.64E-06 
ENSMUSG00000067653 Ankrd23 ankyrin repeat domain 23 1.31 3.86E-04 
ENSMUSG00000032586 Traip TRAF-interacting protein 1.31 8.16E-06 
ENSMUSG00000016194 Hsd11b1 hydroxysteroid 11-beta dehydrogenase 1 1.29 2.08E-06 
ENSMUSG00000039146 Ifi44l interferon-induced protein 44 like 1.29 1.44E-04 
ENSMUSG00000015340 Cybb cytochrome b-245, beta polypeptide 1.29 5.88E-11 
ENSMUSG00000003283 Hck hemopoietic cell kinase 1.29 4.79E-08 
ENSMUSG00000094094  1.29 4.52E-04 
ENSMUSG00000076598  1.29 8.48E-04 
ENSMUSG00000022769 Sdf2l1 stromal cell-derived factor 2-like 1 1.29 3.53E-09 
ENSMUSG00000039934 Gsap gamma-secretase activating protein 1.29 1.55E-08 
ENSMUSG00000030149 Klrk1 killer cell lectin-like receptor subfamily K, member 1 1.28 3.15E-06 
ENSMUSG00000056501 Cebpb CCAAT/enhancer binding protein (C/EBP), beta 1.28 8.63E-06 
ENSMUSG00000028312 Smc2 structural maintenance of chromosomes 2 1.28 7.13E-09 
ENSMUSG00000021702 Thbs4 thrombospondin 4 1.28 1.42E-06 
ENSMUSG00000030790 Adm adrenomedullin 1.28 3.52E-05 
ENSMUSG00000038156 Spon1 spondin 1, (f-spondin) extracellular matrix protein 1.28 5.66E-10 
ENSMUSG00000025492 Ifitm3 interferon induced transmembrane protein 3 1.28 3.57E-10 
ENSMUSG00000054203 Ifi205 interferon activated gene 205 1.27 6.15E-07 
ENSMUSG00000026185 Igfbp5 insulin-like growth factor binding protein 5 1.27 2.00E-09 
ENSMUSG00000020469 Myl7 myosin, light polypeptide 7, regulatory 1.27 1.13E-04 
ENSMUSG00000024338 Psmb8 proteasome (prosome, macropain) subunit, beta type 8 (large 
multifunctional peptidase 7) 
1.27 5.88E-09 
ENSMUSG00000070777 Ceacam20 carcinoembryonic antigen-related cell adhesion molecule 20 1.27 2.86E-08 
ENSMUSG00000023913 Pla2g7 phospholipase A2, group VII (platelet-activating factor 
acetylhydrolase, plasma) 
1.27 2.09E-09 
ENSMUSG00000046841 Ckap4 cytoskeleton-associated protein 4 1.26 1.74E-09 
ENSMUSG00000069793 Slfn9 schlafen 9 1.26 2.12E-05 
ENSMUSG00000061577 Gpr114 G protein-coupled receptor 114 1.26 7.66E-05 
ENSMUSG00000046223 Plaur plasminogen activator, urokinase receptor 1.26 6.46E-05 
ENSMUSG00000032561 Acpp acid phosphatase, prostate 1.26 2.98E-10 
ENSMUSG00000060508 Nlrp9b NLR family, pyrin domain containing 9B 1.26 2.98E-04 
ENSMUSG00000055541 Lair1 leukocyte-associated Ig-like receptor 1 1.26 1.08E-07 
ENSMUSG00000001517 Foxm1 forkhead box M1 1.26 3.40E-07 
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ENSMUSG00000047810 Ccdc88b coiled-coil domain containing 88B 1.26 1.67E-08 
ENSMUSG00000064147 Rab44 RAB44, member RAS oncogene family 1.26 8.07E-04 
ENSMUSG00000086320  1.25 4.35E-07 
ENSMUSG00000022651 Retnlg resistin like gamma 1.25 1.44E-04 
ENSMUSG00000020120 Plek pleckstrin 1.25 1.47E-09 
ENSMUSG00000026177 Slc11a1 solute carrier family 11 (proton-coupled divalent metal ion 
transporters), member 1 
1.25 1.63E-06 
ENSMUSG00000035692 Isg15 ISG15 ubiquitin-like modifier 1.25 9.87E-07 
ENSMUSG00000037405 Icam1 intercellular adhesion molecule 1 1.25 5.74E-10 
ENSMUSG00000031490 Eif4ebp1 eukaryotic translation initiation factor 4E binding protein 1 1.24 2.82E-08 
ENSMUSG00000093916  1.24 1.26E-03 
ENSMUSG00000034361 Cpne2 copine II 1.24 1.98E-10 
ENSMUSG00000020256 Aldh1l2 aldehyde dehydrogenase 1 family, member L2 1.24 3.91E-05 
ENSMUSG00000022548 Apod apolipoprotein D 1.24 3.59E-05 
ENSMUSG00000021187 Tc2n tandem C2 domains, nuclear 1.24 4.30E-08 
ENSMUSG00000031821 Gins2 GINS complex subunit 2 (Psf2 homolog) 1.24 2.53E-06 
ENSMUSG00000003355 Fkbp11 FK506 binding protein 11 1.23 1.31E-06 
ENSMUSG00000080917  1.23 6.40E-04 
ENSMUSG00000099296  1.23 1.51E-03 
ENSMUSG00000039748 Exo1 exonuclease 1 1.23 5.55E-06 
ENSMUSG00000017737 Mmp9 matrix metallopeptidase 9 1.23 1.43E-05 
ENSMUSG00000028885 Smpdl3b sphingomyelin phosphodiesterase, acid-like 3B 1.22 1.58E-06 
ENSMUSG00000022650 Retnlb resistin like beta 1.22 1.92E-11 
ENSMUSG00000026039 Sgol2a shugoshin-like 2a (S. pombe) 1.22 2.19E-05 
ENSMUSG00000027333 Smox spermine oxidase 1.22 2.29E-07 
ENSMUSG00000037731 Themis2 thymocyte selection associated family member 2 1.21 3.21E-07 
ENSMUSG00000049134 Nrap nebulin-related anchoring protein 1.21 2.86E-06 
ENSMUSG00000091956 C2cd4b C2 calcium-dependent domain containing 4B 1.21 1.36E-03 
ENSMUSG00000029299 Abcg3 ATP-binding cassette, sub-family G (WHITE), member 3 1.21 5.46E-06 
ENSMUSG00000017146 Brca1 breast cancer 1 1.21 5.98E-08 
ENSMUSG00000007682 Dio2 deiodinase, iodothyronine, type II 1.21 8.34E-04 
ENSMUSG00000033538 Casp4 caspase 4, apoptosis-related cysteine peptidase 1.21 3.12E-08 
ENSMUSG00000029798 Herc6 hect domain and RLD 6 1.20 1.65E-07 
ENSMUSG00000096768 Erdr1 erythroid differentiation regulator 1 1.20 3.25E-04 
ENSMUSG00000037411 Serpine1 serine (or cysteine) peptidase inhibitor, clade E, member 1 1.20 1.54E-06 
ENSMUSG00000067780 Pi15 peptidase inhibitor 15 1.20 3.94E-07 
ENSMUSG00000052125 F730043M19Ri
k 
RIKEN cDNA F730043M19 gene 1.20 2.20E-04 
ENSMUSG00000032575 Manf mesencephalic astrocyte-derived neurotrophic factor 1.20 6.95E-08 
ENSMUSG00000025665 Rps6ka6 ribosomal protein S6 kinase polypeptide 6 1.20 1.89E-05 
ENSMUSG00000024300 Myo1f myosin IF 1.20 1.54E-07 
ENSMUSG00000092730 Snora24 small nucleolar RNA, H/ACA box 24 1.20 3.83E-04 
ENSMUSG00000036944 Tmem71 transmembrane protein 71 1.20 1.71E-04 
ENSMUSG00000022696 Sidt1 SID1 transmembrane family, member 1 1.20 1.37E-06 
ENSMUSG00000033268 Duox1 dual oxidase 1 1.20 5.51E-04 
ENSMUSG00000037313 Tacc3 transforming, acidic coiled-coil containing protein 3 1.19 3.01E-09 
ENSMUSG00000073598 1700066B19Ri
k 
RIKEN cDNA 1700066B19 gene 1.19 7.78E-07 
ENSMUSG00000035673 Sbno2 strawberry notch homolog 2 (Drosophila) 1.19 2.67E-08 
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ENSMUSG00000018920 Cxcl16 chemokine (C-X-C motif) ligand 16 1.19 2.31E-08 
ENSMUSG00000022146 Osmr oncostatin M receptor 1.18 3.72E-08 
ENSMUSG00000058099 Nfam1 Nfat activating molecule with ITAM motif 1 1.18 9.34E-06 
ENSMUSG00000047230 Cldn2 claudin 2 1.18 1.24E-04 
ENSMUSG00000085873  1.18 7.43E-04 
ENSMUSG00000024730 Ms4a8a membrane-spanning 4-domains, subfamily A, member 8A 1.18 2.00E-08 
ENSMUSG00000040522 Tlr8 toll-like receptor 8 1.18 8.56E-06 
ENSMUSG00000013483 Card14 caspase recruitment domain family, member 14 1.18 3.26E-06 
ENSMUSG00000040033 Stat2 signal transducer and activator of transcription 2 1.18 2.09E-07 
ENSMUSG00000028633 Ctps cytidine 5'-triphosphate synthase 1.18 6.01E-08 
ENSMUSG00000021196 Pfkp phosphofructokinase, platelet 1.18 3.06E-09 
ENSMUSG00000028028 Alpk1 alpha-kinase 1 1.17 4.61E-08 
ENSMUSG00000004296  1.17 1.05E-03 
ENSMUSG00000090307 1700071M16Ri
k 
RIKEN cDNA 1700071M16 gene 1.17 3.04E-04 
ENSMUSG00000027379 Bub1 budding uninhibited by benzimidazoles 1 homolog (S. cerevisiae) 1.17 1.05E-06 
ENSMUSG00000026068 Il18rap interleukin 18 receptor accessory protein 1.17 2.48E-05 
ENSMUSG00000036875 Dna2 DNA replication helicase 2 homolog (yeast) 1.17 2.31E-06 
ENSMUSG00000028194 Ddah1 dimethylarginine dimethylaminohydrolase 1 1.17 1.73E-08 
ENSMUSG00000017715 Pgs1 phosphatidylglycerophosphate synthase 1 1.17 3.00E-06 
ENSMUSG00000038058 Nod1 nucleotide-binding oligomerization domain containing 1 1.17 1.62E-06 
ENSMUSG00000053541  1.17 1.03E-06 
ENSMUSG00000054404 Slfn5 schlafen 5 1.16 5.48E-09 
ENSMUSG00000020057 Dram1 DNA-damage regulated autophagy modulator 1 1.16 7.02E-08 
ENSMUSG00000073409 H2-Q8 histocompatibility 2, Q region locus 8 1.16 3.92E-08 
ENSMUSG00000028718 Stil Scl/Tal1 interrupting locus 1.16 1.88E-06 
ENSMUSG00000020572 Nampt nicotinamide phosphoribosyltransferase 1.16 1.29E-07 
ENSMUSG00000046971 Pla2g4f phospholipase A2, group IVF 1.16 1.44E-03 
ENSMUSG00000051220 Ercc6l excision repair cross-complementing rodent repair deficiency 
complementation group 6 like 
1.16 9.97E-08 
ENSMUSG00000048636  1.16 2.45E-03 
ENSMUSG00000043953 Ccrl2 chemokine (C-C motif) receptor-like 2 1.16 9.18E-05 
ENSMUSG00000093809  1.15 2.73E-03 
ENSMUSG00000000028 Cdc45 cell division cycle 45 1.15 3.62E-07 
ENSMUSG00000068086 Cyp2d9 cytochrome P450, family 2, subfamily d, polypeptide 9 1.15 1.13E-03 
ENSMUSG00000034394 Lif leukemia inhibitory factor 1.15 6.82E-04 
ENSMUSG00000042306 S100a14 S100 calcium binding protein A14 1.15 3.82E-08 
ENSMUSG00000030022 Adamts9 a disintegrin-like and metallopeptidase (reprolysin type) with 
thrombospondin type 1 motif, 9 
1.15 1.17E-06 
ENSMUSG00000020914 Top2a topoisomerase (DNA) II alpha 1.15 6.61E-09 
ENSMUSG00000069456 Rdh16 retinol dehydrogenase 16 1.15 2.03E-06 
ENSMUSG00000022964 Tmem50b transmembrane protein 50B 1.15 1.04E-06 
ENSMUSG00000072621 Slfn10-ps schlafen 10, pseudogene 1.15 1.18E-03 
ENSMUSG00000086479  1.14 1.73E-03 
ENSMUSG00000027408 Cpxm1 carboxypeptidase X 1 (M14 family) 1.14 4.39E-05 
ENSMUSG00000027199 Gatm glycine amidinotransferase (L-arginine:glycine amidinotransferase) 1.14 2.82E-07 
ENSMUSG00000024795 Kif20b kinesin family member 20B 1.14 2.93E-04 
ENSMUSG00000020303 Stc2 stanniocalcin 2 1.14 4.60E-06 
ENSMUSG00000015451  1.14 1.16E-04 
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ENSMUSG00000017716 Birc5 baculoviral IAP repeat-containing 5 1.14 3.44E-08 
ENSMUSG00000032254 Kif23 kinesin family member 23 1.14 1.74E-08 
ENSMUSG00000069792 Wfdc17 WAP four-disulfide core domain 17 1.14 1.64E-03 
ENSMUSG00000024989 Cep55 centrosomal protein 55 1.14 1.43E-07 
ENSMUSG00000027994 Ccdc109b coiled-coil domain containing 109B 1.14 3.81E-06 
ENSMUSG00000032115 Hyou1 hypoxia up-regulated 1 1.13 3.88E-07 
ENSMUSG00000030474 Siglece sialic acid binding Ig-like lectin E 1.13 2.55E-03 
ENSMUSG00000022218 Tgm1 transglutaminase 1, K polypeptide 1.13 7.39E-04 
ENSMUSG00000030921 Trim30a tripartite motif-containing 30A 1.13 6.29E-09 
ENSMUSG00000022847 Thpo thrombopoietin 1.13 3.25E-03 
ENSMUSG00000065870  1.12 5.40E-04 
ENSMUSG00000003617 Cp ceruloplasmin 1.12 1.55E-08 
ENSMUSG00000026581 Sell selectin, lymphocyte 1.12 4.73E-07 
ENSMUSG00000024481 Lvrn laeverin 1.12 1.24E-03 
ENSMUSG00000022824 Muc13 mucin 13, epithelial transmembrane 1.12 8.79E-08 
ENSMUSG00000028766 Alpl alkaline phosphatase, liver/bone/kidney 1.12 3.19E-06 
ENSMUSG00000068227 Il2rb interleukin 2 receptor, beta chain 1.12 4.31E-05 
ENSMUSG00000040010 Slc7a5 solute carrier family 7 (cationic amino acid transporter, y+ system), 
member 5 
1.12 1.40E-05 
ENSMUSG00000041695 Kcnj2 potassium inwardly-rectifying channel, subfamily J, member 2 1.12 7.05E-04 
ENSMUSG00000030413 Pglyrp1 peptidoglycan recognition protein 1 1.11 1.32E-08 
ENSMUSG00000033777 Tlr13 toll-like receptor 13 1.11 8.33E-07 
ENSMUSG00000016498 Pdcd1lg2 programmed cell death 1 ligand 2 1.11 2.92E-03 
ENSMUSG00000056529 Ptafr platelet-activating factor receptor 1.11 2.50E-06 
ENSMUSG00000029414 Kntc1 kinetochore associated 1 1.11 4.48E-07 
ENSMUSG00000022148 Fyb FYN binding protein 1.11 3.92E-08 
ENSMUSG00000029561 Oasl2 2'-5' oligoadenylate synthetase-like 2 1.11 1.20E-05 
ENSMUSG00000053063 Clec12a C-type lectin domain family 12, member a 1.11 5.15E-05 
ENSMUSG00000052271 Bhlha15 basic helix-loop-helix family, member a15 1.10 5.20E-04 
ENSMUSG00000028965 Tnfrsf9 tumor necrosis factor receptor superfamily, member 9 1.10 7.97E-04 
ENSMUSG00000046295 Ankle1 ankyrin repeat and LEM domain containing 1 1.10 1.40E-03 
ENSMUSG00000027907 S100a11 S100 calcium binding protein A11 (calgizzarin) 1.10 1.92E-06 
ENSMUSG00000097467  1.09 4.26E-03 
ENSMUSG00000083161  1.09 4.30E-03 
ENSMUSG00000088252 Snord13 small nucleolar RNA, C/D box 13 1.09 1.35E-03 
ENSMUSG00000096954  1.09 3.65E-05 
ENSMUSG00000010601 Apol7a apolipoprotein L 7a 1.08 2.49E-05 
ENSMUSG00000021553 Slc28a3 solute carrier family 28 (sodium-coupled nucleoside transporter), 
member 3 
1.08 1.06E-03 
ENSMUSG00000039005 Tlr4 toll-like receptor 4 1.08 7.29E-06 
ENSMUSG00000000386 Mx1 MX dynamin-like GTPase 1 1.08 3.65E-04 
ENSMUSG00000026464  1.08 4.88E-04 
ENSMUSG00000029657 Hsph1 heat shock 105kDa/110kDa protein 1 1.08 1.64E-03 
ENSMUSG00000021109 Hif1a hypoxia inducible factor 1, alpha subunit 1.08 1.73E-06 
ENSMUSG00000056018 1700008F21Rik RIKEN cDNA 1700008F21 gene 1.07 6.67E-04 
ENSMUSG00000042759 Apobr apolipoprotein B receptor 1.07 2.19E-04 
ENSMUSG00000035929 H2-Q4 histocompatibility 2, Q region locus 4 1.07 1.11E-06 
ENSMUSG00000047330 Kcne4 potassium voltage-gated channel, Isk-related subfamily, gene 4 1.07 3.25E-05 
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ENSMUSG00000079553 Kifc1 kinesin family member C1 1.07 1.72E-03 
ENSMUSG00000005413 Hmox1 heme oxygenase (decycling) 1 1.07 2.70E-04 
ENSMUSG00000055447 Cd47 CD47 antigen (Rh-related antigen, integrin-associated signal 
transducer) 
1.07 2.52E-07 
ENSMUSG00000070315 4930581F22Rik RIKEN cDNA 4930581F22 gene 1.07 2.84E-03 
ENSMUSG00000045328 Cenpe centromere protein E 1.07 2.47E-04 
ENSMUSG00000071637  1.07 2.14E-07 
ENSMUSG00000089844 A530032D15Ri
k 
RIKEN cDNA A530032D15Rik gene 1.07 4.34E-04 
ENSMUSG00000060063 Alox5ap arachidonate 5-lipoxygenase activating protein 1.07 2.00E-05 
ENSMUSG00000017002 Slpi secretory leukocyte peptidase inhibitor 1.07 5.84E-03 
ENSMUSG00000038379 Ttk Ttk protein kinase 1.06 7.62E-07 
ENSMUSG00000079343 C1s2 complement component 1, s subcomponent 2 1.06 1.31E-05 
ENSMUSG00000084384  1.06 2.14E-03 
ENSMUSG00000034311 Kif4 kinesin family member 4 1.06 4.03E-09 
ENSMUSG00000074300 BC030870 cDNA sequence BC030870 1.06 5.38E-06 
ENSMUSG00000070390 Nlrp1b NLR family, pyrin domain containing 1B 1.06 1.38E-03 
ENSMUSG00000067367 Lyar Ly1 antibody reactive clone 1.06 2.05E-07 
ENSMUSG00000061540 Orm2 orosomucoid 2 1.06 5.66E-03 
ENSMUSG00000000031  1.06 6.47E-03 
ENSMUSG00000037601 Nme1 NME/NM23 nucleoside diphosphate kinase 1 1.06 6.31E-06 
ENSMUSG00000005667 Mthfd2 methylenetetrahydrofolate dehydrogenase (NAD+ dependent), 
methenyltetrahydrofolate cyclohydrolase 
1.06 3.28E-05 
ENSMUSG00000027496 Aurka aurora kinase A 1.06 2.63E-07 
ENSMUSG00000041135 Ripk2 receptor (TNFRSF)-interacting serine-threonine kinase 2 1.06 2.47E-06 
ENSMUSG00000026656 Fcgr2b Fc receptor, IgG, low affinity IIb 1.06 2.89E-07 
ENSMUSG00000028555 Ttc39a tetratricopeptide repeat domain 39A 1.05 1.64E-07 
ENSMUSG00000049037 Clec4a1 C-type lectin domain family 4, member a1 1.05 2.87E-04 
ENSMUSG00000049988 Lrrc25 leucine rich repeat containing 25 1.05 2.29E-03 
ENSMUSG00000032908 Sgpp2 sphingosine-1-phosphate phosphotase 2 1.05 4.34E-08 
ENSMUSG00000022860 Chodl chondrolectin 1.05 8.04E-04 
ENSMUSG00000058290 Espl1 extra spindle pole bodies 1 (S. cerevisiae) 1.05 1.46E-05 
ENSMUSG00000020869 Lrrc59 leucine rich repeat containing 59 1.05 6.98E-08 
ENSMUSG00000078780 Gm5150 predicted gene 5150 1.05 5.84E-03 
ENSMUSG00000030043 Tacr1 tachykinin receptor 1 1.04 5.56E-05 
ENSMUSG00000074345 Tnfaip8l3 tumor necrosis factor, alpha-induced protein 8-like 3 1.04 2.75E-03 
ENSMUSG00000051682 Treml4 triggering receptor expressed on myeloid cells-like 4 1.04 1.66E-03 
ENSMUSG00000096672  1.04 6.47E-03 
ENSMUSG00000025473 Adam8 a disintegrin and metallopeptidase domain 8 1.04 1.39E-04 
ENSMUSG00000033107 Rnf125 ring finger protein 125 1.04 3.95E-05 
ENSMUSG00000032815 Fanca Fanconi anemia, complementation group A 1.04 4.77E-05 
ENSMUSG00000023832 Acat2 acetyl-Coenzyme A acetyltransferase 2 1.04 1.74E-05 
ENSMUSG00000053318 Slamf8 SLAM family member 8 1.04 9.56E-04 
ENSMUSG00000091747  1.04 3.92E-09 
ENSMUSG00000039682 Lap3 leucine aminopeptidase 3 1.04 1.18E-06 
ENSMUSG00000030659 Nucb2 nucleobindin 2 1.04 1.45E-05 
ENSMUSG00000029605 Oas1b 2'-5' oligoadenylate synthetase 1B 1.03 5.95E-03 
ENSMUSG00000025059 Gyk glycerol kinase 1.03 7.95E-04 
ENSMUSG00000002835 Chaf1a chromatin assembly factor 1, subunit A (p150) 1.03 2.78E-06 
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ENSMUSG00000027326 Casc5 cancer susceptibility candidate 5 1.03 7.67E-06 
ENSMUSG00000020185 E2f7 E2F transcription factor 7 1.03 3.54E-04 
ENSMUSG00000027962 Vcam1 vascular cell adhesion molecule 1 1.03 1.37E-06 
ENSMUSG00000026107 Nabp1 nucleic acid binding protein 1 1.03 1.62E-05 
ENSMUSG00000051235 Gen1 Gen homolog 1, endonuclease (Drosophila) 1.03 1.80E-04 
ENSMUSG00000033031 C330027C09Ri
k 
RIKEN cDNA C330027C09 gene 1.03 6.16E-05 
ENSMUSG00000085550  1.03 7.74E-03 
ENSMUSG00000006442 Srm spermidine synthase 1.03 1.47E-04 
ENSMUSG00000044201 Cdc25c cell division cycle 25C 1.03 3.47E-04 
ENSMUSG00000043629 1700019D03Ri
k 
RIKEN cDNA 1700019D03 gene 1.03 1.10E-06 
ENSMUSG00000069300 Hist1h2bj histone cluster 1, H2bj 1.02 2.41E-04 
ENSMUSG00000032584 Mst1r macrophage stimulating 1 receptor (c-met-related tyrosine kinase) 1.02 7.65E-06 
ENSMUSG00000024677 Ms4a6b membrane-spanning 4-domains, subfamily A, member 6B 1.02 6.01E-06 
ENSMUSG00000037868 Egr2 early growth response 2 1.02 2.69E-03 
ENSMUSG00000021831 Ero1l ERO1-like (S. cerevisiae) 1.02 7.19E-06 
ENSMUSG00000027248 Pdia3 protein disulfide isomerase associated 3 1.02 7.31E-07 
ENSMUSG00000072620 Slfn2 schlafen 2 1.02 8.83E-07 
ENSMUSG00000030748 Il4ra interleukin 4 receptor, alpha 1.02 2.88E-07 
ENSMUSG00000006517 Mvd mevalonate (diphospho) decarboxylase 1.02 7.06E-06 
ENSMUSG00000025986 Slc39a10 solute carrier family 39 (zinc transporter), member 10 1.02 4.67E-06 
ENSMUSG00000016028 Celsr1 cadherin, EGF LAG seven-pass G-type receptor 1 (flamingo 
homolog, Drosophila) 
1.02 1.34E-06 
ENSMUSG00000021728 Emb embigin 1.02 2.91E-05 
ENSMUSG00000032400 Zwilch zwilch kinetochore protein 1.02 1.30E-05 
ENSMUSG00000074519 Etohi1 ethanol induced 1 1.02 6.43E-04 
ENSMUSG00000061207 Stk19 serine/threonine kinase 19 1.02 2.81E-05 
ENSMUSG00000027171 Prrg4 proline rich Gla (G-carboxyglutamic acid) 4 (transmembrane) 1.01 1.64E-03 
ENSMUSG00000078616  1.01 4.72E-03 
ENSMUSG00000032344 Mb21d1 Mab-21 domain containing 1 1.01 3.24E-04 
ENSMUSG00000074656 Eif2s2 eukaryotic translation initiation factor 2, subunit 2 (beta) 1.01 4.59E-04 
ENSMUSG00000079620 Muc4 mucin 4 1.01 3.65E-06 
ENSMUSG00000046591 Ticrr TOPBP1-interacting checkpoint and replication regulator 1.01 7.09E-05 
ENSMUSG00000022587 Ly6e lymphocyte antigen 6 complex, locus E 1.01 1.67E-07 
ENSMUSG00000027896 Slc16a4 solute carrier family 16 (monocarboxylic acid transporters), member 
4 
1.01 5.03E-04 
ENSMUSG00000081723  1.01 6.58E-03 
ENSMUSG00000026480 Ncf2 neutrophil cytosolic factor 2 1.01 3.44E-06 
ENSMUSG00000036777 Anln anillin, actin binding protein 1.01 1.38E-06 
ENSMUSG00000026864 Hspa5 heat shock protein 5 1.00 3.17E-04 
ENSMUSG00000092392  1.00 2.82E-04 
ENSMUSG00000045106 Ccdc73 coiled-coil domain containing 73 1.00 5.54E-03 
ENSMUSG00000028864 Hgf hepatocyte growth factor 1.00 1.91E-04 
ENSMUSG00000028873 Cdca8 cell division cycle associated 8 1.00 6.67E-06 
ENSMUSG00000026009 Icos inducible T cell co-stimulator 1.00 1.16E-03 
ENSMUSG00000024924 Vldlr very low density lipoprotein receptor -1.00 4.83E-05 
ENSMUSG00000032372 Plscr2 phospholipid scramblase 2 -1.00 3.87E-05 
ENSMUSG00000022836 Mylk myosin, light polypeptide kinase -1.00 1.25E-09 
ENSMUSG00000033768 Nrxn2 neurexin II -1.00 5.87E-03 
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ENSMUSG00000033174 Mgll monoglyceride lipase -1.01 5.61E-07 
ENSMUSG00000038984 Tspyl5 testis-specific protein, Y-encoded-like 5 -1.01 7.38E-03 
ENSMUSG00000025213 Kazald1 Kazal-type serine peptidase inhibitor domain 1 -1.01 6.09E-03 
ENSMUSG00000033618 Map3k13 mitogen-activated protein kinase kinase kinase 13 -1.01 1.15E-05 
ENSMUSG00000050368 Hoxd10 homeobox D10 -1.01 6.40E-05 
ENSMUSG00000036334 Igsf10 immunoglobulin superfamily, member 10 -1.01 1.84E-07 
ENSMUSG00000059201 Lep leptin -1.01 6.92E-03 
ENSMUSG00000045613 Chrm2 cholinergic receptor, muscarinic 2, cardiac -1.01 5.19E-07 
ENSMUSG00000002944 Cd36 CD36 antigen -1.02 1.26E-06 
ENSMUSG00000047604 Frat2 frequently rearranged in advanced T cell lymphomas 2 -1.02 5.08E-05 
ENSMUSG00000004360 9330159F19Rik RIKEN cDNA 9330159F19 gene -1.02 4.00E-04 
ENSMUSG00000038298 Pdzk1 PDZ domain containing 1 -1.02 8.45E-03 
ENSMUSG00000061013 Mkx mohawk homeobox -1.02 6.46E-05 
ENSMUSG00000020620 Abca8b ATP-binding cassette, sub-family A (ABC1), member 8b -1.02 4.78E-05 
ENSMUSG00000030278 Cidec cell death-inducing DFFA-like effector c -1.02 4.08E-05 
ENSMUSG00000058070 Eml1 echinoderm microtubule associated protein like 1 -1.02 7.72E-09 
ENSMUSG00000056666 Retsat retinol saturase (all trans retinol 13,14 reductase) -1.03 1.26E-08 
ENSMUSG00000034579 Pla2g3 phospholipase A2, group III -1.03 2.73E-05 
ENSMUSG00000069805 Fbp1 fructose bisphosphatase 1 -1.03 3.12E-03 
ENSMUSG00000022010 Tsc22d1 TSC22 domain family, member 1 -1.03 7.31E-09 
ENSMUSG00000046618 Olfml2a olfactomedin-like 2A -1.03 1.00E-04 
ENSMUSG00000050520 Cldn8 claudin 8 -1.03 8.14E-04 
ENSMUSG00000019775 Rgs17 regulator of G-protein signaling 17 -1.04 2.54E-04 
ENSMUSG00000021373 Cap2 CAP, adenylate cyclase-associated protein, 2 (yeast) -1.04 3.27E-06 
ENSMUSG00000021763 BC067074 cDNA sequence BC067074 -1.04 3.33E-03 
ENSMUSG00000021838 Samd4 sterile alpha motif domain containing 4 -1.04 1.35E-05 
ENSMUSG00000021573 Tppp tubulin polymerization promoting protein -1.04 3.00E-06 
ENSMUSG00000040957 Cables1 CDK5 and Abl enzyme substrate 1 -1.04 1.03E-07 
ENSMUSG00000010066 Cacna2d2 calcium channel, voltage-dependent, alpha 2/delta subunit 2 -1.04 4.17E-05 
ENSMUSG00000003657 Calb2 calbindin 2 -1.05 1.78E-05 
ENSMUSG00000031712 Il15 interleukin 15 -1.05 7.27E-06 
ENSMUSG00000027858 Tspan2 tetraspanin 2 -1.05 1.36E-05 
ENSMUSG00000040896 Kcnd3 potassium voltage-gated channel, Shal-related family, member 3 -1.05 3.69E-07 
ENSMUSG00000032064 Dixdc1 DIX domain containing 1 -1.05 7.17E-06 
ENSMUSG00000020672 Sntg2 syntrophin, gamma 2 -1.05 7.52E-06 
ENSMUSG00000018861 Fdxr ferredoxin reductase -1.05 9.81E-06 
ENSMUSG00000029369 Afm afamin -1.05 9.73E-06 
ENSMUSG00000061780 Cfd complement factor D (adipsin) -1.05 8.42E-05 
ENSMUSG00000060843 Ctnna3 catenin (cadherin associated protein), alpha 3 -1.05 1.50E-05 
ENSMUSG00000028461 Ccdc107 coiled-coil domain containing 107 -1.05 1.43E-06 
ENSMUSG00000041828 Abca8a ATP-binding cassette, sub-family A (ABC1), member 8a -1.06 1.08E-06 
ENSMUSG00000029333 Rasgef1b RasGEF domain family, member 1B -1.06 7.69E-06 
ENSMUSG00000032324 Tspan3 tetraspanin 3 -1.06 3.29E-06 
ENSMUSG00000079037 Prnp prion protein -1.06 4.44E-08 
ENSMUSG00000090136 Gm10177 predicted gene 10177 -1.06 2.18E-03 
ENSMUSG00000056481 Cd248 CD248 antigen, endosialin -1.06 9.91E-06 
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ENSMUSG00000030092 Cntn6 contactin 6 -1.06 4.64E-03 
ENSMUSG00000069919 Hba-a1 hemoglobin alpha, adult chain 1 -1.06 1.14E-04 
ENSMUSG00000027359 Slc27a2 solute carrier family 27 (fatty acid transporter), member 2 -1.07 8.62E-06 
ENSMUSG00000034157 Cipc CLOCK interacting protein, circadian -1.07 4.70E-06 
ENSMUSG00000019326 Aoc3 amine oxidase, copper containing 3 -1.07 3.91E-09 
ENSMUSG00000022383  -1.07 2.21E-07 
ENSMUSG00000019359 Gdpd2 glycerophosphodiester phosphodiesterase domain containing 2 -1.07 6.06E-04 
ENSMUSG00000029130 Rnf32 ring finger protein 32 -1.07 2.45E-04 
ENSMUSG00000044550 Tceal3 transcription elongation factor A (SII)-like 3 -1.07 4.59E-03 
ENSMUSG00000020889 Nr1d1 nuclear receptor subfamily 1, group D, member 1 -1.07 3.87E-04 
ENSMUSG00000044749 Abca6 ATP-binding cassette, sub-family A (ABC1), member 6 -1.07 3.40E-04 
ENSMUSG00000025716 Myo3a myosin IIIA -1.07 2.66E-05 
ENSMUSG00000027015 Cybrd1 cytochrome b reductase 1 -1.07 3.07E-05 
ENSMUSG00000068699 Flnc filamin C, gamma -1.07 2.25E-09 
ENSMUSG00000037362 Nov nephroblastoma overexpressed gene -1.08 4.50E-04 
ENSMUSG00000034472 Rasd2 RASD family, member 2 -1.08 3.72E-05 
ENSMUSG00000042476 Abcb4 ATP-binding cassette, sub-family B (MDR/TAP), member 4 -1.08 5.06E-03 
ENSMUSG00000021294 Kif26a kinesin family member 26A -1.08 1.13E-03 
ENSMUSG00000040543 Pitpnm3 PITPNM family member 3 -1.08 3.34E-06 
ENSMUSG00000059824 Dbp D site albumin promoter binding protein -1.08 1.73E-04 
ENSMUSG00000029838 Ptn pleiotrophin -1.09 6.57E-06 
ENSMUSG00000044921 Rassf9 Ras association (RalGDS/AF-6) domain family (N-terminal) member 
9 
-1.09 9.58E-05 
ENSMUSG00000040147 Maob monoamine oxidase B -1.09 2.60E-07 
ENSMUSG00000079440 Alpi alkaline phosphatase, intestinal -1.09 4.94E-06 
ENSMUSG00000007655 Cav1 caveolin 1, caveolae protein -1.09 1.09E-08 
ENSMUSG00000039405 Prss23 protease, serine 23 -1.09 1.64E-07 
ENSMUSG00000038756 Ttll6 tubulin tyrosine ligase-like family, member 6 -1.09 3.89E-03 
ENSMUSG00000022878 Adipoq adiponectin, C1Q and collagen domain containing -1.09 1.87E-05 
ENSMUSG00000098220  -1.09 2.87E-03 
ENSMUSG00000032278 Paqr5 progestin and adipoQ receptor family member V -1.09 2.68E-09 
ENSMUSG00000035783 Acta2 actin, alpha 2, smooth muscle, aorta -1.10 5.06E-11 
ENSMUSG00000025272 Tro trophinin -1.10 3.69E-04 
ENSMUSG00000041559 Fmod fibromodulin -1.10 6.74E-04 
ENSMUSG00000038555 Reep2 receptor accessory protein 2 -1.10 8.59E-04 
ENSMUSG00000038393 Txnip thioredoxin interacting protein -1.10 1.41E-09 
ENSMUSG00000038370 Pcp4l1 Purkinje cell protein 4-like 1 -1.10 5.80E-08 
ENSMUSG00000047146 Tet1 tet methylcytosine dioxygenase 1 -1.10 1.12E-05 
ENSMUSG00000076435 Acsf2 acyl-CoA synthetase family member 2 -1.11 1.00E-09 
ENSMUSG00000064343  -1.11 1.91E-03 
ENSMUSG00000067889 Sptbn2 spectrin beta, non-erythrocytic 2 -1.11 5.28E-07 
ENSMUSG00000046329 Slc25a23 solute carrier family 25 (mitochondrial carrier; phosphate carrier), 
member 23 
-1.11 1.15E-07 
ENSMUSG00000028255 Clca1 chloride channel calcium activated 1 -1.11 3.73E-10 
ENSMUSG00000055653 Gpc3 glypican 3 -1.11 7.52E-07 
ENSMUSG00000040505 Abcg5 ATP-binding cassette, sub-family G (WHITE), member 5 -1.11 1.55E-03 
ENSMUSG00000032192 Gnb5 guanine nucleotide binding protein (G protein), beta 5 -1.12 7.81E-05 
ENSMUSG00000029201 Ugdh UDP-glucose dehydrogenase -1.12 5.86E-08 
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ENSMUSG00000032514 Ttc21a tetratricopeptide repeat domain 21A -1.12 3.13E-03 
ENSMUSG00000057123 Gja5 gap junction protein, alpha 5 -1.12 1.71E-04 
ENSMUSG00000028003 Lrat lecithin-retinol acyltransferase (phosphatidylcholine-retinol-O-
acyltransferase) 
-1.12 1.51E-04 
ENSMUSG00000023829 Slc22a1 solute carrier family 22 (organic cation transporter), member 1 -1.13 1.49E-07 
ENSMUSG00000060181 Slc35e3 solute carrier family 35, member E3 -1.13 1.22E-06 
ENSMUSG00000049176 Frmpd4 FERM and PDZ domain containing 4 -1.13 3.19E-03 
ENSMUSG00000057880 Abat 4-aminobutyrate aminotransferase -1.13 5.66E-08 
ENSMUSG00000000253 Gmpr guanosine monophosphate reductase -1.13 8.75E-05 
ENSMUSG00000071656 Lrrn4cl LRRN4 C-terminal like -1.13 4.31E-05 
ENSMUSG00000046460 Sh2d7 SH2 domain containing 7 -1.13 1.24E-03 
ENSMUSG00000038776 Ephx1 epoxide hydrolase 1, microsomal -1.13 1.25E-08 
ENSMUSG00000074971 Fibin fin bud initiation factor homolog (zebrafish) -1.14 4.71E-05 
ENSMUSG00000053963 6330403A02Ri
k 
RIKEN cDNA 6330403A02 gene -1.14 4.19E-07 
ENSMUSG00000032609 Klhdc8b kelch domain containing 8B -1.14 1.11E-04 
ENSMUSG00000027698 Nceh1 neutral cholesterol ester hydrolase 1 -1.14 7.49E-08 
ENSMUSG00000019278 Dpep1 dipeptidase 1 (renal) -1.14 9.69E-09 
ENSMUSG00000074826 Gm10767 predicted gene 10767 -1.14 2.42E-03 
ENSMUSG00000043439 E130012A19Ri
k 
RIKEN cDNA E130012A19 gene -1.15 3.06E-06 
ENSMUSG00000050097 Ces2b carboxyesterase 2B -1.15 5.89E-06 
ENSMUSG00000035686 Thrsp thyroid hormone responsive -1.15 8.18E-04 
ENSMUSG00000089960 Ugt1a1 UDP glucuronosyltransferase 1 family, polypeptide A1 -1.15 2.70E-05 
ENSMUSG00000042254 Cilp cartilage intermediate layer protein, nucleotide pyrophosphohydrolase -1.15 1.18E-07 
ENSMUSG00000062542 Syt9 synaptotagmin IX -1.15 2.83E-03 
ENSMUSG00000038167 Plekhg6 pleckstrin homology domain containing, family G (with RhoGef 
domain) member 6 
-1.15 1.27E-06 
ENSMUSG00000029864 Gstk1 glutathione S-transferase kappa 1 -1.15 1.50E-09 
ENSMUSG00000049409 Prokr1 prokineticin receptor 1 -1.16 8.42E-04 
ENSMUSG00000029868 Trpv6 transient receptor potential cation channel, subfamily V, member 6 -1.16 2.62E-03 
ENSMUSG00000033717 Adra2a adrenergic receptor, alpha 2a -1.16 2.57E-08 
ENSMUSG00000027894 Slc6a17 solute carrier family 6 (neurotransmitter transporter), member 17 -1.16 3.67E-05 
ENSMUSG00000087535  -1.16 2.31E-03 
ENSMUSG00000087582  -1.16 1.75E-03 
ENSMUSG00000021567 Nkd2 naked cuticle 2 homolog (Drosophila) -1.16 1.09E-06 
ENSMUSG00000018659 Pnpo pyridoxine 5'-phosphate oxidase -1.17 9.84E-09 
ENSMUSG00000060548 Tnfrsf19 tumor necrosis factor receptor superfamily, member 19 -1.17 6.45E-05 
ENSMUSG00000018570 2810408A11Ri
k 
RIKEN cDNA 2810408A11 gene -1.17 7.30E-05 
ENSMUSG00000036585 Fgf1 fibroblast growth factor 1 -1.17 7.30E-08 
ENSMUSG00000069917 Hba-a2 hemoglobin alpha, adult chain 2 -1.18 3.66E-05 
ENSMUSG00000027318 Adam33 a disintegrin and metallopeptidase domain 33 -1.18 1.17E-03 
ENSMUSG00000024049 Myom1 myomesin 1 -1.18 1.30E-08 
ENSMUSG00000033419 Snap91 synaptosomal-associated protein 91 -1.19 8.95E-04 
ENSMUSG00000063430 Wscd2 WSC domain containing 2 -1.19 3.33E-07 
ENSMUSG00000026463 Atp2b4 ATPase, Ca++ transporting, plasma membrane 4 -1.19 1.25E-12 
ENSMUSG00000020431 Adcy1 adenylate cyclase 1 -1.19 3.18E-04 
ENSMUSG00000020439 Smtn smoothelin -1.19 2.45E-10 
ENSMUSG00000025194 Abcc2 ATP-binding cassette, sub-family C (CFTR/MRP), member 2 -1.19 1.95E-03 
ENSMUSG00000074207 Adh1 alcohol dehydrogenase 1 (class I) -1.19 4.02E-08 
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ENSMUSG00000062410 Hsd3b3 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-
isomerase 3 
-1.20 8.79E-09 
ENSMUSG00000031636 Pdlim3 PDZ and LIM domain 3 -1.20 4.13E-10 
ENSMUSG00000087347  -1.21 1.75E-03 
ENSMUSG00000055493 Epm2a epilepsy, progressive myoclonic epilepsy, type 2 gene alpha -1.21 1.69E-04 
ENSMUSG00000020405 Fabp6 fatty acid binding protein 6, ileal (gastrotropin) -1.21 1.72E-03 
ENSMUSG00000023094 Msrb2 methionine sulfoxide reductase B2 -1.21 2.61E-04 
ENSMUSG00000049971 Glt1d1 glycosyltransferase 1 domain containing 1 -1.21 1.29E-05 
ENSMUSG00000027556 Car1 carbonic anhydrase 1 -1.22 1.99E-08 
ENSMUSG00000094651 Gal3st2 galactose-3-O-sulfotransferase 2 -1.22 3.37E-07 
ENSMUSG00000012705 Retn resistin -1.22 1.17E-04 
ENSMUSG00000032648 Pygm muscle glycogen phosphorylase -1.22 2.55E-07 
ENSMUSG00000013415 Igf2bp1 insulin-like growth factor 2 mRNA binding protein 1 -1.22 3.78E-05 
ENSMUSG00000001663 Gstt1 glutathione S-transferase, theta 1 -1.23 3.56E-07 
ENSMUSG00000050751 Pgbd5 piggyBac transposable element derived 5 -1.23 1.42E-04 
ENSMUSG00000021792 Fam213a family with sequence similarity 213, member A -1.23 8.45E-09 
ENSMUSG00000049811 Fam161a family with sequence similarity 161, member A -1.23 2.52E-05 
ENSMUSG00000032649 Colgalt2 collagen beta(1-O)galactosyltransferase 2 -1.23 6.59E-04 
ENSMUSG00000069601 Ank3 ankyrin 3, epithelial -1.23 2.29E-08 
ENSMUSG00000021943 Gdf10 growth differentiation factor 10 -1.23 1.42E-03 
ENSMUSG00000031700 Gpt2 glutamic pyruvate transaminase (alanine aminotransferase) 2 -1.23 8.55E-09 
ENSMUSG00000018217 Pmp22 peripheral myelin protein 22 -1.23 2.26E-11 
ENSMUSG00000062257 Opcml opioid binding protein/cell adhesion molecule-like -1.23 2.28E-06 
ENSMUSG00000022490 Ppp1r1a protein phosphatase 1, regulatory (inhibitor) subunit 1A -1.24 1.41E-04 
ENSMUSG00000087528  -1.24 6.85E-04 
ENSMUSG00000018566 Slc2a4 solute carrier family 2 (facilitated glucose transporter), member 4 -1.25 4.98E-08 
ENSMUSG00000052957 Gas1 growth arrest specific 1 -1.25 1.42E-06 
ENSMUSG00000044860 Gm1123 predicted gene 1123 -1.26 1.84E-08 
ENSMUSG00000048498 Cd300e CD300e antigen -1.26 9.20E-04 
ENSMUSG00000061100 Retnla resistin like alpha -1.26 8.86E-04 
ENSMUSG00000020653 Klf11 Kruppel-like factor 11 -1.26 1.81E-06 
ENSMUSG00000028976 Slc2a5 solute carrier family 2 (facilitated glucose transporter), member 5 -1.26 1.04E-04 
ENSMUSG00000062760 1810041L15Rik RIKEN cDNA 1810041L15 gene -1.26 1.37E-05 
ENSMUSG00000029309 Sparcl1 SPARC-like 1 -1.27 6.23E-13 
ENSMUSG00000030865 Chp2 calcineurin-like EF hand protein 2 -1.27 4.03E-09 
ENSMUSG00000050505 Pcdh20 protocadherin 20 -1.27 9.18E-04 
ENSMUSG00000036814 Slc6a20a solute carrier family 6 (neurotransmitter transporter), member 20A -1.27 4.17E-04 
ENSMUSG00000031790 Mmp15 matrix metallopeptidase 15 -1.27 2.98E-11 
ENSMUSG00000030711 Sult1a1 sulfotransferase family 1A, phenol-preferring, member 1 -1.27 1.18E-05 
ENSMUSG00000038967 Pdk2 pyruvate dehydrogenase kinase, isoenzyme 2 -1.28 5.51E-08 
ENSMUSG00000004038 Gstm3 glutathione S-transferase, mu 3 -1.28 1.14E-04 
ENSMUSG00000074218 Cox7a1 cytochrome c oxidase subunit VIIa 1 -1.29 1.96E-09 
ENSMUSG00000032122 Slc37a2 solute carrier family 37 (glycerol-3-phosphate transporter), member 2 -1.29 1.23E-05 
ENSMUSG00000072720 Myo18b myosin XVIIIb -1.30 3.68E-06 
ENSMUSG00000031173 Otc ornithine transcarbamylase -1.30 6.40E-07 
ENSMUSG00000025545 Clybl citrate lyase beta like -1.30 2.22E-08 
ENSMUSG00000068748 Ptprz1 protein tyrosine phosphatase, receptor type Z, polypeptide 1 -1.30 2.47E-05 
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ENSMUSG00000015354 Pcolce2 procollagen C-endopeptidase enhancer 2 -1.30 4.79E-06 
ENSMUSG00000020334 Slc22a4 solute carrier family 22 (organic cation transporter), member 4 -1.30 1.63E-05 
ENSMUSG00000098132 Rassf10 Ras association (RalGDS/AF-6) domain family (N-terminal) member 
10 
-1.30 4.31E-05 
ENSMUSG00000046275 Tusc5 tumor suppressor candidate 5 -1.31 5.38E-06 
ENSMUSG00000031938 4931406C07Ri
k 
RIKEN cDNA 4931406C07 gene -1.31 1.60E-09 
ENSMUSG00000032607 Amt aminomethyltransferase -1.31 1.19E-07 
ENSMUSG00000024978 Gpam glycerol-3-phosphate acyltransferase, mitochondrial -1.31 4.14E-11 
ENSMUSG00000010122 Slc47a1 solute carrier family 47, member 1 -1.31 2.00E-04 
ENSMUSG00000050315 Synpo2 synaptopodin 2 -1.31 5.31E-16 
ENSMUSG00000070704 Ugt2b36 UDP glucuronosyltransferase 2 family, polypeptide B36 -1.32 2.08E-04 
ENSMUSG00000072723  -1.32 2.59E-05 
ENSMUSG00000074736 Syndig1 synapse differentiation inducing 1 -1.32 1.11E-05 
ENSMUSG00000023046 Igfbp6 insulin-like growth factor binding protein 6 -1.33 6.05E-07 
ENSMUSG00000030409 Dmpk dystrophia myotonica-protein kinase -1.33 2.36E-13 
ENSMUSG00000027397 Slc20a1 solute carrier family 20, member 1 -1.33 3.04E-08 
ENSMUSG00000020080 Hkdc1 hexokinase domain containing 1 -1.33 4.66E-08 
ENSMUSG00000040703 Cyp2s1 cytochrome P450, family 2, subfamily s, polypeptide 1 -1.33 3.29E-11 
ENSMUSG00000058135 Gstm1 glutathione S-transferase, mu 1 -1.34 5.70E-11 
ENSMUSG00000026489 Adck3 aarF domain containing kinase 3 -1.34 2.66E-08 
ENSMUSG00000055748 Gsdmc4 gasdermin C4 -1.34 1.65E-05 
ENSMUSG00000064036 Mro maestro -1.34 8.67E-05 
ENSMUSG00000027761 Aadac arylacetamide deacetylase (esterase) -1.34 2.66E-06 
ENSMUSG00000023057 Fabp2 fatty acid binding protein 2, intestinal -1.34 7.70E-05 
ENSMUSG00000005540 Fcer2a Fc receptor, IgE, low affinity II, alpha polypeptide -1.34 6.42E-08 
ENSMUSG00000087291 Gm11946 predicted gene 11946 -1.34 1.35E-05 
ENSMUSG00000032387 Rbpms2 RNA binding protein with multiple splicing 2 -1.35 1.01E-07 
ENSMUSG00000023800 Tiam2 T cell lymphoma invasion and metastasis 2 -1.35 8.03E-10 
ENSMUSG00000061825 Ces2c carboxylesterase 2C -1.35 2.35E-08 
ENSMUSG00000063011 Msln mesothelin -1.35 2.66E-04 
ENSMUSG00000045348 Nyap1 neuronal tyrosine-phosphorylated phosphoinositide 3-kinase adaptor 
1 
-1.35 1.36E-06 
ENSMUSG00000041073 Nacad NAC alpha domain containing -1.36 3.42E-08 
ENSMUSG00000031877 Ces2g carboxylesterase 2G -1.36 1.77E-06 
ENSMUSG00000047496 Rnf152 ring finger protein 152 -1.36 1.80E-09 
ENSMUSG00000036832 Lpar3 lysophosphatidic acid receptor 3 -1.37 2.69E-04 
ENSMUSG00000006360 Crip1 cysteine-rich protein 1 (intestinal) -1.37 8.34E-11 
ENSMUSG00000020019 Ntn4 netrin 4 -1.38 7.93E-10 
ENSMUSG00000034785 Dio1 deiodinase, iodothyronine, type I -1.38 3.84E-09 
ENSMUSG00000019970 Sgk1 serum/glucocorticoid regulated kinase 1 -1.38 1.70E-06 
ENSMUSG00000028356 Ambp alpha 1 microglobulin/bikunin -1.38 1.78E-04 
ENSMUSG00000025196 Cpn1 carboxypeptidase N, polypeptide 1 -1.38 3.50E-08 
ENSMUSG00000050103 Agmo alkylglycerol monooxygenase -1.39 1.43E-07 
ENSMUSG00000021236 Entpd5 ectonucleoside triphosphate diphosphohydrolase 5 -1.39 4.76E-11 
ENSMUSG00000043430 Psapl1 prosaposin-like 1 -1.39 2.99E-04 
ENSMUSG00000022546 Gpt glutamic pyruvic transaminase, soluble -1.39 3.75E-08 
ENSMUSG00000026726 Cubn cubilin (intrinsic factor-cobalamin receptor) -1.39 1.31E-04 
ENSMUSG00000067818 Myl9 myosin, light polypeptide 9, regulatory -1.40 3.84E-17 
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ENSMUSG00000038725 Pkhd1l1 polycystic kidney and hepatic disease 1-like 1 -1.40 3.70E-07 
ENSMUSG00000074882 Cyp2c68 cytochrome P450, family 2, subfamily c, polypeptide 68 -1.41 2.43E-05 
ENSMUSG00000018830 Myh11 myosin, heavy polypeptide 11, smooth muscle -1.41 8.75E-17 
ENSMUSG00000073608 Gm6086 predicted gene 6086 -1.41 9.00E-06 
ENSMUSG00000060600 Eno3 enolase 3, beta muscle -1.41 9.62E-09 
ENSMUSG00000074004 B3gnt6 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 6 
(core 3 synthase) 
-1.42 3.35E-06 
ENSMUSG00000019577 Pdk4 pyruvate dehydrogenase kinase, isoenzyme 4 -1.43 6.04E-05 
ENSMUSG00000063296 Tmem117 transmembrane protein 117 -1.43 1.01E-09 
ENSMUSG00000017607 Tns4 tensin 4 -1.43 1.12E-09 
ENSMUSG00000034687 Fras1 Fraser syndrome 1 homolog (human) -1.43 1.22E-06 
ENSMUSG00000049336 Tenm2 teneurin transmembrane protein 2 -1.44 7.51E-06 
ENSMUSG00000027559 Car3 carbonic anhydrase 3 -1.44 1.38E-06 
ENSMUSG00000022040 Ephx2 epoxide hydrolase 2, cytoplasmic -1.44 5.81E-10 
ENSMUSG00000019945 1700040L02Rik RIKEN cDNA 1700040L02 gene -1.44 2.23E-06 
ENSMUSG00000028464 Tpm2 tropomyosin 2, beta -1.44 9.14E-17 
ENSMUSG00000033207 Mamdc2 MAM domain containing 2 -1.45 6.06E-10 
ENSMUSG00000023336 Wfdc1 WAP four-disulfide core domain 1 -1.45 4.36E-09 
ENSMUSG00000046589 Lrrc8e leucine rich repeat containing 8 family, member E -1.46 6.73E-09 
ENSMUSG00000032085 Tagln transgelin -1.47 6.02E-18 
ENSMUSG00000019989 Enpp3 ectonucleotide pyrophosphatase/phosphodiesterase 3 -1.48 5.04E-09 
ENSMUSG00000025658 Cnksr2 connector enhancer of kinase suppressor of Ras 2 -1.48 1.26E-06 
ENSMUSG00000035184 Fam124a family with sequence similarity 124, member A -1.49 2.45E-07 
ENSMUSG00000028039 Efna3 ephrin A3 -1.49 2.37E-05 
ENSMUSG00000052485 Tmem171 transmembrane protein 171 -1.49 3.99E-12 
ENSMUSG00000029772 Ahcyl2 S-adenosylhomocysteine hydrolase-like 2 -1.50 2.51E-14 
ENSMUSG00000031937 Vstm5 V-set and transmembrane domain containing 5 -1.51 2.70E-06 
ENSMUSG00000051726 Kcnf1 potassium voltage-gated channel, subfamily F, member 1 -1.53 1.42E-07 
ENSMUSG00000040812 Agbl2 ATP/GTP binding protein-like 2 -1.54 1.05E-07 
ENSMUSG00000038591 Colec10 collectin sub-family member 10 -1.54 5.73E-09 
ENSMUSG00000037071 Scd1 stearoyl-Coenzyme A desaturase 1 -1.54 1.95E-06 
ENSMUSG00000042751 Nmnat2 nicotinamide nucleotide adenylyltransferase 2 -1.55 1.29E-08 
ENSMUSG00000028755 Cda cytidine deaminase -1.56 2.40E-10 
ENSMUSG00000031725 Ces1f carboxylesterase 1F -1.56 6.11E-13 
ENSMUSG00000026418 Tnni1 troponin I, skeletal, slow 1 -1.57 7.24E-06 
ENSMUSG00000032883 Acsl3 acyl-CoA synthetase long-chain family member 3 -1.58 2.00E-12 
ENSMUSG00000095385 D630033O11Ri
k 
RIKEN cDNA D630033O11 gene -1.59 2.76E-05 
ENSMUSG00000020068  -1.59 5.69E-08 
ENSMUSG00000002565 Scin scinderin -1.59 3.73E-13 
ENSMUSG00000060780 Lrrtm1 leucine rich repeat transmembrane neuronal 1 -1.60 2.46E-05 
ENSMUSG00000054619 Mettl7a1 methyltransferase like 7A1 -1.60 1.19E-13 
ENSMUSG00000032854 Ugt8a UDP galactosyltransferase 8A -1.61 1.42E-05 
ENSMUSG00000085375  -1.61 3.54E-07 
ENSMUSG00000055730 Ces2a carboxylesterase 2A -1.61 1.48E-05 
ENSMUSG00000039323 Igfbp2 insulin-like growth factor binding protein 2 -1.62 4.78E-07 
ENSMUSG00000021367 Edn1 endothelin 1 -1.63 4.70E-12 
ENSMUSG00000081169  -1.63 2.11E-06 
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ENSMUSG00000020182 Ddc dopa decarboxylase -1.66 5.19E-14 
ENSMUSG00000030554 Synm synemin, intermediate filament protein -1.67 1.36E-21 
ENSMUSG00000028088 Fmo5 flavin containing monooxygenase 5 -1.67 2.08E-12 
ENSMUSG00000027870 Hao2 hydroxyacid oxidase 2 -1.68 7.60E-13 
ENSMUSG00000047501 Cldn4 claudin 4 -1.69 1.19E-12 
ENSMUSG00000052131 Akr1b7 aldo-keto reductase family 1, member B7 -1.70 3.64E-06 
ENSMUSG00000026614 Slc30a10 solute carrier family 30, member 10 -1.70 9.71E-07 
ENSMUSG00000027875 Hmgcs2 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2 -1.72 4.54E-18 
ENSMUSG00000040584 Abcb1a ATP-binding cassette, sub-family B (MDR/TAP), member 1A -1.73 1.85E-07 
ENSMUSG00000026208 Des desmin -1.74 9.86E-26 
ENSMUSG00000061808 Ttr transthyretin -1.74 8.04E-12 
ENSMUSG00000056973 Ces1d carboxylesterase 1D -1.75 3.67E-15 
ENSMUSG00000041012 Cmtm8 CKLF-like MARVEL transmembrane domain containing 8 -1.76 2.27E-10 
ENSMUSG00000020793 Galr2 galanin receptor 2 -1.77 4.66E-08 
ENSMUSG00000053399 Adamts18 a disintegrin-like and metallopeptidase (reprolysin type) with 
thrombospondin type 1 motif, 18 
-1.77 3.52E-06 
ENSMUSG00000029811 Aoc1 amine oxidase, copper-containing 1 -1.77 7.50E-21 
ENSMUSG00000027401 Tgm3 transglutaminase 3, E polypeptide -1.78 4.10E-06 
ENSMUSG00000027513 Pck1 phosphoenolpyruvate carboxykinase 1, cytosolic -1.80 3.61E-17 
ENSMUSG00000024727 Trpm6 transient receptor potential cation channel, subfamily M, member 6 -1.82 3.04E-08 
ENSMUSG00000079355 Ackr4 atypical chemokine receptor 4 -1.84 4.09E-13 
ENSMUSG00000025002 Cyp2c55 cytochrome P450, family 2, subfamily c, polypeptide 55 -1.87 1.14E-06 
ENSMUSG00000059430 Actg2 actin, gamma 2, smooth muscle, enteric -1.88 2.18E-20 
ENSMUSG00000001349 Cnn1 calponin 1 -1.89 5.36E-28 
ENSMUSG00000051295 9630028B13Ri
k 
RIKEN cDNA 9630028B13 gene -1.90 1.02E-12 
ENSMUSG00000019762 Iyd iodotyrosine deiodinase -1.95 8.93E-09 
ENSMUSG00000024575 Pde6a phosphodiesterase 6A, cGMP-specific, rod, alpha -1.97 1.09E-10 
ENSMUSG00000026166 Ccl20 chemokine (C-C motif) ligand 20 -1.98 8.73E-09 
ENSMUSG00000073424 Cyp4f15 cytochrome P450, family 4, subfamily f, polypeptide 15 -2.00 7.78E-08 
ENSMUSG00000029630 Cyp3a25 cytochrome P450, family 3, subfamily a, polypeptide 25 -2.01 1.89E-07 
ENSMUSG00000030399 Ckm creatine kinase, muscle -2.07 7.98E-21 
ENSMUSG00000060615 Ang4 angiogenin, ribonuclease A family, member 4 -2.07 2.41E-10 
ENSMUSG00000092586 Ly6g6c lymphocyte antigen 6 complex, locus G6C -2.08 3.99E-08 
ENSMUSG00000026701 Prdx6 peroxiredoxin 6 -2.10 1.92E-19 
ENSMUSG00000010311 Optc opticin -2.13 1.92E-17 
ENSMUSG00000081488  -2.15 1.24E-13 
ENSMUSG00000028713 Cyp4b1 cytochrome P450, family 4, subfamily b, polypeptide 1 -2.19 4.72E-12 
ENSMUSG00000037762 Slc16a9 solute carrier family 16 (monocarboxylic acid transporters), member 
9 
-2.20 2.41E-23 
ENSMUSG00000084174 Sycn syncollin -2.23 2.52E-17 
ENSMUSG00000035557 Krt17 keratin 17 -2.29 2.14E-14 
ENSMUSG00000039760 Il22ra2 interleukin 22 receptor, alpha 2 -2.33 1.79E-17 
ENSMUSG00000057074 Ces1g carboxylesterase 1G -2.37 1.29E-13 
ENSMUSG00000049580 Tsku tsukushi -2.42 4.47E-21 
ENSMUSG00000022491 Glycam1 glycosylation dependent cell adhesion molecule 1 -2.83 2.54E-36 
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Table S4 Differentially expressed genes of BALB/c (YPIII Δcnfy infected 5 dpi vs. YPIII infected 
5 dpi) 
Ensembl ID Gene symbol Gene name log2 fold 
change 
p-value 
ENSMUSG00000031551 Ido1 indoleamine 2,3-dioxygenase 1 2.74 4.41E-26 
ENSMUSG00000068086 Cyp2d9 cytochrome P450, family 2, subfamily d, polypeptide 9 2.08 9.23E-09 
ENSMUSG00000029417 Cxcl9 chemokine (C-X-C motif) ligand 9 1.98 2.92E-09 
ENSMUSG00000074195 Clca4b chloride channel calcium activated 4B 1.98 2.15E-08 
ENSMUSG00000036123 Slc9a3 solute carrier family 9 (sodium/hydrogen exchanger), member 3 1.95 2.05E-09 
ENSMUSG00000032068 Plet1 placenta expressed transcript 1 1.86 9.10E-10 
ENSMUSG00000020826 Nos2 nitric oxide synthase 2, inducible 1.84 1.39E-09 
ENSMUSG00000032122 Slc37a2 solute carrier family 37 (glycerol-3-phosphate transporter), member 
2 
1.71 7.43E-09 
ENSMUSG00000074115 Saa1 serum amyloid A 1 1.60 1.13E-06 
ENSMUSG00000000805 Car4 carbonic anhydrase 4 1.58 2.44E-13 
ENSMUSG00000028527 Ak4 adenylate kinase 4 1.54 3.32E-07 
ENSMUSG00000053862 Slc51b solute carrier family 51, beta subunit 1.54 4.55E-10 
ENSMUSG00000057465 Saa2 serum amyloid A 2 1.51 6.13E-09 
ENSMUSG00000099065 1.50 5.45E-09 
ENSMUSG00000047728 BC025446 cDNA sequence BC025446 1.49 2.61E-06 
ENSMUSG00000021214 Akr1c18 aldo-keto reductase family 1, member C18 1.47 5.10E-05 
ENSMUSG00000049281 Scn3b sodium channel, voltage-gated, type III, beta 1.44 7.29E-07 
ENSMUSG00000078922 Tgtp1 T cell specific GTPase 1 1.43 3.42E-06 
ENSMUSG00000065629 1.43 2.03E-04 
ENSMUSG00000010601 Apol7a apolipoprotein L 7a 1.41 4.84E-08 
ENSMUSG00000075602 Ly6a lymphocyte antigen 6 complex, locus A 1.37 1.30E-08 
ENSMUSG00000026880 Stom stomatin 1.36 1.51E-11 
ENSMUSG00000035186 Ubd ubiquitin D 1.36 5.37E-09 
ENSMUSG00000064400 1.36 4.06E-04 
ENSMUSG00000041481 1.34 3.88E-09 
ENSMUSG00000079363 Gbp4 guanylate binding protein 4 1.31 2.29E-05 
ENSMUSG00000050982 Apol10a apolipoprotein L 10A 1.30 6.15E-05 
ENSMUSG00000027375 Mal myelin and lymphocyte protein, T cell differentiation protein 1.29 4.04E-08 
ENSMUSG00000024411 Aqp4 aquaporin 4 1.28 3.17E-05 
ENSMUSG00000076526 1.28 2.03E-04 
ENSMUSG00000045725 Prr15 proline rich 15 1.27 1.23E-08 
ENSMUSG00000041202 Pla2g2d phospholipase A2, group IID 1.27 4.22E-08 
ENSMUSG00000032010 Usp2 ubiquitin specific peptidase 2 1.25 4.17E-06 
ENSMUSG00000056148 Rdh9 retinol dehydrogenase 9 1.25 1.08E-04 
ENSMUSG00000028269 1.25 9.80E-05 
ENSMUSG00000053279 Aldh1a1 aldehyde dehydrogenase family 1, subfamily A1 1.24 3.33E-08 
ENSMUSG00000025557 Slc15a1 solute carrier family 15 (oligopeptide transporter), member 1 1.24 9.06E-05 
ENSMUSG00000045932 Ifit2 interferon-induced protein with tetratricopeptide repeats 2 1.23 4.68E-07 
ENSMUSG00000071356 Reg3b regenerating islet-derived 3 beta 1.23 4.09E-04 
ENSMUSG00000079362 Gbp6 guanylate binding protein 6 1.23 1.11E-05 
ENSMUSG00000027820 Mme membrane metallo endopeptidase 1.23 1.66E-04 
ENSMUSG00000030762 Aqp8 aquaporin 8 1.22 4.19E-04 
ENSMUSG00000030017 Reg3g regenerating islet-derived 3 gamma 1.22 6.17E-04 
ENSMUSG00000030742 Lat linker for activation of T cells 1.21 1.83E-04 
ENSMUSG00000061531 Tmem236 transmembrane protein 236 1.21 1.98E-06 
ENSMUSG00000024731 Ms4a10 membrane-spanning 4-domains, subfamily A, member 10 1.20 9.56E-05 
ENSMUSG00000034438 Gbp8 guanylate-binding protein 8 1.20 2.97E-06 
ENSMUSG00000095866 1.20 6.16E-05 
ENSMUSG00000037649 H2-DMa histocompatibility 2, class II, locus DMa 1.19 3.87E-08 
ENSMUSG00000054072 Iigp1 interferon inducible GTPase 1 1.18 4.52E-04 
ENSMUSG00000054588 1.17 9.75E-04 
ENSMUSG00000076598 1.17 2.38E-03 
ENSMUSG00000026009 Icos inducible T cell co-stimulator 1.17 1.39E-04 
ENSMUSG00000028270 Gbp2 guanylate binding protein 2 1.17 2.39E-06 
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ENSMUSG00000059824 Dbp D site albumin promoter binding protein 1.17 1.01E-04 
ENSMUSG00000027225 Duoxa2 dual oxidase maturation factor 2 1.17 4.85E-04 
ENSMUSG00000024673 Ms4a1 membrane-spanning 4-domains, subfamily A, member 1 1.17 1.67E-07 
ENSMUSG00000025150 Cbr2 carbonyl reductase 2 1.16 1.86E-07 
ENSMUSG00000035686 Thrsp thyroid hormone responsive 1.16 1.03E-03 
ENSMUSG00000079507 H2-Q1 histocompatibility 2, Q region locus 1 1.16 6.19E-06 
ENSMUSG00000096638 1.16 8.33E-05 
ENSMUSG00000068606 Gm4841 predicted gene 4841 1.16 1.11E-04 
ENSMUSG00000078853 Igtp interferon gamma induced GTPase 1.15 3.48E-04 
ENSMUSG00000033715 Akr1c14 aldo-keto reductase family 1, member C14 1.15 9.96E-05 
ENSMUSG00000059898 Dsc3 desmocollin 3 1.14 3.53E-04 
ENSMUSG00000041193 Pla2g5 phospholipase A2, group V 1.14 1.97E-06 
ENSMUSG00000012705 Retn resistin 1.13 8.55E-04 
ENSMUSG00000074261 Erich4 glutamate rich 4 1.13 2.18E-03 
ENSMUSG00000058908 Pla2g2a phospholipase A2, group IIA (platelets, synovial fluid) 1.13 4.77E-04 
ENSMUSG00000096498 1.12 3.76E-03 
ENSMUSG00000023959 Clic5 chloride intracellular channel 5 1.12 1.70E-06 
ENSMUSG00000048852 Gm12185 predicted gene 12185 1.12 2.16E-04 
ENSMUSG00000068227 Il2rb interleukin 2 receptor, beta chain 1.11 3.45E-05 
ENSMUSG00000093861 1.11 6.05E-04 
ENSMUSG00000005763 Cd247 CD247 antigen 1.11 2.34E-04 
ENSMUSG00000015437 Gzmb granzyme B 1.10 1.74E-03 
ENSMUSG00000064346 1.10 1.30E-03 
ENSMUSG00000094559 Cyp2d34 cytochrome P450, family 2, subfamily d, polypeptide 34 1.10 3.22E-06 
ENSMUSG00000068105 Tnfrsf13c tumor necrosis factor receptor superfamily, member 13c 1.10 3.70E-06 
ENSMUSG00000090942 F830016B08
Rik 
RIKEN cDNA F830016B08 gene 1.10 9.07E-05 
ENSMUSG00000055069 Rab39 RAB39, member RAS oncogene family 1.09 1.22E-03 
ENSMUSG00000020407 Upp1 uridine phosphorylase 1 1.09 1.40E-03 
ENSMUSG00000028544 Slc5a9 solute carrier family 5 (sodium/glucose cotransporter), member 9 1.08 9.47E-05 
ENSMUSG00000040264 Gbp2b guanylate binding protein 2b 1.08 4.07E-04 
ENSMUSG00000086706 1.08 1.76E-03 
ENSMUSG00000090136 Gm10177 predicted gene 10177 1.08 3.90E-03 
ENSMUSG00000025203 Scd2 stearoyl-Coenzyme A desaturase 2 1.07 3.62E-04 
ENSMUSG00000095193 Gm20939 predicted gene, 20939 1.07 3.16E-03 
ENSMUSG00000022582 Ly6g lymphocyte antigen 6 complex, locus G 1.07 1.08E-04 
ENSMUSG00000025479 Cyp2e1 cytochrome P450, family 2, subfamily e, polypeptide 1 1.06 9.18E-04 
ENSMUSG00000075010 AW112010 expressed sequence AW112010 1.05 2.80E-06 
ENSMUSG00000079103 Tgm7 transglutaminase 7 1.05 1.24E-03 
ENSMUSG00000024670 Cd6 CD6 antigen 1.05 2.57E-03 
ENSMUSG00000024338 Psmb8 proteasome (prosome, macropain) subunit, beta type 8 (large 
multifunctional peptidase 7) 
1.05 1.37E-06 
ENSMUSG00000084806 Gm15232 predicted gene 15232 1.05 1.77E-03 
ENSMUSG00000073555 Gm4951 predicted gene 4951 1.05 4.23E-05 
ENSMUSG00000042943 1.04 1.84E-03 
ENSMUSG00000038037 Socs1 suppressor of cytokine signaling 1 1.04 1.71E-03 
ENSMUSG00000037321 Tap1 transporter 1, ATP-binding cassette, sub-family B (MDR/TAP) 1.04 8.26E-07 
ENSMUSG00000064364 1.03 3.28E-03 
ENSMUSG00000030149 Klrk1 killer cell lectin-like receptor subfamily K, member 1 1.03 1.14E-04 
ENSMUSG00000087070 Gm12505 predicted gene 12505 1.03 1.03E-04 
ENSMUSG00000043931 Gimap7 GTPase, IMAP family member 7 1.03 4.30E-05 
ENSMUSG00000068299 1700019G17
Rik 
RIKEN cDNA 1700019G17 gene 1.02 1.19E-03 
ENSMUSG00000039304 Tnfsf10 tumor necrosis factor (ligand) superfamily, member 10 1.02 4.76E-05 
ENSMUSG00000054435 Gimap4 GTPase, IMAP family member 4 1.02 3.57E-07 
ENSMUSG00000070777 Ceacam20 carcinoembryonic antigen-related cell adhesion molecule 20 1.01 8.22E-06 
ENSMUSG00000023073 Slc10a2 solute carrier family 10, member 2 1.01 3.95E-03 
ENSMUSG00000046031 Fam26f family with sequence similarity 26, member F 1.01 2.05E-03 
ENSMUSG00000078921 Tgtp2 T cell specific GTPase 2 1.00 2.24E-04 
ENSMUSG00000091649 Phf11b PHD finger protein 11B 1.00 7.66E-04 
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ENSMUSG00000044162 Tnip3 TNFAIP3 interacting protein 3 1.00 4.77E-06 
ENSMUSG00000050232 Cxcr3 chemokine (C-X-C motif) receptor 3 1.00 3.87E-03 
ENSMUSG00000024529 Lox lysyl oxidase -1.01 1.22E-03 
ENSMUSG00000022548 Apod apolipoprotein D -1.01 2.83E-04 
ENSMUSG00000039109 F13a1 coagulation factor XIII, A1 subunit -1.02 3.37E-06 
ENSMUSG00000036356 Csgalnact1 chondroitin sulfate N-acetylgalactosaminyltransferase 1 -1.02 1.38E-04 
ENSMUSG00000019772 Vip vasoactive intestinal polypeptide -1.03 1.29E-05 
ENSMUSG00000007440 Pcdha11 protocadherin alpha 11 -1.03 1.22E-03 
ENSMUSG00000072949 Acot1 acyl-CoA thioesterase 1 -1.04 4.67E-04 
ENSMUSG00000044017 Gpr133 G protein-coupled receptor 133 -1.05 1.67E-06 
ENSMUSG00000097451 -1.06 1.87E-06 
ENSMUSG00000029675 Eln elastin -1.09 2.74E-05 
ENSMUSG00000022032 Scara5 scavenger receptor class A, member 5 (putative) -1.09 5.72E-07 
ENSMUSG00000081448 -1.11 2.75E-04 
ENSMUSG00000026938 Fcna ficolin A -1.11 7.91E-04 
ENSMUSG00000028766 Alpl alkaline phosphatase, liver/bone/kidney -1.12 4.67E-07 
ENSMUSG00000040152 Thbs1 thrombospondin 1 -1.13 7.51E-10 
ENSMUSG00000054555 Adam12 a disintegrin and metallopeptidase domain 12 (meltrin alpha) -1.13 9.50E-05 
ENSMUSG00000025716 Myo3a myosin IIIA -1.14 7.10E-06 
ENSMUSG00000022894 Adamts5 a disintegrin-like and metallopeptidase (reprolysin type) with 
thrombospondin type 1 motif, 5 (aggrecanase-2) 
-1.15 1.93E-08 
ENSMUSG00000031722 Hp haptoglobin -1.16 2.86E-04 
ENSMUSG00000058427 Cxcl2 chemokine (C-X-C motif) ligand 2 -1.16 6.16E-05 
ENSMUSG00000023034 Nr4a1 nuclear receptor subfamily 4, group A, member 1 -1.17 1.42E-04 
ENSMUSG00000037225 Fgf2 fibroblast growth factor 2 -1.17 4.59E-04 
ENSMUSG00000020363 Gfpt2 glutamine fructose-6-phosphate transaminase 2 -1.19 5.50E-06 
ENSMUSG00000022367 Has2 hyaluronan synthase 2 -1.20 1.62E-04 
ENSMUSG00000022651 Retnlg resistin like gamma -1.28 1.68E-05 
ENSMUSG00000061048 Cdh3 cadherin 3 -1.28 6.62E-05 
ENSMUSG00000063011 Msln mesothelin -1.28 5.07E-04 
ENSMUSG00000006403 Adamts4 a disintegrin-like and metallopeptidase (reprolysin type) with 
thrombospondin type 1 motif, 4 
-1.31 3.26E-06 
ENSMUSG00000000318 Clec10a C-type lectin domain family 10, member A -1.32 6.14E-07 
ENSMUSG00000024087 Cyp1b1 cytochrome P450, family 1, subfamily b, polypeptide 1 -1.35 1.53E-06 
ENSMUSG00000028111 Ctsk cathepsin K -1.46 1.76E-08 
ENSMUSG00000027656 Wisp2 WNT1 inducible signaling pathway protein 2 -1.59 1.69E-05 
ENSMUSG00000048636 -1.62 7.05E-06 
ENSMUSG00000040809 Chil3 chitinase-like 3 -1.93 1.06E-07 
ENSMUSG00000002289 Angptl4 angiopoietin-like 4 -2.03 3.57E-12 
ENSMUSG00000068196 Col8a1 collagen, type VIII, alpha 1 -2.34 3.55E-20 
 
Table S5 Differentially expressed genes of BALB/c (uninfected 42 dpi vs. uninfected 5 dpi) 
Ensembl ID Gene 
symbol 
Gene name log2 fold 
change 
p-value 
ENSMUSG00000006403 Adamts4 a disintegrin-like and metallopeptidase (reprolysin type) with 
thrombospondin type 1 motif, 4 
1.99 5.05E-10 
ENSMUSG00000055116 Arntl aryl hydrocarbon receptor nuclear translocator-like 1.87 1.66E-16 
ENSMUSG00000084671  1.60 3.18E-08 
ENSMUSG00000022389 Tef thyrotroph embryonic factor -1.83 1.24E-12 
ENSMUSG00000059824 Dbp D site albumin promoter binding protein -2.39 1.25E-15 
ENSMUSG00000038550 Ciart circadian associated repressor of transcription -2.54 2.77E-15 
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Table S6 Differentially expressed genes of BALB/c (YPIII infected 42 dpi vs. YPIII infected 5 dpi) 
Ensembl ID Gene 
symbol 
Gene name log2 fold 
change 
p-value 
ENSMUSG00000057074 Ces1g carboxylesterase 1G 3.38 6.70E-26 
ENSMUSG00000041559 Fmod fibromodulin 3.07 6.57E-23 
ENSMUSG00000010311 Optc opticin 3.03 1.82E-32 
ENSMUSG00000022491 Glycam1 glycosylation dependent cell adhesion molecule 1 3.02 8.56E-41 
ENSMUSG00000030399 Ckm creatine kinase, muscle 3.00 1.33E-43 
ENSMUSG00000092586 Ly6g6c lymphocyte antigen 6 complex, locus G6C 2.95 6.15E-15 
ENSMUSG00000012705 Retn resistin 2.90 4.02E-19 
ENSMUSG00000069917 Hba-a2 hemoglobin alpha, adult chain 2 2.89 4.03E-24 
ENSMUSG00000032122 Slc37a2 solute carrier family 37 (glycerol-3-phosphate transporter), member 2 2.83 9.53E-22 
ENSMUSG00000069919 Hba-a1 hemoglobin alpha, adult chain 1 2.67 1.93E-23 
ENSMUSG00000000805 Car4 carbonic anhydrase 4 2.58 2.25E-33 
ENSMUSG00000025479 Cyp2e1 cytochrome P450, family 2, subfamily e, polypeptide 1 2.54 1.98E-16 
ENSMUSG00000057123 Gja5 gap junction protein, alpha 5 2.51 1.21E-18 
ENSMUSG00000022227 Mcpt1 mast cell protease 1 2.50 1.31E-11 
ENSMUSG00000037071 Scd1 stearoyl-Coenzyme A desaturase 1 2.45 3.99E-14 
ENSMUSG00000056973 Ces1d carboxylesterase 1D 2.42 9.57E-28 
ENSMUSG00000020793 Galr2 galanin receptor 2 2.40 8.94E-14 
ENSMUSG00000035686 Thrsp thyroid hormone responsive 2.36 1.22E-11 
ENSMUSG00000018830 Myh11 myosin, heavy polypeptide 11, smooth muscle 2.35 1.46E-43 
ENSMUSG00000032925 Itgbl1 integrin, beta-like 1 2.33 1.25E-09 
ENSMUSG00000051295 9630028B13
Rik 
RIKEN cDNA 9630028B13 gene 2.31 1.75E-19 
ENSMUSG00000047976 Kcna1 potassium voltage-gated channel, shaker-related subfamily, member 1 2.30 1.80E-16 
ENSMUSG00000042254 Cilp cartilage intermediate layer protein, nucleotide pyrophosphohydrolase 2.28 3.08E-27 
ENSMUSG00000001349 Cnn1 calponin 1 2.28 3.31E-40 
ENSMUSG00000041378 Cldn5 claudin 5 2.24 3.51E-14 
ENSMUSG00000071361 Mcpt9 mast cell protease 9 2.23 5.63E-09 
ENSMUSG00000030546 Plin1 perilipin 1 2.23 2.36E-13 
ENSMUSG00000060548 Tnfrsf19 tumor necrosis factor receptor superfamily, member 19 2.22 2.02E-14 
ENSMUSG00000061780 Cfd complement factor D (adipsin) 2.21 1.65E-16 
ENSMUSG00000097960 A330074K2
2Rik 
RIKEN cDNA A330074K22 gene 2.21 9.83E-10 
ENSMUSG00000034579 Pla2g3 phospholipase A2, group III 2.20 3.67E-19 
ENSMUSG00000060615 Ang4 angiogenin, ribonuclease A family, member 4 2.19 7.17E-12 
ENSMUSG00000044309 Apol7c apolipoprotein L 7c 2.18 3.37E-14 
ENSMUSG00000023885 Thbs2 thrombospondin 2 2.18 1.14E-28 
ENSMUSG00000064999  2.17 5.26E-28 
ENSMUSG00000041202 Pla2g2d phospholipase A2, group IID 2.17 3.03E-23 
ENSMUSG00000023046 Igfbp6 insulin-like growth factor binding protein 6 2.17 1.65E-18 
ENSMUSG00000062760 1810041L15
Rik 
RIKEN cDNA 1810041L15 gene 2.17 1.02E-13 
ENSMUSG00000095130  2.16 1.93E-09 
ENSMUSG00000040488 Ltbp4 latent transforming growth factor beta binding protein 4 2.16 1.85E-30 
ENSMUSG00000030554 Synm synemin, intermediate filament protein 2.16 2.01E-35 
ENSMUSG00000062329 Cytl1 cytokine-like 1 2.15 6.61E-10 
ENSMUSG00000073424 Cyp4f15 cytochrome P450, family 4, subfamily f, polypeptide 15 2.15 3.18E-09 
ENSMUSG00000015354 Pcolce2 procollagen C-endopeptidase enhancer 2 2.14 9.73E-15 
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ENSMUSG00000058914 C1qtnf3 C1q and tumor necrosis factor related protein 3 2.12 5.81E-10 
ENSMUSG00000024727 Trpm6 transient receptor potential cation channel, subfamily M, member 6 2.12 1.09E-10 
ENSMUSG00000026208 Des desmin 2.11 1.33E-37 
ENSMUSG00000076614  2.11 5.91E-08 
ENSMUSG00000024575 Pde6a phosphodiesterase 6A, cGMP-specific, rod, alpha 2.11 4.14E-12 
ENSMUSG00000022878 Adipoq adiponectin, C1Q and collagen domain containing 2.10 3.14E-16 
ENSMUSG00000029309 Sparcl1 SPARC-like 1 2.09 1.02E-32 
ENSMUSG00000022226 Mcpt2 mast cell protease 2 2.09 5.21E-08 
ENSMUSG00000059430 Actg2 actin, gamma 2, smooth muscle, enteric 2.08 1.20E-24 
ENSMUSG00000084671  2.07 4.18E-13 
ENSMUSG00000045348 Nyap1 neuronal tyrosine-phosphorylated phosphoinositide 3-kinase adaptor 1 2.05 5.30E-14 
ENSMUSG00000020963 Tshr thyroid stimulating hormone receptor 2.04 2.54E-08 
ENSMUSG00000051726 Kcnf1 potassium voltage-gated channel, subfamily F, member 1 2.04 4.65E-13 
ENSMUSG00000035557 Krt17 keratin 17 2.03 7.85E-14 
ENSMUSG00000031725 Ces1f carboxylesterase 1F 2.03 1.01E-20 
ENSMUSG00000030711 Sult1a1 sulfotransferase family 1A, phenol-preferring, member 1 2.01 4.47E-12 
ENSMUSG00000028713 Cyp4b1 cytochrome P450, family 4, subfamily b, polypeptide 1 2.01 1.09E-10 
ENSMUSG00000026574 Dpt dermatopontin 2.00 8.48E-24 
ENSMUSG00000026676 Ccdc3 coiled-coil domain containing 3 2.00 2.47E-16 
ENSMUSG00000048096 Lmod1 leiomodin 1 (smooth muscle) 2.00 4.15E-25 
ENSMUSG00000034936 Arl4d ADP-ribosylation factor-like 4D 1.99 5.93E-14 
ENSMUSG00000024076 Vit vitrin 1.99 7.05E-10 
ENSMUSG00000029369 Afm afamin 1.99 8.32E-17 
ENSMUSG00000055632 Hmcn2 hemicentin 2 1.98 1.23E-25 
ENSMUSG00000026489 Adck3 aarF domain containing kinase 3 1.98 1.33E-17 
ENSMUSG00000029603 Dtx1 deltex 1 homolog (Drosophila) 1.97 3.02E-17 
ENSMUSG00000037762 Slc16a9 solute carrier family 16 (monocarboxylic acid transporters), member 9 1.97 1.48E-19 
ENSMUSG00000033207 Mamdc2 MAM domain containing 2 1.97 1.61E-17 
ENSMUSG00000058135 Gstm1 glutathione S-transferase, mu 1 1.96 3.71E-22 
ENSMUSG00000061825 Ces2c carboxylesterase 2C 1.96 4.82E-16 
ENSMUSG00000026418 Tnni1 troponin I, skeletal, slow 1 1.95 6.76E-09 
ENSMUSG00000019970 Sgk1 serum/glucocorticoid regulated kinase 1 1.95 1.33E-11 
ENSMUSG00000033327 Tnxb tenascin XB 1.94 3.15E-23 
ENSMUSG00000076612  1.94 8.93E-08 
ENSMUSG00000034324 Tmem132c transmembrane protein 132C 1.94 8.33E-10 
ENSMUSG00000063430 Wscd2 WSC domain containing 2 1.92 3.15E-18 
ENSMUSG00000041073 Nacad NAC alpha domain containing 1.92 3.40E-16 
ENSMUSG00000067818 Myl9 myosin, light polypeptide 9, regulatory 1.91 9.21E-31 
ENSMUSG00000038725 Pkhd1l1 polycystic kidney and hepatic disease 1-like 1 1.90 4.13E-14 
ENSMUSG00000039329 Tex19.1 testis expressed gene 19.1 1.90 6.17E-07 
ENSMUSG00000030762 Aqp8 aquaporin 8 1.90 3.75E-08 
ENSMUSG00000025658 Cnksr2 connector enhancer of kinase suppressor of Ras 2 1.90 1.27E-10 
ENSMUSG00000060600 Eno3 enolase 3, beta muscle 1.90 1.39E-14 
ENSMUSG00000026463 Atp2b4 ATPase, Ca++ transporting, plasma membrane 4 1.90 9.07E-30 
ENSMUSG00000032648 Pygm muscle glycogen phosphorylase 1.89 5.18E-17 
ENSMUSG00000028464 Tpm2 tropomyosin 2, beta 1.89 1.27E-27 
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ENSMUSG00000030409 Dmpk dystrophia myotonica-protein kinase 1.88 1.21E-26 
ENSMUSG00000032085 Tagln transgelin 1.88 1.30E-28 
ENSMUSG00000076540  1.87 9.86E-07 
ENSMUSG00000025784 Clec3b C-type lectin domain family 3, member b 1.87 2.52E-19 
ENSMUSG00000027397 Slc20a1 solute carrier family 20, member 1 1.87 7.59E-15 
ENSMUSG00000026879 Gsn gelsolin 1.87 2.04E-25 
ENSMUSG00000027559 Car3 carbonic anhydrase 3 1.86 3.99E-10 
ENSMUSG00000099065  1.86 1.51E-13 
ENSMUSG00000022546 Gpt glutamic pyruvic transaminase, soluble 1.86 1.95E-13 
ENSMUSG00000050860 Phospho1 phosphatase, orphan 1 1.85 5.58E-07 
ENSMUSG00000025213 Kazald1 Kazal-type serine peptidase inhibitor domain 1 1.85 3.22E-07 
ENSMUSG00000037624 Kcnk2 potassium channel, subfamily K, member 2 1.84 2.47E-12 
ENSMUSG00000046329 Slc25a23 solute carrier family 25 (mitochondrial carrier; phosphate carrier), member 
23 
1.84 2.02E-19 
ENSMUSG00000049580 Tsku tsukushi 1.83 2.87E-13 
ENSMUSG00000004110 Cacna1e calcium channel, voltage-dependent, R type, alpha 1E subunit 1.83 1.68E-14 
ENSMUSG00000076569  1.83 1.10E-07 
ENSMUSG00000021200 Asb2 ankyrin repeat and SOCS box-containing 2 1.83 3.28E-19 
ENSMUSG00000003379 Cd79a CD79A antigen (immunoglobulin-associated alpha) 1.83 4.73E-16 
ENSMUSG00000085375  1.82 2.08E-08 
ENSMUSG00000042474 Faim3 Fas apoptotic inhibitory molecule 3 1.80 3.88E-16 
ENSMUSG00000084174 Sycn syncollin 1.80 3.55E-12 
ENSMUSG00000074207 Adh1 alcohol dehydrogenase 1 (class I) 1.79 1.41E-16 
ENSMUSG00000047394 Odf3b outer dense fiber of sperm tails 3B 1.79 3.04E-06 
ENSMUSG00000061068 Mcpt4 mast cell protease 4 1.79 3.76E-06 
ENSMUSG00000022371 Col14a1 collagen, type XIV, alpha 1 1.79 2.26E-20 
ENSMUSG00000024670 Cd6 CD6 antigen 1.79 8.19E-08 
ENSMUSG00000014846 Tppp3 tubulin polymerization-promoting protein family member 3 1.79 1.49E-15 
ENSMUSG00000068263 Efcc1 EF hand and coiled-coil domain containing 1 1.78 4.70E-12 
ENSMUSG00000034059 Ypel4 yippee-like 4 (Drosophila) 1.78 1.98E-07 
ENSMUSG00000020439 Smtn smoothelin 1.78 1.22E-21 
ENSMUSG00000005540 Fcer2a Fc receptor, IgE, low affinity II, alpha polypeptide 1.78 1.67E-13 
ENSMUSG00000050315 Synpo2 synaptopodin 2 1.77 4.90E-28 
ENSMUSG00000017817 Jph2 junctophilin 2 1.77 1.00E-18 
ENSMUSG00000041012 Cmtm8 CKLF-like MARVEL transmembrane domain containing 8 1.77 5.52E-11 
ENSMUSG00000076538  1.76 5.89E-06 
ENSMUSG00000068289 Cma2 chymase 2, mast cell 1.76 5.02E-06 
ENSMUSG00000026614 Slc30a10 solute carrier family 30, member 10 1.76 4.27E-07 
ENSMUSG00000041828 Abca8a ATP-binding cassette, sub-family A (ABC1), member 8a 1.76 2.69E-16 
ENSMUSG00000076596  1.75 5.98E-06 
ENSMUSG00000040666 Sh3bgr SH3-binding domain glutamic acid-rich protein 1.75 5.89E-12 
ENSMUSG00000090223 Pcp4 Purkinje cell protein 4 1.75 2.81E-07 
ENSMUSG00000071984 Fndc1 fibronectin type III domain containing 1 1.75 5.96E-18 
ENSMUSG00000033152 Podxl2 podocalyxin-like 2 1.74 1.20E-07 
ENSMUSG00000028755 Cda cytidine deaminase 1.74 5.60E-13 
ENSMUSG00000021573 Tppp tubulin polymerization promoting protein 1.74 7.46E-15 
ENSMUSG00000032243 Itga11 integrin alpha 11 1.74 1.56E-13 
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ENSMUSG00000078794 Dact3 dapper homolog 3, antagonist of beta-catenin (xenopus) 1.74 6.18E-11 
ENSMUSG00000001943 Vsig2 V-set and immunoglobulin domain containing 2 1.74 2.73E-16 
ENSMUSG00000068874 Selenbp1 selenium binding protein 1 1.74 3.10E-14 
ENSMUSG00000055653 Gpc3 glypican 3 1.73 1.29E-15 
ENSMUSG00000054619 Mettl7a1 methyltransferase like 7A1 1.73 9.92E-16 
ENSMUSG00000005338 Cadm3 cell adhesion molecule 3 1.73 3.18E-14 
ENSMUSG00000026077 Npas2 neuronal PAS domain protein 2 1.73 1.93E-11 
ENSMUSG00000038967 Pdk2 pyruvate dehydrogenase kinase, isoenzyme 2 1.72 6.62E-14 
ENSMUSG00000043122 A530016L2
4Rik 
RIKEN cDNA A530016L24 gene 1.72 7.61E-06 
ENSMUSG00000043439 E130012A1
9Rik 
RIKEN cDNA E130012A19 gene 1.72 6.37E-12 
ENSMUSG00000020081 Tacr2 tachykinin receptor 2 1.72 6.02E-16 
ENSMUSG00000063564 Col23a1 collagen, type XXIII, alpha 1 1.72 1.51E-13 
ENSMUSG00000034785 Dio1 deiodinase, iodothyronine, type I 1.72 1.72E-13 
ENSMUSG00000065645  1.72 5.31E-10 
ENSMUSG00000061808 Ttr transthyretin 1.71 2.87E-12 
ENSMUSG00000020427 Igfbp3 insulin-like growth factor binding protein 3 1.71 4.58E-18 
ENSMUSG00000095285  1.71 3.26E-07 
ENSMUSG00000058571 Gpc6 glypican 6 1.71 1.94E-12 
ENSMUSG00000046532 Ar androgen receptor 1.71 1.66E-12 
ENSMUSG00000076580  1.71 6.51E-06 
ENSMUSG00000031636 Pdlim3 PDZ and LIM domain 3 1.70 2.71E-19 
ENSMUSG00000022425 Enpp2 ectonucleotide pyrophosphatase/phosphodiesterase 2 1.70 1.27E-20 
ENSMUSG00000001663 Gstt1 glutathione S-transferase, theta 1 1.70 3.54E-13 
ENSMUSG00000046743 Fat4 FAT tumor suppressor homolog 4 (Drosophila) 1.70 4.47E-23 
ENSMUSG00000020251 Glt8d2 glycosyltransferase 8 domain containing 2 1.69 2.25E-07 
ENSMUSG00000040289 Hey1 hairy/enhancer-of-split related with YRPW motif 1 1.69 3.42E-07 
ENSMUSG00000055116 Arntl aryl hydrocarbon receptor nuclear translocator-like 1.69 5.77E-14 
ENSMUSG00000076928  1.69 2.78E-06 
ENSMUSG00000035783 Acta2 actin, alpha 2, smooth muscle, aorta 1.69 5.05E-24 
ENSMUSG00000058070 Eml1 echinoderm microtubule associated protein like 1 1.69 2.91E-22 
ENSMUSG00000038776 Ephx1 epoxide hydrolase 1, microsomal 1.68 1.69E-17 
ENSMUSG00000081488  1.68 3.44E-09 
ENSMUSG00000029096 Htra3 HtrA serine peptidase 3 1.68 4.30E-13 
ENSMUSG00000036123 Slc9a3 solute carrier family 9 (sodium/hydrogen exchanger), member 3 1.68 2.36E-07 
ENSMUSG00000035258 Abi3bp ABI gene family, member 3 (NESH) binding protein 1.68 3.04E-18 
ENSMUSG00000001270 Ckb creatine kinase, brain 1.67 1.07E-21 
ENSMUSG00000027894 Slc6a17 solute carrier family 6 (neurotransmitter transporter), member 17 1.67 4.95E-10 
ENSMUSG00000068748 Ptprz1 protein tyrosine phosphatase, receptor type Z, polypeptide 1 1.67 2.69E-08 
ENSMUSG00000051228 Nyx nyctalopin 1.66 1.70E-06 
ENSMUSG00000009075 Cabp7 calcium binding protein 7 1.66 1.06E-05 
ENSMUSG00000020099 Unc5b unc-5 homolog B (C. elegans) 1.66 4.96E-16 
ENSMUSG00000019278 Dpep1 dipeptidase 1 (renal) 1.66 8.13E-17 
ENSMUSG00000025780 Itih5 inter-alpha (globulin) inhibitor H5 1.66 1.04E-17 
ENSMUSG00000036395 Glb1l2 galactosidase, beta 1-like 2 1.66 2.64E-06 
ENSMUSG00000000125 Wnt3 wingless-type MMTV integration site family, member 3 1.66 1.36E-05 
ENSMUSG00000036854 Hspb6 heat shock protein, alpha-crystallin-related, B6 1.65 4.28E-10 
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ENSMUSG00000004038 Gstm3 glutathione S-transferase, mu 3 1.65 2.54E-07 
ENSMUSG00000030092 Cntn6 contactin 6 1.65 6.47E-06 
ENSMUSG00000047842 Diras2 DIRAS family, GTP-binding RAS-like 2 1.65 1.76E-07 
ENSMUSG00000002565 Scin scinderin 1.65 4.57E-14 
ENSMUSG00000053199 Arhgap20 Rho GTPase activating protein 20 1.65 4.97E-15 
ENSMUSG00000018566 Slc2a4 solute carrier family 2 (facilitated glucose transporter), member 4 1.65 1.40E-13 
ENSMUSG00000056481 Cd248 CD248 antigen, endosialin 1.65 1.48E-12 
ENSMUSG00000073608 Gm6086 predicted gene 6086 1.64 2.50E-07 
ENSMUSG00000060780 Lrrtm1 leucine rich repeat transmembrane neuronal 1 1.64 1.15E-05 
ENSMUSG00000059146 Ntrk3 neurotrophic tyrosine kinase, receptor, type 3 1.64 3.26E-06 
ENSMUSG00000022309 Angpt1 angiopoietin 1 1.63 9.69E-10 
ENSMUSG00000020672 Sntg2 syntrophin, gamma 2 1.63 5.66E-13 
ENSMUSG00000040543 Pitpnm3 PITPNM family member 3 1.63 9.60E-13 
ENSMUSG00000020811 Wscd1 WSC domain containing 1 1.63 1.41E-05 
ENSMUSG00000079440 Alpi alkaline phosphatase, intestinal 1.63 8.09E-12 
ENSMUSG00000021319 Sfrp4 secreted frizzled-related protein 4 1.63 5.20E-08 
ENSMUSG00000063873 Slc24a3 solute carrier family 24 (sodium/potassium/calcium exchanger), member 3 1.62 6.94E-22 
ENSMUSG00000070000 Fcho1 FCH domain only 1 1.62 3.64E-10 
ENSMUSG00000020334 Slc22a4 solute carrier family 22 (organic cation transporter), member 4 1.62 1.53E-07 
ENSMUSG00000028255 Clca1 chloride channel calcium activated 1 1.62 6.43E-20 
ENSMUSG00000079037 Prnp prion protein 1.62 4.52E-17 
ENSMUSG00000038173 Enpp6 ectonucleotide pyrophosphatase/phosphodiesterase 6 1.62 1.85E-06 
ENSMUSG00000019326 Aoc3 amine oxidase, copper containing 3 1.61 8.88E-20 
ENSMUSG00000043631 Ecm2 extracellular matrix protein 2, female organ and adipocyte specific 1.61 4.25E-13 
ENSMUSG00000018740 Slc25a35 solute carrier family 25, member 35 1.61 1.92E-15 
ENSMUSG00000038555 Reep2 receptor accessory protein 2 1.61 4.22E-07 
ENSMUSG00000027217 Tspan18 tetraspanin 18 1.61 2.89E-16 
ENSMUSG00000048498 Cd300e CD300e antigen 1.61 1.48E-05 
ENSMUSG00000034156 Bzrap1 benzodiazepine receptor associated protein 1 1.61 1.04E-05 
ENSMUSG00000046658 Zfp316 zinc finger protein 316 1.61 1.36E-13 
ENSMUSG00000095612  1.60 2.37E-06 
ENSMUSG00000060843 Ctnna3 catenin (cadherin associated protein), alpha 3 1.60 8.94E-12 
ENSMUSG00000038218  1.60 1.53E-06 
ENSMUSG00000005339 Fcer1a Fc receptor, IgE, high affinity I, alpha polypeptide 1.60 3.04E-05 
ENSMUSG00000024049 Myom1 myomesin 1 1.60 4.19E-15 
ENSMUSG00000021575 Ahrr aryl-hydrocarbon receptor repressor 1.60 5.17E-11 
ENSMUSG00000086596 Susd5 sushi domain containing 5 1.60 2.82E-05 
ENSMUSG00000061356 Nuggc nuclear GTPase, germinal center associated 1.60 1.27E-08 
ENSMUSG00000035504 Reep6 receptor accessory protein 6 1.60 2.88E-13 
ENSMUSG00000028047 Thbs3 thrombospondin 3 1.60 1.78E-12 
ENSMUSG00000049971 Glt1d1 glycosyltransferase 1 domain containing 1 1.60 5.72E-09 
ENSMUSG00000064267 Hvcn1 hydrogen voltage-gated channel 1 1.59 3.99E-14 
ENSMUSG00000001604 Tcea3 transcription elongation factor A (SII), 3 1.59 5.03E-13 
ENSMUSG00000055322 Tns1 tensin 1 1.59 1.95E-22 
ENSMUSG00000032607 Amt aminomethyltransferase 1.59 1.34E-11 
ENSMUSG00000028020 Glrb glycine receptor, beta subunit 1.58 1.55E-05 
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ENSMUSG00000059401 Mamld1 mastermind-like domain containing 1 1.58 2.34E-07 
ENSMUSG00000023336 Wfdc1 WAP four-disulfide core domain 1 1.58 1.21E-11 
ENSMUSG00000028179 Cth cystathionase (cystathionine gamma-lyase) 1.58 3.63E-14 
ENSMUSG00000001334 Fndc5 fibronectin type III domain containing 5 1.58 2.68E-08 
ENSMUSG00000029134 Plb1 phospholipase B1 1.58 3.77E-06 
ENSMUSG00000021792 Fam213a family with sequence similarity 213, member A 1.58 4.36E-14 
ENSMUSG00000052957 Gas1 growth arrest specific 1 1.57 1.19E-10 
ENSMUSG00000060586 H2-Eb1 histocompatibility 2, class II antigen E beta 1.57 1.26E-17 
ENSMUSG00000034687 Fras1 Fraser syndrome 1 homolog (human) 1.57 1.74E-08 
ENSMUSG00000094124  1.57 7.99E-07 
ENSMUSG00000095416  1.57 1.60E-06 
ENSMUSG00000052305 Hbb-b1 hemoglobin, beta adult major chain 1.57 2.87E-06 
ENSMUSG00000020159 Gabrp gamma-aminobutyric acid (GABA) A receptor, pi 1.56 2.65E-08 
ENSMUSG00000076613  1.56 1.25E-05 
ENSMUSG00000094651 Gal3st2 galactose-3-O-sulfotransferase 2 1.56 4.12E-11 
ENSMUSG00000025002 Cyp2c55 cytochrome P450, family 2, subfamily c, polypeptide 55 1.56 4.70E-05 
ENSMUSG00000026840 Lamc3 laminin gamma 3 1.56 4.41E-07 
ENSMUSG00000037206 Islr immunoglobulin superfamily containing leucine-rich repeat 1.56 2.56E-13 
ENSMUSG00000022265 Ank progressive ankylosis 1.56 3.57E-16 
ENSMUSG00000098132 Rassf10 Ras association (RalGDS/AF-6) domain family (N-terminal) member 10 1.56 7.54E-07 
ENSMUSG00000061080 Lsamp limbic system-associated membrane protein 1.56 4.52E-07 
ENSMUSG00000026117 Zap70 zeta-chain (TCR) associated protein kinase 1.56 4.53E-07 
ENSMUSG00000070867 Trabd2b TraB domain containing 2B 1.56 4.95E-08 
ENSMUSG00000001865 Cpa3 carboxypeptidase A3, mast cell 1.56 1.15E-05 
ENSMUSG00000020388 Pdlim4 PDZ and LIM domain 4 1.55 6.37E-09 
ENSMUSG00000074818 Pdzd7 PDZ domain containing 7 1.55 1.50E-09 
ENSMUSG00000019989 Enpp3 ectonucleotide pyrophosphatase/phosphodiesterase 3 1.55 3.48E-11 
ENSMUSG00000076563  1.55 8.26E-06 
ENSMUSG00000016552 Foxred2 FAD-dependent oxidoreductase domain containing 2 1.55 1.32E-07 
ENSMUSG00000044749 Abca6 ATP-binding cassette, sub-family A (ABC1), member 6 1.55 6.22E-08 
ENSMUSG00000004105 Angptl2 angiopoietin-like 2 1.55 8.68E-13 
ENSMUSG00000074882 Cyp2c68 cytochrome P450, family 2, subfamily c, polypeptide 68 1.55 2.69E-06 
ENSMUSG00000066513 Klk1b4 kallikrein 1-related pepidase b4 1.54 4.12E-05 
ENSMUSG00000076435 Acsf2 acyl-CoA synthetase family member 2 1.54 1.21E-17 
ENSMUSG00000061740 Cyp2d22 cytochrome P450, family 2, subfamily d, polypeptide 22 1.54 2.47E-09 
ENSMUSG00000027513 Pck1 phosphoenolpyruvate carboxykinase 1, cytosolic 1.54 3.16E-13 
ENSMUSG00000027401 Tgm3 transglutaminase 3, E polypeptide 1.54 6.20E-05 
ENSMUSG00000020395 Itk IL2 inducible T cell kinase 1.54 7.34E-12 
ENSMUSG00000027870 Hao2 hydroxyacid oxidase 2 1.54 5.80E-11 
ENSMUSG00000053279 Aldh1a1 aldehyde dehydrogenase family 1, subfamily A1 1.54 8.22E-12 
ENSMUSG00000049241 Hcar1 hydrocarboxylic acid receptor 1 1.54 2.59E-07 
ENSMUSG00000028545 Bend5 BEN domain containing 5 1.53 1.84E-08 
ENSMUSG00000039760 Il22ra2 interleukin 22 receptor, alpha 2 1.53 1.35E-09 
ENSMUSG00000037379 Spon2 spondin 2, extracellular matrix protein 1.53 1.27E-12 
ENSMUSG00000007097 Atp1a2 ATPase, Na+/K+ transporting, alpha 2 polypeptide 1.53 7.11E-13 
ENSMUSG00000048644 Ctxn1 cortexin 1 1.53 1.71E-05 
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ENSMUSG00000067276 Capn6 calpain 6 1.53 8.18E-06 
ENSMUSG00000040420 Cdh18 cadherin 18 1.53 5.70E-05 
ENSMUSG00000022836 Mylk myosin, light polypeptide kinase 1.53 2.09E-20 
ENSMUSG00000096635  1.52 2.36E-12 
ENSMUSG00000029095 Ablim2 actin-binding LIM protein 2 1.52 2.89E-07 
ENSMUSG00000030630 Fah fumarylacetoacetate hydrolase 1.52 4.14E-13 
ENSMUSG00000073557 Ppp1r12b protein phosphatase 1, regulatory (inhibitor) subunit 12B 1.52 2.40E-19 
ENSMUSG00000083282 Ctsf cathepsin F 1.52 1.20E-11 
ENSMUSG00000022199 Slc22a17 solute carrier family 22 (organic cation transporter), member 17 1.52 5.28E-05 
ENSMUSG00000030577 Cd22 CD22 antigen 1.52 8.51E-14 
ENSMUSG00000040841 Six5 sine oculis-related homeobox 5 1.52 2.63E-07 
ENSMUSG00000032482 Cspg5 chondroitin sulfate proteoglycan 5 1.52 4.51E-05 
ENSMUSG00000027985 Lef1 lymphoid enhancer binding factor 1 1.52 4.04E-10 
ENSMUSG00000038167 Plekhg6 pleckstrin homology domain containing, family G (with RhoGef domain) 
member 6 
1.52 1.08E-10 
ENSMUSG00000024395 Lims2 LIM and senescent cell antigen like domains 2 1.51 2.81E-11 
ENSMUSG00000053963 6330403A02
Rik 
RIKEN cDNA 6330403A02 gene 1.51 1.64E-12 
ENSMUSG00000029811 Aoc1 amine oxidase, copper-containing 1 1.51 6.32E-16 
ENSMUSG00000027761 Aadac arylacetamide deacetylase (esterase) 1.51 1.04E-07 
ENSMUSG00000095351  1.51 1.78E-05 
ENSMUSG00000022040 Ephx2 epoxide hydrolase 2, cytoplasmic 1.51 3.37E-11 
ENSMUSG00000037813 D630003M2
1Rik 
RIKEN cDNA D630003M21 gene 1.51 8.06E-07 
ENSMUSG00000061603 Akap6 A kinase (PRKA) anchor protein 6 1.51 1.09E-12 
ENSMUSG00000040584 Abcb1a ATP-binding cassette, sub-family B (MDR/TAP), member 1A 1.51 6.01E-06 
ENSMUSG00000027863 Cd2 CD2 antigen 1.51 3.87E-12 
ENSMUSG00000038209 Itln1 intelectin 1 (galactofuranose binding) 1.50 3.89E-13 
ENSMUSG00000042751 Nmnat2 nicotinamide nucleotide adenylyltransferase 2 1.50 3.61E-09 
ENSMUSG00000004098 Col5a3 collagen, type V, alpha 3 1.50 2.61E-10 
ENSMUSG00000096341  -1.51 1.79E-09 
ENSMUSG00000022582 Ly6g lymphocyte antigen 6 complex, locus G -1.52 1.98E-07 
ENSMUSG00000076370  -1.52 2.89E-07 
ENSMUSG00000064472  -1.53 8.57E-05 
ENSMUSG00000004371 Il11 interleukin 11 -1.53 5.78E-05 
ENSMUSG00000095857  -1.54 6.98E-06 
ENSMUSG00000051748 Wfdc21 WAP four-disulfide core domain 21 -1.55 6.93E-05 
ENSMUSG00000064742  -1.56 2.12E-05 
ENSMUSG00000057359  -1.57 3.87E-06 
ENSMUSG00000064346  -1.57 1.19E-05 
ENSMUSG00000093999  -1.58 9.32E-06 
ENSMUSG00000024697 Gna14 guanine nucleotide binding protein, alpha 14 -1.58 2.49E-10 
ENSMUSG00000095624  -1.58 3.47E-05 
ENSMUSG00000042265 Trem1 triggering receptor expressed on myeloid cells 1 -1.59 2.80E-06 
ENSMUSG00000077565  -1.60 2.18E-11 
ENSMUSG00000094199  -1.61 2.37E-06 
ENSMUSG00000094400  -1.61 2.25E-05 
ENSMUSG00000094471  -1.62 1.23E-05 
ENSMUSG00000095396  -1.65 1.36E-05 
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ENSMUSG00000065373  -1.68 1.82E-07 
ENSMUSG00000093983  -1.69 3.03E-06 
ENSMUSG00000030144 Clec4d C-type lectin domain family 4, member d -1.69 6.64E-07 
ENSMUSG00000029371 Cxcl5 chemokine (C-X-C motif) ligand 5 -1.70 8.74E-06 
ENSMUSG00000000182 Fgf23 fibroblast growth factor 23 -1.71 1.12E-05 
ENSMUSG00000044103 Il1f9 interleukin 1 family, member 9 -1.71 3.16E-08 
ENSMUSG00000026822 Lcn2 lipocalin 2 -1.74 6.01E-10 
ENSMUSG00000093916  -1.74 3.28E-06 
ENSMUSG00000021091 Serpina3n serine (or cysteine) peptidase inhibitor, clade A, member 3N -1.80 1.15E-16 
ENSMUSG00000040026 Saa3 serum amyloid A 3 -1.82 1.17E-08 
ENSMUSG00000096434  -1.85 1.77E-06 
ENSMUSG00000000982 Ccl3 chemokine (C-C motif) ligand 3 -1.85 5.63E-07 
ENSMUSG00000047728 BC025446 cDNA sequence BC025446 -1.87 7.06E-08 
ENSMUSG00000001131 Timp1 tissue inhibitor of metalloproteinase 1 -1.87 8.67E-11 
ENSMUSG00000065104  -1.88 1.32E-07 
ENSMUSG00000027399 Il1a interleukin 1 alpha -1.92 1.50E-10 
ENSMUSG00000031722 Hp haptoglobin -1.92 1.82E-09 
ENSMUSG00000064689  -1.97 1.02E-08 
ENSMUSG00000096222  -2.10 3.25E-10 
ENSMUSG00000027832 Ptx3 pentraxin related gene -2.11 5.49E-09 
ENSMUSG00000030142 Clec4e C-type lectin domain family 4, member e -2.11 9.08E-09 
ENSMUSG00000069792 Wfdc17 WAP four-disulfide core domain 17 -2.12 1.21E-09 
ENSMUSG00000073530 Pappa2 pappalysin 2 -2.16 6.07E-14 
ENSMUSG00000048636  -2.16 1.53E-09 
ENSMUSG00000022651 Retnlg resistin like gamma -2.16 3.73E-13 
ENSMUSG00000094655  -2.17 9.84E-18 
ENSMUSG00000059657 Stfa2l1 stefin A2 like 1 -2.37 6.41E-10 
ENSMUSG00000005800 Mmp8 matrix metallopeptidase 8 -2.39 3.46E-12 
ENSMUSG00000029380 Cxcl1 chemokine (C-X-C motif) ligand 1 -2.41 7.94E-14 
ENSMUSG00000064246 Chil1 chitinase-like 1 -2.47 4.18E-18 
ENSMUSG00000022126 Irg1 immunoresponsive gene 1 -2.64 1.69E-20 
ENSMUSG00000040809 Chil3 chitinase-like 3 -2.69 1.21E-13 
ENSMUSG00000025746 Il6 interleukin 6 -2.84 6.21E-16 
ENSMUSG00000058427 Cxcl2 chemokine (C-X-C motif) ligand 2 -3.03 1.86E-23 
 
Table S7 Differentially expressed genes of BALB/c (YPIII Δcnfy infected 42 dpi vs. YPIII Δcnfy 
infected 5 dpi) 
Ensembl ID Gene symbol Gene name log2 fold 
change 
p-value 
ENSMUSG00000022491 Glycam1 glycosylation dependent cell adhesion molecule 1 2.89 5.20E-38 
ENSMUSG00000057074 Ces1g carboxylesterase 1G 2.68 6.06E-17 
ENSMUSG00000084671  2.34 5.57E-15 
ENSMUSG00000028713 Cyp4b1 cytochrome P450, family 4, subfamily b, polypeptide 1 2.31 2.82E-13 
ENSMUSG00000039760 Il22ra2 interleukin 22 receptor, alpha 2 2.27 7.46E-17 
ENSMUSG00000056973 Ces1d carboxylesterase 1D 2.20 2.28E-23 
ENSMUSG00000084174 Sycn syncollin 2.17 1.52E-16 
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ENSMUSG00000060615 Ang4 angiogenin, ribonuclease A family, member 4 2.06 2.66E-10 
ENSMUSG00000030399 Ckm creatine kinase, muscle 2.03 2.31E-20 
ENSMUSG00000073424 Cyp4f15 cytochrome P450, family 4, subfamily f, polypeptide 15 1.96 1.36E-07 
ENSMUSG00000092586 Ly6g6c lymphocyte antigen 6 complex, locus G6C 1.95 2.64E-07 
ENSMUSG00000081488  1.92 3.66E-11 
ENSMUSG00000037762 Slc16a9 solute carrier family 16 (monocarboxylic acid transporters), member 9 1.88 2.00E-17 
ENSMUSG00000026166 Ccl20 chemokine (C-C motif) ligand 20 1.87 4.20E-08 
ENSMUSG00000049580 Tsku tsukushi 1.81 2.55E-12 
ENSMUSG00000039329 Tex19.1 testis expressed gene 19.1 1.80 2.63E-06 
ENSMUSG00000024575 Pde6a phosphodiesterase 6A, cGMP-specific, rod, alpha 1.80 3.39E-09 
ENSMUSG00000024727 Trpm6 transient receptor potential cation channel, subfamily M, member 6 1.78 5.26E-08 
ENSMUSG00000035557 Krt17 keratin 17 1.77 5.01E-09 
ENSMUSG00000087291 Gm11946 predicted gene 11946 1.77 5.61E-09 
ENSMUSG00000064999  1.76 2.63E-18 
ENSMUSG00000030554 Synm synemin, intermediate filament protein 1.71 1.48E-22 
ENSMUSG00000057123 Gja5 gap junction protein, alpha 5 1.69 7.24E-09 
ENSMUSG00000020793 Galr2 galanin receptor 2 1.69 1.45E-07 
ENSMUSG00000020182 Ddc dopa decarboxylase 1.69 1.26E-14 
ENSMUSG00000019970 Sgk1 serum/glucocorticoid regulated kinase 1 1.67 6.69E-09 
ENSMUSG00000028039 Efna3 ephrin A3 1.66 1.82E-06 
ENSMUSG00000040812 Agbl2 ATP/GTP binding protein-like 2 1.65 6.23E-09 
ENSMUSG00000029811 Aoc1 amine oxidase, copper-containing 1 1.65 2.07E-18 
ENSMUSG00000022227 Mcpt1 mast cell protease 1 1.65 8.19E-06 
ENSMUSG00000059430 Actg2 actin, gamma 2, smooth muscle, enteric 1.64 7.41E-16 
ENSMUSG00000025002 Cyp2c55 cytochrome P450, family 2, subfamily c, polypeptide 55 1.64 2.03E-05 
ENSMUSG00000026614 Slc30a10 solute carrier family 30, member 10 1.63 2.91E-06 
ENSMUSG00000026701 Prdx6 peroxiredoxin 6 1.62 3.45E-12 
ENSMUSG00000061808 Ttr transthyretin 1.61 2.65E-10 
ENSMUSG00000045348 Nyap1 neuronal tyrosine-phosphorylated phosphoinositide 3-kinase adaptor 1 1.60 5.97E-09 
ENSMUSG00000027875 Hmgcs2 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2 1.60 7.33E-16 
ENSMUSG00000026077 Npas2 neuronal PAS domain protein 2 1.58 2.29E-09 
ENSMUSG00000027318 Adam33 a disintegrin and metallopeptidase domain 33 1.56 1.26E-05 
ENSMUSG00000028356 Ambp alpha 1 microglobulin/bikunin 1.56 1.90E-05 
ENSMUSG00000019762 Iyd iodotyrosine deiodinase 1.56 4.68E-06 
ENSMUSG00000051295 9630028B13Ri
k 
RIKEN cDNA 9630028B13 gene 1.55 6.32E-09 
ENSMUSG00000093999  1.54 1.14E-05 
ENSMUSG00000055116 Arntl aryl hydrocarbon receptor nuclear translocator-like 1.53 1.51E-11 
ENSMUSG00000041559 Fmod fibromodulin 1.52 1.50E-06 
ENSMUSG00000027870 Hao2 hydroxyacid oxidase 2 1.52 9.79E-11 
ENSMUSG00000010311 Optc opticin 1.52 1.84E-09 
ENSMUSG00000053399 Adamts18 a disintegrin-like and metallopeptidase (reprolysin type) with 
thrombospondin type 1 motif, 18 
1.52 6.88E-05 
ENSMUSG00000001349 Cnn1 calponin 1 1.51 1.75E-18 
ENSMUSG00000038591 Colec10 collectin sub-family member 10 1.51 8.84E-09 
ENSMUSG00000031877 Ces2g carboxylesterase 2G 1.51 7.58E-08 
ENSMUSG00000078921 Tgtp2 T cell specific GTPase 2 -1.50 4.39E-08 
ENSMUSG00000042265 Trem1 triggering receptor expressed on myeloid cells 1 -1.50 1.91E-05 
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ENSMUSG00000001095 Slc13a2 solute carrier family 13 (sodium-dependent dicarboxylate transporter), 
member 2 
-1.51 4.49E-12 
ENSMUSG00000029484 Anxa3 annexin A3 -1.51 1.99E-12 
ENSMUSG00000064400  -1.51 8.15E-05 
ENSMUSG00000021281 Tnfaip2 tumor necrosis factor, alpha-induced protein 2 -1.51 1.59E-10 
ENSMUSG00000075010 AW112010 expressed sequence AW112010 -1.52 1.73E-11 
ENSMUSG00000064346  -1.52 1.15E-05 
ENSMUSG00000074417 Pira11 paired-Ig-like receptor A11 -1.52 8.95E-07 
ENSMUSG00000029553 Tfec transcription factor EC -1.53 9.97E-06 
ENSMUSG00000024679 Ms4a6d membrane-spanning 4-domains, subfamily A, member 6D -1.53 3.27E-10 
ENSMUSG00000037095 Lrg1 leucine-rich alpha-2-glycoprotein 1 -1.53 1.74E-07 
ENSMUSG00000040253 Gbp7 guanylate binding protein 7 -1.53 1.73E-07 
ENSMUSG00000058427 Cxcl2 chemokine (C-X-C motif) ligand 2 -1.55 9.98E-07 
ENSMUSG00000022651 Retnlg resistin like gamma -1.56 2.36E-06 
ENSMUSG00000001670 Tat tyrosine aminotransferase -1.56 1.27E-11 
ENSMUSG00000029082 Bst1 bone marrow stromal cell antigen 1 -1.57 5.86E-09 
ENSMUSG00000026580 Selp selectin, platelet -1.57 2.82E-08 
ENSMUSG00000016496 Cd274 CD274 antigen -1.57 2.97E-11 
ENSMUSG00000078161 Erich3 glutamate rich 3 -1.57 8.86E-06 
ENSMUSG00000026073 Il1r2 interleukin 1 receptor, type II -1.57 1.45E-06 
ENSMUSG00000065629  -1.58 3.86E-05 
ENSMUSG00000096528 G430049J08Ri
k 
RIKEN cDNA G430049J08 gene -1.59 1.14E-11 
ENSMUSG00000026880 Stom stomatin -1.61 1.88E-15 
ENSMUSG00000027360 Hdc histidine decarboxylase -1.61 8.64E-06 
ENSMUSG00000095788 Sirpb1a signal-regulatory protein beta 1A -1.62 1.10E-05 
ENSMUSG00000037411 Serpine1 serine (or cysteine) peptidase inhibitor, clade E, member 1 -1.63 1.11E-10 
ENSMUSG00000012428 Steap4 STEAP family member 4 -1.63 2.13E-12 
ENSMUSG00000025161 Slc16a3 solute carrier family 16 (monocarboxylic acid transporters), member 3 -1.63 1.32E-08 
ENSMUSG00000074892 B3galt5 UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, polypeptide 5 -1.65 1.29E-11 
ENSMUSG00000013974 Mcemp1 mast cell expressed membrane protein 1 -1.65 5.17E-06 
ENSMUSG00000030144 Clec4d C-type lectin domain family 4, member d -1.65 2.17E-06 
ENSMUSG00000025877 Hk3 hexokinase 3 -1.66 6.91E-08 
ENSMUSG00000000982 Ccl3 chemokine (C-C motif) ligand 3 -1.66 1.11E-05 
ENSMUSG00000027514 Zbp1 Z-DNA binding protein 1 -1.67 4.38E-11 
ENSMUSG00000038550 Ciart circadian associated repressor of transcription -1.68 2.31E-07 
ENSMUSG00000046031 Fam26f family with sequence similarity 26, member F -1.68 5.46E-07 
ENSMUSG00000029084 Cd38 CD38 antigen -1.70 1.86E-09 
ENSMUSG00000079014 Serpina3i serine (or cysteine) peptidase inhibitor, clade A, member 3I -1.71 2.52E-07 
ENSMUSG00000068452 Duox2 dual oxidase 2 -1.71 6.41E-12 
ENSMUSG00000079516 Reg3a regenerating islet-derived 3 alpha -1.72 3.49E-06 
ENSMUSG00000030187 Klra2 killer cell lectin-like receptor, subfamily A, member 2 -1.73 1.48E-09 
ENSMUSG00000056054 S100a8 S100 calcium binding protein A8 (calgranulin A) -1.74 7.38E-06 
ENSMUSG00000074115 Saa1 serum amyloid A 1 -1.74 1.20E-07 
ENSMUSG00000078853 Igtp interferon gamma induced GTPase -1.75 5.74E-08 
ENSMUSG00000068606 Gm4841 predicted gene 4841 -1.75 8.70E-09 
ENSMUSG00000028270 Gbp2 guanylate binding protein 2 -1.76 1.55E-12 
ENSMUSG00000048852 Gm12185 predicted gene 12185 -1.76 1.06E-08 
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ENSMUSG00000078763 Slfn1 schlafen 1 -1.77 1.10E-10 
ENSMUSG00000097423  -1.77 3.70E-09 
ENSMUSG00000031444 F10 coagulation factor X -1.77 6.94E-09 
ENSMUSG00000075270 Pde11a phosphodiesterase 11A -1.78 1.17E-07 
ENSMUSG00000044254 Pcsk9 proprotein convertase subtilisin/kexin type 9 -1.78 5.25E-14 
ENSMUSG00000021091 Serpina3n serine (or cysteine) peptidase inhibitor, clade A, member 3N -1.78 7.76E-16 
ENSMUSG00000085977  -1.78 1.69E-07 
ENSMUSG00000041293 Gpr110 G protein-coupled receptor 110 -1.79 3.50E-06 
ENSMUSG00000038751 Ptk6 PTK6 protein tyrosine kinase 6 -1.79 2.41E-14 
ENSMUSG00000046688 Tifa TRAF-interacting protein with forkhead-associated domain -1.80 2.18E-13 
ENSMUSG00000028859 Csf3r colony stimulating factor 3 receptor (granulocyte) -1.80 7.17E-12 
ENSMUSG00000047562 Mmp10 matrix metallopeptidase 10 -1.80 2.41E-06 
ENSMUSG00000040809 Chil3 chitinase-like 3 -1.81 2.47E-06 
ENSMUSG00000079362 Gbp6 guanylate binding protein 6 -1.81 1.29E-10 
ENSMUSG00000021950 Anxa8 annexin A8 -1.82 1.67E-07 
ENSMUSG00000079012 Serpina3m serine (or cysteine) peptidase inhibitor, clade A, member 3M -1.83 5.16E-09 
ENSMUSG00000043613 Mmp3 matrix metallopeptidase 3 -1.83 3.75E-08 
ENSMUSG00000060183 Cxcl11 chemokine (C-X-C motif) ligand 11 -1.83 2.00E-07 
ENSMUSG00000078922 Tgtp1 T cell specific GTPase 1 -1.83 4.68E-09 
ENSMUSG00000034438 Gbp8 guanylate-binding protein 8 -1.83 2.50E-12 
ENSMUSG00000047798 Cd300lf CD300 antigen like family member F -1.83 6.35E-10 
ENSMUSG00000053101 Gpr141 G protein-coupled receptor 141 -1.83 4.15E-11 
ENSMUSG00000028269  -1.85 8.33E-09 
ENSMUSG00000053113 Socs3 suppressor of cytokine signaling 3 -1.87 2.53E-09 
ENSMUSG00000082976 Gm15056 predicted gene 15056 -1.90 1.57E-07 
ENSMUSG00000000204 Slfn4 schlafen 4 -1.90 4.73E-14 
ENSMUSG00000035105 Egln3 egl-9 family hypoxia-inducible factor 3 -1.91 2.81E-14 
ENSMUSG00000050747 Trim15 tripartite motif-containing 15 -1.91 3.71E-07 
ENSMUSG00000024401 Tnf tumor necrosis factor -1.92 3.27E-12 
ENSMUSG00000054588  -1.95 5.54E-08 
ENSMUSG00000056071 S100a9 S100 calcium binding protein A9 (calgranulin B) -1.97 4.28E-07 
ENSMUSG00000066363 Serpina3f serine (or cysteine) peptidase inhibitor, clade A, member 3F -1.97 1.41E-12 
ENSMUSG00000082292  -1.97 6.06E-10 
ENSMUSG00000029380 Cxcl1 chemokine (C-X-C motif) ligand 1 -1.98 1.87E-09 
ENSMUSG00000087070 Gm12505 predicted gene 12505 -1.99 1.78E-13 
ENSMUSG00000073530 Pappa2 pappalysin 2 -2.01 1.81E-10 
ENSMUSG00000055978 Fut2 fucosyltransferase 2 -2.02 7.60E-17 
ENSMUSG00000027068 Dhrs9 dehydrogenase/reductase (SDR family) member 9 -2.03 8.28E-18 
ENSMUSG00000027398 Il1b interleukin 1 beta -2.05 5.96E-11 
ENSMUSG00000029371 Cxcl5 chemokine (C-X-C motif) ligand 5 -2.05 7.81E-08 
ENSMUSG00000027399 Il1a interleukin 1 alpha -2.10 5.26E-12 
ENSMUSG00000041481  -2.11 1.05E-19 
ENSMUSG00000021214 Akr1c18 aldo-keto reductase family 1, member C18 -2.12 6.66E-09 
ENSMUSG00000041193 Pla2g5 phospholipase A2, group V -2.13 5.92E-18 
ENSMUSG00000049281 Scn3b sodium channel, voltage-gated, type III, beta -2.14 4.49E-13 
ENSMUSG00000024697 Gna14 guanine nucleotide binding protein, alpha 14 -2.17 9.32E-18 
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ENSMUSG00000090942 F830016B08Ri
k 
RIKEN cDNA F830016B08 gene -2.18 2.43E-14 
ENSMUSG00000024411 Aqp4 aquaporin 4 -2.19 1.31E-12 
ENSMUSG00000028655 Mfsd2a major facilitator superfamily domain containing 2A -2.19 2.45E-09 
ENSMUSG00000079363 Gbp4 guanylate binding protein 4 -2.21 1.13E-12 
ENSMUSG00000031722 Hp haptoglobin -2.22 1.69E-11 
ENSMUSG00000034855 Cxcl10 chemokine (C-X-C motif) ligand 10 -2.23 3.03E-13 
ENSMUSG00000025746 Il6 interleukin 6 -2.23 1.49E-09 
ENSMUSG00000042102 Dmgdh dimethylglycine dehydrogenase precursor -2.25 4.05E-09 
ENSMUSG00000030017 Reg3g regenerating islet-derived 3 gamma -2.25 2.27E-10 
ENSMUSG00000057465 Saa2 serum amyloid A 2 -2.26 1.25E-17 
ENSMUSG00000032068 Plet1 placenta expressed transcript 1 -2.27 6.89E-14 
ENSMUSG00000059089 Fcgr4 Fc receptor, IgG, low affinity IV -2.31 2.15E-18 
ENSMUSG00000030142 Clec4e C-type lectin domain family 4, member e -2.32 2.78E-10 
ENSMUSG00000005800 Mmp8 matrix metallopeptidase 8 -2.35 1.21E-10 
ENSMUSG00000040026 Saa3 serum amyloid A 3 -2.37 1.17E-13 
ENSMUSG00000044162 Tnip3 TNFAIP3 interacting protein 3 -2.37 6.74E-25 
ENSMUSG00000022582 Ly6g lymphocyte antigen 6 complex, locus G -2.38 3.26E-16 
ENSMUSG00000054072 Iigp1 interferon inducible GTPase 1 -2.40 1.34E-12 
ENSMUSG00000071356 Reg3b regenerating islet-derived 3 beta -2.43 2.82E-12 
ENSMUSG00000047728 BC025446 cDNA sequence BC025446 -2.45 1.16E-13 
ENSMUSG00000073555 Gm4951 predicted gene 4951 -2.46 1.45E-20 
ENSMUSG00000028527 Ak4 adenylate kinase 4 -2.46 4.48E-16 
ENSMUSG00000040264 Gbp2b guanylate binding protein 2b -2.48 7.14E-16 
ENSMUSG00000031551 Ido1 indoleamine 2,3-dioxygenase 1 -2.48 3.77E-22 
ENSMUSG00000075602 Ly6a lymphocyte antigen 6 complex, locus A -2.49 1.21E-24 
ENSMUSG00000052270 Fpr2 formyl peptide receptor 2 -2.57 5.56E-18 
ENSMUSG00000029417 Cxcl9 chemokine (C-X-C motif) ligand 9 -2.63 3.25E-15 
ENSMUSG00000074195 Clca4b chloride channel calcium activated 4B -2.66 5.24E-14 
ENSMUSG00000022126 Irg1 immunoresponsive gene 1 -2.68 1.84E-20 
ENSMUSG00000064246 Chil1 chitinase-like 1 -2.69 5.36E-19 
ENSMUSG00000020826 Nos2 nitric oxide synthase 2, inducible -2.81 3.76E-20 
ENSMUSG00000026822 Lcn2 lipocalin 2 -2.89 1.81E-21 
 
Table S8 Differentially expressed genes of BALB/c (YPIII infected 42 dpi vs. uninfected 42 dpi) 
Ensembl ID Gene symbol Gene name log2 fold 
change 
p-value 
ENSMUSG00000031722 Hp haptoglobin 2.68 6.17E-15 
ENSMUSG00000027656 Wisp2 WNT1 inducible signaling pathway protein 2 2.37 1.93E-10 
ENSMUSG00000032496 Ltf lactotransferrin 2.22 8.68E-09 
ENSMUSG00000076614  2.15 3.06E-08 
ENSMUSG00000022227 Mcpt1 mast cell protease 1 2.10 1.24E-08 
ENSMUSG00000022226 Mcpt2 mast cell protease 2 1.98 2.41E-07 
ENSMUSG00000069919 Hba-a1 hemoglobin alpha, adult chain 1 1.79 4.03E-12 
ENSMUSG00000027398 Il1b interleukin 1 beta 1.76 3.56E-08 
ENSMUSG00000079105 C7 complement component 7 1.73 5.79E-08 
ENSMUSG00000076540  1.73 5.98E-06 
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ENSMUSG00000020473 Aebp1 AE binding protein 1 1.71 4.50E-18 
ENSMUSG00000000204 Slfn4 schlafen 4 1.68 1.31E-10 
ENSMUSG00000030474 Siglece sialic acid binding Ig-like lectin E 1.67 5.99E-06 
ENSMUSG00000032484 Ngp neutrophilic granule protein 1.66 1.35E-06 
ENSMUSG00000095130  1.64 4.80E-06 
ENSMUSG00000024011 Pi16 peptidase inhibitor 16 1.64 7.85E-11 
ENSMUSG00000019987 Arg1 arginase, liver 1.63 2.95E-07 
ENSMUSG00000076596  1.63 2.64E-05 
ENSMUSG00000069917 Hba-a2 hemoglobin alpha, adult chain 2 1.62 1.92E-09 
ENSMUSG00000076538  1.62 3.22E-05 
ENSMUSG00000028111 Ctsk cathepsin K 1.62 9.32E-10 
ENSMUSG00000095682  1.62 7.71E-06 
ENSMUSG00000016024 Lbp lipopolysaccharide binding protein 1.60 1.78E-12 
ENSMUSG00000026822 Lcn2 lipocalin 2 1.59 9.67E-07 
ENSMUSG00000028859 Csf3r colony stimulating factor 3 receptor (granulocyte) 1.58 7.91E-09 
ENSMUSG00000096461  1.58 3.45E-05 
ENSMUSG00000012017 Scarf2 scavenger receptor class F, member 2 1.57 4.62E-07 
ENSMUSG00000043613 Mmp3 matrix metallopeptidase 3 1.55 4.45E-06 
ENSMUSG00000040133 Gpr176 G protein-coupled receptor 176 1.54 2.09E-05 
ENSMUSG00000042436 Mfap4 microfibrillar-associated protein 4 1.53 4.42E-09 
ENSMUSG00000024529 Lox lysyl oxidase 1.50 2.32E-06 
ENSMUSG00000095351  1.49 2.33E-05 
ENSMUSG00000042265 Trem1 triggering receptor expressed on myeloid cells 1 1.49 6.14E-05 
ENSMUSG00000039252 Lgi2 leucine-rich repeat LGI family, member 2 1.48 7.16E-07 
ENSMUSG00000032068 Plet1 placenta expressed transcript 1 1.48 1.18E-06 
ENSMUSG00000017002 Slpi secretory leukocyte peptidase inhibitor 1.48 1.24E-04 
ENSMUSG00000079012 Serpina3m serine (or cysteine) peptidase inhibitor, clade A, member 3M 1.47 3.75E-06 
ENSMUSG00000021260 Hhipl1 hedgehog interacting protein-like 1 1.46 3.95E-05 
ENSMUSG00000089672 Gp49a glycoprotein 49 A 1.46 4.33E-07 
ENSMUSG00000001506 Col1a1 collagen, type I, alpha 1 1.45 6.71E-12 
ENSMUSG00000066363 Serpina3f serine (or cysteine) peptidase inhibitor, clade A, member 3F 1.45 1.02E-06 
ENSMUSG00000032691 Nlrp3 NLR family, pyrin domain containing 3 1.44 1.33E-06 
ENSMUSG00000056071 S100a9 S100 calcium binding protein A9 (calgranulin B) 1.43 2.39E-04 
ENSMUSG00000047562 Mmp10 matrix metallopeptidase 10 1.43 1.96E-04 
ENSMUSG00000030732 Chrdl2 chordin-like 2 1.42 1.21E-04 
ENSMUSG00000058427 Cxcl2 chemokine (C-X-C motif) ligand 2 1.41 8.26E-05 
ENSMUSG00000056427 Slit3 slit homolog 3 (Drosophila) 1.41 2.25E-11 
ENSMUSG00000024164 C3 complement component 3 1.39 1.76E-13 
ENSMUSG00000036412 Arsi arylsulfatase i 1.39 4.37E-05 
ENSMUSG00000027360 Hdc histidine decarboxylase 1.39 1.52E-04 
ENSMUSG00000031380 Figf c-fos induced growth factor 1.39 1.07E-06 
ENSMUSG00000064147 Rab44 RAB44, member RAS oncogene family 1.38 1.70E-04 
ENSMUSG00000076612  1.37 1.63E-04 
ENSMUSG00000021091 Serpina3n serine (or cysteine) peptidase inhibitor, clade A, member 3N 1.37 1.38E-09 
ENSMUSG00000047798 Cd300lf CD300 antigen like family member F 1.36 1.06E-05 
ENSMUSG00000027408 Cpxm1 carboxypeptidase X 1 (M14 family) 1.35 9.41E-07 
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ENSMUSG00000031239 Itm2a integral membrane protein 2A 1.35 9.46E-06 
ENSMUSG00000052749 Trim30b tripartite motif-containing 30B 1.33 3.16E-04 
ENSMUSG00000076580  1.32 4.70E-04 
ENSMUSG00000038725 Pkhd1l1 polycystic kidney and hepatic disease 1-like 1 1.31 1.12E-07 
ENSMUSG00000074151 Nlrc5 NLR family, CARD domain containing 5 1.30 4.19E-07 
ENSMUSG00000023885 Thbs2 thrombospondin 2 1.30 1.79E-11 
ENSMUSG00000032796 Lama1 laminin, alpha 1 1.30 5.87E-07 
ENSMUSG00000021702 Thbs4 thrombospondin 4 1.30 5.56E-07 
ENSMUSG00000026442 Nfasc neurofascin 1.29 2.49E-06 
ENSMUSG00000031596 Slc7a2 solute carrier family 7 (cationic amino acid transporter, y+ system), 
member 2 
1.29 1.38E-06 
ENSMUSG00000031375 Bgn biglycan 1.28 1.02E-10 
ENSMUSG00000073418 C4b complement component 4B (Chido blood group) 1.28 3.35E-11 
ENSMUSG00000029675 Eln elastin 1.27 7.93E-07 
ENSMUSG00000020264 Slc36a2 solute carrier family 36 (proton/amino acid symporter), member 2 1.27 1.81E-04 
ENSMUSG00000029371 Cxcl5 chemokine (C-X-C motif) ligand 5 1.27 9.92E-04 
ENSMUSG00000005800 Mmp8 matrix metallopeptidase 8 1.26 7.05E-04 
ENSMUSG00000000031  1.26 1.14E-03 
ENSMUSG00000095416  1.26 9.74E-05 
ENSMUSG00000032690 Oas2 2'-5' oligoadenylate synthetase 2 1.25 2.78E-05 
ENSMUSG00000021950 Anxa8 annexin A8 1.25 3.79E-04 
ENSMUSG00000028369 Svep1 sushi, von Willebrand factor type A, EGF and pentraxin domain 
containing 1 
1.25 5.08E-10 
ENSMUSG00000024481 Lvrn laeverin 1.24 5.33E-05 
ENSMUSG00000058914 C1qtnf3 C1q and tumor necrosis factor related protein 3 1.24 2.51E-04 
ENSMUSG00000072941 Sod3 superoxide dismutase 3, extracellular 1.24 3.92E-09 
ENSMUSG00000022032 Scara5 scavenger receptor class A, member 5 (putative) 1.23 1.32E-08 
ENSMUSG00000027996 Sfrp2 secreted frizzled-related protein 2 1.22 1.71E-04 
ENSMUSG00000024087 Cyp1b1 cytochrome P450, family 1, subfamily b, polypeptide 1 1.22 6.43E-05 
ENSMUSG00000067203  1.22 1.06E-06 
ENSMUSG00000004296  1.22 4.54E-04 
ENSMUSG00000076587  1.20 1.71E-03 
ENSMUSG00000041734 Kirrel kin of IRRE like (Drosophila) 1.20 1.13E-07 
ENSMUSG00000073555 Gm4951 predicted gene 4951 1.20 9.08E-06 
ENSMUSG00000030144 Clec4d C-type lectin domain family 4, member d 1.19 1.23E-03 
ENSMUSG00000041577 Prelp proline arginine-rich end leucine-rich repeat 1.19 2.03E-13 
ENSMUSG00000001865 Cpa3 carboxypeptidase A3, mast cell 1.18 7.75E-04 
ENSMUSG00000045322 Tlr9 toll-like receptor 9 1.18 4.69E-04 
ENSMUSG00000023046 Igfbp6 insulin-like growth factor binding protein 6 1.17 6.37E-07 
ENSMUSG00000041695 Kcnj2 potassium inwardly-rectifying channel, subfamily J, member 2 1.17 3.08E-04 
ENSMUSG00000074417 Pira11 paired-Ig-like receptor A11 1.17 2.24E-04 
ENSMUSG00000015947 Fcgr1 Fc receptor, IgG, high affinity I 1.17 1.10E-05 
ENSMUSG00000031480 Thsd1 thrombospondin, type I, domain 1 1.17 6.64E-04 
ENSMUSG00000026185 Igfbp5 insulin-like growth factor binding protein 5 1.17 3.55E-08 
ENSMUSG00000030427 Lilra6 leukocyte immunoglobulin-like receptor, subfamily A (with TM 
domain), member 6 
1.16 2.51E-04 
ENSMUSG00000052353 Cemip cell migration inducing protein, hyaluronan binding 1.16 1.65E-03 
ENSMUSG00000027225 Duoxa2 dual oxidase maturation factor 2 1.15 6.10E-04 
ENSMUSG00000020695 Mrc2 mannose receptor, C type 2 1.15 4.34E-08 
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ENSMUSG00000046245 Pilra paired immunoglobin-like type 2 receptor alpha 1.15 2.91E-05 
ENSMUSG00000096638  1.14 9.95E-05 
ENSMUSG00000072812 Ahnak2 AHNAK nucleoprotein 2 1.14 1.25E-07 
ENSMUSG00000038456 Dennd2a DENN/MADD domain containing 2A 1.14 2.90E-06 
ENSMUSG00000000901 Mmp11 matrix metallopeptidase 11 1.14 2.52E-04 
ENSMUSG00000036437 Npy1r neuropeptide Y receptor Y1 1.14 7.74E-06 
ENSMUSG00000025877 Hk3 hexokinase 3 1.13 4.17E-04 
ENSMUSG00000060063 Alox5ap arachidonate 5-lipoxygenase activating protein 1.13 4.32E-06 
ENSMUSG00000038156 Spon1 spondin 1, (f-spondin) extracellular matrix protein 1.13 2.84E-08 
ENSMUSG00000031762 Mt2 metallothionein 2 1.13 5.15E-04 
ENSMUSG00000025355 Mmp19 matrix metallopeptidase 19 1.12 3.58E-06 
ENSMUSG00000022371 Col14a1 collagen, type XIV, alpha 1 1.12 6.63E-09 
ENSMUSG00000041449  1.12 2.61E-04 
ENSMUSG00000049103 Ccr2 chemokine (C-C motif) receptor 2 1.12 2.20E-06 
ENSMUSG00000048965 Mrgpre MAS-related GPR, member E 1.11 1.19E-04 
ENSMUSG00000062593 Lilrb4 leukocyte immunoglobulin-like receptor, subfamily B, member 4 1.11 2.03E-04 
ENSMUSG00000053113 Socs3 suppressor of cytokine signaling 3 1.11 4.51E-04 
ENSMUSG00000095285  1.11 7.53E-04 
ENSMUSG00000026773 Pfkfb3 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 1.10 6.20E-07 
ENSMUSG00000094134  1.10 4.88E-03 
ENSMUSG00000025701 Alox5 arachidonate 5-lipoxygenase 1.09 1.76E-05 
ENSMUSG00000040809 Chil3 chitinase-like 3 1.09 4.34E-03 
ENSMUSG00000032334 Loxl1 lysyl oxidase-like 1 1.09 3.30E-07 
ENSMUSG00000029661 Col1a2 collagen, type I, alpha 2 1.09 4.47E-08 
ENSMUSG00000076653  1.09 8.57E-06 
ENSMUSG00000053889  1.08 4.19E-04 
ENSMUSG00000052212 Cd177 CD177 antigen 1.08 8.35E-08 
ENSMUSG00000052270 Fpr2 formyl peptide receptor 2 1.08 6.36E-04 
ENSMUSG00000001435 Col18a1 collagen, type XVIII, alpha 1 1.08 3.48E-07 
ENSMUSG00000036545 Adamts2 a disintegrin-like and metallopeptidase (reprolysin type) with 
thrombospondin type 1 motif, 2 
1.08 3.46E-07 
ENSMUSG00000041673 Lrrc18 leucine rich repeat containing 18 1.08 2.14E-04 
ENSMUSG00000098470 C1rb complement component 1, r subcomponent B 1.07 1.65E-04 
ENSMUSG00000064246 Chil1 chitinase-like 1 1.07 1.38E-03 
ENSMUSG00000000552 Zfp385a zinc finger protein 385A 1.07 3.57E-04 
ENSMUSG00000005465 Il27ra interleukin 27 receptor, alpha 1.07 3.71E-04 
ENSMUSG00000079227 Ccr5 chemokine (C-C motif) receptor 5 1.07 1.31E-06 
ENSMUSG00000029070 Mxra8 matrix-remodelling associated 8 1.07 1.56E-07 
ENSMUSG00000016763 Scube1 signal peptide, CUB domain, EGF-like 1 1.07 1.42E-06 
ENSMUSG00000025784 Clec3b C-type lectin domain family 3, member b 1.06 1.27E-07 
ENSMUSG00000076613  1.06 2.98E-03 
ENSMUSG00000070691 Runx3 runt related transcription factor 3 1.06 1.27E-05 
ENSMUSG00000037003 Tenc1 tensin like C1 domain-containing phosphatase 1.06 3.90E-08 
ENSMUSG00000015053 Gata2 GATA binding protein 2 1.06 2.17E-03 
ENSMUSG00000044456 Rin3 Ras and Rab interactor 3 1.06 3.55E-06 
ENSMUSG00000040345 Arhgap9 Rho GTPase activating protein 9 1.06 1.36E-04 
ENSMUSG00000078763 Slfn1 schlafen 1 1.06 1.35E-04 
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ENSMUSG00000050989 Sepn1 selenoprotein N, 1 1.06 2.13E-06 
ENSMUSG00000022623 Shank3 SH3/ankyrin domain gene 3 1.05 2.02E-04 
ENSMUSG00000022091 Sorbs3 sorbin and SH3 domain containing 3 1.05 2.34E-07 
ENSMUSG00000022860 Chodl chondrolectin 1.05 3.64E-04 
ENSMUSG00000034059 Ypel4 yippee-like 4 (Drosophila) 1.05 1.59E-03 
ENSMUSG00000095612  1.04 1.74E-03 
ENSMUSG00000033327 Tnxb tenascin XB 1.04 8.67E-08 
ENSMUSG00000041193 Pla2g5 phospholipase A2, group V 1.04 7.86E-05 
ENSMUSG00000020901 Pik3r5 phosphoinositide-3-kinase, regulatory subunit 5, p101 1.04 1.24E-05 
ENSMUSG00000006344 Ggt5 gamma-glutamyltransferase 5 1.04 1.15E-06 
ENSMUSG00000046207 Pik3r6 phosphoinositide-3-kinase, regulatory subunit 6 1.04 9.48E-04 
ENSMUSG00000028874 Fgr Gardner-Rasheed feline sarcoma viral (Fgr) oncogene homolog 1.03 3.99E-05 
ENSMUSG00000002847 Pla1a phospholipase A1 member A 1.03 5.82E-03 
ENSMUSG00000064080 Fbln2 fibulin 2 1.03 2.49E-07 
ENSMUSG00000020889 Nr1d1 nuclear receptor subfamily 1, group D, member 1 1.03 6.26E-04 
ENSMUSG00000022102 Dok2 docking protein 2 1.03 2.78E-03 
ENSMUSG00000084159  1.03 2.14E-04 
ENSMUSG00000079014 Serpina3i serine (or cysteine) peptidase inhibitor, clade A, member 3I 1.02 2.80E-03 
ENSMUSG00000054555 Adam12 a disintegrin and metallopeptidase domain 12 (meltrin alpha) 1.01 6.93E-04 
ENSMUSG00000043531 Sorcs1 VPS10 domain receptor protein SORCS 1 1.01 1.09E-03 
ENSMUSG00000076508  1.01 4.82E-03 
ENSMUSG00000040254 Sema3d sema domain, immunoglobulin domain (Ig), short basic domain, 
secreted, (semaphorin) 3D 
1.01 2.99E-06 
ENSMUSG00000024620 Pdgfrb platelet derived growth factor receptor, beta polypeptide 1.01 4.20E-07 
ENSMUSG00000042286 Stab1 stabilin 1 1.01 1.99E-07 
ENSMUSG00000076695  1.01 5.45E-03 
ENSMUSG00000031765 Mt1 metallothionein 1 1.01 6.80E-05 
ENSMUSG00000024053 Emilin2 elastin microfibril interfacer 2 1.01 7.62E-06 
ENSMUSG00000068196 Col8a1 collagen, type VIII, alpha 1 1.00 7.70E-05 
ENSMUSG00000018339 Gpx3 glutathione peroxidase 3 1.00 1.42E-05 
ENSMUSG00000025479 Cyp2e1 cytochrome P450, family 2, subfamily e, polypeptide 1 1.00 6.75E-04 
ENSMUSG00000033715 Akr1c14 aldo-keto reductase family 1, member C14 -1.01 6.01E-04 
ENSMUSG00000029664 Tfpi2 tissue factor pathway inhibitor 2 -1.01 1.95E-05 
ENSMUSG00000051235 Gen1 Gen homolog 1, endonuclease (Drosophila) -1.02 7.80E-05 
ENSMUSG00000064343  -1.02 3.49E-03 
ENSMUSG00000077711  -1.02 8.03E-04 
ENSMUSG00000078784 1810022K09Ri
k 
RIKEN cDNA 1810022K09 gene -1.02 2.96E-04 
ENSMUSG00000063383 Zfp947 zinc finger protein 947 -1.02 1.48E-03 
ENSMUSG00000029334 Prkg2 protein kinase, cGMP-dependent, type II -1.02 4.69E-04 
ENSMUSG00000049799 Lrrc19 leucine rich repeat containing 19 -1.02 2.82E-03 
ENSMUSG00000056383 AI987944 expressed sequence AI987944 -1.02 2.99E-04 
ENSMUSG00000039221 Rpl22l1 ribosomal protein L22 like 1 -1.03 3.53E-04 
ENSMUSG00000075983  -1.03 7.87E-03 
ENSMUSG00000026049 Tex30 testis expressed 30 -1.04 2.47E-04 
ENSMUSG00000078193  -1.04 1.75E-04 
ENSMUSG00000065145  -1.04 3.71E-08 
ENSMUSG00000092203 1110038B12Ri
k 
RIKEN cDNA 1110038B12 gene -1.05 7.13E-08 
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ENSMUSG00000094245  -1.05 2.38E-03 
ENSMUSG00000032372 Plscr2 phospholipid scramblase 2 -1.05 8.75E-06 
ENSMUSG00000098274 Rpl24 ribosomal protein L24 -1.06 5.11E-06 
ENSMUSG00000064356 ATP8 ATP synthase F0 subunit 8 -1.07 7.33E-04 
ENSMUSG00000064339  -1.07 1.07E-04 
ENSMUSG00000064840  -1.07 3.05E-03 
ENSMUSG00000065258  -1.07 1.85E-05 
ENSMUSG00000054630 Ugt2b5 UDP glucuronosyltransferase 2 family, polypeptide B5 -1.07 1.70E-06 
ENSMUSG00000088273  -1.08 4.53E-03 
ENSMUSG00000059898 Dsc3 desmocollin 3 -1.08 5.82E-05 
ENSMUSG00000064647  -1.08 8.18E-04 
ENSMUSG00000094199  -1.08 1.68E-03 
ENSMUSG00000071748  -1.08 2.66E-05 
ENSMUSG00000064945 Rny3 RNA, Y3 small cytoplasmic (associated with Ro protein) -1.08 7.30E-07 
ENSMUSG00000072762  -1.09 2.39E-04 
ENSMUSG00000039114 Nrn1 neuritin 1 -1.10 4.64E-03 
ENSMUSG00000088604  -1.10 1.79E-06 
ENSMUSG00000009628 Tex15 testis expressed gene 15 -1.10 4.94E-04 
ENSMUSG00000047534 Mis18bp1 MIS18 binding protein 1 -1.11 1.56E-05 
ENSMUSG00000070704 Ugt2b36 UDP glucuronosyltransferase 2 family, polypeptide B36 -1.11 8.23E-04 
ENSMUSG00000078435 AU041133 expressed sequence AU041133 -1.11 5.23E-04 
ENSMUSG00000094026  -1.12 3.25E-03 
ENSMUSG00000032854 Ugt8a UDP galactosyltransferase 8A -1.13 1.95E-03 
ENSMUSG00000074800  -1.13 7.09E-06 
ENSMUSG00000054091 1810037I17Rik RIKEN cDNA 1810037I17 gene -1.13 1.57E-07 
ENSMUSG00000058748 Zfp958 zinc finger protein 958 -1.14 1.62E-04 
ENSMUSG00000064901  -1.14 2.81E-07 
ENSMUSG00000056531 Ccdc18 coiled-coil domain containing 18 -1.14 1.42E-04 
ENSMUSG00000081094  -1.15 2.60E-06 
ENSMUSG00000035133 Arhgap5 Rho GTPase activating protein 5 -1.15 3.11E-04 
ENSMUSG00000025528 2010106E10Ri
k 
RIKEN cDNA 2010106E10 gene -1.15 1.32E-03 
ENSMUSG00000093864  -1.17 7.48E-04 
ENSMUSG00000076501  -1.17 1.62E-08 
ENSMUSG00000088516  -1.17 2.76E-08 
ENSMUSG00000026166 Ccl20 chemokine (C-C motif) ligand 20 -1.17 1.32E-04 
ENSMUSG00000064653  -1.18 4.10E-04 
ENSMUSG00000064472  -1.18 2.39E-03 
ENSMUSG00000089308  -1.18 8.59E-04 
ENSMUSG00000096341  -1.18 3.18E-06 
ENSMUSG00000005802 Slc30a4 solute carrier family 30 (zinc transporter), member 4 -1.19 2.80E-07 
ENSMUSG00000060419  -1.20 8.96E-05 
ENSMUSG00000080921  -1.20 4.13E-06 
ENSMUSG00000060149 BC002059 cDNA sequence BC002059 -1.21 3.61E-04 
ENSMUSG00000078546 2210404O09Ri
k 
RIKEN cDNA 2210404O09 gene -1.22 3.85E-04 
ENSMUSG00000029273 Sult1d1 sulfotransferase family 1D, member 1 -1.22 5.84E-05 
ENSMUSG00000022034 Esco2 establishment of cohesion 1 homolog 2 (S. cerevisiae) -1.23 3.91E-07 
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ENSMUSG00000065876  -1.23 1.49E-04 
ENSMUSG00000095857  -1.23 3.63E-04 
ENSMUSG00000090136 Gm10177 predicted gene 10177 -1.25 1.79E-04 
ENSMUSG00000056032  -1.25 4.62E-06 
ENSMUSG00000021714 Cenpk centromere protein K -1.27 3.54E-05 
ENSMUSG00000080365  -1.27 2.90E-05 
ENSMUSG00000019888 Mgat4c MGAT4 family, member C -1.29 5.65E-05 
ENSMUSG00000047344 Lancl3 LanC lantibiotic synthetase component C-like 3 (bacterial) -1.30 8.08E-05 
ENSMUSG00000089855  -1.31 1.69E-04 
ENSMUSG00000095624  -1.31 5.86E-04 
ENSMUSG00000023073 Slc10a2 solute carrier family 10, member 2 -1.33 1.50E-04 
ENSMUSG00000064352  -1.35 3.24E-05 
ENSMUSG00000094400  -1.35 3.94E-04 
ENSMUSG00000076332  -1.37 4.24E-08 
ENSMUSG00000064346  -1.39 1.25E-04 
ENSMUSG00000025912 Mybl1 myeloblastosis oncogene-like 1 -1.41 1.95E-08 
ENSMUSG00000093413  -1.42 4.10E-06 
ENSMUSG00000028175 Depdc1a DEP domain containing 1a -1.44 1.03E-07 
ENSMUSG00000098178  -1.46 1.72E-09 
ENSMUSG00000095396  -1.46 1.18E-04 
ENSMUSG00000081043  -1.46 1.33E-05 
ENSMUSG00000095738  -1.46 6.50E-05 
ENSMUSG00000029821 Dfna5 deafness, autosomal dominant 5 (human) -1.47 5.32E-10 
ENSMUSG00000057359  -1.48 1.40E-05 
ENSMUSG00000062083  -1.48 4.49E-09 
ENSMUSG00000064358 COX3 cytochrome c oxidase subunit III -1.49 3.53E-07 
ENSMUSG00000064360 ND3 NADH dehydrogenase subunit 3 -1.50 1.85E-09 
ENSMUSG00000065104  -1.50 2.85E-05 
ENSMUSG00000076320  -1.53 5.18E-10 
ENSMUSG00000067870  -1.54 9.19E-08 
ENSMUSG00000091509  -1.56 1.27E-07 
ENSMUSG00000056412  -1.56 4.85E-06 
ENSMUSG00000076355  -1.57 2.07E-08 
ENSMUSG00000095422  -1.58 1.27E-05 
ENSMUSG00000064355  -1.61 2.99E-08 
ENSMUSG00000076370  -1.61 4.87E-08 
ENSMUSG00000064823  -1.65 1.25E-08 
ENSMUSG00000093983  -1.67 3.64E-06 
ENSMUSG00000077345  -1.71 2.02E-08 
ENSMUSG00000096801  -1.80 2.98E-07 
ENSMUSG00000087412  -1.80 4.43E-07 
ENSMUSG00000092661  -1.82 1.41E-15 
ENSMUSG00000077565  -1.87 3.58E-15 
ENSMUSG00000064689  -1.89 4.72E-08 
ENSMUSG00000077082  -1.89 1.78E-13 
ENSMUSG00000064742  -1.91 1.80E-07 
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ENSMUSG00000083705 Gm8624 predicted gene 8624 -2.04 5.79E-13 
ENSMUSG00000096222  -2.14 1.63E-10 
ENSMUSG00000065373  -2.17 1.26E-11 
ENSMUSG00000093999  -2.51 5.82E-13 
 
Table S9 Differentially expressed genes of BALB/c (YPIII Δcnfy infected 42 dpi vs. uninfected 
42 dpi) 
Ensembl ID Gene symbol Gene name log2 fold 
change 
p-value 
ENSMUSG00000076614  1.94 6.22E-07 
ENSMUSG00000017002 Slpi secretory leukocyte peptidase inhibitor 1.80 3.21E-06 
ENSMUSG00000058427 Cxcl2 chemokine (C-X-C motif) ligand 2 1.74 1.62E-06 
ENSMUSG00000022227 Mcpt1 mast cell protease 1 1.72 3.19E-06 
ENSMUSG00000022226 Mcpt2 mast cell protease 2 1.72 7.66E-06 
ENSMUSG00000019987 Arg1 arginase, liver 1.64 3.85E-07 
ENSMUSG00000032068 Plet1 placenta expressed transcript 1 1.57 2.50E-07 
ENSMUSG00000027398 Il1b interleukin 1 beta 1.51 2.23E-06 
ENSMUSG00000071361 Mcpt9 mast cell protease 9 1.46 1.64E-04 
ENSMUSG00000076633  1.40 2.91E-04 
ENSMUSG00000043613 Mmp3 matrix metallopeptidase 3 1.38 4.71E-05 
ENSMUSG00000076612  1.31 3.19E-04 
ENSMUSG00000042265 Trem1 triggering receptor expressed on myeloid cells 1 1.30 5.69E-04 
ENSMUSG00000068289 Cma2 chymase 2, mast cell 1.27 9.80E-04 
ENSMUSG00000031722 Hp haptoglobin 1.22 5.28E-04 
ENSMUSG00000094769  1.19 1.11E-03 
ENSMUSG00000030144 Clec4d C-type lectin domain family 4, member d 1.09 3.65E-03 
ENSMUSG00000029380 Cxcl1 chemokine (C-X-C motif) ligand 1 1.08 3.11E-03 
ENSMUSG00000096326  1.08 5.11E-03 
ENSMUSG00000025893 Kbtbd3 kelch repeat and BTB (POZ) domain containing 3 -1.00 1.81E-03 
ENSMUSG00000086269  -1.02 8.83E-03 
ENSMUSG00000020607 Fam84a family with sequence similarity 84, member A -1.03 2.32E-03 
ENSMUSG00000029644 Pdx1 pancreatic and duodenal homeobox 1 -1.04 7.27E-03 
ENSMUSG00000038094 Atp13a4 ATPase type 13A4 -1.06 1.70E-03 
ENSMUSG00000050520 Cldn8 claudin 8 -1.06 6.73E-05 
ENSMUSG00000054932 Afp alpha fetoprotein -1.07 5.76E-03 
ENSMUSG00000039114 Nrn1 neuritin 1 -1.07 5.69E-03 
ENSMUSG00000024558 Mapk4 mitogen-activated protein kinase 4 -1.08 1.12E-03 
ENSMUSG00000076589  -1.12 3.47E-03 
ENSMUSG00000042734 Ttc9 tetratricopeptide repeat domain 9 -1.13 1.23E-03 
ENSMUSG00000030725 Lipt2 lipoyl(octanoyl) transferase 2 (putative) -1.15 6.76E-04 
ENSMUSG00000024912 Fosl1 fos-like antigen 1 -1.16 1.46E-03 
ENSMUSG00000091844 Ccdc168 coiled-coil domain containing 168 -1.18 1.42E-03 
ENSMUSG00000009628 Tex15 testis expressed gene 15 -1.18 1.99E-04 
ENSMUSG00000027801 Tm4sf4 transmembrane 4 superfamily member 4 -1.23 1.02E-03 
ENSMUSG00000024827 Gldc glycine decarboxylase -1.28 7.67E-04 
ENSMUSG00000048455 Sprr1b small proline-rich protein 1B -1.57 6.66E-07 
ENSMUSG00000071665 Foxr2 forkhead box R2 -1.58 8.25E-07 
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Table S10 Differentially expressed genes of BALB/c (YPIII infected 42 dpi vs. YPIII Δcnfy 
infected 42 dpi) 
Ensembl ID Gene symbol Gene name log2 fold 
change 
pvalue 
ENSMUSG00000027656 Wisp2 WNT1 inducible signaling pathway protein 2 2.11 1.23E-08 
ENSMUSG00000069917 Hba-a2 hemoglobin alpha, adult chain 2 1.89 3.06E-12 
ENSMUSG00000069919 Hba-a1 hemoglobin alpha, adult chain 1 1.81 1.54E-12 
ENSMUSG00000024011 Pi16 peptidase inhibitor 16 1.78 1.78E-12 
ENSMUSG00000032496 Ltf lactotransferrin 1.77 4.74E-06 
ENSMUSG00000021260 Hhipl1 hedgehog interacting protein-like 1 1.75 1.02E-06 
ENSMUSG00000020473 Aebp1 AE binding protein 1 1.69 7.98E-18 
ENSMUSG00000032484 Ngp neutrophilic granule protein 1.69 8.68E-07 
ENSMUSG00000042985 Upk3b uroplakin 3B 1.64 2.45E-05 
ENSMUSG00000079105 C7 complement component 7 1.58 6.07E-07 
ENSMUSG00000024481 Lvrn laeverin 1.52 1.01E-06 
ENSMUSG00000029675 Eln elastin 1.51 5.51E-09 
ENSMUSG00000031722 Hp haptoglobin 1.46 9.50E-06 
ENSMUSG00000038725 Pkhd1l1 polycystic kidney and hepatic disease 1-like 1 1.45 4.43E-09 
ENSMUSG00000028111 Ctsk cathepsin K 1.44 3.39E-08 
ENSMUSG00000016024 Lbp lipopolysaccharide binding protein 1.43 1.50E-10 
ENSMUSG00000058914 C1qtnf3 C1q and tumor necrosis factor related protein 3 1.42 2.83E-05 
ENSMUSG00000023034 Nr4a1 nuclear receptor subfamily 4, group A, member 1 1.41 1.06E-06 
ENSMUSG00000076580  1.40 2.14E-04 
ENSMUSG00000033170 Card10 caspase recruitment domain family, member 10 1.39 2.29E-07 
ENSMUSG00000023046 Igfbp6 insulin-like growth factor binding protein 6 1.39 4.27E-09 
ENSMUSG00000023885 Thbs2 thrombospondin 2 1.39 7.05E-13 
ENSMUSG00000001506 Col1a1 collagen, type I, alpha 1 1.38 6.51E-11 
ENSMUSG00000022032 Scara5 scavenger receptor class A, member 5 (putative) 1.38 1.60E-10 
ENSMUSG00000041577 Prelp proline arginine-rich end leucine-rich repeat 1.38 1.58E-17 
ENSMUSG00000071656 Lrrn4cl LRRN4 C-terminal like 1.37 1.90E-07 
ENSMUSG00000020889 Nr1d1 nuclear receptor subfamily 1, group D, member 1 1.37 5.57E-06 
ENSMUSG00000022860 Chodl chondrolectin 1.37 4.60E-06 
ENSMUSG00000036036 Zfp57 zinc finger protein 57 1.36 1.90E-05 
ENSMUSG00000032243 Itga11 integrin alpha 11 1.35 3.80E-09 
ENSMUSG00000056427 Slit3 slit homolog 3 (Drosophila) 1.35 1.26E-10 
ENSMUSG00000084159  1.35 1.61E-06 
ENSMUSG00000036437 Npy1r neuropeptide Y receptor Y1 1.35 1.44E-07 
ENSMUSG00000020695 Mrc2 mannose receptor, C type 2 1.34 1.84E-10 
ENSMUSG00000059146 Ntrk3 neurotrophic tyrosine kinase, receptor, type 3 1.33 1.26E-04 
ENSMUSG00000033327 Tnxb tenascin XB 1.33 1.11E-11 
ENSMUSG00000076596  1.31 7.37E-04 
ENSMUSG00000025784 Clec3b C-type lectin domain family 3, member b 1.30 1.21E-10 
ENSMUSG00000027996 Sfrp2 secreted frizzled-related protein 2 1.30 6.30E-05 
ENSMUSG00000022371 Col14a1 collagen, type XIV, alpha 1 1.30 1.80E-11 
ENSMUSG00000041329 Atp1b2 ATPase, Na+/K+ transporting, beta 2 polypeptide 1.30 3.00E-06 
ENSMUSG00000095682  1.30 3.39E-04 
SUPPLEMENTARY INFORMATION 
 
254 
 
ENSMUSG00000095130  1.29 2.85E-04 
ENSMUSG00000038463 Olfml2b olfactomedin-like 2B 1.29 5.73E-11 
ENSMUSG00000031762 Mt2 metallothionein 2 1.29 7.56E-05 
ENSMUSG00000032334 Loxl1 lysyl oxidase-like 1 1.28 2.26E-09 
ENSMUSG00000040734 Ppp1r13l protein phosphatase 1, regulatory (inhibitor) subunit 13 like 1.28 9.25E-05 
ENSMUSG00000079012 Serpina3m serine (or cysteine) peptidase inhibitor, clade A, member 3M 1.27 4.27E-05 
ENSMUSG00000029070 Mxra8 matrix-remodelling associated 8 1.27 4.40E-10 
ENSMUSG00000040488 Ltbp4 latent transforming growth factor beta binding protein 4 1.26 9.54E-12 
ENSMUSG00000037624 Kcnk2 potassium channel, subfamily K, member 2 1.25 7.58E-07 
ENSMUSG00000031480 Thsd1 thrombospondin, type I, domain 1 1.25 2.52E-04 
ENSMUSG00000058571 Gpc6 glypican 6 1.25 1.53E-07 
ENSMUSG00000068196 Col8a1 collagen, type VIII, alpha 1 1.25 9.72E-07 
ENSMUSG00000041378 Cldn5 claudin 5 1.25 4.53E-06 
ENSMUSG00000042436 Mfap4 microfibrillar-associated protein 4 1.24 1.30E-06 
ENSMUSG00000029096 Htra3 HtrA serine peptidase 3 1.24 5.12E-08 
ENSMUSG00000039004 Bmp6 bone morphogenetic protein 6 1.24 2.24E-05 
ENSMUSG00000027931 Npr1 natriuretic peptide receptor 1 1.23 8.86E-07 
ENSMUSG00000040254 Sema3d sema domain, immunoglobulin domain (Ig), short basic domain, 
secreted, (semaphorin) 3D 
1.23 1.46E-08 
ENSMUSG00000041482 Piezo2 piezo-type mechanosensitive ion channel component 2 1.22 2.57E-08 
ENSMUSG00000036545 Adamts2 a disintegrin-like and metallopeptidase (reprolysin type) with 
thrombospondin type 1 motif, 2 
1.22 8.67E-09 
ENSMUSG00000038456 Dennd2a DENN/MADD domain containing 2A 1.21 5.94E-07 
ENSMUSG00000072941 Sod3 superoxide dismutase 3, extracellular 1.21 7.89E-09 
ENSMUSG00000003573 Homer3 homer homolog 3 (Drosophila) 1.20 3.50E-05 
ENSMUSG00000074766 Ism1 isthmin 1 homolog (zebrafish) 1.20 7.96E-05 
ENSMUSG00000031765 Mt1 metallothionein 1 1.19 2.72E-06 
ENSMUSG00000031871 Cdh5 cadherin 5 1.18 3.91E-11 
ENSMUSG00000023411 Nfatc4 nuclear factor of activated T cells, cytoplasmic, calcineurin 
dependent 4 
1.18 3.08E-06 
ENSMUSG00000040612 Ildr2 immunoglobulin-like domain containing receptor 2 1.18 7.91E-06 
ENSMUSG00000094124  1.17 1.74E-04 
ENSMUSG00000059401 Mamld1 mastermind-like domain containing 1 1.17 8.46E-05 
ENSMUSG00000037003 Tenc1 tensin like C1 domain-containing phosphatase 1.17 1.32E-09 
ENSMUSG00000031375 Bgn biglycan 1.17 3.58E-09 
ENSMUSG00000028369 Svep1 sushi, von Willebrand factor type A, EGF and pentraxin domain 
containing 1 
1.16 6.87E-09 
ENSMUSG00000038112 AW551984 expressed sequence AW551984 1.16 1.23E-04 
ENSMUSG00000067203  1.16 2.96E-06 
ENSMUSG00000024663 Rab3il1 RAB3A interacting protein (rabin3)-like 1 1.15 1.21E-06 
ENSMUSG00000057706 Mex3b mex3 homolog B (C. elegans) 1.15 5.20E-04 
ENSMUSG00000030546 Plin1 perilipin 1 1.15 6.10E-05 
ENSMUSG00000054555 Adam12 a disintegrin and metallopeptidase domain 12 (meltrin alpha) 1.15 1.23E-04 
ENSMUSG00000045333 Zfp423 zinc finger protein 423 1.15 2.55E-05 
ENSMUSG00000021903 Galnt15 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 15 
1.15 5.09E-06 
ENSMUSG00000034659 Tmem109 transmembrane protein 109 1.15 2.07E-09 
ENSMUSG00000048387 Osr1 odd-skipped related 1 (Drosophila) 1.14 1.35E-06 
ENSMUSG00000022091 Sorbs3 sorbin and SH3 domain containing 3 1.14 1.85E-08 
ENSMUSG00000028341 Nr4a3 nuclear receptor subfamily 4, group A, member 3 1.14 1.16E-06 
ENSMUSG00000020357 Flt4 FMS-like tyrosine kinase 4 1.14 5.76E-09 
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ENSMUSG00000047414 Flrt2 fibronectin leucine rich transmembrane protein 2 1.14 8.05E-07 
ENSMUSG00000041734 Kirrel kin of IRRE like (Drosophila) 1.14 4.48E-07 
ENSMUSG00000059201 Lep leptin 1.14 2.25E-03 
ENSMUSG00000064080 Fbln2 fibulin 2 1.14 1.31E-08 
ENSMUSG00000026574 Dpt dermatopontin 1.14 9.33E-09 
ENSMUSG00000072812 Ahnak2 AHNAK nucleoprotein 2 1.14 1.39E-07 
ENSMUSG00000062991 Nrg1 neuregulin 1 1.13 4.37E-05 
ENSMUSG00000025479 Cyp2e1 cytochrome P450, family 2, subfamily e, polypeptide 1 1.13 1.18E-04 
ENSMUSG00000065645  1.13 2.11E-05 
ENSMUSG00000052488 Cherp calcium homeostasis endoplasmic reticulum protein 1.13 5.53E-08 
ENSMUSG00000002799 Jag2 jagged 2 1.13 4.74E-04 
ENSMUSG00000041559 Fmod fibromodulin 1.13 4.30E-05 
ENSMUSG00000043388 Tmem130 transmembrane protein 130 1.13 1.09E-03 
ENSMUSG00000035863 Palm paralemmin 1.12 2.43E-07 
ENSMUSG00000024299 Adamts10 a disintegrin-like and metallopeptidase (reprolysin type) with 
thrombospondin type 1 motif, 10 
1.12 1.03E-06 
ENSMUSG00000031380 Figf c-fos induced growth factor 1.12 5.75E-05 
ENSMUSG00000028047 Thbs3 thrombospondin 3 1.12 3.32E-07 
ENSMUSG00000076540  1.12 3.30E-03 
ENSMUSG00000069893 9930111J21Rik
1 
RIKEN cDNA 9930111J21 gene 1 1.12 2.10E-04 
ENSMUSG00000024940 Ltbp3 latent transforming growth factor beta binding protein 3 1.12 1.50E-09 
ENSMUSG00000017817 Jph2 junctophilin 2 1.12 7.76E-09 
ENSMUSG00000040133 Gpr176 G protein-coupled receptor 176 1.12 1.62E-03 
ENSMUSG00000085795 Zfp703 zinc finger protein 703 1.11 4.36E-06 
ENSMUSG00000012017 Scarf2 scavenger receptor class F, member 2 1.11 2.26E-04 
ENSMUSG00000027230 Creb3l1 cAMP responsive element binding protein 3-like 1 1.11 4.50E-07 
ENSMUSG00000051811 Cox6b2 cytochrome c oxidase subunit VIb polypeptide 2 1.11 5.05E-04 
ENSMUSG00000020614 Fam20a family with sequence similarity 20, member A 1.10 7.51E-05 
ENSMUSG00000032997 Chpf chondroitin polymerizing factor 1.10 2.31E-05 
ENSMUSG00000061535 C1qtnf7 C1q and tumor necrosis factor related protein 7 1.10 3.89E-05 
ENSMUSG00000034675 Dbn1 drebrin 1 1.10 9.91E-08 
ENSMUSG00000000794 Kcnn3 potassium intermediate/small conductance calcium-activated 
channel, subfamily N, member 3 
1.10 1.81E-05 
ENSMUSG00000045799  1.10 4.91E-06 
ENSMUSG00000038146 Notch3 notch 3 1.10 1.65E-05 
ENSMUSG00000013921 Clip3 CAP-GLY domain containing linker protein 3 1.09 2.38E-06 
ENSMUSG00000059921 Unc5c unc-5 homolog C (C. elegans) 1.09 2.66E-04 
ENSMUSG00000024620 Pdgfrb platelet derived growth factor receptor, beta polypeptide 1.09 4.77E-08 
ENSMUSG00000033200 Tpsg1 tryptase gamma 1 1.09 2.28E-05 
ENSMUSG00000070802 Pnmal2 PNMA-like 2 1.09 8.43E-06 
ENSMUSG00000020205 Phlda1 pleckstrin homology-like domain, family A, member 1 1.09 3.31E-06 
ENSMUSG00000078794 Dact3 dapper homolog 3, antagonist of beta-catenin (xenopus) 1.09 1.71E-05 
ENSMUSG00000031517 Gpm6a glycoprotein m6a 1.09 2.86E-05 
ENSMUSG00000015468 Notch4 notch 4 1.08 6.44E-05 
ENSMUSG00000026249 Serpine2 serine (or cysteine) peptidase inhibitor, clade E, member 2 1.08 8.35E-06 
ENSMUSG00000074743 Thbd thrombomodulin 1.08 5.09E-08 
ENSMUSG00000030222 Rerg RAS-like, estrogen-regulated, growth-inhibitor 1.08 1.77E-04 
ENSMUSG00000037379 Spon2 spondin 2, extracellular matrix protein 1.08 4.06E-07 
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ENSMUSG00000039252 Lgi2 leucine-rich repeat LGI family, member 2 1.08 2.13E-04 
ENSMUSG00000037326 Capn15 calpain 15 1.08 6.27E-05 
ENSMUSG00000062329 Cytl1 cytokine-like 1 1.08 1.09E-03 
ENSMUSG00000026399 Cd55 CD55 antigen 1.07 1.42E-08 
ENSMUSG00000029420 Rimbp2 RIMS binding protein 2 1.07 1.97E-04 
ENSMUSG00000009614 Sardh sarcosine dehydrogenase 1.07 4.33E-04 
ENSMUSG00000056481 Cd248 CD248 antigen, endosialin 1.07 2.62E-06 
ENSMUSG00000027257 Pacsin3 protein kinase C and casein kinase substrate in neurons 3 1.07 3.82E-05 
ENSMUSG00000004098 Col5a3 collagen, type V, alpha 3 1.07 4.65E-06 
ENSMUSG00000053293 Pom121 nuclear pore membrane protein 121 1.07 1.15E-06 
ENSMUSG00000026208 Des desmin 1.06 9.71E-11 
ENSMUSG00000024164 C3 complement component 3 1.06 2.11E-08 
ENSMUSG00000061048 Cdh3 cadherin 3 1.06 3.31E-04 
ENSMUSG00000032735 Ablim3 actin binding LIM protein family, member 3 1.06 1.14E-04 
ENSMUSG00000022099 Dmtn dematin actin binding protein 1.06 5.84E-05 
ENSMUSG00000050288 Fzd2 frizzled homolog 2 (Drosophila) 1.06 8.29E-05 
ENSMUSG00000057280 Musk muscle, skeletal, receptor tyrosine kinase 1.06 7.42E-05 
ENSMUSG00000026586 Prrx1 paired related homeobox 1 1.05 2.15E-04 
ENSMUSG00000021186 Fbln5 fibulin 5 1.05 1.08E-06 
ENSMUSG00000040809 Chil3 chitinase-like 3 1.05 6.24E-03 
ENSMUSG00000019467 Arhgef25 Rho guanine nucleotide exchange factor (GEF) 25 1.05 1.93E-08 
ENSMUSG00000039477 Tnrc18 trinucleotide repeat containing 18 1.05 1.09E-07 
ENSMUSG00000026748 Plxdc2 plexin domain containing 2 1.05 5.64E-06 
ENSMUSG00000021130 Galnt16 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 16 
1.05 8.24E-04 
ENSMUSG00000063382 Bcl9l B cell CLL/lymphoma 9-like 1.05 2.40E-06 
ENSMUSG00000001911 Nfix nuclear factor I/X 1.05 8.18E-09 
ENSMUSG00000026204 Ptprn protein tyrosine phosphatase, receptor type, N 1.05 1.29E-04 
ENSMUSG00000021070 Bdkrb2 bradykinin receptor, beta 2 1.05 4.03E-05 
ENSMUSG00000037225 Fgf2 fibroblast growth factor 2 1.04 1.77E-03 
ENSMUSG00000043155 Hpdl 4-hydroxyphenylpyruvate dioxygenase-like 1.04 4.01E-04 
ENSMUSG00000037335 Hand1 heart and neural crest derivatives expressed transcript 1 1.04 2.37E-04 
ENSMUSG00000022475 Hdac7 histone deacetylase 7 1.04 2.30E-05 
ENSMUSG00000025355 Mmp19 matrix metallopeptidase 19 1.04 1.37E-05 
ENSMUSG00000044017 Gpr133 G protein-coupled receptor 133 1.04 1.05E-06 
ENSMUSG00000008734 Gprc5b G protein-coupled receptor, family C, group 5, member B 1.04 1.17E-05 
ENSMUSG00000037411 Serpine1 serine (or cysteine) peptidase inhibitor, clade E, member 1 1.04 3.70E-05 
ENSMUSG00000022665 Ccdc80 coiled-coil domain containing 80 1.04 1.42E-07 
ENSMUSG00000070509 Rgma repulsive guidance molecule family member A 1.04 1.82E-05 
ENSMUSG00000098470 C1rb complement component 1, r subcomponent B 1.04 2.39E-04 
ENSMUSG00000036446 Lum lumican 1.03 8.29E-07 
ENSMUSG00000090399  1.03 2.92E-04 
ENSMUSG00000025409 Mbd6 methyl-CpG binding domain protein 6 1.03 9.57E-06 
ENSMUSG00000026211 Obsl1 obscurin-like 1 1.03 1.02E-04 
ENSMUSG00000030787 Lyve1 lymphatic vessel endothelial hyaluronan receptor 1 1.03 6.53E-08 
ENSMUSG00000030116 Mfap5 microfibrillar associated protein 5 1.03 2.77E-04 
ENSMUSG00000035112 Wnk4 WNK lysine deficient protein kinase 4 1.03 4.65E-07 
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ENSMUSG00000094686 Ccl21a chemokine (C-C motif) ligand 21A (serine) 1.03 5.07E-07 
ENSMUSG00000022484 Hoxc10 homeobox C10 1.03 1.38E-03 
ENSMUSG00000025402 Nab2 Ngfi-A binding protein 2 1.03 2.30E-04 
ENSMUSG00000026193 Fn1 fibronectin 1 1.03 2.80E-08 
ENSMUSG00000045322 Tlr9 toll-like receptor 9 1.03 2.15E-03 
ENSMUSG00000050234 Gja4 gap junction protein, alpha 4 1.02 1.99E-03 
ENSMUSG00000031875 Cmtm3 CKLF-like MARVEL transmembrane domain containing 3 1.02 2.35E-04 
ENSMUSG00000097353  1.02 2.29E-03 
ENSMUSG00000073418 C4b complement component 4B (Chido blood group) 1.02 1.11E-07 
ENSMUSG00000021294 Kif26a kinesin family member 26A 1.02 5.48E-04 
ENSMUSG00000019997 Ctgf connective tissue growth factor 1.02 2.42E-05 
ENSMUSG00000020627 Klhl29 kelch-like 29 1.02 4.56E-04 
ENSMUSG00000027221 Chst1 carbohydrate (keratan sulfate Gal-6) sulfotransferase 1 1.02 1.93E-05 
ENSMUSG00000039377 Hlx H2.0-like homeobox 1.01 1.85E-05 
ENSMUSG00000000957 Mmp14 matrix metallopeptidase 14 (membrane-inserted) 1.01 8.74E-09 
ENSMUSG00000020810 Cygb cytoglobin 1.01 2.64E-05 
ENSMUSG00000037966 Ninj1 ninjurin 1 1.01 1.14E-05 
ENSMUSG00000029661 Col1a2 collagen, type I, alpha 2 1.01 4.11E-07 
ENSMUSG00000036412 Arsi arylsulfatase i 1.01 2.51E-03 
ENSMUSG00000019539 Rcn3 reticulocalbin 3, EF-hand calcium binding domain 1.01 1.50E-07 
ENSMUSG00000001930 Vwf Von Willebrand factor homolog 1.01 8.43E-08 
ENSMUSG00000027840 Wnt2b wingless-type MMTV integration site family, member 2B 1.01 2.87E-07 
ENSMUSG00000071984 Fndc1 fibronectin type III domain containing 1 1.01 4.33E-07 
ENSMUSG00000020886 Dlg4 discs, large homolog 4 (Drosophila) 1.01 2.15E-05 
ENSMUSG00000071516 Hist1h2ai histone cluster 1, H2ai 1.01 8.84E-06 
ENSMUSG00000018672 Copz2 coatomer protein complex, subunit zeta 2 1.01 8.43E-05 
ENSMUSG00000020042 Btbd11 BTB (POZ) domain containing 11 1.01 4.78E-04 
ENSMUSG00000026797 Stxbp1 syntaxin binding protein 1 1.01 7.16E-06 
ENSMUSG00000044456 Rin3 Ras and Rab interactor 3 1.01 9.66E-06 
ENSMUSG00000034107 Ano7 anoctamin 7 1.01 2.02E-06 
ENSMUSG00000027523 Gnas GNAS (guanine nucleotide binding protein, alpha stimulating) 
complex locus 
1.00 8.72E-05 
ENSMUSG00000033960 9430020K01Ri
k 
RIKEN cDNA 9430020K01 gene 1.00 3.08E-07 
ENSMUSG00000062825 Actg1 actin, gamma, cytoplasmic 1 1.00 5.54E-08 
ENSMUSG00000028339 Col15a1 collagen, type XV, alpha 1 1.00 2.50E-07 
ENSMUSG00000025223 Ldb1 LIM domain binding 1 1.00 1.82E-07 
ENSMUSG00000010175 Prox1 prospero homeobox 1 1.00 3.76E-07 
ENSMUSG00000026185 Igfbp5 insulin-like growth factor binding protein 5 1.00 2.16E-06 
ENSMUSG00000036158 Prickle1 prickle homolog 1 (Drosophila) 1.00 2.72E-06 
ENSMUSG00000060594 Layn layilin 1.00 1.30E-04 
ENSMUSG00000030218 Mgp matrix Gla protein 1.00 6.82E-05 
ENSMUSG00000089308  -1.02 4.22E-03 
ENSMUSG00000081094  -1.04 1.94E-05 
ENSMUSG00000083992  -1.05 3.77E-04 
ENSMUSG00000076940 2010309G21Ri
k 
RIKEN cDNA 2010309G21 gene -1.05 5.86E-03 
ENSMUSG00000083337  -1.06 1.44E-03 
ENSMUSG00000084416  -1.06 8.34E-05 
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ENSMUSG00000080440  -1.06 1.39E-03 
ENSMUSG00000094026  -1.07 4.89E-03 
ENSMUSG00000064358 COX3 cytochrome c oxidase subunit III -1.08 2.30E-04 
ENSMUSG00000064945 Rny3 RNA, Y3 small cytoplasmic (associated with Ro protein) -1.10 4.82E-07 
ENSMUSG00000056412  -1.11 1.33E-03 
ENSMUSG00000094655  -1.12 1.12E-05 
ENSMUSG00000095584  -1.13 2.65E-03 
ENSMUSG00000087819  -1.13 4.70E-04 
ENSMUSG00000076332  -1.15 4.62E-06 
ENSMUSG00000064346  -1.16 1.45E-03 
ENSMUSG00000080921  -1.17 7.03E-06 
ENSMUSG00000064352  -1.18 2.62E-04 
ENSMUSG00000074800  -1.18 2.23E-06 
ENSMUSG00000056032  -1.19 1.32E-05 
ENSMUSG00000064653  -1.20 2.91E-04 
ENSMUSG00000078193  -1.21 1.15E-05 
ENSMUSG00000064360 ND3 NADH dehydrogenase subunit 3 -1.21 1.19E-06 
ENSMUSG00000064472  -1.22 1.75E-03 
ENSMUSG00000077711  -1.23 4.78E-05 
ENSMUSG00000095422  -1.24 6.54E-04 
ENSMUSG00000065104  -1.27 3.67E-04 
ENSMUSG00000095396  -1.28 7.57E-04 
ENSMUSG00000095624  -1.30 7.03E-04 
ENSMUSG00000096801  -1.31 2.08E-04 
ENSMUSG00000064355  -1.33 4.75E-06 
ENSMUSG00000090136 Gm10177 predicted gene 10177 -1.35 4.16E-05 
ENSMUSG00000057359  -1.36 6.79E-05 
ENSMUSG00000076355  -1.37 1.05E-06 
ENSMUSG00000076320  -1.39 1.96E-08 
ENSMUSG00000094400  -1.40 2.45E-04 
ENSMUSG00000095738  -1.41 1.21E-04 
ENSMUSG00000080365  -1.43 2.38E-06 
ENSMUSG00000077345  -1.49 1.15E-06 
ENSMUSG00000093413  -1.53 5.43E-07 
ENSMUSG00000093983  -1.54 1.97E-05 
ENSMUSG00000067870  -1.55 6.84E-08 
ENSMUSG00000062083  -1.56 5.06E-10 
ENSMUSG00000092661  -1.62 1.38E-12 
ENSMUSG00000077082  -1.63 2.55E-10 
ENSMUSG00000064823  -1.64 1.65E-08 
ENSMUSG00000064689  -1.67 1.43E-06 
ENSMUSG00000076370  -1.67 1.21E-08 
ENSMUSG00000064742  -1.77 1.35E-06 
ENSMUSG00000087412  -1.80 4.16E-07 
ENSMUSG00000096222  -1.82 6.23E-08 
ENSMUSG00000077565  -1.93 4.36E-16 
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ENSMUSG00000083705 Gm8624 predicted gene 8624 -1.99 1.66E-12 
ENSMUSG00000065373  -2.07 9.30E-11 
ENSMUSG00000093999  -2.27 8.28E-11 
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